

## CLINICAL PRACTICE GUIDELINES

# 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Developed in Collaboration With and Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association

### Writing Committee Members\*

Roger S. Blumenthal, MD, FACC, FAHA, FASPC, FNLA, Chair; Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA, Vice Chair; Mario Gaudino, MD, FAHA, FACC, JC Liaison†; Heather M. Johnson, MD, MS, FAHA, FACC, FASPC, JC Liaison‡; Timothy S. Anderson, MD, MASS§; Vera A. Bittner, MD, MSPH, FACC, FAHA, MNLA, MAACVPR||; Ron Blankstein, MD, FACC; LaPrincess C. Brewer, MD, MPH, FACC, FAHA; Leslie Cho, MD, FACC¶; Sarah D. de Ferranti, MD, MPH, FAHA; Eugenia Gianos, MD, FACC, FAHA, FNLA; Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC; Kristen F. Gradney, MHA, RDN, LDN#; Ijeoma Isiadinso, MD, MPH, FACC\*\*; Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA, FASPC; Joel C. MARRS, PharmD, MPH, FAHA, FNLA††; Seth S. Martin, MD, MHS, FACC, FAHA, FASPC; Kellie H. McLain, ANP-BC, CLS, FNLA, AACC; Laxmi S. Mehta, MD, FACC, FAHA, FNLA; Samia Mora, MD, MHS, FACC, FAHA; Wudeneh M. Mulugeta, MD, MPH, MS, FACP, FACPM##; Pradeep Natarajan, MD, MMSCFACC, FAHA; Ann Marie Navar, MD, PhD, FAHA, FACC, FASPC; Carl E. Orringer, MD, FACC, MNLA; Tamar S. Polonsky, MD, MSCI; Harmony R. Reynolds, MD, FACC, FAHA; Joseph J. Saseen, PharmD, MNLA, FACC, FAHA§§; Michael D. Shapiro, DO, MPH, FACC, FAHA, FASPC, FNLA|||; Daniel E. Soffer, MD, MNLA, FACP‡; Sheila A. Tynes, MHA, PMP¶¶; Chloé D. Villavaso, MN, APRN, ACNS-BC, FPCNA, AACC###; Salim S. Virani, MD, PhD, FACC, FASPC\*\*\*; John T. Wilkins, MD, MSc, FAHA

\*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for detailed information. †ACC/AHA Joint Committee on Clinical Practice Guidelines liaison. ‡Former ACC/AHA Joint Committee on Clinical Practice Guidelines member; current member during the writing effort. §American Geriatrics Society representative. ¶American Association of Cardiovascular and Pulmonary Rehabilitation representative. ¶¶ACC/AHA Task Force on Performance Measures liaison. #Patient representative. \*\*Association of Black Cardiologists representative. ††American Pharmacists Association representative. ##American College of Preventive Medicine representative. §§National Lipid Association representative. |||American Society for Preventive Cardiology representative. ¶¶¶AHA/ACC Guidelines Staff Consultant. ###Preventive Cardiovascular Nurses Association representative. \*\*\*American Diabetes Association representative.

Peer Review Committee Members and AHA/ACC Joint Committee on Clinical Practice Guidelines Members, see page \_\_\_\_.

The American Heart Association requests that this document be cited as follows: Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, MARRS JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes DE, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2026;153:e000000000001423

© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

*Circulation* is available at [www.ahajournals.org/journal/circ](http://www.ahajournals.org/journal/circ)

**AIM:** The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.”

**METHODS:** A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.

**STRUCTURE:** The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

**Key Words:** AHA Scientific Statements ■ anticholesteremic agents ■ atherosclerosis ■ atherosclerotic disease ■ cardiovascular disease ■ cardiovascular diseases ■ cholesterol ■ drug interactions ■ dyslipidemia(s) ■ HDL ■ hydroxymethylglutaryl-CoA reductase inhibitors ■ hypercholesterolemia ■ hyperlipid(a)emia/s ■ hyperlipoproteinemia type II ■ hypertriglyceridemia ■ hypolipidemic agents ■ LDL ■ lipids ■ lipoprotein(a) ■ risk factors ■ simvastatin ■ primary prevention ■ risk Adjustment ■ risk assessment ■ statin(s) ■ triglycerides

## TABLE OF CONTENTS

|   |      |  |      |
|---|------|--|------|
| Abstract . . . . .  | eXXX | 4.1.6. When to Refer to a Registered Dietitian Nutritionist . . . . .  | eXXX |
| What Is New . . . . .   | eXXX | 4.2. Medical Management . . . . .  | eXXX |
| Top Take-Home Messages . . . . .  | eXXX | 4.2.1. Pharmacological Therapy . . . . .   | eXXX |
| Preamble . . . . .  | eXXX | 4.2.2. Referring to a Clinical Lipid Specialist . . . . .  | eXXX |
| 1. Introduction . . . . .   | eXXX | 4.2.3. Primary Prevention in Adults . . . . .  | eXXX |
| 1.1. Methodology and Evidence Review . . . . .  | eXXX | 4.2.4. Severe Hypercholesterolemia (LDL-C $\geq$ 190 mg/dL [4.9 mmol/L]) . . . . .                                       | eXXX |
| 1.2. Organization of the Writing Committee . . . . .                                      | eXXX | 4.2.5. Diabetes in Adults Without Established ASCVD . . . . .  | eXXX |
| 1.3. Relationships With Industry and Other Entities . . . . .                             | eXXX | 4.2.6. Secondary ASCVD Prevention . . . . .  | eXXX |
| 1.4. Peer Review Committee . . . . .  | eXXX | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men $\geq$ 40 or Women $\geq$ 45 Years) . . . . . | eXXX |
| 1.5. Scope of the Guideline . . . . .   | eXXX | 4.2.8. Considerations in Patient Management . . . . .  | eXXX |
| 1.6. Class of Recommendations and Level of Evidence . . . . .                             | eXXX | 4.2.9. Management of Hypertriglyceridemia . . . . .  | eXXX |
| 2. Definitions and Classifications . . . . .  | eXXX | 4.2.10. Approach to Patients With Elevated Lp(a) . . . . .   | eXXX |
| 2.1. Definitions . . . . .  | eXXX | 4.2.11. Management of Statin-Attributed Muscle Symptoms . . . . .  | eXXX |
| 2.2. Abbreviations . . . . .  | eXXX | 5. Complications of Management . . . . .   | eXXX |
| 3. Evaluation and Diagnosis . . . . .   | eXXX | 5.1. Medication Safety and Therapy-Associated Side Effects . . . . .   | eXXX |
| 3.1. Screening in Children and Adults . . . . .   | eXXX | 5.2. Statin-Cardiovascular Drug Interactions . . . . .   | eXXX |
| 3.2. Measurement of TC, LDL-C, HDL-C, TG, and Non-HDL-C . . . . .                         | eXXX | 6. Evidence Gaps and Future Directions . . . . .   | eXXX |
| 3.3. Measurement of ApoB . . . . .  | eXXX | 6.1. Limitations and Knowledge Gaps . . . . .  | eXXX |
| 3.4. Measurement of Lp(a) . . . . .   | eXXX | 6.2. Randomized Controlled Trials . . . . .  | eXXX |
| 3.5. Monitoring and Follow-Up . . . . .   | eXXX | 6.3. Improving Cardiovascular Risk Assessment . . . . .  | eXXX |
| 4. Management . . . . .   | eXXX | 6.4. Refining the Clinician-Patient Risk Discussion . . . . .  | eXXX |
| 4.1. Lifestyle Management . . . . .   | eXXX | References . . . . .   | eXXX |
| 4.1.1. Primordial Prevention of Dyslipidemia: Childhood Through Adulthood . . . . .       | eXXX |  |      |
| 4.1.2. Dietary Approaches in Dyslipidemia . . . . .                                       | eXXX |  |      |
| 4.1.3. Attainment and Maintenance of Healthy Weight in People With Dyslipidemia . . . . . | eXXX |  |      |
| 4.1.4. Physical Activity . . . . .  | eXXX |  |      |
| 4.1.5. Dietary Supplements . . . . .  | eXXX |  |      |

## Appendix 1

Writing Committee Relationships With Industry and Other Entities . . . . .eXXX

## Appendix 2

Peer Review Committee Relationships With Industry and Other Entities . . . . .eXXX

## WHAT IS NEW

Table 1 highlights new and/or substantially revised practice-changing recommendations since the last iteration of the guideline and is not a comprehensive list of all updates. Some of these recommendations have corresponding footnotes not captured in this table.

## TOP TAKE-HOME MESSAGES

1. Treat dyslipidemia earlier to reduce lifelong risk of prolonged exposure to atherogenic lipoproteins. Health behavior counseling to support lifestyle optimization should start in youth, with early consideration of pharmacotherapy in youth with familial hypercholesterolemia (FH) and in young adulthood in individuals with low-density lipoprotein cholesterol (LDL-C)  $\geq 160$  mg/dL or a strong family history of premature atherosclerotic cardiovascular disease (ASCVD).
2. Use the more contemporary American Heart Association Predicting Risk of cardiovascular disease EVENTS (PREVENT™) equations instead of the older Pooled Cohort Equations (PCE) for 10- and 30-year risk assessment to guide lipid-lowering therapy (LLT) in primary prevention in adults aged 30 to 79 years. Use the “CPR” Model: A) Calculate 10-year ASCVD risk; B) Personalize the estimated risk to the specific patient by considering factors not included in PREVENT-ASCVD equations; and C) possibly Reclassify with selective use of coronary artery calcium (CAC) and Reassess treatment recommendations.
3. Low-density lipoprotein (LDL)-lowering therapy can be considered in adults for primary prevention of ASCVD with a 10-year PREVENT-ASCVD risk estimate of 3% to  $<5\%$  (borderline risk) and should be considered for those at 5% to  $<10\%$  (intermediate risk) 10-year risk after a clinician–patient discussion.
4. LDL-C and non-high-density lipoprotein cholesterol (HDL-C) treatment goals are back to guide LLT. Percentage reduction in LDL-C remains a priority for all individuals as well, with goal for % reduction depending on the level of ASCVD risk.
5. Apolipoprotein B (ApoB) testing can be useful to improve risk assessment and guide therapy once LDL-C and non-HDL-C goals are met, particularly in those with elevated triglycerides (TG) ( $>200$  mg/dL), diabetes, or low achieved LDL-C ( $<70$  mg/dL). ApoB measurement helps identify adults

with residual elevated lipoprotein-related risk that may be underestimated by the standard lipid profile alone and may be useful in the diagnosis of specific lipid and lipoprotein disorders.

6. Lipoprotein(a) [Lp(a)] should be measured at least once to identify those individuals at higher risk of ASCVD. It is considered as a risk-enhancing factor at levels  $\geq 125$  nmol/L (50 mg/dL), which is associated with about a 1.4-fold increased ASCVD risk, and values  $\geq 250$  nmol/L (100 mg/dL) are associated with  $\geq 2$ -fold higher estimated risk. The presence of elevated Lp(a) should be an indication for more intensified LDL-C lowering and management of other risk factors.
7. CAC scoring in men at least 40 years of age and women at least 45 years of age can improve risk assessment and guide LDL-C and non-HDL-C goals. Both the absolute amount of CAC and the corresponding standardized percentile (currently based on age, sex, and race) have prognostic importance and help to reclassify risk in adults.
8. LDL-lowering therapy is recommended for primary prevention in adults aged 40 to 75 years with diabetes, chronic kidney disease stage 3 or 4, or human immunodeficiency virus, regardless of LDL-C level. After age 75 years, LDL-C-lowering pharmacotherapy can be considered in conjunction with lifestyle interventions to reduce ASCVD risk.
9. In secondary prevention, a goal of LDL-C  $<55$  mg/dL (1.4 mmol/L) and non-HDL-C  $<85$  mg/dL (2.2 mmol/L) is recommended for those at very high risk of ASCVD events. Although a smaller number of patients with ASCVD not at very high risk have an LDL-C goal of at least  $<70$  mg/dL, the majority of those with a history of ASCVD events will likely qualify for an LDL-C goal of  $<55$  mg/dL.
10. In patients with persistently elevated TG, statin therapy remains the foundation of pharmacotherapy as an adjunct to lifestyle intervention to reduce ASCVD risk. Treatment for prevention of pancreatitis may also include TG-lowering therapies, especially in individuals with TG levels  $\geq 1000$  mg/dL (11.3 mmol/L).

## PREAMBLE

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, based on systematic methods to evaluate and classify evidence, provide a foundation for delivering high-quality cardiovascular care. When applicable, the guidelines also provide economic value statements that apply cost-effectiveness analyses. The methodology for these economic value statements can be found in the AHA/ACC Statement on Cost Value Methodology.<sup>1</sup>

**Table 1. What Is New**

| New or Revised | Section Title   | 2018 Recommendation   | 2026 Recommendation  |
|----------------|---|---|--|
| Revised        | 3.2. Measurement of TC, LDL-C, HDL-C, TG, and Non-HDL-C     | COR 2a: For adults with an LDL-C level <70 mg/dL (<1.8 mmol/L), measurement of direct LDL-C or modified LDL-C estimate is reasonable to improve accuracy over the Friedewald formula.                                       | COR 1: In adults and children who have undergone a standard lipid profile, use of either the Martin/Hopkins equation or the Sampson/NIH equation is preferred over calculation by the Friedewald equation to estimate LDL-C.   |
| New            | 3.3. Measurement of ApoB                                    | N/A   | COR 2a: In adults on LLT, particularly those with ASCVD, CKM syndrome, type 2 diabetes, and/or elevated TG, measurement of apoB is reasonable to guide decisions regarding further therapeutic intensification once LDL-C and/or non-HDL-C goals are achieved.   |
| New            | 3.4. Measurement of Lp(a)                                   | N/A   | COR 1: In all adults, measurement of Lp(a) concentration is recommended at least once for ASCVD risk assessment.   |
| New            | 4.1.5. Dietary Supplements                                  | N/A   | COR 3: In individuals with dyslipidemia, the use of dietary supplements is not recommended to lower LDL-C or TG based on limited and inconsistent data and/or limited benefits in lipid-lowering and reduction in ASCVD risk.  |
| New            | 4.1.6. When to Refer to a Registered Dietitian Nutritionist | N/A   | COR 1: In individuals with fasting TG $\geq$ 1000 mg/dL (11.3 mmol/L) referral to an RDN is recommended to create an individualized treatment plan aimed at reducing TG and the risk of pancreatitis.  |
| New            | 4.1.6. When to Refer to a Registered Dietitian Nutritionist | N/A   | COR 2a: In individuals with fasting TG $\geq$ 150 to 999 mg/dL ( $\geq$ 1.7-11.3 mmol/L) and features of the CKM syndrome, referral to an RDN is recommended to provide counseling on evidence-based dietary patterns that can be beneficial to improve lipoprotein levels and reduce the risk of pancreatitis.  |
| New            | 4.2.3.2. PREVENT-ASCVD Equations                            | N/A   | COR 1: In adults aged 30 to 79 y without ASCVD or subclinical atherosclerosis and with an LDL-C level between 70 and 189 mg/dL (1.8-4.9 mmol/L), the PREVENT-ASCVD equations should be used to estimate 10-y ASCVD risk, with categorization as having low (<3%), borderline (3% to <5%), intermediate (5% to <10%), or high ( $\geq$ 10%) risk.   |
| Revised        | 4.2.3.3. Risk Enhancers                                     | COR 2b: In patients at borderline risk, in risk discussion, the presence of risk-enhancing factors may justify initiation of moderate-intensity statin therapy.   | COR 2a: In adults without ASCVD with a borderline 10-y ASCVD risk estimate (3% to <5%) by the PREVENT-ASCVD equations, consideration of risk enhancers is reasonable to personalize risk assessment and the potential benefit of initiating LLT as an adjunct to lifestyle management to reduce ASCVD risk.  |
| New            | 4.2.3.3. Risk Enhancers                                     | N/A   | COR 2a: In adults without ASCVD with a borderline 10-y ASCVD risk estimate (3% to <5%) by the PREVENT-ASCVD equations, if hsCRP is measured and is $\geq$ 2 mg/L on 2 successive occasions with no identifiable underlying cause of hsCRP elevation, high-intensity statin therapy can be useful to reduce the risk of ASCVD events.   |
| New            | 4.2.3.4. Reproductive Risk Markers                          | N/A   | COR 2a: In adults without ASCVD, consideration of reproductive risk markers, such as early menopause (<45 y old) and history of adverse pregnancy outcomes (gestational hypertension, preeclampsia, gestational diabetes, preterm delivery) is reasonable to personalize ASCVD risk assessment when considering the potential benefit of initiating LLT as an adjunct to lifestyle management for primary ASCVD prevention.  |
| Revised        | 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis   | COR 2a: In intermediate-risk or selected borderline-risk adults, if the decision about statin use remains uncertain, it is reasonable to use a CAC score in the decision to withhold, postpone, or initiate statin therapy. | COR 1: In adults at intermediate risk and select adults at borderline risk with no prior ASCVD, if the decision regarding LLT remains uncertain, a CAC score should be used for further risk stratification and to guide the decision to withhold, postpone, or initiate therapy.  |
| New            | 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis   | N/A   | COR 2a: In adults at intermediate risk or select adults at borderline risk who undergo CAC testing, if the CAC score is 0 AU and there is preference to avoid LLT and focus on lifestyle management and no higher risk conditions (FH or severe hypercholesterolemia $\geq$ 190 mg/dL, diabetes and age >40 y, current cigarette smoking, strong family history of premature ASCVD) are present, it is reasonable to defer therapy and reassess with repeat CAC testing in 3 to 7 y to personalize management. |

(Continued)

**Table 1. Continued**

| New or Revised | Section Title  | 2018 Recommendation  | 2026 Recommendation   |
|----------------|--|--|---|
| New            | 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis  | N/A  | COR 1: In adults at intermediate risk and select adults at borderline risk, if the CAC score is >0 AU, it is recommended to initiate LLT, particularly if the CAC score is $\geq 100$ AU or $\geq 75$ th standardized percentile to reduce ASCVD risk.  |
| New            | 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis  | N/A  | COR 2a: In adults at intermediate or high risk with no prior ASCVD, if there is uncertainty about the intensity of LLT, a CAC score can be useful to refine treatment goals and decide whether to intensify lipid-lowering therapies.   |
| New            | 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis  | N/A  | COR 1: In adults with no prior ASCVD, if incidental CAC is identified on noncardiac CT scans (eg, by visual estimation or a validated artificial intelligence–based algorithm), the presence of coronary atherosclerosis should be considered during decision-making about initiation or intensification of LLT to reduce ASCVD risk.   |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 1: In adults at low (<3%) 10-y estimated risk for ASCVD who have an LDL-C <160 mg/dL (4.1 mmol/L) and a 30-y risk estimate of <10% (for those aged 30-59 y), counseling on health behaviors is recommended to reduce LDL-C and risk for ASCVD.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 2a: In adults at low (<3%) 10-y estimated risk for ASCVD but with an LDL-C of 160 to 189 mg/dL (4.1-4.9 mmol/L) or a 30-y ASCVD risk $\geq 10\%$ (for those aged 30-59 y), a moderate-intensity statin is reasonable to reduce cumulative exposure to atherogenic lipoproteins.   |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 2a: In adults at borderline (3% to <5%) 10-y estimated risk for ASCVD risk in whom a decision is made to initiate statin therapy for primary prevention, a moderate-intensity statin is reasonable to achieve $\geq 30\%$ to 49% LDL-C reduction and to reduce ASCVD risk.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 1: In adults at intermediate (5% to <10%) 10-y estimated risk for ASCVD, at least a moderate-intensity statin is recommended to achieve $\geq 30\%$ to 49% LDL-C reduction and to reduce ASCVD risk; for those in the higher end of this risk range, a high-intensity statin is beneficial to further reduce LDL-C by $\geq 50\%$ and reduce ASCVD risk.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 2a: In adults at borderline (3% to <5%) or intermediate (5% to <10%) 10-y estimated risk for ASCVD in whom statin therapy is initiated, it is reasonable to treat to a goal of LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C <130 mg/dL (3.4 mmol/L) to reduce ASCVD risk.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 1: In adults at high ( $\geq 10\%$ ) 10-y risk for ASCVD in whom LLT is initiated for primary prevention, high-intensity statin therapy is recommended to achieve an LDL-C reduction of $\geq 50\%$ to reduce the risk of ASCVD.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 2a: In adults at high ( $\geq 10\%$ ) 10-y risk for ASCVD in whom a decision to initiate statin therapy is made, it is reasonable to treat to a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) to reduce ASCVD risk.  |
| New            | 4.2.3.7. Management in Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) | N/A  | COR 2a: In adults at high ( $\geq 10\%$ ) 10-y estimated risk for ASCVD on maximally tolerated statin, it is reasonable to add ezetimibe if a goal LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) is not achieved.  |
| New            | 4.2.4.1. Role of Risk Assessment in HeFH   | N/A  | COR 3: In individuals with HeFH, standard risk assessment tools developed for the general population should not be used to calculate 10- or 30-y ASCVD risk.  |
| New            | 4.3.3.2. Genetic Testing for FH  | N/A  | COR 2a: In adults with severe hypercholesterolemia with an LDL-C $\geq 190$ mg/dL (4.9 mmol/L) without an identified secondary cause, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH can be useful to identify those with FH who are at higher risk of ASCVD events.   |
| Revised        | 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq 190$ mg/dL (4.9 mmol/L)  | COR 2a: In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (4.9 mmol/L) who achieve less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C level of 100 mg/dL or higher (2.6 mmol/L), ezetimibe therapy is reasonable. | COR 1: In adults with severe hypercholesterolemia with an LDL-C $\geq 190$ mg/dL (4.9 mmol/L) and without clinical ASCVD, additional ASCVD risk factors, HeFH, or subclinical atherosclerosis who are on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb and/or bempedoic acid is recommended to achieve a goal of LDL-C <100 mg/dL (2.6 mmol/L) and a non-HDL-C goal of <130 mg/dL (3.4 mmol/L) and to reduce ASCVD risk. |

(Continued)

**Table 1. Continued**

| New or Revised | Section Title  | 2018 Recommendation  | 2026 Recommendation  |
|----------------|--|--|--|
| Revised        | 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq$ 190 mg/dL (4.9 mmol/L)                              | COR 2b: In patients 30 to 75 y of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher (2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. | COR 1: In adults with severe hypercholesterolemia with LDL-C $\geq$ 190 mg/dL (4.9 mmol/L) without clinical ASCVD but with clinical or genetic confirmation of HeFH, additional ASCVD risk factors, or documented coronary calcification, who are on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb and/or bempedoic acid to achieve a goal of LDL-C $<$ 70 mg/dL (1.8 mmol/L) and non-HDL-C $<$ 100 mg/dL (2.4 mmol/L) is recommended to lower LDL-C and reduce ASCVD risk. |
| New            | 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq$ 190 mg/dL (4.9 mmol/L)                              | N/A  | COR 1: In adults with severe hypercholesterolemia with LDL-C $\geq$ 190 mg/dL (4.9 mmol/L) with clinical ASCVD, who are on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb, or bempedoic acid is recommended to achieve a goal of LDL-C $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L) to lower LDL-C and reduce ASCVD risk.   |
| New            | 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq$ 190 mg/dL (4.9 mmol/L)                              | N/A  | COR 2a: In adults with severe hypercholesterolemia with or without clinical ASCVD and LDL-C $\geq$ 100 mg/dL (2.6 mmol/L) despite maximally tolerated statin with or without ezetimibe therapy, treatment with inclisiran is reasonable to lower LDL-C.  |
| New            | 4.2.4.4. Severe Hypercholesterolemia With Clinical or Genetic Confirmation of HoFH                         | N/A  | COR 2b: In adults with clinical or genetic confirmation of HoFH currently on maximally tolerated statin therapy, ezetimibe, and PCSK9 mAb with an LDL-C $\geq$ 100 mg/dL (2.6 mmol/L), the addition of evinacumab may be reasonable to lower LDL-C.  |
| Revised        | 4.2.5. Diabetes in Adults Without Established ASCVD  | COR 1: In adults 40 to 75 y of age with diabetes, regardless of estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated.  | COR 1: In adults 40 to 75 y of age with diabetes and without clinical ASCVD, moderate-intensity statin therapy is indicated to achieve $\geq$ 30% to 49% reduction in LDL-C and a goal of LDL-C $<$ 100 mg/dL (2.6 mmol/L) and non-HDL-C $<$ 130 mg/dL (3.4 mmol/L) to reduce ASCVD risk.  |
| Revised        | 4.2.5. Diabetes in Adults Without Established ASCVD  | COR 2a: In adults with diabetes who have multiple ASCVD risk factors, it is reasonable to prescribe high-intensity statin therapy with the aim to reduce LDL-C levels by 50% or more.  | COR 2a: In adults 40 to 75 y of age with diabetes who have multiple ASCVD risk factors, it is reasonable to prescribe high-intensity statin therapy to achieve $\geq$ 50% reduction in LDL-C and a goal of LDL-C $<$ 70 mg/dL (1.8 mmol/L) and non-HDL-C $<$ 100 mg/dL (2.6 mmol/L) to reduce ASCVD risk.  |
| Revised        | 4.2.6. Secondary ASCVD Prevention  | COR 1: In patients who are 75 y of age or younger with clinical ASCVD, high-intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels.                                | COR 1: In adults with clinical ASCVD who are not at very high risk, high-intensity statin therapy should be initiated to achieve $\geq$ 50% reduction in LDL-C and a goal of LDL-C $<$ 70 mg/dL (1.8 mmol/L) and non-HDL-C $<$ 100 mg/dL to reduce the risk of recurrent ASCVD events.   |
| New            | 4.2.6. Secondary ASCVD Prevention  | N/A  | COR 2a: In adults with clinical ASCVD who are not at very high risk and on maximally tolerated statin therapy, it is reasonable to add ezetimibe, a PCSK9 mAb, or bempedoic acid (selected based on the degree of LDL-C lowering needed and patient preference) to achieve a goal LDL-C $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L) and to reduce the risk of ASCVD events.  |
| New            | 4.2.6. Secondary ASCVD Prevention  | N/A  | COR 2a: In adults with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, ezetimibe and/or a PCSK9 mAb should be added (selected based on the degree of LDL-C lowering needed and patient preference) to achieve a goal of LDL-C $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L) and to reduce risk of ASCVD events.  |
| New            | 4.2.6. Secondary ASCVD Prevention  | N/A  | COR 2a: In adults with clinical ASCVD who are at very high risk on maximally tolerated statin therapy, it is reasonable to add bempedoic acid to a statin, with or without ezetimibe and/or PCSK9 mAb, to reach an LDL-C goal $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L) to reduce the risk of ASCVD events.  |
| New            | 4.2.6. Secondary ASCVD Prevention  | N/A  | COR 2a: In adults with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with or without ezetimibe, it is reasonable to add inclisiran in those unable to tolerate or obtain evolocumab or alirocumab or have a strong preference for less frequent dosing to achieve an LDL-C goal $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L).  |
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men $\geq$ 40 or Women $\geq$ 45 y) | N/A  | COR 1: In adults with a CAC score of $\geq$ 1000 AU, treatment with LDL-C-lowering therapies with consideration of statin therapy as first-line is recommended to achieve a $\geq$ 50% reduction in LDL-C and a goal of LDL-C $<$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $<$ 85 mg/dL (2.2 mmol/L).   |

(Continued)

**Table 1. Continued**

| New or Revised | Section Title   | 2018 Recommendation | 2026 Recommendation   |
|----------------|---|---------------------|---|
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 y)          | N/A                 | COR 1: In adults with a CAC score of ≥300 to 999 AU, treatment with LDL-C lowering therapies with consideration of statin therapy as first line is recommended to achieve at least a 50% lowering in LDL-C and a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L).  |
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 y)          | N/A                 | COR 1: In adults with a CAC score of ≥100 to 299 AU or ≥75th standardized percentile, treatment with LDL-C lowering therapies, with consideration of statins as first-line therapy, is recommended to achieve a goal LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L).  |
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 y)          | N/A                 | COR 2a: In adults with a CAC score of 1 to 99 AU and <75th standardized percentile, or with an incidental finding of mild CAC on noncardiac CT scan, treatment with moderate-intensity statin therapy is reasonable to achieve a ≥30% to 49% reduction in LDL-C and a goal of LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C <130 mg/dL (3.4 mmol/L).  |
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45y)           | N/A                 | COR 2a: In adults with a CAC score of ≥300 to 999 AU, it is reasonable to intensify therapy by increasing the intensity of statin therapy or, if needed, adding ezetimibe, a PCSK9 mAb or bempedoic acid to achieve a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L).  |
| New            | 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 y)          | N/A                 | COR 2a: Among adults with no prior ASCVD who have moderate to severe incidental coronary atherosclerosis identified on noncardiac CT scans (eg, by visual estimation or a validated artificial-intelligence based algorithm), it is reasonable to initiate high-intensity statin therapy to achieve at least a ≥50% reduction in LDL-C and a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L); if mild incidental CAC is found, moderate-intensity statin therapy is reasonable to achieve a >30% to 49% reduction in LDL-C and a goal LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C goal <130 mg/dL. |
| New            | 4.2.8.1. Children and Adolescents   | N/A                 | COR 2a: In children and adolescents with a clinical presentation consistent with FH, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH can be useful to guide diagnosis, cascade testing, and treatment.  |
| New            | 4.2.8.4. Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating | N/A                 | COR 2a: In pregnant individuals with severe fasting hypertriglyceridemia (TG ≥500 mg/dL [5.7 mmol/L]), the use of fibrates (after the first trimester) or high-dose omega-3 ethyl esters is reasonable as an adjunct to lifestyle management to lower TG levels and reduce the risk of pancreatitis.  |
| New            | 4.2.8.8. Adults With CKD—Stage 3 or Higher  | N/A                 | COR 1: In adults with CKD stage 3 or higher and clinical ASCVD, LLT with high-intensity statin therapy with or without ezetimibe and/or a PCSK9 mAb is recommended to achieve a ≥50% reduction in LDL-C levels and a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) to reduce ASCVD risk.  |
| New            | 4.2.8.9. Persons Living With HIV  | N/A                 | COR 1: In people living with HIV aged 40 to 75 on stable combination antiretroviral therapy, statin therapy is recommended to reduce risk of a first ASCVD event and reduce the rate of coronary atherosclerosis progression.   |
| New            | 4.2.8.10. Adults With Cancer or History of Cancer   | N/A                 | COR 1: Adult cancer survivors with life expectancy of at least 2 y who otherwise qualify for LLT should be treated similarly to people without history of cancer to reduce the risk of ASCVD events.  |
| New            | 4.2.9. Management of Hypertriglyceridemia   | N/A                 | COR 1: In adults with clinical ASCVD and LDL-C ≥55 mg/dL (1.4 mmol/L) and non-HDL-C ≥85 mg/dL on maximally tolerated statin with persistently elevated TG levels ≥150 to 999 mg/dL (1.7–11.3 mmol/L), intensification of LDL-C-lowering therapy is recommended to reduce ASCVD risk.  |
| New            | 4.2.9. Management of Hypertriglyceridemia   | N/A                 | COR 1: In adults with familial chylomicronemia syndrome and fasting TG ≥1000 mg/dL (11.3 mmol/L), olezarsen (an apoC3 inhibitor) is recommended, as an adjunct to diet, to lower TG levels and reduce the risk of pancreatitis.   |
| New            | 4.2.9. Management of Hypertriglyceridemia   | N/A                 | COR 1: In adults aged 40 to 75 y without a history of ASCVD or diabetes who have persistently elevated TG levels ≥150 to 499 mg/dL (≥1.7–5.6 mmol/L), it is recommended to estimate 10-y ASCVD risk by the PREVENT equations to guide a benefit-risk discussion regarding further optimization of diet and lifestyle management as well as the potential initiation of statin therapy to reduce ASCVD risk.   |

(Continued)

**Table 1. Continued**

| New or Revised | Section Title                                    | 2018 Recommendation | 2026 Recommendation   |
|----------------|--|---------------------|---|
| New            | 4.2.10. Approach to Patients With Elevated Lp(a) | N/A                 | COR 1: In all individuals with elevated Lp(a) ( $\geq 125$ nmol/L or $\geq 50$ mg/dL), optimal early control of modifiable cardiovascular risk factors is recommended to reduce ASCVD risk.   |
| New            | 4.2.10. Approach to Patients With Elevated Lp(a) | N/A                 | COR 1: In individuals with clinical ASCVD and elevated Lp(a) who have not achieved LDL-C and non-HDL-C treatment goals on maximally tolerated statin therapy, the addition of a PCSK9 mAb with proven cardiovascular benefit is recommended to achieve treatment goals and reduce ASCVD risk. |

apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CKD, chronic kidney disease; CKM, cardiovascular-kidney-metabolic; CT, computed tomography; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein-cholesterol; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein(a); mAb, monoclonal antibody; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; PREVENT, Predicting Risk of Cardiovascular Disease EVENTS; RDN, registered dietitian nutritionist; TC, total cholesterol; and TG, triglycerides.

The ACC/AHA Guideline Core Principles and Development Process publication describes best practices for cardiology clinicians and provides additional background on the methodology used in the creation of guidelines.<sup>2</sup> Details about the alignment between the US Food and Drug Administration approval processes for drugs and devices and AHA/ACC guideline methodology can be found in the Guidance for Incorporating FDA Processes.<sup>3</sup>

Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Guidelines are the official policy of the ACC and AHA. For some guidelines, the ACC and AHA collaborate with other organizations.

*Catherine M. Otto, MD, FAHA, FACC, Chair,  
ACC/AHA Joint Committee on Clinical  
Practice Guidelines*

## 1. INTRODUCTION

### 1.1. Methodology and Evidence Review

The recommendations listed in this guideline are evidence-based whenever possible. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from October 2024 to December 2024. Select key studies published through April 2025 were added by the guideline writing committee as appropriate. The final evidence tables summarize the evidence used by the writing committee to formulate recommendations. References selected and published in the present guideline are not all-inclusive.

### 1.2. Organization of the Writing Committee

The writing committee consisted of general cardiologists, preventive cardiologists, cardiac imaging experts, internal medicine specialists, primary care physicians, geriatricians, clinical lipid specialists, an interventional cardiologist, a cardiothoracic surgeon, advanced practice nurses, clinical pharmacists, a registered dietitian nutritionist, and a patient advocate. The writing committee included representatives from the AHA, ACC, American Association of Cardiovascular and Pulmonary Rehabilitation, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association.

### 1.3. Relationships With Industry and Other Entities

The ACC and AHA have rigorous policies and methods to ensure that documents are developed without bias or improper influence. The complete policy on RWI can be found [online](#). Appendix 1 of the guideline lists writing committee members' comprehensive and relevant RWI.

**Table 2. Associated AHA/ACC Publications**

| Title  | Organization | Publication Year (Reference) |
|--|--------------|------------------------------|
| Recommendations for management of clinically significant drug-drug interactions with statins | AHA          | 2016 <sup>5</sup>            |
| Primary prevention of cardiovascular disease   | ACC/AHA      | 2019 <sup>6</sup>            |
| Decision pathway on management of ASCVD risk in persistent hypertriglyceridemia              | ACC          | 2021 <sup>7</sup>            |
| Decision pathway on the role of non-statin therapies   | ACC          | 2022 <sup>8</sup>            |

ACC indicates American College of Cardiology; AHA, American Heart Association; and ASCVD, atherosclerotic cardiovascular disease.

**Table 3. Applying the American College of Cardiology/American Heart Association Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care\* (Updated December 2024)**

| CLASS (STRENGTH) OF RECOMMENDATION   | LEVEL (QUALITY) OF EVIDENCE†‡  |
|--|--|
| <p><b>Class 1 (STRONG) Benefit &gt;&gt;&gt; Risk</b></p> <p><b>Suggested phrases for writing recommendations:</b></p> <ul style="list-style-type: none"> <li>• Is recommended</li> <li>• Is indicated/useful/effective/beneficial</li> <li>• Should be performed/administered/other</li> <li>• Comparative-Effectiveness Phrases†:                             <ul style="list-style-type: none"> <li>- Treatment/strategy A is recommended/indicated in preference to treatment B</li> <li>- Treatment A should be chosen over treatment B</li> </ul> </li> </ul> | <p><b>Level A</b></p> <ul style="list-style-type: none"> <li>• High-quality evidence‡ from more than 1 RCT</li> <li>• Meta-analyses of high-quality RCTs</li> <li>• One or more RCTs corroborated by high-quality registry studies</li> </ul>  |
| <p><b>Class 2a (MODERATE) Benefit &gt;&gt; Risk</b></p> <p><b>Suggested phrases for writing recommendations:</b></p> <ul style="list-style-type: none"> <li>• Is reasonable</li> <li>• Can be useful/effective/beneficial</li> <li>• Comparative-Effectiveness Phrases†:                             <ul style="list-style-type: none"> <li>- Treatment/strategy A is probably recommended/indicated in preference to treatment B</li> <li>- It is reasonable to choose treatment A over treatment B</li> </ul> </li> </ul>  | <p><b>Level B-R (Randomized)</b></p> <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more RCTs</li> <li>• Meta-analyses of moderate-quality RCTs</li> </ul>  |
| <p><b>Class 2b (WEAK) Benefit ≥ Risk</b></p> <p><b>Suggested phrases for writing recommendations:</b></p> <ul style="list-style-type: none"> <li>• May/might be reasonable</li> <li>• May/might be considered</li> <li>• Usefulness/effectiveness is unknown/unclear/uncertain or not well-established</li> </ul>  | <p><b>Level B-NR (Nonrandomized)</b></p> <ul style="list-style-type: none"> <li>• Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</li> <li>• Meta-analyses of such studies</li> </ul>                               |
| <p><b>Class 3: No Benefit (MODERATE) Benefit = Risk (Generally, LOE A or B use only)</b></p> <p><b>Suggested phrases for writing recommendations:</b></p> <ul style="list-style-type: none"> <li>• Is not recommended</li> <li>• Is not indicated/useful/effective/beneficial</li> <li>• Should not be performed/administered/other</li> </ul>   | <p><b>Level C-LD (Limited Data)</b></p> <ul style="list-style-type: none"> <li>• Randomized or nonrandomized observational or registry studies with limitations of design or execution</li> <li>• Meta-analyses of such studies</li> <li>• Physiological or mechanistic studies in human subjects</li> </ul> |
| <p><b>Class 3: HARM (STRONG) Risk &gt; Benefit</b></p> <p><b>Suggested phrases for writing recommendations:</b></p> <ul style="list-style-type: none"> <li>• Potentially harmful</li> <li>• Causes harm</li> <li>• Associated with excess morbidity/mortality</li> <li>• Should not be performed/administered/other</li> </ul>   | <p><b>Level C-EO (Expert Opinion)</b></p> <ul style="list-style-type: none"> <li>• Consensus of expert opinion based on clinical experience</li> </ul>   |

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

\* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR 1 and 2a; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely-used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

Downloaded from <http://ahajournals.org> by on March 15, 2026

## 1.4. Peer Review Committee

The Joint Committee appointed a peer review committee to review the guideline. The peer review committee comprised individuals nominated by the ACC, AHA, and the collaborating organizations. [Appendix 2](#) of the guidelines lists reviewers' comprehensive and relevant RWI.

## 1.5. Scope of the Guideline

In developing this guideline, the writing committee reviewed previously published ACC/AHA guidelines and other relevant clinical publications. Table 2 contains a list of these publications deemed pertinent to this writing effort and is intended for use as a resource. Clinicians should be advised that this guideline retires and replaces the previously published "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol."

The scope of the "2026 Guideline on the Management of Dyslipidemia" is to practically address the evaluation, management, and monitoring of patients with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein (a) [Lp(a)]. This guideline is retitled from the "2018 Guideline on Management of Blood Cholesterol" to the "2026 Guideline on Management of Dyslipidemias" to reflect the evolving understanding of ASCVD risk associated with atherogenic lipoproteins beyond LDL particles, including TG and remnant particles, and Lp(a). The guideline also addresses the implementation of newer therapeutic agents that reduce these atherogenic lipoproteins, as well as the latest advances in CVD risk assessment that are relevant to the management of persons with dyslipidemia in both primary and secondary prevention settings. This guideline also includes new recommendations based on high-quality evidence from major large randomized, placebo-controlled cardiovascular outcomes trials published since the 2018 cholesterol guideline, including FOURIER<sup>1</sup> (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), ODYSSEY OUTCOMES<sup>2</sup> (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), CLEAR OUTCOMES<sup>3</sup> (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen), and REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention).<sup>4</sup>

Major patient management groups include: 1) primary prevention with LDL-C 70 to 189 mg/dL; 2) severe hypercholesterolemia with LDL-C  $\geq$ 190 mg/dL; 3) diabetes; 4) clinical ASCVD; 5) subclinical atherosclerosis; and 6) hypertriglyceridemia. Special considerations are reviewed for the management of elevated Lp(a); dyslipidemia in children, young adults, and older adults; persons planning pregnancy, during pregnancy, and while lactating; heart failure; chronic inflammatory diseases, chronic

kidney disease, persons living with human immunodeficiency virus; and persons with statin-attributed muscle symptoms. Management considerations based on race or ethnicity are also provided.

## 1.6. Class of Recommendations and Level of Evidence

The Class of Recommendation (COR) indicates the strength of recommendation and encompasses estimated benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence supporting the intervention based on the type, quantity, and consistency of data from clinical trials and other sources (Table 3).<sup>9</sup>

## 2. DEFINITIONS AND CLASSIFICATIONS

### 2.1. Definitions

Cardiovascular-kidney-metabolic (CKM) syndrome: The common characteristics of the CKM syndrome include abdominal obesity (high body mass index [BMI] and/or large waist circumference), insulin-resistant glucose metabolism (hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes), dyslipidemia (high serum TG and low serum high-density lipoprotein cholesterol [HDL-C] concentrations), increased blood pressure, and sometimes microalbuminuria, proteinuria, or chronic kidney disease (CKD).<sup>1</sup>

Children: In this guideline, children are defined as age 18 years or younger.

Clinical ASCVD: ASCVD includes history of acute coronary syndromes (ACS), myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD).<sup>2</sup> ASCVD at very high risk is defined as  $\geq$ 2 major ASCVD events (ACS within the past 12 months, history of MI [other than recent ACS], history of ischemic stroke, symptomatic PAD) or with 1 major ASCVD event and  $\geq$ 2 high-risk features (age  $\geq$ 65 years, coronary bypass or percutaneous intervention, current smoker, diabetes, history of heart failure [HF], hypertension, LDL-C  $\geq$ 100 mg/dL [2.6 mmol/L] despite maximally tolerated statin plus ezetimibe).

Dyslipidemias: Dyslipidemias considered in this guideline include elevated blood cholesterol, hypertriglyceridemia, and elevated Lp(a).

Lifestyle management: Lifestyle management encompasses an assessment of each individual's baseline behavioral habits and counseling regarding healthy lifestyle habits. It includes information regarding heart-healthy eating patterns, regular physical activity, avoidance of all nicotine-delivery products, healthy sleep habits, and maintaining a healthy weight. This includes the lifestyle elements of the AHA's Life's Essential 8<sup>TM3</sup> in addition to stress management.

Subclinical atherosclerosis: Subclinical atherosclerosis is identified by the presence of atheromatous disease in  $\geq 1$  arterial territories before there are any signs, symptoms, or events attributable to clinically manifest atherosclerotic disease in those territories.<sup>4</sup>

## 2.2. Abbreviations

| Abbreviation | Meaning/Phrase                               |
|--------------|--|
| ACS          | acute coronary syndrome                      |
| AOR          | adjusted odds ratio                          |
| apo(a)       | apolipoprotein(a)                            |
| apoB         | apolipoprotein B                             |
| ARR          | absolute risk reduction                      |
| ASCVD        | atherosclerotic cardiovascular disease       |
| AU           | Agatston units                               |
| BMI          | body mass index                              |
| CAC          | coronary artery calcium                      |
| CAD          | coronary artery disease                      |
| CHD          | coronary heart disease                       |
| CI           | confidence interval                          |
| CID          | chronic inflammatory diseases                |
| CK           | creatinine kinase                            |
| CKD          | chronic kidney disease                       |
| CKM          | cardiovascular-kidney-metabolic              |
| CT           | computed tomography                          |
| CCTA         | coronary computed tomography angiography     |
| CVD          | cardiovascular disease                       |
| CVOT         | cardiovascular outcome trial                 |
| CYP3A4       | cytochrome P450 3A4                          |
| DASH         | Dietary Approach to Stop Hypertension        |
| DDI          | drug–drug interactions                       |
| DHA          | docosahexaenoic acid                         |
| eGFR         | estimated glomerular filtration rate         |
| EPA          | eicosapentaenoic acid                        |
| FCS          | familial chylomicronemia syndrome            |
| FDA          | US Food and Drug Administration              |
| FH           | familial hypercholesterolemia                |
| HDL-C        | high-density lipoprotein-cholesterol         |
| HeFH         | heterozygous familial hypercholesterolemia   |
| HF           | heart failure                                |
| HFrEF        | heart failure with reduced ejection fraction |
| HIV          | human immunodeficiency virus                 |
| HoFH         | homozygous familial hypercholesterolemia     |
| HR           | hazard ratio                                 |
| hsCRP        | high-sensitivity C-reactive protein          |
| IPE          | icosapent ethyl                              |
| LDL          | low-density lipoprotein                      |
| LDL-C        | low-density lipoprotein cholesterol          |

| Abbreviation | Meaning/Phrase   |
|--------------|--|
| LLT          | lipid-lowering therapy                                   |
| Lp(a)        | lipoprotein(a)   |
| LPL          | lipoprotein lipase                                       |
| mAb          | monoclonal antibody                                      |
| MACE         | major adverse cardiovascular events                      |
| MASLD        | metabolic dysfunction-associated steatotic liver disease |
| MCS          | multifactorial chylomicronemia syndrome                  |
| MI           | myocardial infarction                                    |
| NIH          | National Institutes of Health                            |
| PAD          | peripheral artery disease                                |
| PCSK9        | proprotein convertase subtilisin/kexin type 9            |
| PCSK9i       | proprotein convertase subtilisin/kexin type 9 inhibitor  |
| PLHIV        | persons living with HIV                                  |
| PREVENT      | Predicting Risk of cardiovascular disease EVENTS         |
| PRS          | polygenic risk scoring                                   |
| QOL          | quality of life  |
| RCT          | randomized controlled trial                              |
| RDN          | registered dietitian nutritionist                        |
| RNA          | ribonucleic acid   |
| RRR          | relative risk reduction                                  |
| SAMS         | statin-attributed muscle symptoms                        |
| TC           | total cholesterol  |
| TG           | triglycerides  |
| VLDL         | very-low-density lipoprotein                             |

## 3. EVALUATION AND DIAGNOSIS

### 3.1. Screening in Children and Adults

**Recommendations for Screening in Children and Adults**  
Referenced studies that support recommendations are summarized in the Evidence Table.

| COR | LOE  | Recommendations  |
|-----|------|--|
| 1   | B-NR | 1. In adults, screening with a lipid profile is recommended beginning at age 19 y and at least every 5 y thereafter to identify treatable ASCVD risk, with frequent screening recommended for individuals with additional ASCVD risk factors. <sup>1,2</sup>               |
| 1   | B-NR | 2. In children 9 to 11 y of age not previously tested, it is recommended to screen with a lipid profile to identify familial hypercholesterolemia (FH) and other significant lipid disorders. <sup>3–6</sup>   |
| 2a  | B-NR | 3. In individuals with first- or second-degree relatives with premature ASCVD, severe hypercholesterolemia, or FH, it is reasonable to perform screening with a single lipid profile (eg, cascade screening) starting at $\geq 2$ y of age to identify FH. <sup>7–10</sup> |

### Synopsis

Abnormal lipid levels are common in adults and children (age 18 years and younger), affecting 20% to 25%

of the population.<sup>2,11,12</sup> Epidemiologic studies and randomized clinical trials (RCTs) demonstrate apolipoprotein B (apoB)-containing lipoprotein particles are an important cause of ASCVD,<sup>1</sup> and lipid-lowering therapy (LLT) lowers ASCVD risk.<sup>13</sup> Screening asymptomatic individuals can identify both multifactorial dyslipidemias and monogenic disorders, such as FH (Section 4.2.4.3, “Severe Hypercholesterolemia With LDL-C  $\geq 190$  mg/dL (4.9 mmol/L)”), which may not present as clinical ASCVD for decades. Early exposure to hypercholesterolemia in childhood is associated with prevalent and incident subclinical atherosclerosis<sup>14</sup> and an increased risk of ASCVD in middle age,<sup>5,15</sup> and the duration of exposure to high low-density lipoprotein cholesterol (LDL-C) is an important driver of ASCVD risk,<sup>16</sup> making it essential to identify lipid disorders early. Childhood lipid screening can identify FH, and timely identification allows for earlier treatment, which has been shown to be safe and effective in lowering LDL-C in short- and medium-term randomized controlled trials (RCTs),<sup>17</sup> as well reducing premature ASCVD in long-term follow-up of 1 RCT.<sup>10</sup>

### Recommendation-Specific Supportive Text

1. In the United States, approximately 25% of adults have an LDL-C  $\geq 130$  mg/dL (3.4 mmol/L),<sup>2,11</sup> and severe lipid abnormalities such as the heterozygous familial hypercholesterolemia (HeFH) phenotype affect 1 in 250 to 300 individuals.<sup>18–20</sup> Despite this prevalence and the well-established causal relationship between elevated cholesterol and ASCVD, many adults—particularly young adults—are unaware of their lipid levels and go untreated.<sup>11,21</sup> No clinical trials have demonstrated any benefits or harms of lipid screening in younger adults to reduce ASCVD events.<sup>22</sup> However, the established causal relationship between apoB-containing lipoproteins and ASCVD, the availability of effective LLTs that reduce ASCVD morbidity and mortality with greater benefits in younger adults,<sup>1</sup> and the low cost and broad acceptability of lipid testing collectively support universal lipid screening of adults. Young adults without known lipid disorders can be screened every 5 years, starting at age 19 years, with the frequency of screening increasing with age and in the presence of additional ASCVD risk factors.
2. Lipid abnormalities affect ~20% of adolescents, with about 5% having an LDL-C  $\geq 130$  mg/dL (3.4 mmol/L)<sup>2</sup> and 1 in 250 US children having HeFH.<sup>23</sup> Longitudinal pediatric studies show that childhood lipid levels correlate with subclinical atherosclerosis in childhood and into young adulthood and predict risk of adult ASCVD.<sup>5</sup> Mendelian
- randomization studies indicate that genetically mediated low LDL-C is associated with low lifetime ASCVD risk, emphasizing the importance of early detection and treatment of individuals with dyslipidemia.<sup>24</sup> Current rates of lipid screening in the general US pediatric population are low, between 10% and 20%.<sup>25,26</sup> Family history alone is not sufficient to identify childhood lipid disorders,<sup>14</sup> as up to half of those with a high LDL-C do not report a family history of hypercholesterolemia or premature ASCVD.<sup>3</sup> Universal lipid screening in childhood is feasible and identifies FH as well as other lipid disorders, as shown in the Netherlands,<sup>27,28</sup> United Kingdom,<sup>8,9</sup> United States (West Virginia),<sup>3</sup> Slovenia,<sup>4</sup> and Slovakia,<sup>29</sup> and has been recommended in pediatric guidelines.<sup>30,31</sup> Screening at ages 9 to 11 years is recommended because subclinical atherosclerosis, as assessed by carotid intimal medial thickness, may be detected as early as 8 to 10 years of age,<sup>32</sup> and because screening later in adolescence is less optimal due to declines in total cholesterol (TC) and LDL-C levels of 10% to 20% during mid- to late puberty before rising to adult levels<sup>23,33</sup>; however, “catch up” screening can be performed for those missed at earlier age intervals. Screening should be performed with a non-fasting TC and HDL-C to calculate non-HDL-C, or a fasting lipid profile; apoB measurement is not part of routine pediatric lipid screening.
3. The HeFH phenotype affects 1 in 250 to 300 individuals<sup>18–20</sup> and is associated with a 2- to 4-fold higher risk of premature ASCVD, with even higher rates in young adults,<sup>34</sup> affecting as many as 20% of adults presenting with a premature MI.<sup>7</sup> However, as many as 90% of affected individuals are not diagnosed.<sup>35–37</sup> Lipid testing of first- or second-degree relatives of individuals with FH (which includes siblings and children as well as parents, grandparents, aunts, and uncles) who may have an even more immediate risk for ASCVD (“reverse cascade screening”) can identify other affected individuals<sup>38</sup> and may be cost effective in some health care systems.<sup>39</sup> Panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH should be considered if there is a family history of premature ASCVD or significant primary hypercholesterolemia in those with high lipid levels, as recommended by the US Centers for Disease Control and Prevention (Section 4.2.4.2, “Genetic Testing for FH”).<sup>40</sup> Importantly, cascade lipid screening is feasible and can be beneficial as early as 2 years of age to encourage early adoption of heart-healthy lifestyle behaviors, support timely identification and management of inherited lipid disorders, and bolster family cascade screening.<sup>8,41,42</sup>

### 3.2. Measurement of TC, LDL-C, HDL-C, TG, and Non-HDL-C

| Recommendations for Measurement of TC, LDL-C, HDL-C, TG, and Non-HDL-C                |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. In adults and children, a standard nonfasting or fasting lipid profile is recommended to document baseline lipid levels, estimate ASCVD risk, and guide initiation of LLT. <sup>1-4,5</sup>   |
| 1   | B-NR | 2. In adults and children with a family history of dyslipidemia or premature ASCVD, a personally known or suspected disorder in TG metabolism, or whose nonfasting lipid profile reveals a TG level $\geq 400$ mg/dL ( $\geq 4.5$ mmol/L), a fasting lipid profile should be performed to more accurately estimate the LDL-C level. <sup>4,6-10</sup>                        |
| 1   | B-NR | 3. In adults and children who have undergone a standard lipid profile, use of either the Martin/Hopkins equation or the Sampson/National Institutes of Health (NIH) equation is preferred over calculation by the Friedewald equation to estimate LDL-C. <sup>6,7,11-13</sup>  |
| 1   | B-NR | 4. In adults and children who have undergone a standard lipid profile, use of either the Martin/Hopkins equation or Sampson/NIH equation is preferred over direct LDL-C measurement (other than by beta-quantification) to estimate LDL-C. <sup>7,11,14,15</sup>   |
| 1   | B-NR | 5. In adults and children who have undergone a standard lipid profile, reporting of non-HDL-C is recommended for ASCVD risk assessment and to guide initiation and monitoring of LLT. <sup>16-19</sup>   |
| 3: No Benefit   | B-NR | 6. In adults and children, routine advanced lipoprotein testing (eg, gradient gel electrophoresis, density gradient ultracentrifugation, nuclear magnetic resonance spectroscopy, ion mobility analysis) to assess lipoprotein subclasses and parameters such as LDL particle size is not recommended to estimate ASCVD risk and guide initiation of LLT. <sup>9,10,20</sup> |

#### Synopsis

A standard lipid profile entails direct measurement of TC, HDL-C, and TG, with estimation of LDL-C. Non-HDL-C is calculated as TC-HDL-C. The lipid profile establishes baseline lipid levels and is essential in estimating ASCVD risk, guiding initiation of LLT, and monitoring response to therapy. LDL-C levels often vary little between fasting and nonfasting states, and postprandial increases in TG are generally small. Certain conditions such as visceral adiposity and diabetes may predispose individuals to higher levels of LDL-C and TG. Because fasting and nonfasting LDL-C levels have similar prognostic value, nonfasting samples can be used for most individuals. Fasting is most helpful for those with a history of increased TG (particularly if  $\geq 400$  mg/dL [ $\geq 4.5$  mmol/L]) and/or a family history of premature ASCVD or genetic dyslipidemia. Although LDL-C levels have histori-

cally been estimated using the Friedewald equation, the Martin/Hopkins and Sampson/NIH equations are preferred over the Friedewald equation because they provide greater accuracy across a wide range of LDL-C and TG levels. This is particularly true for those with TG levels  $\geq 150$  mg/dL ( $\geq 1.7$  mmol/L), LDL-C levels  $< 70$  mg/dL (1.8 mmol/L), or non-HDL-C levels  $< 100$  mg/dL (2.6 mmol/L). Measurement of apoB is another option and is covered in Section 3.3, "Measurement of ApoB."

#### Recommendation-Specific Supportive Text

1. A standard lipid profile, which entails measurement of TC, HDL-C, and TG and calculation of LDL-C and non-HDL-C, is useful in nearly all adults. Beyond providing a means to document baseline lipid levels, a standard lipid profile assists in estimation of ASCVD risk<sup>21,22</sup> and guidance on use and intensity of LLT.<sup>23</sup> Fasting may not be practical for many adults, as it requires specific timing of blood draws and, often, the need to return on another day for testing.<sup>24</sup> Because LDL-C levels in persons with normal TG usually differ minimally with normal food intake,<sup>1-3,5</sup> there is less justification for fasting in most adults. Several studies have noted similar prognostic value of fasting and nonfasting LDL-C and non-HDL-C levels for predicting long-term adverse events.<sup>1,2,4</sup> Fasting may be preferred on a limited basis when estimating residual risk in an individual being treated with LLT, diagnosing hypertriglyceridemia, and screening adults with a family history of premature ASCVD or genetic dyslipidemia.
2. The Friedewald equation has historically been used to estimate LDL-C levels.<sup>25</sup> Although the Friedewald equation is prone to inaccuracies as TG levels increase,<sup>6,7</sup> it is not until the TG level is  $\geq 400$  mg/dL ( $\geq 4.5$  mmol/L) that the LDL-C level is no longer reported.<sup>8</sup> Even though observed changes in TG levels are generally small with fasting, certain factors may predispose to larger differences, such as high baseline TG levels, dietary composition, and time since the last meal.<sup>24</sup> Repeat lipid testing while fasting can help with estimation of the LDL-C level in adults with a nonfasting TG level  $\geq 400$  mg/dL ( $\geq 4.5$  mmol/L). A similar approach may also be considered in individuals with known or suspected disorders in TG metabolism and/or a nonfasting TG level  $\geq 200$  mg/dL ( $\geq 2.3$  mmol/L)<sup>26</sup> if further evaluation of hypertriglyceridemia is warranted.<sup>27</sup>
3. The Friedewald equation is prone to inaccuracies as TG levels increase<sup>1</sup> and LDL-C and non-HDL-C levels fall<sup>11</sup>; more than 20 equations have been developed to improve upon these limitations.<sup>28</sup> Although beta-quantification (ultracentrifugation)

is the gold standard method for LDL-C measurement,<sup>29</sup> it is expensive and time-consuming to perform and is not run in most laboratories. Both the Martin/Hopkins equation and the Sampson/NIH equation have been among those most widely studied, with ultracentrifugation-based measurement used as the reference standard. Across widely varying TG levels (as low as  $\geq 150$  mg/dL [1.7 mmol/L]) and LDL-C levels (as low as  $< 40$  mg/dL [1.0 mmol/L]), these equations have outperformed the Friedewald equation in terms of more accurately estimating LDL-C levels<sup>7,11–13,28,30</sup> in both fasting and nonfasting states.<sup>12</sup>

4. The Friedewald equation cannot be used if the TG level is  $\geq 400$  mg/dL ( $\geq 4.5$  mmol/L).<sup>6,8</sup> Although several alternative assays for direct LDL-C measurement have been developed that vary in methodology and the reagents used (eg, precipitation, electrophoresis, density gradient ultracentrifugation, nuclear magnetic resonance),<sup>31</sup> they are limited by insufficient standardization and validation,<sup>6–8</sup> along with added cost. The Martin/Hopkins and Sampson/NIH equations represent preferred means for estimating LDL-C. Both have been validated in large cohorts, with greater accuracy in estimating LDL-C across widely varying TG levels and LDL-C levels.<sup>7,11–13,28,30</sup>
5. Non-HDL-C is a composite measure of the cholesterol content of all atherogenic lipoproteins.<sup>32</sup> It is easily calculated at no additional cost from a standard lipid profile (non-HDL-C = TC – HDL-C), correlates well with levels of apoB,<sup>33,34</sup> and has less discordance with apoB compared with LDL-C. It is particularly useful when TG levels are  $\geq 150$  mg/dL. Similar to apoB, it is a better predictor of ASCVD risk than LDL-C,<sup>16–19,35</sup> while also helping to improve upon lipid goal attainment.<sup>36</sup> Thus, strong support exists for routine reporting of non-HDL-C as part of a standard lipid profile.<sup>37,38</sup>
6. TC, HDL-C, LDL-C, and TG are carried within lipoprotein particles that vary in size, density, and charge.<sup>39</sup> Multiple advanced lipoprotein assays allow fractionation of these lipoprotein particles (eg, gradient gel electrophoresis, density gradient ultracentrifugation, nuclear magnetic resonance spectroscopy, ion mobility analysis), with the intended goal of improving CVD risk assessment and optimizing treatment.<sup>40–42</sup> Most reported parameters from advanced lipoprotein testing do not meaningfully reclassify or enable improved management of CVD risk beyond indices provided with a standard lipid profile (including non-HDL-C) along with measurement of apoB or Lp(a).<sup>41–45</sup> Lack of standardization across assays, the potential for information overload, and uncertainty as to which patients are most

likely to benefit from such testing are important limitations for its routine use.<sup>44</sup> Advanced lipoprotein testing should be limited to scenarios where availability of such information is likely to meaningfully change the treatment plan.

### 3.3. Measurement of ApoB

| Recommendations for Measurement of ApoB   |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 2a  | B-NR | 1. In adults on LLT, particularly those with ASCVD, CKM syndrome, type 2 diabetes, and/or elevated TG, measurement of apoB is reasonable to guide decisions regarding further therapeutic intensification once LDL-C and/or non-HDL-C goals are achieved. <sup>1–8</sup> |
| 2b  | B-NR | 2. In adults not on LLT, measurement of apoB may be reasonable to enhance ASCVD risk assessment, guide decisions about initiation of LLT, and characterize inherited lipid disorders. <sup>2,9–12</sup>  |

### Synopsis

LDL-C remains the traditional lipid marker for ASCVD risk assessment and treatment targets, but it reflects the cholesterol mass within LDL particles rather than the number of atherogenic lipoproteins. In contrast, apoB directly measures atherogenic particle number, with 1 molecule per LDL, very-low-density lipoprotein (VLDL), and Lp(a) particle. ApoB predicts ASCVD risk more accurately than LDL-C in cases of disagreement, or discordance, where LDL-C and apoB provide differing risk estimates.<sup>1,13</sup> Clinically significant discordance often occurs when LDL-C is at goal but apoB remains elevated above the treatment goal, indicating persistent atherogenic particle burden and potential need for therapy intensification. This pattern is most common in individuals with cardiometabolic disease, including ASCVD, CKM syndrome, diabetes, and/or TG  $\geq 150$  mg/dL, although it may occur at lower TG levels. In such scenarios, apoB serves as a more reliable marker for ASCVD risk and therapeutic guidance.<sup>2–4,14</sup> In the context of hypertriglyceridemia, apoB can also aid in the identification and characterization of lipid phenotypes, such as inherited lipid disorders, including familial combined hyperlipidemia, familial dysbetalipoproteinemia, multifactorial severe hypertriglyceridemia, and familial chylomicronemia syndromes (FCS).<sup>12</sup>

ApoB identifies residual CVD risk in statin-treated populations, including those who have achieved LDL-C goals. Observational studies and post hoc analyses from RCTs consistently demonstrate that apoB levels remain significantly associated with cardiovascular events, independent of LDL-C.<sup>2–4,14</sup> In primary prevention, atherogenic lipids and apoB are individually associated with incident MI, but only apoB remains significant when assessed together (adjusted hazard ratio per 1 SD, 1.27 [95% CI,

1.15–1.40];  $P < 0.001$ ).<sup>2</sup> Similarly, in secondary prevention, only apoB was associated with MI in a large study.<sup>2</sup>

### Recommendation-Specific Supportive Text

1. ApoB directly quantifies the number of atherogenic lipoproteins, providing a more accurate measure of atherogenic particle burden than LDL-C, which reflects the cholesterol mass carried by LDL particles. This distinction is clinically relevant in populations with CKM syndrome, in which cholesterol-depleted LDL particles are common.<sup>1</sup> In such settings, particularly in individuals with established ASCVD, CKM syndrome, diabetes, and/or elevated TG, discordance between LDL-C and apoB may be observed. LDL-C may appear at goal while apoB remains elevated, masking residual risk and possibly leading to undertreatment. Observational studies and post hoc analyses from randomized trials demonstrate that apoB is more strongly associated with cardiovascular events than LDL-C or non-HDL-C when the Friedewald equation is used to estimate LDL-C.<sup>1–4</sup> These findings highlight the utility of apoB in identifying individuals who may benefit from therapeutic intensification, even after apparent LDL-C goal attainment. The Martin/Hopkins method to estimate LDL-C markedly reduces discordance with apoB compared with the Friedewald equation. Among individuals with LDL-C  $< 70$  mg/dL (1.8 mmol/L) or  $< 100$  mg/dL (2.6 mmol/L) by Martin/Hopkins, only ~2% and ~1% of individuals had non-HDL-C and apoB levels exceeding guideline targets.<sup>15,16</sup> Measurement of apoB can support decisions regarding nonstatin therapies, such as ezetimibe, bempedoic acid, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb), or inclisiran.<sup>2,3</sup>
2. ApoB measurement enhances the accuracy of ASCVD risk assessment in untreated populations by directly assessing the number of atherogenic particles, including LDL, VLDL, and Lp(a). ApoB provides a more direct marker of lipoprotein particle number, bypassing the variability introduced by lipoprotein composition. Integrating apoB into routine risk stratification has been supported by large cohort studies and meta-analyses, which consistently demonstrate its superior predictive value compared with traditional lipid markers.<sup>2,9–11,17,18</sup> When more accurate methods, such as the Martin/Hopkins calculation, are used to estimate LDL-C compared with the Friedewald formula, the prevalence of discordance between LDL-C and apoB is markedly reduced.<sup>15,16</sup> ApoB measurement is standardized and unaffected by fasting status. By incorporating apoB measurement in persons with hypertriglyceridemia or diabetes, clinicians may

better identify high-risk individuals who may otherwise be overlooked by traditional metrics, enabling the timely initiation of LLTs. ApoB can also aid in the identification and characterization of lipid phenotypes, such as atherogenic dyslipidemia and inherited lipid disorders, as previously discussed.

### 3.4. Measurement of Lp(a)

| Recommendations for Measurement of Lp(a)<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
|---|------|--|
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. In all adults, measurement of Lp(a) concentration is recommended at least once for ASCVD risk assessment. <sup>1–4</sup>  |
| 1   | B-NR | 2. In individuals with FH, premature ASCVD, or high Lp(a), cascade testing of first-degree family members for high Lp(a) concentration is recommended to identify those at increased ASCVD risk. <sup>5–8</sup>  |
| 1   | B-NR | 3. For individuals undergoing measurement of Lp(a), use of laboratories employing assays that are insensitive to apolipoprotein(a) [apo(a)] isoforms and traceable to official reference standard materials is recommended to more accurately measure Lp(a) and characterize ASCVD risk. <sup>9–12</sup> |

### Synopsis



Lp(a) is an LDL-like particle that is structurally distinct from LDL, as it carries a single apoprotein(a) strand bound to its apoB-100 component. Lp(a) concentrations are mostly genetically determined by the *LPA* gene, and population distributions vary by ancestry (highest levels in individuals of African ancestry). Prospective studies have found robust associations for Lp(a) with ASCVD outcomes and calcific aortic valve disease, and genetic studies support causal associations. ASCVD risk increases in a continuous manner with higher Lp(a) concentrations, regardless of ancestry.<sup>13</sup> An Lp(a) concentration of 125 nmol/L (50 mg/dL) is considered high and is associated with approximately a 40% relative risk increase in ASCVD (Table 4) compared with individuals with low Lp(a) levels.<sup>1,2</sup> Lp(a) likely contributes to ASCVD through multiple mechanisms, including proatherogenic and proinflammatory effects that may be in part mediated by the oxidized phospholipids on Lp(a). As Lp(a) concentrations remain similar over time and are minimally modified by lifestyle factors,<sup>14</sup> a single measurement is generally sufficient. Secondary causes of high Lp(a) include kidney, liver, or thyroid disease; pregnancy; menopause; and some medications. Inflammation may increase or decrease Lp(a).<sup>14</sup> ASCVD risk is particularly high for individuals with elevated Lp(a) and other risk factors, and measuring Lp(a) helps with risk stratification. Cascade Lp(a) testing has potential value for enhanced screening in families with high Lp(a), especially if there is a personal or family history of premature ASCVD.

**Table 4. ASCVD Risk Related to Lp(a) Concentrations\***

| Lp(a) concentration nmol/L (mg/dL) | ASCVD Relative Risk: Increase Compared With Population Median (20 nmol/L, 7 mg/dL) |
|------------------------------------|--|
| 430 nmol/L (180 mg/dL)             | 4-fold   |
| 350 nmol/L (150 mg/dL)             | 3-fold   |
| 250 nmol/L (100 mg/dL)             | 2-fold   |
| 125 nmol/L (50 mg/dL)              | 1.4-fold   |
| 75–124 nmol/L (30–49 mg/dL)        | 1.2-fold   |
| <75 nmol/L (<30 mg/dL)             | Reference  |

Data in the table are derived from the UK Biobank Study,<sup>14</sup> are intended as a general guide and may differ in other populations. For example, relative risk of 2-fold has been observed for levels of 200 nmol/L in some populations. Equivalence of levels between nmol/L and mg/dL is approximate. An Lp(a) level of 50 mg/dL (125 nmol/L, ~80th percentile) is associated with an ~40% relative risk increase in ASCVD compared with 7 mg/dL (20 nmol/L, median in a reference population).<sup>12</sup> An Lp(a) level of 100 mg/dL ( $\geq 250$  nmol/L, ~95th percentile) approximately doubles the ASCVD risk. An Lp(a) level of 180 mg/dL ( $\geq 430$  nmol/L, ~99th percentile) increases the ASCVD risk by ~4-fold, similar to the risk of heterozygous familial hypercholesterolemia.

\*Lp(a) concentrations in this threshold range may be considered for repeat testing.

ASCVD indicates atherosclerotic cardiovascular disease; and Lp(a), lipoprotein (a).

### Recommendation-Specific Supportive Text

- Prospective studies have found robust associations between high Lp(a) and nonfatal ASCVD outcomes, aortic valve disease, CVD, and all-cause mortality in both primary and secondary prevention populations.<sup>1,3</sup> The association of Lp(a) with ASCVD risk is independent of LDL-C and other risk factors, even among individuals with low LDL-C.<sup>1</sup> Because Lp(a) is predominantly a genetic risk factor, measuring it with the first (or any) lipid profile might be the best occasion for early identification of individuals with elevated Lp(a) to encourage healthful behaviors and initiate earlier preventive therapies. Measuring Lp(a) once is generally enough to detect a high Lp(a),<sup>4</sup> because Lp(a) levels are predominantly genetically determined and remain stable except for some conditions, such as the menopause transition or if a secondary cause of elevated Lp(a) is present (eg, kidney, liver, thyroid disease, pregnancy, certain medications). Lp(a) concentrations are typically highest in individuals of African or South Asian ancestry, although the impact on relative risk of ASCVD is similar regardless of ethnicity/ancestry.<sup>2,3</sup> Genetic testing for Lp(a) is not advised for clinical purposes as the measured Lp(a) concentration is sufficient for ASCVD risk assessment. Fasting is not required for Lp(a) testing.
- Lp(a) concentration is mostly determined by genetics and is inherited with autosomal codominant transmission of genetic variants, resulting in lifelong exposure to genetically elevated Lp(a).<sup>5,6</sup> Young individuals with elevated Lp(a) have increased risk of future ASCVD events and calcific aortic stenosis, independent of

and additive to other risk factors, such as LDL-C.<sup>7</sup> Cascade testing by measuring Lp(a) concentration in first-degree family members (parent, sibling, offspring) of individuals with high Lp(a) is beneficial to identify other affected family members at increased ASCVD risk, especially if there is a personal or family history of premature ASCVD or premature aortic stenosis, or FH.<sup>6,8</sup> Elevated Lp(a) is common in patients with FH; however, FH does not cause elevated Lp(a). Rather, evidence shows that elevated Lp(a) increases the likelihood that an individual with genetic FH will be clinically recognized (ascertainment bias).<sup>15</sup>

- There may be variability in Lp(a) measurements due to apo(a) isoform size and the number of kringle IV-type 2 repeats, and there are different methods to measure Lp(a).<sup>9</sup> This size variation affects the accuracy of mass-based assays and contributes to substantial interindividual variability in Lp(a) levels. Laboratories should report the assay name and the units by which the assay is calibrated. Lp(a) concentration is reported as mass concentration (mg/dL) or molar concentration (nmol/L). It is preferable to measure Lp(a) using assays that are calibrated in molar units (ie, nmol/L) and that are apo(a) isoform-insensitive (measure the concentration of Lp(a) particles regardless of apo(a) size).<sup>10</sup> It is difficult to compare results measured by different assays and laboratories,<sup>11</sup> although Lp(a) concentrations measured by both mass and molar concentration identify high-risk individuals. Efforts to standardize and harmonize Lp(a) measurement are ongoing.<sup>12</sup> Assays that are traceable to official reference standards can be traced back to a recognized, established standard, such as those maintained by the National Institute of Standards and Technology. This ensures the measurement is consistent and reliable compared with a known standard.<sup>16</sup>

### 3.5. Monitoring and Follow-Up

**Recommendation for Monitoring and Follow-Up**  
Referenced studies that support recommendation are summarized in the Evidence Table.

| COR | LOE | Recommendation  |
|-----|-----|---|
| 1   | A   | 1. In individuals on LLT, clinicians should perform a lipid profile 4 to 12 wk after initiation or dose adjustment and every 6 to 12 mo thereafter to assess efficacy and adherence to LLTs. <sup>1,2</sup> |

### Synopsis

In addition to lifestyle management, initiation of LLT is an important step in reducing ASCVD risk. Assessment of response to treatment initiation and adherence to therapy is equally important. Response to LLT can vary significantly from one patient to another<sup>3</sup> as a result of differences in pharmacogenomics, dietary factors, specific lipoprotein

phenotype, and interactions with other medications.<sup>4</sup> This variation in response to LLT has been associated with ASCVD outcomes.<sup>3</sup> Adherence to LLT remains low and is associated with ASCVD outcomes.<sup>5</sup> Performance of a lipid profile provides the most objective evidence to assess response to LLT and expected ASCVD outcomes. A nonfasting lipid profile suffices in most cases unless the patient has known hypertriglyceridemia, in which case a fasting lipid profile should be performed. Nonfasting lipid profiles reflect typical daily physiology, improve patient convenience, and allow for improved adherence to testing at regular intervals. Response to therapy is assessed as a percentage reduction in LDL-C from baseline, as well as achievement of absolute LDL-C and non-HDL-C goals. LDL-C and non-HDL-C thresholds indicate the levels at which consideration should be given to treatment intensification (Figure 1).

### Recommendation-Specific Supportive Text

1. High-quality evidence from RCTs evaluating statin and nonstatin therapy supports monitoring response to treatment with a lipid profile 4 to 12 weeks after initiation or intensification of therapy and every 6

to 12 months thereafter.<sup>1,2,6–8</sup> The frequency for subsequent lipid profiles should be individualized based on ASCVD risk, the degree of LDL-C reduction needed, the medication used, time to steady state, patient adherence, and stability of lipid levels. For patients requiring no change in therapy, a stable response, and no clinical changes, a lipid profile every 12 months is appropriate. Response to statin therapy can vary substantially and is associated with future ASCVD events.<sup>3</sup> Measuring a lipid profile provides the most objective assessment of this variation. Inadequate response to treatment may lead to further intensification of lifestyle or statin regimen, and/or initiation of a nonstatin LLT. Lipid profile measurement is associated with improved medication adherence.<sup>9–11</sup> Monitoring and discussion of results between a clinician and patient could refine discussions for treatment intensification and provide a collaborative opportunity to assess adherence-related barriers and should be incentivized by health systems. Finally, performance of a lipid profile reduces therapeutic inertia (failure to initiate or intensify therapy when indicated).<sup>9,11–13</sup>

## Lipoprotein Goals for ASCVD Risk Reduction

| Patient population          | LDL-C <100 mg/dL (2.6 mmol/L)<br>Non-HDL-C <130 mg/dL (3.4 mmol/L)                       | LDL-C <70 mg/dL (1.8 mmol/L)<br>Non-HDL-C <100 mg/dL (2.6 mmol/L)   | LDL-C <55 mg/dL (1.4 mmol/L)<br>Non-HDL-C <85 mg/dL (2.2 mmol/L) |
|-----------------------------|--|---|--|
| Primary prevention          | PREVENT-ASCVD <10%<br>• If TG ≥150 mg/dL to 499 mg/dL, apoB goal: <90 mg/dL              | PREVENT-ASCVD ≥10%<br>• If TG ≥150 mg/dL to 499 mg/dL, apoB goal: <70 mg/dL   | N/A  |
| Severe hypercholesterolemia | Without FH, ASCVD risk factors, and subclinical atherosclerosis                          | With FH, ASCVD risk factors, or subclinical atherosclerosis   | Severe hypercholesterolemia or HeFH with clinical ASCVD          |
| Diabetes                    | Without ASCVD risk factors or diabetes-specific risk modifiers<br>• apoB goal: <90 mg/dL | With ASCVD risk factors or diabetes-specific risk factors<br>• apoB goal: <70 mg/dL   | N/A  |
| Subclinical atherosclerosis | CAC = 1–99 AU and <75th percentile for age, sex, and race                                | • CAC ≥100 to 299 AU or ≥75th percentile for age, sex, race<br>• CAC ≥300 to 999 AU<br>◦ Optional goal: LDL-C <55 mg/dL, non-HDL-C <85 mg/dL and consider apoB goal <55 mg/dL | CAC ≥1000 AU   |
| Hypertriglyceridemia        | <50 y old with no additional risk enhancers  | • With clinical ASCVD not at very high risk<br>◦ apoB goal: <70 mg/dL<br>• Age 40–75 y with ≥1 ASCVD risk factor<br>◦ apoB goal: <70 mg/dL                                    | With clinical ASCVD at very high risk<br>• apoB goal: <55 mg/dL  |
| Clinical ASCVD              | N/A  | Not at very high risk<br>• Optional goal: LDL-C <55 mg/dL, non-HDL-C <85 mg/dL and consider apoB goal <55 mg/dL   | • At very high risk<br>◦ apoB goal: <55 mg/dL<br>• With CKD      |

 2026 Dyslipidemia  
© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 1. Lipoprotein Goals for ASCVD Risk Reduction.**

apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; AU, Agatston units; CAC, coronary artery calcium; CKD, chronic kidney disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and TG, triglycerides.

## 4. MANAGEMENT

### 4.1. Lifestyle Management

#### Synopsis

Healthy lifestyle habits, including implementation of each of the components of the AHA Life's Essential 8,<sup>1</sup> are imperative to optimize cardiovascular health, with a relative risk reduction (RRR) of approximately 50% in adverse CVD outcomes noted even in individuals with genetic predisposition to ASCVD.<sup>2</sup> A healthy diet, as described by the "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease," has been given a Class 1A recommendation for the reduction of CVD events.<sup>3,4</sup> To target residual risk due to suboptimal lifestyle habits, clinicians should adequately assess a patient's baseline behavioral habits, which can be streamlined through the use of lifestyle screening tools integrated into the electronic medical record, digital health technologies, and team-based care.<sup>5</sup> Lifestyle management is foundational for ASCVD risk reduction and should accompany medical therapy to obtain the best outcomes. This section focuses on lifestyle management for the treatment of dyslipidemia.

#### 4.1.1. Primordial Prevention of Dyslipidemia: Childhood Through Adulthood

| Recommendation for Primordial Prevention of Dyslipidemia: Childhood Through Adulthood    |     |   |
|--|-----|---|
| Referenced studies that support the recommendation are summarized in the Evidence Table. |     |   |
| COR  | LOE | Recommendation  |
| 1  | A   | 1. In children and healthy adults, healthy dietary patterns, regular physical activity, maintenance of a healthy weight, healthy sleep, stress management, and avoidance of tobacco products should be promoted and reinforced lifelong to reduce the risk for dyslipidemia and ASCVD. <sup>1-4</sup> |

#### Synopsis

Preventing or delaying the onset of dyslipidemia (primordial prevention) is anticipated to optimize lipid-related ASCVD risk. Prolonged and persistent exposure to atherogenic lipoproteins accelerates the risk of ASCVD events. Optimization of health-related behaviors will reduce the risk of developing dyslipidemia. Primordial prevention measures are more likely to be effective when introduced early in life, established as habits, and longitudinally sustained. Environmental and social determinants of health are additionally associated with the likelihood of developing dyslipidemia.

#### Recommendation-Specific Supportive Text

1. Atherosclerosis is accelerated by premature and persistent elevations in the concentration of apoB-containing lipoproteins, principally LDL particles. Among young adults who died from trauma, dyslipidemia was associated with an increased likelihood

of coronary atherosclerosis on autopsy.<sup>1,5</sup> Persistent dyslipidemia among children and young adults is associated with a heightened risk of future coronary artery disease (CAD) and a greater likelihood of dyslipidemia in adulthood.<sup>2,6,7</sup> Inherited genetic variants that raise and lower LDL-C levels increase and decrease ASCVD proportionally more than rates achieved in typical RCTs, which last 3 to 5 years.<sup>3,8,9</sup> This suggests that long-term exposure to different LDL-C levels has greater impact on ASCVD outcomes than observed in RCTs because of the duration of exposure. Thus, it is critically important to optimize healthy lifestyle habits as early as possible to prevent the development of dyslipidemia at a young age. Dietary factors strongly influence the likelihood of developing dyslipidemia, and promoting heart-healthy dietary patterns in childhood and adolescence is associated with reduced risk for dyslipidemia.<sup>4,10</sup> Regular brisk physical activity,<sup>11-13</sup> maintaining a normal weight, and tobacco cessation and abstinence are also associated with more favorable lipids and cardiovascular outcomes.<sup>14</sup> Additional factors may influence dyslipidemia risk, including lower income,<sup>15-17</sup> food insecurity,<sup>18,19</sup> occupation,<sup>20,21</sup> and various environmental indices.<sup>22-24</sup>

#### 4.1.2. Dietary Approaches in Dyslipidemia

##### 4.1.2.1. Dietary Management of LDL-C Disorders

| Recommendation for Dietary Management of LDL-C Disorders                                 |     |   |
|--|-----|---|
| Referenced studies that support the recommendation are summarized in the Evidence Table. |     |   |
| COR  | LOE | Recommendation  |
| 1  | B-R | 1. In adults and children with or without ASCVD, a diet emphasizing intake of fruits, vegetables, nuts, legumes, whole grains, and fiber, while replacing saturated and trans fats with dietary monounsaturated and polyunsaturated fats, is recommended to decrease LDL-C levels and reduce ASCVD risk. <sup>1-4</sup> |

#### Synopsis

RCTs and observational studies have consistently shown a strong association between eating patterns such as the Mediterranean, the Dietary Approach to Stop Hypertension (DASH), and vegetarian diets with improved cardiovascular outcomes.<sup>5-7</sup> Studies of healthy eating patterns, including high intake of fruits and vegetables, nuts and seeds, fiber-rich foods such as legumes and whole grains, and monounsaturated and polyunsaturated fats, have demonstrated modest effects on LDL-C lowering.<sup>5</sup> Additional LDL-C reduction can be seen, however, with vegetarian diets, particularly with added fiber, soy protein, and nuts.<sup>1,8</sup> An important component of controlling LDL-C through diet is avoiding saturated fat.<sup>9</sup> There is a graded association between elevated LDL-C levels and intake of saturated fat, which is typically found in red meat, butter, high-fat milk, coconut oil, and palm and palm kernel oil (often referred

to as tropical oils).<sup>2</sup> When saturated fats are replaced with unsaturated fats, there is a strong association with reduced LDL-C levels. Sources of polyunsaturated fats include fish, nuts, flax and chia seeds, and oils, particularly corn, sunflower, and soybean oil; sources of monounsaturated fats include olive oil, avocados, and nuts. Focusing on healthy eating patterns that limit saturated fat while increasing unsaturated fat produces more consistent LDL-C lowering than restricting dietary cholesterol.<sup>3</sup> The health benefits of this exchange can be offset by excess processed sugar and other aspects of ultra-processed foods.

### Recommendation-Specific Supportive Text

1. Although healthy eating patterns provide multiple cardiovascular benefits, including weight reduction, decreased inflammation, and improved control of blood pressure and glucose, the direct effect on LDL-C tends to be more modest. There may be individual variation in LDL-C lowering in response to dietary changes, particularly changes in saturated fat intake, which are influenced by bile acid production, reabsorption in the gut, and genetic polymorphisms.<sup>10</sup> In a randomized crossover trial, 62 overweight adults were assigned to the Mediterranean diet versus a vegan diet for 16 weeks each.<sup>4</sup> The LDL-C decreased by 14.8 mg/dL (95% CI, -23.5 to -6.2

mg/dL;  $P < 0.001$ ) with the vegan diet but did not decrease significantly with the Mediterranean diet. In a meta-analysis of RCTs, there was a 7.7 mg/dL (0.20 mmol/L [95% CI, 0.07-0.33];  $P = 0.003$ ) lowering of LDL-C with plant-based sources of protein compared with meat.<sup>11</sup> The mean LDL-C lowering with vegetarian or vegan versus omnivorous diets was 11.6 mg/dL (-0.30 mmol/L [95% CI, -0.40 to -0.19];  $P < 0.001$ ).<sup>8</sup> One serving of nuts per day was associated with a 4.8 mg/dL (95% CI, -5.5 to -4.2) decrease in LDL-C.<sup>12</sup> Fiber intake can have a small effect on LDL-C lowering; 3 daily servings of oatmeal (28 g each) could lower the LDL-C by <5 mg/dL (0.13 mmol/L).<sup>13</sup> The Portfolio diet, which added nuts, soy protein, fiber, and a plant sterol-enriched margarine, decreased the mean LDL-C by 26 mg/dL (95% CI, -31 to -21 mg/dL;  $P < 0.001$ ).<sup>1</sup>

#### 4.1.2.2. Lifestyle Management of Hypertriglyceridemia

| Recommendations for Lifestyle Management of Hypertriglyceridemia                      |     |  |
|---|-----|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |     |  |
| COR   | LOE | Recommendations  |
| 1   | A   | 1. In adults with fasting TG levels of 150 to 499 mg/dL (1.7–5.6 mmol/L), a diet that is low in added sugar, refined carbohydrates, and saturated fat, and that minimizes alcohol (Figure 2) is beneficial to reduce TG and ASCVD risk. <sup>1–4</sup> |

### Health Behavior Interventions in Patients With Hypertriglyceridemia

| Implemented shared decision-making intervention | TG ≥150 to 499 mg/dL* (1.7 to <5.7 mmol/L)  | TG ≥500 to 999 mg/dL* (5.7 to <11.3 mmol/L) | TG ≥1000 mg/dL† (≥11.3 mmol/L) |
|---|---|---|--------------------------------|
| Added sugars (percent calories)                 | <6%   | <5%   | Eliminate                      |
| Total fat (percent calories)                    | 30%–35%   | 20%–25%‡                                    | 10%–15%§¶                      |
| Alcohol   | Avoid   | Abstain completely                          | Abstain completely             |
| Physical activity                               | At least 150 minutes/week of accumulated moderate-intensity or 75 minutes/week of vigorous intensity aerobic activity (or equivalent combination of both) and 2 days/week of upper and lower body resistance exercise |   |                                |
| Weight loss (percent body weight)               | Recommended weight loss goal of 5%–10% for patients who are overweight or obese with elevated TG  |   |                                |

2026 Dyslipidemia © 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 2. Health Behavior Interventions in Patients With Hypertriglyceridemia.**

\*Referral to an RDN and lipid specialist advised. †Referral to an RDN necessary. ‡Clinicians may opt to reduce total fat as a percent of calories in some patients to 10% to 15% (examples include those with a history of pancreatitis or those at the higher end of this range). §Limitation of total fat to 10% to 15% of total daily intake, with guidance from an RDN is essential for patients with FCS. ¶For those with TG disorders outside of FCS, individually tailored total fat limitation under the guidance of an RDN can be beneficial due to variable response to diet. ||Although clinicians should aim for a patient to achieve the guideline-directed amount of physical activity, any physical activity is likely beneficial in sedentary individuals and should be encouraged to reduce cardiometabolic risk. FCS indicates familial chylomicronemia syndrome; RDN, registered dietitian nutritionist; and TG, triglycerides. Adapted with permission from Virani et al,<sup>13</sup> with additional information obtained from Arnett et al.<sup>10</sup> © 2021 American College of Cardiology Foundation.

| Recommendations for Lifestyle Management of Hypertriglyceridemia (Continued) |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 1  | B-NR | 2. In adults with fasting TG levels of 500 to 999 mg/dL (5.7–11.3 mmol/L), a diet that is low in added sugar, refined carbohydrates, and saturated fat, with no alcohol and individualized limitation of total fat (Figure 2) is beneficial to reduce TG for the reduction of ASCVD risk and risk of pancreatitis. <sup>2-4</sup>  |
| 1  | B-NR | 3. In adults with fasting TG levels of $\geq 1000$ mg/dL (11.3 mmol/L), a diet that is very low in total fat and refined carbohydrates, with elimination of alcohol and added sugars (Figure 2) is beneficial to reduce TG and risk for pancreatitis. <sup>5</sup>   |
| 1  | B-NR | 4. In adults with fasting TG levels $\geq 150$ mg/dL (1.7 mmol/L) or nonfasting TG levels $\geq 175$ mg/dL (2 mmol/L), improvement in lifestyle factors related to overweight/obesity and CKM syndrome, weight loss of 5% to 10%, moderate-to-vigorous intensity physical activity of $\geq 150$ min/wk, and upper and lower body resistance exercise 2 d/wk (Figure 2) are beneficial to reduce TG. <sup>6-10</sup> |

## Synopsis

Elevated TG-rich lipoproteins are associated with ASCVD events and contribute to ASCVD risk.<sup>11</sup> Lifestyle management represents the first line of therapy for the treatment of hypertriglyceridemia, with a more than 70% reduction in TG noted in highly responsive individuals.<sup>12,13</sup> Dietary strategies are a critical component of lifestyle management, complemented by physical activity and weight loss.<sup>13</sup> Recommended dietary patterns should not only reduce TG levels, but also have evidence for cardiovascular event reduction; preferred diets are predominantly plant based (Mediterranean, DASH, vegan/vegetarian) as recommended in the “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.”<sup>10,14</sup> Across these dietary approaches, limitation of simple carbohydrate content (particularly processed carbohydrates, including all added sugars) results in substantial TG lowering.<sup>2,13</sup> Although referral to a registered dietitian nutritionist (RDN) can be advantageous for all individuals with dyslipidemia, it is likely to be even more helpful in those with severe hypertriglyceridemia where more stringent dietary restrictions are needed.<sup>15</sup> In fact, studies have shown improved TG lowering with counseling by an RDN over standard of care.<sup>16</sup>

## Recommendation-Specific Supportive Text

1. Dietary recommendations for hypertriglyceridemia, which include limitation of added sugars, total fat, and alcohol, should be individualized based on magnitude of TG elevation and the clinical syndrome, as illustrated in Figure 2.<sup>13,17,18</sup> Supportive evidence also comes from the PREDIMED (Prevención con Dieta Mediterránea) trial, which showed a reduction in major adverse cardiovascular events

- (MACE) among primary prevention individuals at high ASCVD risk treated with a Mediterranean diet that was supplemented by either olive oil or nuts.<sup>1</sup>
2. With respect to diets for individuals with moderately elevated TG, liver-derived TG-rich lipoproteins are the predominant lipoprotein excess. In these individuals, very low carbohydrate diets lower TG more effectively than low carbohydrate diets ( $\sim 24$  mg/dL versus  $\sim 16$  mg/dL mean lowering), showing good efficacy even with a less restrictive low carbohydrate diet.<sup>2</sup> The type and quality of carbohydrate (ie, higher quality includes dietary fiber, whole grains, lower glycemic index, or glycemic load) can also influence the degree of TG lowering and health benefits.<sup>3</sup> Low glycemic index vegetables and fruits assist with lowering hypertriglyceridemia,<sup>13,19</sup> and at least 2 servings of fish per week (particularly fatty fish) is beneficial, along with lean proteins.<sup>13,20</sup> In controlled feeding trials carried out in adults, replacement of every 1% of energy from carbohydrates with monounsaturated fatty acids or polyunsaturated fatty acids reduced TG by  $\sim 1.7$  mg/dL (0.02 mmol/L) and 2.3 mg/dL (0.03 mmol/L).<sup>20</sup>
  3. Severely elevated TG levels (eg,  $\geq 1000$  mg/dL) are far less common, and when present, suggest intestinally derived chylomicron and chylomicron remnants in excess. The risk for acute pancreatitis is substantially increased at TG levels  $\geq 1000$  mg/dL.<sup>13</sup> Both low-fat and low-carbohydrate diets reduce TG levels in subjects with multifactorial chylomicronemia syndrome (MCS).<sup>5</sup> In FCS, patients have even less lipoprotein lipase functionality and limited ability to clear chylomicrons. Patients with FCS require more significant dietary fat restrictions to 10% to 15% of calories from fat or less to avoid pancreatitis, as well as the elimination of alcohol and added sugars.<sup>13</sup> To meet adequate daily nutrition and caloric requirements, the diet may need to be supplemented with fat-soluble vitamins, minerals, and medium-chain TG oil.<sup>21,22</sup> Specific recommendations should be individualized in these rare conditions, and supervision by a clinical lipid specialist and an RDN is encouraged.
  4. Hypertriglyceridemia is often related to a genetic predisposition (primarily polygenic, rarely monogenic); however, plasma levels are largely influenced by lifestyle and concomitant features of the CKM syndrome.<sup>13</sup> Reduction in alcohol, treatment of underlying overweight/obesity, diabetes, prediabetes, and insulin resistance, with an emphasis on glycemic control and improvement of insulin resistance can offer benefits.<sup>12,14</sup> Carbohydrate-induced hypertriglyceridemia may also be a culprit in those without genetic TG disorders,<sup>23</sup> with a need to focus on limiting processed carbohydrates for TG reduction. In those with elevated TG, more substantial reductions are noted with greater weight loss, but

with variable response.<sup>24</sup> In 1 large meta-analysis, per 1 kg of weight lost, TG were reduced by 4.0 mg/dL (95% CI, -5.24 to -2.77 mg/dL [-0.045 mmol/L, -0.059 to -0.031 mmol/L]) with lifestyle change (diet, exercise, or both).<sup>6,7</sup> As discussed in Section 4.1.4, “Physical Activity,” adequate physical activity (at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity, plus 2 days per week of upper and lower body resistance exercise)<sup>8,9,12,13</sup> is beneficial for TG lowering due to improvement of insulin sensitivity, maintenance of a healthy weight (after a 5%-10% weight loss), and direct effects on TG clearance.<sup>25</sup>

### 4.1.3. Attainment and Maintenance of Healthy Weight in People With Dyslipidemia

| Recommendation for Attainment and Maintenance of a Healthy Weight in Dyslipidemia       |      |   |
|---|------|---|
| Referenced studies that support the recommendation is summarized in the Evidence Table. |      |   |
| COR   | LOE  | Recommendation  |
| 1   | B-NR | 1. In individuals with overweight or obesity and dyslipidemia, counseling and treatment to achieve weight reduction and maintenance of a healthy weight are recommended to improve dyslipidemia. <sup>1-4</sup> |

### Synopsis

Obesity increases cardiovascular risk through worsening of CKM risk factors, inflammation, and adiposopathy (“sick fat”). The typical lipid profile of individuals with obesity often includes elevated TG, reduced HDL-C, and increased small cholesterol-depleted LDL particles. In the setting of obesity and CKM risk factors, non-HDL-C and apoB levels will more accurately reflect atherogenic risk than LDL-C.<sup>5</sup> Dietary patterns that are predominantly plant-based (Mediterranean, DASH, vegan/vegetarian) have the strongest evidence for LDL-C reduction<sup>6</sup> and for improvement in cardiovascular outcomes.<sup>7</sup> In contrast, dietary patterns that are lower in carbohydrates have been associated with greater weight and TG reduction.<sup>8</sup> Although ketogenic diets are associated with significant short-term weight and TG reduction, LDL-C can be increased substantially in some individuals, particularly when there is high consumption of animal products. This dietary approach is restrictive and can be difficult to sustain.<sup>9-11</sup> A comprehensive lifestyle approach, including physical activity, is most beneficial for weight reduction and improved metabolic and cardiovascular outcomes.<sup>1,12</sup>

### Recommendation-Specific Supportive Text

1. Weight reduction interventions to achieve ≥5% weight loss should be offered to all individuals with dyslipidemia and overweight or obesity. This should include lifestyle counseling and support

that is tailored to the patient's specific comorbidities, dietary and pharmacological preferences, and accessibility of interventions, with a plan for sustainability and consideration for consultation with an RDN (Section 4.1.6, “When to Refer to a Registered Dietitian Nutritionist”).<sup>13</sup> Medical and surgical therapies for weight reduction can achieve and sustain weight reduction and improve lipid profiles.<sup>5</sup> Weight reduction is typically associated with greater reductions in TG levels (~1.3-4.0 mg/dL/kg weight loss) and only modest LDL-C lowering (~0.3-1.7 mg/dL/kg weight loss).<sup>1,14</sup> The glucagon-like peptide-1 receptor agonists have evidence for improvement in cardiovascular outcomes along with a notable effect in lowering TG and LDL-C levels, which appears to be greater than other obesity pharmacotherapy, but generally proportional to weight loss.<sup>2-5</sup> Observational studies of patients undergoing metabolic bariatric surgery have demonstrated reductions in TG and LDL-C and cardiovascular outcomes benefit.<sup>1</sup> Although there is a substantial amount of data related to weight loss and the impact on lipoproteins, these are rarely the primary outcomes of the study, and it is difficult to isolate the exact impact of weight loss, dietary composition changes, and physical activity.



### 4.1.4. Physical Activity

| Recommendation for Physical Activity   |     |   |
|--|-----|---|
| Referenced studies that support the recommendation are summarized in the Evidence Table. |     |   |
| COR  | LOE | Recommendation  |
| 1  | B-R | 1. In individuals with dyslipidemia, regular physical activity that includes moderate-to-vigorous intensity aerobic exercise for ≥150 min/wk along with upper and lower body resistance exercise 2 d/wk should be recommended as part of a program to improve blood lipids and cardiovascular health. <sup>10,15,24</sup> |

### Synopsis

Physical activity is the cornerstone of a healthy lifestyle, ideal cardiovascular health, and CKM risk factor management, including dyslipidemia.<sup>1-3</sup> The benefits of physical activity include CVD prevention (from primordial to secondary) and reductions in cardiovascular and all-cause mortality.<sup>1,4,5</sup> Individuals with dyslipidemia are less likely to meet guideline-recommended levels of aerobic and resistance (muscle-strengthening) physical activity compared with those without dyslipidemia.<sup>6,7</sup> Meta-analyses<sup>8-10</sup> have shown favorable effects of several exercise types (eg, walking, aerobic, resistance, aquatic)<sup>10,11</sup> on lipids and lipoproteins<sup>12</sup> across various populations (healthy adults, older adults, women across the life course, and those with CKM conditions).<sup>13,14</sup> Physical activity has favorable effects on blood lipids, with a tendency toward higher HDL-C, lower TG, and less consistently lower LDL-C.<sup>10,15,16</sup> To maximize

these benefits of physical activity, multi-level strategies are required in health care and community settings. Assessing physical activity as a “vital sign” at each patient encounter, with subsequent prescription/counseling and appropriate referrals, may promote long-term sustainability and health behavioral support.<sup>1,17,18</sup> Clinicians should use reliable physical activity assessment tools to promote physical activity while accounting for patients’ personal preferences, practicality, and social determinants (eg, social/structural barriers and facilitators).<sup>4,18,19</sup>

### Recommendation-Specific Supportive Text

1. Aerobic and resistance training have a modest effect on lipids with potential dose responses.<sup>5,10,15,16,20–23</sup> A meta-analysis of 148 RCTs of exercise training interventions (in adults whose dyslipidemia status was unknown) found significant improvements in lipids, with an increase in HDL-C (2.11 mg/dL [95% CI, 1.43-2.79 mg/dL], 0.024 mmol/L [95% CI, 0.016 to 0.032 mmol/L]), a decrease in LDL-C (−7.22 mg/dL [95% CI, −9.08 to 5.35 mg/dL], −0.187 mmol/L [95% CI, −0.235 to −0.138 mmol/L]), and a decrease in TG (−8.01 mg/dL [95% CI, −10.45 to −5.58], −0.090 mmol/L [95% CI, −0.118 to −0.063]).<sup>10</sup> These improvements in lipid profiles have been observed in middle-aged and older adults<sup>13,14,24,25</sup> and individuals with diabetes and obesity.<sup>11,26</sup> Changes in lipids in response to exercise may depend on baseline levels, fitness level, and exercise duration (versus intensity) parameters.<sup>15,23,27</sup> Adults should aim for ≥150 minutes of moderate-intensity or 75 to 150 minutes of vigorous-intensity aerobic physical activity per week or an equivalent combination of moderate- and vigorous-intensity aerobic activity supplemented with resistance exercise (≥2 days/week).<sup>1</sup> This guidance is aligned directly with federal recommendations and endorsed by the AHA Life’s Essential 8™.<sup>2,28</sup> Physical activity may be an adjunct to lipid-lowering medications and result in additional cardiovascular benefit.<sup>20,29,30</sup> Combining physical activity and healthy diet as a part of comprehensive lifestyle management helps improve lipid profiles.<sup>27,31,32</sup> Validated, person-centered physical activity assessment resources, including wearable devices, may assist clinicians and their patients with individualization of physical activity goals and strategies.<sup>4,17,33–35</sup>

#### 4.1.5. Dietary Supplements

**Recommendation for Dietary Supplements**  
Referenced studies that support the recommendation are summarized in the Evidence Table.

| COR                  | LOE        | Recommendation   |
|----------------------|------------|--|
| <b>3: No Benefit</b> | <b>B-R</b> | 1. In individuals with dyslipidemia, the use of dietary supplements is not recommended to lower LDL-C or TG based on limited and inconsistent data and/or limited benefits in lipid-lowering and reduction in ASCVD risk. <sup>1–4</sup> |

### Synopsis

There has been a steady increase in the reported use of dietary supplements to prevent chronic disease. A National Health and Nutrition Examination Survey (NHANES) analysis from 2017 to March 2020 in individuals with ASCVD reported that 73% of participants were taking at least 1 dietary supplement, with almost one-fifth reporting taking 1 supplement “for heart health.”<sup>5</sup> The US Dietary Supplement Health and Education Act of 1994 defines a dietary supplement as a product that is taken by mouth and contains ≥1 dietary ingredients meant to supplement the diet and not to be used as a conventional food or sole diet item; examples of dietary supplements include vitamins, minerals, herbs, amino acids, and enzymes.<sup>6</sup> A number of dietary supplements targeting cholesterol lowering have been evaluated in small RCTs with limited and inconsistent findings. One RCT compared the impact of rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice on lipid markers.<sup>3</sup> None of the supplements demonstrated a significant decrease in LDL-C compared with placebo. There is value to clinicians providing patient education on the inconsistent and limited evidence for benefit with dietary supplements to reduce the risk of ASCVD.



### Recommendation-Specific Supportive Text

1. The use of dietary supplements for lipid lowering and heart health continues to increase, both with and without coadministered US Food and Drug Administration (FDA)-approved LLT.<sup>5</sup> There is a common perception that dietary supplements are safer than FDA-approved medications, but regulation of supplements is much less stringent, with fewer requirements for safety, efficacy, and manufacturing quality.<sup>6</sup> Fish oil is commonly taken for perceived effects on lipid lowering, with trials and guidelines recommending against nonprescription fish oils because these products have not demonstrated clinical benefit in patients with hypertriglyceridemia or ASCVD.<sup>7–10</sup> Potential adverse effects can arise with fish oil consumption, especially an increase in LDL-C and an increased risk of atrial fibrillation.<sup>4</sup> Agents such as berberine, garlic/onion, turmeric, and red yeast rice have been associated with modest reductions in TC and LDL-C, while cinnamon showed no significant cholesterol lowering, but results are inconsistent across trials.<sup>1,2,11–13</sup> The SPORT (Supplements, Placebo, or Rosuvastatin Trial) randomized adults without established ASCVD who had LDL-C levels between 70 and 189 mg/dL and a 10-year ASCVD risk based on the PCE of 5% to 20% into 1 of 3 groups: rosuvastatin 5 mg daily, 1 of 6 commonly used dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast

rice), or a placebo to assess their impact on lipid markers.<sup>3</sup> Rosuvastatin showed an LDL-C reduction of 37.9% (95% CI, -42.1 to -33.6), which was superior to supplements or placebo ( $P<0.001$ ).<sup>3</sup> In contrast, when using a hierarchical statistical testing approach, the dietary supplements (in the doses studied) did not demonstrate a significant decrease in LDL-C compared with placebo.

#### 4.1.6. When to Refer to a Registered Dietitian Nutritionist

| Recommendations for When to Refer to a Registered Dietitian Nutritionist              |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. In individuals with fasting TG $\geq 1000$ mg/dL (11.3 mmol/L), referral to an RDN is recommended to create an individualized treatment plan aimed at reducing TG and the risk of pancreatitis. <sup>1</sup>  |
| 2a  | B-NR | 2. In individuals with fasting TG $\geq 150$ to 999 mg/dL ( $\geq 1.7$ –11.3 mmol/L) and features of the CKM syndrome, referral to an RDN to provide counseling on evidence-based dietary patterns can be beneficial to improve lipoprotein levels and reduce the risk of pancreatitis. <sup>2–4</sup> |

#### Synopsis

Medical nutrition therapy provided by an RDN is helpful in lipid lowering and can be cost-effective in the management of dyslipidemia, mainly due to a reduction of the burden of pharmacotherapy.<sup>4,5</sup> RDN counseling sessions are generally only covered by Medicare for patients with diabetes or CKD and selectively for conditions such as dyslipidemia, depending on the patient's insurance plan.<sup>6</sup> Broader coverage for medical nutrition therapy provided by RDNs could provide access to cost-effective lifetime behavior change that can significantly impact the management of patients with dyslipidemias.

#### Recommendation-Specific Supportive Text

1. In patients with TG  $\geq 1000$  mg/dL (11.3 mmol/L), tailored medical nutrition therapy is of paramount importance, particularly in the presence of FCS or MCS.<sup>7</sup> At TG levels  $\geq 500$  to 700 mg/dL (5.7–7.9 mmol/L), the capacity of the enzyme lipoprotein lipase to hydrolyze fatty acids from TG-rich lipoproteins (chylomicrons, VLDL) becomes saturated, leading to chylomicronemia and increased risk of pancreatitis.<sup>8,9</sup> In addition to addressing potential secondary causes of hypertriglyceridemia and physical activity, treatment of chylomicronemia should include elimination of alcohol, elimination of added sugars, and very limited total fat intake (10%–15% of calories from fat) until chylomicrons are cleared and TG levels significantly improve.<sup>7</sup> The value of an RDN in the management of patients

with hypertriglyceridemia is even greater when TG are  $\geq 1000$  mg/dL (11.3 mmol/L) based on the potential to reduce the high risk of pancreatitis.<sup>1</sup> The design of a specific eating plan with potential use of medium-chain TG oil in select patients to achieve adequate caloric intake requires assessment and counseling beyond the expertise of most clinicians.<sup>10</sup>

2. Medical nutrition therapy provided by an RDN is a core component of dietary education and nutrition interventions with both clinical efficacy and cost-effectiveness for the improvement of dyslipidemias and CKM syndrome. Risk factor optimization and long-term adherence have been tied to a greater number of sessions completed with an RDN.<sup>3</sup> A large meta-analysis, comparing medical nutrition therapy provided by RDNs versus usual care, showed improvement in TC (mean difference, -20.8 mg/dL [95% CI, -40.6 to -1.1 mg/dL];  $P=0.04$ ); LDL-C (-11.6 mg/dL [95% CI, -21.1 to -2.0 mg/dL];  $P=0.02$ ), and TG levels (-32.6 mg/dL [95% CI, -57.8 to -7.3 mg/dL];  $P=0.01$ ). In adults with hypertriglyceridemia, dietary advice should be individualized to the patient's TG levels, clinical syndrome, and personal dietary preferences.<sup>1</sup> Observational data in patients with severe hypertriglyceridemia with a mean TG level of  $\geq 500$  mg/dL (5.6 mmol/L) show the benefit of reducing TG with medical nutrition therapy provided by an RDN with reductions noted both independently and in conjunction with medical therapy.<sup>1,3</sup>

## 4.2. Medical Management

### 4.2.1. Pharmacological Therapy

#### Synopsis

Lipid-lowering medications are an integral component of optimal treatment of adults with elevated ASCVD risk. Numerous cardiovascular outcome trials (CVOT) have demonstrated safety, tolerability, and efficacy for both LDL-C lowering and ASCVD risk reduction, justifying statins as the cornerstone of pharmacotherapy to lower LDL-C and risk of ASCVD events.<sup>1</sup> Nonstatin medications that lower LDL-C and apoB have evolved from oral agents, with modest effects to more potent subcutaneously administered options. TG-lowering medications are used to manage severe hypertriglyceridemia and mitigate risk of acute pancreatitis. Although some TG-lowering medications (ie, fibrates, niacin) may have small LDL-C-lowering or raising effects, RCTs do not support their use as add-on treatment to statin therapy for ASCVD risk reduction due to a lack of proven ASCVD event lowering.<sup>2</sup> Icosapent ethyl (IPE) is the only primary TG-lowering medication that reduces ASCVD event risk in combination with statin therapy in individuals at high risk of ASCVD with moderate TG elevations after achieving sufficient LDL-C lowering.<sup>3</sup> Of note, cardiovascular

**Table 5. Characteristics of Common Lipid-Lowering Medications to Treat Dyslipidemia\***

| Class                                      | Mechanism of Action  | Medications    | Typical Dose Range   | Dosing Frequency   | Comments†  |
|--|--|----------------|----------------------|--|--|
| <b>LDL-C-Lowering Medications</b>          |  |                |                      |  |  |
| HMG-CoA reductase inhibitors (aka statins) | Competitively inhibits HMG-CoA reductase (rate-limiting step of endogenous cholesterol production); increases LDL receptor expression on the surface of hepatocytes  | Atorvastatin   | 10–80 mg             | Once daily   | <p>Oral agents</p> <p>First-line therapy for ASCVD risk reduction in nearly all patients</p> <p>Extensive CVOT evidence demonstrates reductions in events over wide range of LDL-C levels in primary and secondary prevention</p> <p>Expected LDL-C reduction: 18%–55%‡</p> <p>Atorvastatin and rosuvastatin can achieve high-intensity LDL-C reductions and are preferred for patients at high/very high ASCVD risk</p> <p>Atorvastatin, pitavastatin, and rosuvastatin have long half-lives that enable dosing any time of the day</p> |
|  |  | Fluvastatin    | 20–80 mg             | Once or twice daily  |  |
|  |  | Lovastatin     | 10–80 mg             | Once or twice daily  |  |
|  |  | Pitavastatin   | 1–4 mg               | Once daily   |  |
|  |  | Pravastatin    | 10–80 mg             | Once daily   |  |
|  |  | Rosuvastatin   | 5–40 mg              | Once daily   |  |
|  |  | Simvastatin    | 5–40 mg              | Once daily   |  |
| Cholesterol absorption inhibitor           | Blocks the sterol transporter protein, NPC1L1, to inhibit intestinal and biliary sterol absorption; increases LDL receptor expression on the surface of hepatocytes secondary to reduced hepatic sterol levels   | Ezetimibe      | 10 mg                | Once daily   | <p>Oral agent</p> <p>CVOT evidence demonstrates reductions in cardiovascular events in very high-risk secondary prevention in combination with a moderate-intensity statin therapy</p> <p>Expected LDL-C reduction: monotherapy, 18%; combination with a statin, 25% incremental reduction‡</p> <p>Drug of choice in sitosterolemia to reduce elevated sitosterol and campesterol</p>  |
| PCSK9 inhibitor: monoclonal antibodies     | Fully human monoclonal antibodies: binds to PCSK9 in the circulation and decreases degradation of LDL receptors  | Alirocumab     | 75–150 mg, or 300 mg | Every 2 wk<br>Every 4 wk   | <p>Subcutaneous agents</p> <p>CVOT evidence demonstrates reductions in cardiovascular events in very high-risk secondary prevention in combination with a maximally tolerated statin therapy</p> <p>Expected LDL-C reduction: 45%–64%‡</p> <p>Lower mean LDL-C reduction (21%–31%) in homozygous FH due to <i>LDLR</i> gene variants<sup>4,5</sup></p>   |
|  |  | Evolocumab     | 140 mg               | Every 2 wk   |  |
| ATP citrate lyase inhibitor                | Inhibits ATP citrate lyase in the liver to decrease cholesterol production upstream of HMG-Co reductase in the cholesterol synthesis pathway; increases LDL receptor expression on the surface of hepatocytes  | Bempedoic acid | 180 mg               | Once daily   | <p>Oral agent</p> <p>CVOT evidence demonstrating reductions in cardiovascular events in individuals treated for high-risk primary and secondary prevention with statin-attributed side effects</p> <p>Prodrug that is activated by very long-chain acyl-CoA synthetase, found primarily in the liver</p> <p>Expected LDL-C reduction: monotherapy in patients with statin-attributed side effects, 21%–24%<sup>6,7</sup> combination with a statin, 17%–18%‡</p>   |
| PCSK9 inhibitor: small interfering RNA     | Utilizes endogenous RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9 and decreases degradation of the LDL receptor   | Inclisiran     | 284 mg               | Initial dose followed by second dose in 3 mo, then every 6 mo thereafter | <p>Subcutaneous agent administered by a health care professional</p> <p>Expected LDL-C reduction: 48%–52%‡</p> <p>CVOT in progress</p>   |
| Bile acid sequestrants                     | Bind bile acids in the gut, interrupt enterohepatic recirculation of bile acids and impede their reabsorption, decrease bile acid pooling in the liver, increase conversion of cholesterol to bile acids; increase LDL receptor expression on the surface of hepatocytes | Cholestyramine | 8–16 g               | Once or twice daily  | <p>Oral agents</p> <p>CVOT evidence from 1 trial demonstrating cardiovascular event reduction in primary prevention men as monotherapy</p> <p>Nonsystemic, add-on to statin therapy or in patients with statin-intolerance</p> <p>Expected LDL-C reduction: 10%–27%‡</p> <p>Gastrointestinal side effects may limit use</p> <p>Both LDL-C lowering and incidence of side effects are dose related</p> <p>May increase serum TG levels; avoid if TG ≥300 mg/dL</p>  |
|  |  | Colesevelam    | 3.75 mg              | Once or twice daily  |  |
|  |  | Colestipol     | 2–16 g               | Once or multiple times daily   |  |

(Continued)

**Table 5. Continued**

| Class   | Mechanism of Action   | Medications               | Typical Dose Range  | Dosing Frequency              | Comments†  |
|---|---|---------------------------|---------------------|-------------------------------|--|
| <b>LDL-C-Lowering Medications Approved Only in HoFH</b> |   |                           |                     |                               |  |
| Microsomal TG transfer protein inhibitor                | Binds and inhibits microsomal TG transfer protein, which is essential for the assembly of apoB-containing lipoproteins, and inhibiting synthesis of chylomicrons and VLDL, which lowers LDL-C | Lomitapide                | 5–60 mg             | Once daily                    | <p>Oral agent</p> <p>Expected LDL-C reduction: 40%–50%‡</p> <p>Only available through a restricted program; several adverse reactions (including hepatotoxicity due to hepatic steatosis exacerbated by concomitant ethanol intake, as well as steatorrhea) and drug-drug interactions</p> <p>Daily vitamin E, linoleic acid, alpha-linolenic acid, EPA, and DHA supplements are needed to mitigate reduced absorption of fat-soluble vitamins/fatty acids</p> <p>Multiple potential drug interactions associated with CYP3A4 metabolism</p>   |
| ANGPTL3 inhibitor                                       | Fully human monoclonal antibody that binds to and inhibits ANGPTL3; ANGPTL3 inhibition enhances remnant lipoprotein clearance, reducing VLDL remnants and their conversion into LDL particles | Evinacumab-dgnb           | 15 mg/kg every 4 wk |                               | <p>Intravenously administered agent</p> <p>Works through an LDL receptor-independent pathway</p> <p>Expected LDL-C reduction: 49%‡</p>   |
| <b>Triglyceride-Lowering Medications</b>                |   |                           |                     |                               |  |
| Fibrates  | Stimulates PPAR-alpha, which activates lipoprotein lipase and reduces apolipoprotein C-III production; increases lipolysis and elimination of TG-rich particles                               | Fenofibrate               | 40–200 mg           | Once daily                    | <p>Oral agents</p> <p>CVOTs show no reduction in cardiovascular events when fenofibrate is added to statin therapy in primary prevention patients with diabetes; CVOT evidence demonstrating reductions in cardiovascular events in primary and secondary prevention patients with gemfibrozil monotherapy</p> <p>First-line option for severe hypertriglyceridemia (<math>\geq 500</math> mg/dL, especially when <math>\geq 1000</math> mg/dL)</p> <p>Expected TG reduction: 30%–50%‡</p> <p>Many different formulations of fenofibrate and fenofibric acid are available with varied dosages</p> <p>Dose may need to be reduced in decreased kidney function; avoid in severe kidney dysfunction</p> <p>Blunted to no TG reduction in patients with familial chylomicronemia syndrome due to reduced lipoprotein lipase activity<sup>8</sup></p> <p>Gemfibrozil should not be combined with statin therapy because of serious potential drug interaction</p> |
|   |   | Fenofibric acid           | 35–135 mg           | Once daily                    |  |
|   |   | Gemfibrozil               | 600 mg              | Twice daily                   |  |
| Omega-3 fatty acids                                     | Reduces hepatic VLDL TG synthesis and/or secretion; enhances TG clearance from circulating VLDL; other mechanisms are possible  | Icosapent ethyl           | 4 g                 | Twice daily with food         | <p>Oral agents</p> <p>First-line option for severe (<math>\geq 500</math> mg/dL) hypertriglyceridemia</p> <p>CVOT evidence demonstrating reductions in cardiovascular events with icosapent ethyl in individuals being treated for primary prevention of ASCVD patients with type 2 diabetes or secondary prevention if TG between 150–499 mg/dL and LDL-C is 41–100 mg/dL despite statin therapy</p> <p>Expected TG reduction: 15%–61%‡</p> <p>Icosapent ethyl contains EPA only</p> <p>Omega-3 acid ethyl esters contain DHA and EPA, which can modestly raise LDL-C (but not apoB)</p> <p>Nonprescription fish oil supplements are not equivalent to, or considered prescription medications, and have variable fatty acid content</p> <p>Give with a fat-containing meal to ensure absorption (pancreatic lipase stimulation breaks ethyl bonds to facilitate absorption)</p>  |
|   |   | Omega-3 acid ethyl esters | 4 g                 | Once or twice daily with food |  |

(Continued)

**Table 5. Continued**

| Class                                    | Mechanism of Action  | Medications              | Typical Dose Range | Dosing Frequency       | Comments†  |
|--|--|--------------------------|--------------------|------------------------|--|
| Niacin                                   | Reduces esterification of hepatic TG, decreases release of free fatty acids from adipose tissue and increases activity of lipoprotein lipase to enhance removal of TG-rich lipoprotein fatty acids | Extended-release niacin  | 500–2000 mg        | Once daily             | Oral agents<br>CVOTs show no reduction in cardiovascular events when added to statin therapy in individuals being treated for secondary prevention of ASCVD<br>Last-line agent for severe hypertriglyceridemia due to relatively high risk of intolerable side effects; must initiate low dose to minimize side effects and slowly titrate up to an effective dose<br>Expected TG reduction: sustained-release, 10%–30%; immediate-release 20%–50%‡<br>Increases insulin resistance, high rates of skin flushing, and significant hepatotoxicity |
|  |  | Immediate-release niacin | 250–6000 mg        | Twice to 3 times daily |  |
| ApoC-III inhibitor: ASO directed therapy | Binds to and degrades apoC-III mRNA; reduces the apoC-III protein, leading to increased clearance of plasma TG and VLDL  | Olezarsen                | 80 mg              | Once monthly           | Subcutaneous agent<br>Only approved for familial chylomicronemia syndrome<br>Expected TG reduction in familial chylomicronemia syndrome: 30% (placebo-corrected is 42.5%)‡   |

\*Dosages and administration from FDA-approved labeling.<sup>9</sup>

†Adverse effects are discussed in Section 5.1, “Medication Safety and Therapy-Associated Side Effects.”

‡Expected lipid-lowering based on estimations from the “2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk,”<sup>10</sup> the “2019 AHA Science Advisory,”<sup>11</sup> or product labeling.<sup>9</sup>

ANGPTL3 indicates angiotensin-like protein 3; ApoC-III, apolipoprotein C-III; ASO, antisense oligonucleotide; ATP, adenosine triphosphate; CVOT, cardiovascular outcome trial; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FH, familial hypercholesterolemia; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme; mRNA, messenger ribonucleic acid; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, proprotein convertase subtilisin/kexin type 9; PPAR- $\alpha$ , peroxisome proliferator-activated receptor- $\alpha$ ; RNA, ribonucleic acid; TG, triglycerides; VLDL, very-low density lipoprotein; and XL, extended release.

benefits were not related to the degree of TG lowering. Characteristics of dyslipidemia medications are summarized in Table 5.

#### 4.2.1.1. Statins

##### Synopsis

Statins have been categorized based on the expected percent reduction in LDL-C as observed in clinical trials.<sup>1</sup> High-intensity statin therapy is expected to lower LDL-C levels by  $\geq 50\%$ , moderate-intensity statin therapy by  $\geq 30\%$  to 49%, and low-intensity statin therapy by  $< 30\%$  (Table 6). In addition to the expected percentage LDL-C reduction, the absolute achieved LDL-C level is also an objective goal of therapy. The magnitude of LDL-C lowering will vary in clinical practice based on the patient population and adherence.<sup>2</sup> Certain populations (especially East Asian ancestry) may be more prone to side effects due to inherited drug metabolism effects; thus, initial treatment should be with lower doses.<sup>3</sup>

Pharmacokinetic profiles among statins are heterogeneous (Table 7), and statin safety has been extensively evaluated.<sup>4</sup> In individuals for whom statin treatment is recommended in this guideline, the benefits of reducing ASCVD events greatly outweigh the risks.<sup>5</sup> Medication safety and therapy-associated side effects are discussed in Section 5.1, “Medication Safety and Therapy-Associated Side Effects.” Common medications that may interact with statins are listed in Table 8. Interactions may not occur with all statins; some are statin and/or dose specific.<sup>6</sup> A clinician tool to assist with managing statin

drug–drug interactions (DDI) is available in the ACC Statin Intolerance Tool (Lipid Manager App).<sup>7</sup>

#### 4.2.1.2. Nonstatin LDL-C-Lowering Medications

##### Synopsis

Nonstatin medications may be needed in addition to statin therapy to further lower LDL-C or as an alternative treatment for patients with statin intolerance.<sup>1,2</sup> Several oral and subcutaneous nonstatin medications are available. Ezetimibe lowers LDL-C levels by a mean of 18% (25% incremental reduction when added to statin therapy) and has a low incidence of side effects.<sup>3,4</sup> Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are potent LDL-C-lowering medications. PCSK9 monoclonal antibodies (mAbs) can lower LDL-C by 45% to 64%, are well tolerated and safe,<sup>5,6</sup> and reduce ASCVD events in patients at very-high risk when added to statin therapy.<sup>7,8</sup> Inclisiran, a small-interfering ribonucleic acid (RNA)-based PCSK9i, lowers LDL-C by 48% to 52%, and is well tolerated with several CVOT currently in progress.<sup>9</sup> Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, lowers LDL-C by 21% to 24% as monotherapy in patients with statin-attributed side effects, and by an additional 17% to 18% in combination with a maximally tolerated statin (although studies of bempedoic acid added to full-dose high-intensity statin are lacking).<sup>10,11</sup> Bile acid sequestrants are not absorbed and do not cause systemic side effects. However, gastrointestinal complaints and DDI limit their use.

Nonstatins in combination with low- or moderate-intensity statin therapy can produce  $\geq 50\%$  LDL-C reduc-

**Table 6. High-, Moderate-, and Low-Intensity Statin Therapy\***

|                                    | High-Intensity   | Moderate-Intensity   | Low-Intensity  |
|------------------------------------|--|--|--|
| <b>Expected % LDL-C Reduction†</b> | ≥50%   | 30%–49%  | <30%   |
| <b>Preferred Statins</b>           | <b>Atorvastatin (40 mg) 80 mg</b><br><b>Rosuvastatin 20 mg (40 mg)</b> | <b>Atorvastatin 10 mg (20 mg)</b><br><b>Rosuvastatin (5 mg) 10 mg</b>  |  |
| <b>Other Statins</b>               | –  | Fluvastatin XL 80 mg<br><b>Fluvastatin 40 mg BID</b><br><b>Lovastatin 40 mg (80 mg)</b><br><b>Pitavastatin 1, 2, 4 mg</b><br><b>Pravastatin 40 mg (80 mg)</b><br><b>Simvastatin 20, 40 mg‡</b> | Fluvastatin 20, 40 mg<br><b>Lovastatin 20 mg</b><br>Pravastatin 10, 20 mg<br>Simvastatin 10 mg |

Expected percentage LDL-C reductions with atorvastatin, rosuvastatin, and simvastatin were estimated using the median reduction in LDL-C from the VOYAGER database.<sup>2</sup> Reductions in LDL-C for other statins (fluvastatin, lovastatin, pitavastatin, and pravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia.<sup>9</sup> **Boldface type** indicates specific statins and doses that were evaluated in placebo-controlled RCTs evaluating ASCVD event lowering,<sup>10–19</sup> and the Cholesterol Treatment Trialists' 2010 meta-analysis.<sup>20</sup> These RCTs demonstrated a reduction in major ASCVD events. Modified with permission from Grundy et al.<sup>1</sup> Copyright 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

\*Expected percentage reductions are estimates from data across large populations. Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice owing to a high degree of heterogeneity seen with LDL-C-lowering medications.<sup>2</sup>

†Expected LDL-C lowering with the dosage listed below each intensity.

‡Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.<sup>9</sup>

BID indicates twice daily; FDA, US Food and Drug Administration; LDL-C, low-density lipoprotein-cholesterol; RCT, randomized controlled trial; and XL, extended release.

tions. Nonstatins remain underutilized<sup>12–14</sup> due to clinical inertia, misconceptions that only statin therapy reduces ASCVD risk, medication access barriers for brand-name products, concerns about potential side effects, and perceived lack of need by clinicians and patients.<sup>15–17</sup>

#### 4.2.1.3. TG-Lowering Medications

##### Synopsis

TG-lowering medications are used to treat severe hypertriglyceridemia (≥500 mg/dL) to reduce the risk of acute pancreatitis and include prescription omega-3 fatty acids, fibrates, and others.<sup>1</sup> Prescription omega-3 fatty acids are highly purified and contain either eicosapentaenoic acid (EPA) monotherapy or docosahexaenoic acid (DHA) in combination with EPA. Gemfibrozil should not be used in combination with a statin due to an increased risk of muscle-related adverse effects; fenofibrate or fenofibric acid are safer options (Section

5.1, “Medication Safety and Therapy-Associated Side Effects”). Olezarsen is a novel antisense oligonucleotide-based apoC-III inhibitor that is approved for FCS. Niacin should generally be avoided due to poor tolerability and adverse effects when used with or without statin therapy.<sup>2</sup> Characteristics of TG-lowering drugs are summarized in Table 5.

Non-HDL-C and apoB reduction are better therapeutic targets for ASCVD risk mitigation in adults with hypertriglyceridemia. Neither fibrates nor niacin are recommended for routine use due to lack of proven reductions in ASCVD events when added to statin therapy.<sup>3–6</sup> Statin therapy lowers TG 10% to 30% in a dose-dependent manner and lowers ASCVD risk in patients with hypertriglyceridemia. Given the breadth of CVOT evidence, statins remain first-line therapy for patients with TG ≥500 mg/dL to reduce ASCVD risk even though they reduce TG less than fibrates or omega-3 fatty acids.<sup>1</sup>

#### 4.2.2. Referring to a Clinical Lipid Specialist

##### Synopsis

Management of dyslipidemias has become increasingly complex due to lower treatment targets for atherogenic lipoproteins, an evolution from a statin-monotherapy approach to combination therapy with multiple agents targeting different aspects of lipid metabolism, as well as the availability of genetic testing to confirm complex inherited lipid disorders. Although standard treatment algorithms can be implemented in most clinical care settings for the majority of patients, individuals with familial lipid disorders, very high levels of atherogenic lipoproteins or TG, or difficulty tolerating lipid-lowering agents may benefit from referral to a lipid specialist for further management.<sup>1–3</sup> A lipid specialist should be an expert in comprehensive risk reduction, as addressing lipid-related risk is one component of cardiovascular disease prevention. Considerations for referral are summarized in Table 9.

#### 4.2.3. Primary Prevention in Adults

##### Synopsis

Primary prevention of ASCVD over the lifespan requires attention to prevention or management of ASCVD risk factors beginning early in life. A major determinant of future ASCVD is elevated levels of atherogenic lipoproteins, with cumulative lifetime exposure closely associated with the likelihood of ASCVD events.<sup>1–6</sup> In younger adults, priority should be given to estimation of lifetime risk and promotion of health behavior modification. Statin therapy is the recommended initial drug choice for primary prevention based on safety, tolerability, efficacy, cost-effectiveness, and the wealth of evidence for ASCVD risk reduction, with additional therapies available to attain optimal LDL-C-lowering as an adjunct to statin therapy.<sup>7</sup> In addition to the general category of adults 30 to 79 years of age, other major risk categories in primary prevention include patients with severe hypercholesterolemia (LDL-C

**Table 7. Pharmacokinetic Properties of Statin Medications**

|              | Absorption           |          | Distribution        |                       | Metabolism           |           |                   | Elimination         |           |
|--------------|----------------------|----------|---------------------|-----------------------|----------------------|-----------|-------------------|---------------------|-----------|
|              | Bio-availability (%) | Tmax (h) | Protein Binding (%) | Lipophilicity (log P) | CYP Hepatic Enzyme   | Pro- Drug | Active Metabolite | Renal Excretion (%) | t1/2 (hr) |
| Atorvastatin | 14                   | 1–2      | ≥98                 | Yes, 4.1              | 3A4                  | No        | Yes               | <2                  | 14        |
| Fluvastatin  | 24                   | <1       | 98                  | Yes, 3.2              | 2C9 (2C8, 3A4 minor) | No        | No                | 5                   | 3         |
| Lovastatin   | <5                   | 2–4      | ≥95                 | Yes, 4.3              | 3A4                  | Yes       | Yes               | 10                  | 2–3       |
| Pitavastatin | 43–51                | 1        | 99                  | Yes, 1.5              | 2C9 (2C8 minor)      | No        | No                | 15                  | 12        |
| Pravastatin  | 17                   | 1–1.5    | 50                  | No, -0.2              | None                 | No        | No                | 20                  | 1.8       |
| Rosuvastatin | 20                   | 3–5      | 88                  | No, -0.3              | 2C9                  | No        | Minimal           | 10                  | 19        |
| Simvastatin  | <5                   | 4        | 95                  | Yes, 4.7              | 3A4                  | Yes       | Yes               | 13                  | 2         |

Atorvastatin, lovastatin, and simvastatin are P-glycoprotein substrates and may be subject to certain drug–drug interactions. Modified with permission from Wiggins et al.<sup>6</sup> © 2016 American Heart Association, Inc.

CYP indicates cytochrome P450; h, hour; Tmax, time until maximum serum concentration achieved; and t1/2, drug half-life.

levels ≥190 mg/dL [4.9 mmol/L]) and adults with diabetes. Patients with severe hypercholesterolemia and adults with diabetes (Section 4.2.5, “Diabetes in Adults Without Established ASCVD”) are candidates for statin therapy. In other adults 30 to 79 years of age, 10-year ASCVD risk assessed with the PREVENT-ASCVD equations should guide therapeutic decisions along with consideration of long-term exposure to elevated atherogenic lipoproteins. The risk discussion should also consider risk enhancers,

reproductive age risk markers, CAC, or possibly polygenic risk scores (PRS) in the future that can favor initiation or intensification of LLT. However, the age of the patient and

**Table 8. Common Medications That May Interact With Statins**

| Avoid use with any statin                 | Can be used with a statin using a risk mitigation strategy* |                             |
|---|---|-----------------------------|
| Gemfibrozil                               | Amiodarone  | Ketoconazole                |
|   | Amlodipine  | Lomitapide                  |
|   | Atazanavir plus ritonavir                                   | Lopinavir plus ritonavir    |
|   | Boceprevir  | Nefazodone                  |
|   | Clarithromycin  | Nelfinavir                  |
|   | Cobicistat-containing products                              | Niacin (≥1 g/d)             |
|   | Colchicine  | Nirmatrelvir plus ritonavir |
|   | Cyclosporine  | Posaconazole                |
|   | Danazol   | Ranolazine                  |
|   | Darunavir plus ritonavir                                    | Rifampin                    |
|   | Diltiazem   | Saquinavir plus ritonavir   |
|   | Dronedarone   | Telaprevir                  |
|   | Erythromycin  | Telithromycin               |
|   | Fenofibrate   | Tipranavir plus ritonavir   |
|   | Fenofibric acid   | Verapamil                   |
|   | Fluconazole   | Voriconazole                |
| Fosamprenavir (with or without ritonavir) | Warfarin  |                             |
| Itraconazole                              |   |                             |

\*Risk mitigation strategies include a) avoiding use of the coadministered interacting medication; b) using an alternative statin that does not have the drug–drug interaction; and c) limiting the statin dose depending upon the statin and the nature of the drug–drug interaction. Modified with permission from Wiggins et al.<sup>6</sup> © 2016 American Heart Association, Inc.

**Table 9. Considerations for Referral to a Lipid Specialist\***

|   |
|---|
| Patients with diagnosed or suspected FH   |
| Patients with homozygous FH   |
| Patients with heterozygous FH who do not achieve treatment targets on maximally tolerated statin plus nonstatin therapy                         |
| Patients with heterozygous FH with statin-attributed side effects on ≥2 statins, including at the lowest dose or with alternate dosing regimens |
| Patients with ASCVD or at high risk of ASCVD  |
| Patients with premature ASCVD (onset age <40 y)   |
| Patients who do not achieve ≥50% LDL-C reduction and LDL-C (or non-HDL-C) targets on maximally tolerated statin plus nonstatin therapy          |
| Patients with statin-attributed side effects on ≥2 statins, including at the lowest dose or with alternate dosing regimens                      |
| Patients who have elevated Lp(a) (≥200 nmol/L or ≥75 mg/dL)   |
| Patients <40 y old with diabetes and dyslipidemia   |
| Patients at high risk for ASCVD or with ASCVD who are on complex medication regimens  |
| Patients receiving treatment for HIV  |
| Patients receiving treatment for cancer   |
| Patients receiving treatments to prevent transplant rejection   |
| Individuals who are considering pregnancy, are pregnant, or are breastfeeding   |
| Patients with heterozygous FH   |
| Patients with hypertriglyceridemia (TG ≥400 mg/dL)  |
| Patients with ASCVD or at high risk of ASCVD requiring LLT  |
| Patients with inherited hyperlipidemias who need genetic testing for diagnosis  |
| Patients with severe/extreme primary hypertriglyceridemia after secondary causes have been ruled out  |
| Patients who may be candidates for treatment with evinacumab, lomitapide, olezarsen, or lipoprotein apheresis                                   |

\*Especially if patients are not achieving lipid/lipoprotein goals on recommended therapies.

ASCVD indicates atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein-cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein-cholesterol; LLT, lipid-lowering therapy; LP(a), lipoprotein (a); and TG, triglycerides.

length of exposure to elevated LDL-C and Lp(a) should be factored into the treatment decision. Once atherosclerosis has developed, risk may remain above that of individuals without atherosclerosis even with intensive LDL-C-lowering therapy.<sup>8</sup>

4.2.3.1. Role of the Individualized Benefit-Risk Discussion

**Recommendation for Role of the Individualized Benefit-Risk Discussion**  
 Referenced studies that support the recommendation are summarized in the Evidence Table.

| COR | LOE  | Recommendation  |
|-----|------|---|
| 1   | B-NR | 1. In individuals with dyslipidemia, clinicians and their patients should engage in a discussion of the patient's ASCVD risk, healthy lifestyle as the foundation of risk reduction, expected risk reduction benefits from LLT, possible harms and DDI, costs, and patient preferences to make individualized treatment decisions and/or consider additional options for evaluation to aid in decision-making. <sup>1-4</sup> |

Synopsis

The “2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol” made the “clinician–patient risk discussion” an integral part of clinical decision-making.<sup>5</sup> In the current guideline, the role of individualized benefit-risk discussions between the clinician and patient is further amplified as a core element of patient-centered care. This discussion may also involve family or other health advocates. Individualized benefit-risk discussions focus on patient education to build trust and support informed decisions. Using simplified, plain language and visual aids, clinician-provided explanation of the patient's estimated ASCVD risk and available treatment options for risk reduction is encouraged. The explanation of treatment options includes discussion of anticipated benefits, potential for adverse effects and DDI, and consideration of costs. The patient should be given an opportunity to verbalize their values, attitudes, abilities, concerns, and personal goals for making sustained lifestyle changes and taking medications. Deciding upon an initial treatment strategy may require 1 or multiple discussions between the patient and clinician and may benefit from reinforcement from multiple clinicians. Additional evaluation may refine risk assessment to improve decision-making. Future encounters should address patient questions/concerns, review treatment response, emphasize adherence, reaffirm benefit, and consider further opportunities to reduce ASCVD risk.

Recommendation-Specific Supportive Text

1. The clinician may use a checklist to facilitate individualized benefit-risk discussions with the patient

Table 10. Checklist for Individualized Benefit-Risk Discussion

|   | Checklist Item  | Recommendation  |
|---|---|---|
| ✓ | ASCVD risk assessment   | Perform ASCVD risk assessment (Sections 4.2.3.2 through 4.2.3.7).<br>When indicated, use the PREVENT-ASCVD Calculator.*<br>Explain risk in absolute and relative terms.<br>Use decision tools to explain risk (eg, PREVENT-ASCVD Calculator*).<br>Consider CAC scan or the presence and severity of atherosclerosis seen on a non-ECG-gated chest CT or a carotid ultrasound.<br>Consider risk enhancers.<br>Consider reproductive age risk markers.                    |
| ✓ | Emphasize healthy lifestyle habits as the foundation of treatment | Review lifestyle habits (eg, diet, physical activity, weight or body mass index, and tobacco use).<br>Endorse a healthy lifestyle and provide relevant advice, materials, or referrals (eg, CardioSmart,† AHA Life's Essential 8,‡ NLA Patient Tear Sheets,§ PCNA Heart Healthy Toolbox,¶ cardiac rehabilitation, dietitian, smoking cessation program).  |
| ✓ | Potential net clinical benefit of pharmacotherapy                 | Recommend a statin as first-line therapy.<br>Consider the combination of statin and nonstatin therapy in selected patients.<br>Discuss potential risk reduction from LLT.<br>Discuss the potential for adverse effects or drug-drug interactions.   |
| ✓ | Cost and convenience considerations                               | Discuss potential out-of-pocket cost of therapy to the patient (eg, insurance plan coverage, tier level, copayment).<br>Discuss administration of medicine by daily oral therapy, time of administration, potential drug interactions, subcutaneous injection every 2 wk versus every 6 mo.   |
| ✓ | Shared decision-making  | Encourage the patient to verbalize what was heard (eg, patient's personal estimated ASCVD risk, available options, and risks/benefits).<br>Invite the patient to ask questions, express values and preferences, and state ability to adhere to lifestyle changes and medications.<br>Refer patients to trustworthy materials to aid in their understanding of issues regarding risk decisions.<br>Collaborate with the patient to determine therapy and follow-up plan. |

\*The PREVENT-ASCVD Online Calculator is available at: <https://professional.heart.org/en/guidelines-and-statements/prevent-calculator>.

†CardioSmart health information is available at: <https://www.cardiosmart.org/topics/healthy-living>.

‡AHA Life's Essential 8 information is available at: <https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8>.

§NLA Patient Tear Sheets information is available at: <https://www.lipid.org/practicetools/tools/tearsheets>.

¶PCNA Heart Healthy Toolbox information is available at: <https://pcna.net/resource/heart-healthy-toolbox/>.

AHA indicates American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CT, computed tomography; ECG, electrocardiogram; LDL-C, low-density lipoprotein-cholesterol; LLT, lipid-lowering therapy; PCNA, Preventive Cardiology Nurses Association; and NLA, National Lipid Association. Adapted with permission from Martin et al.<sup>4</sup> Copyright 2015 American College of Cardiology Foundation.

(Table 10). The elements of this discussion include ASCVD risk assessment, emphasis on healthy lifestyle habits as the foundation of treatment, review of the potential net clinical benefit of pharmacotherapy, cost and convenience considerations, and engaging in shared decision-making. Selective use of a CAC scan may help refine one's ASCVD risk estimate. The distribution of patient preferences for lipid-lowering treatment suggests that individuals across a broad risk range should have individualized benefit-risk discussions.<sup>6</sup> In addition to consideration of absolute 10- and 30-year ASCVD risk, discussing risk relative to peers may provide important context that can increase patient understanding and help align decisions with patient preferences.<sup>7</sup>

Decision aids (eg, pamphlets, videos, or web-based tools) may clarify evidence-based options and help patients consider the choice most consistent with their values. Decision aids enable patients to take an active role in decision-making, improve knowledge, enhance risk perception, clarify personal values, reduce decisional conflict, improve feelings of being informed, and increase satisfaction.<sup>3,8,9</sup>

#### 4.2.3.2. PREVENT-ASCVD Equations

| Recommendation for PREVENT-ASCVD Equations<br>Referenced studies that support the recommendation are summarized in the Evidence Table. |      |  |
|--|------|--|
| COR  | LOE  | Recommendation   |
| 1  | B-NR | 1. In adults aged 30 to 79 y without ASCVD or subclinical atherosclerosis and with an LDL-C level between 70 and 189 mg/dL (1.8–4.9 mmol/L), the PREVENT-ASCVD equations should be used to estimate 10-y ASCVD risk, <sup>1</sup> with categorization as having low (<3%), borderline (3% to <5%), intermediate (5% to <10%), or high (≥10%) 10-y estimated ASCVD risk. <sup>2</sup> |

### Synopsis

Risk assessment for ASCVD aids decision-making for approaches to lipid management in primary prevention and begins with a comprehensive evaluation of the patient. For most individuals, this guideline continues to recommend quantitative absolute risk estimation to assist the benefit-risk discussion between clinicians and patients around the initiation of LLT in primary prevention. Absolute risk estimation allows direct comparison of potential benefits and harms to individualize and quantify expected net clinical benefit related to LLT.<sup>3</sup> After careful consideration of available risk equations (including the endpoints addressed, feasibility of implementation, and accuracy and precision for the populations of interest), the guideline panel recommends use of the newer AHA PREVENT-ASCVD equations<sup>1,3</sup> for estimation of 10-year (and 30-year) risk. This decision was based primarily on the relevance and broad availability of the variables included for risk prediction, the use of the same hard AS-

CVD endpoint as in previous guidelines relevant to LLT, and particularly the greater precision and accuracy of risk estimates afforded by the PREVENT-ASCVD equations. The enhanced precision of PREVENT-ASCVD equations estimates, when compared with the PCE, stems from their derivation in over 3 million contemporary US adults from both population-based and clinical datasets.<sup>1,3</sup> In contrast, the PCE were derived in approximately 25 000 individuals from some older birth cohorts<sup>4</sup> (eg, persons born before 1930 who had different exposures to CVD risk factors across their life course than contemporary groups). Substantially greater accuracy (improved calibration) of the PREVENT-ASCVD equations was demonstrated via careful validation studies performed in more than 3 million separate individuals also from contemporary US samples. Salient features of the PREVENT-ASCVD equations are summarized in Table 11.

The advances in the accuracy and precision of ASCVD risk estimation by the PREVENT-ASCVD equations increase confidence that clinicians can more precisely identify individuals who are likely to experience net clinical benefit from LLT. With the use of this new risk estimation platform, the guideline panel re-examined older decision thresholds to determine the appropriate levels of estimated risk for consideration of LLT initiation in primary prevention.<sup>5</sup> The panel used the same processes and metrics for selecting estimated absolute risk thresholds for consideration of net benefit as were used in prior ACC/AHA/Multisociety guidelines, including the 2013 cholesterol, 2017 high blood pressure, 2018 cholesterol, and 2019 primary prevention guidelines.<sup>4,6–8</sup> Specifically, as shown in Figure 3, panel members examined the following factors to select absolute estimated risk thresholds for defining levels above which LLT can be considered (ie, borderline risk or higher):

1. *Net benefit thresholds for moderate- and high-intensity statin use from primary prevention RCTs.* As described in the 2013 ACC/AHA/Multisociety Cholesterol Guideline,<sup>4</sup> net benefit for statin therapy can be assessed as a joint function of the number-needed-to-treat to prevent 1 hard ASCVD event and the number-needed-to-harm (cause 1 new case of diabetes in adults with prediabetes over 10 years). Although the severity of these 2 outcomes is not equivalent, incident diabetes as a result of statin initiation is the most common serious adverse event attributed to statins. As shown in Figure 4, using data from primary prevention RCTs of statins, net benefit was demonstrated for moderate-intensity statin at an event rate of ≥3% in 10 years.<sup>2,4</sup> In 2013, given the possibility that the PCE overpredicted risk, the guideline panel selected a 10-year predicted risk of ≥5% as the threshold for beginning to consider statin therapy.<sup>4</sup> Given the enhanced accuracy of the PREVENT-ASCVD equations, which provide risk estimates that are approximately 40% to 50% lower

**Table 11. Salient Features of the American Heart Association PREVENT™ Equations**

| The PREVENT equations: |   |
|------------------------|---|
| 1.                     | Included a large, contemporary, representative sample of US adults for derivation (N = ~3.3 million) and external validation (N = ~3.3 million).  |
| 2.                     | Lower limit to begin risk prediction to age 30 y (through 79 y).  |
| 3.                     | Provide sex-specific equations; race/ethnicity is not a variable that added predictive value to the equations and provides estimates adjusted for competing risk of non-CVD death.  |
| 4.                     | Provide a base model for risk prediction that includes commonly available risk factor measures: age, sex, blood pressure, total and HDL-C, diabetes status, tobacco use, kidney function (eGFR), statin use, and antihypertensive medication use (and BMI for heart failure prediction).  |
| 5.                     | Provide optional models with additional inputs, if known/measured, of hbA1c (to capture glycemic status), urinary albumin/creatinine ratio (for proteinuria and CKD), and zip code (to represent social deprivation index and acknowledge social determinants of cardiovascular risk). These factors are not necessary to generate risk estimates, but they may enhance risk prediction if available. |
| 6.                     | Predict 10-year and 30-y outcomes.  |
| 7.                     | Predict risk for hard ASCVD† (relevant for LLT decisions), HF, and total CVD (ASCVD plus HF; relevant for blood pressure-lowering therapy decisions).   |
| 8.                     | Demonstrate similar risk discrimination (C statistics) as the pooled cohort equations for prediction of ASCVD events.   |
| 9.                     | Provide significantly and substantially more accurate risk estimates (improved calibration) for ASCVD than the pooled cohort equations, overall and in all demographic subgroups. In general, risk estimates from PREVENT-ASCVD equations tend to be 40% to 50% lower than 10-y risk estimates from the pooled cohort equations for the same risk factor profile.                                     |


\*For the purposes of risk assessment in decision-making for LLT, the PREVENT-ASCVD equations version should be used to predict hard ASCVD outcomes and assist the patient-clinician risk/benefit discussion.

†Fatal or nonfatal stroke, nonfatal MI, or CHD death. This does not include revascularizations performed without antecedent clinical events, given wide variation in practice patterns. Adapted with permission from Khan et al.<sup>3</sup> © 2023 American Heart Association, Inc.

ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; CVD, cardiovascular disease; CHD, coronary heart disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; hbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; HF, heart failure; LLT, lipid-lowering therapy; and MI, myocardial infarction.


than the PCE, the current guideline panel selected the 10-year estimated ASCVD risk threshold of  $\geq 3\%$  for beginning consideration of LLT.

2. "Crosswalk" between risk estimates from the contemporary PREVENT-ASCVD equations and prior PCE. In general, 10-year risk estimates from

**Figure 3. Rationale for New 10-Year Risk Thresholds in Lipid-Lowering Therapy Using PREVENT-ASCVD.**

ASCVD indicates atherosclerotic cardiovascular disease; LLT, lipid-lowering therapy; PCE, pooled cohort equations; RCTs, randomized controlled trials; and US, United States. Adapted from Khan et al<sup>1</sup> and Khan et al.<sup>3</sup>

## Logic for Defining the Absolute Estimated 10-year ASCVD Risk for Consideration of LLT at $\geq 3\%$ in Primary Prevention



2026 Dyslipidemia  
© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 4. Logic for Defining the Absolute Estimated 10-Year ASCVD Risk for Consideration of LLT at  $\geq 3\%$  in Primary Prevention.**

The graphs plot the number-needed-to-treat to prevent 1 ASCVD event (NNT-benefit; y-axis) as a function of the observed 10-year ASCVD event rate (x-axis) from primary prevention RCTs of statin therapy. The red curves show the number-needed-to-treat to prevent 1 ASCVD event (NNT-benefit) with initiation of (A) moderate-intensity or (B) high-intensity statin, assuming a 35% RRR with moderate-intensity and 45% RRR with high-intensity statin, as has been observed in meta-regression of statin trials. The horizontal black lines represent the number-needed-to-treat to cause 1 case of incident diabetes (NND) over 10 years with (A) moderate-intensity or (B) high-intensity statin. The risk of incident diabetes is higher for high-intensity than lower-intensity statins. Individuals with baseline normoglycemia rarely develop elevations in glucose sufficient to cause a new diagnosis of diabetes. Individuals who develop statin-attributed diabetes almost universally have documented prediabetes and are already near the threshold for diagnosis of diabetes. The points where the red curves and the horizontal black lines cross (blue circle;  $\sim 3\%$  10-year event rates for moderate-intensity and  $\sim 7\%$  for high-intensity statin) represent the points at which the NNT-benefit and the NND are equal. Therefore, at risk levels higher than indicated by the dashed lines, there is expected net clinical benefit (potential benefit  $>$  potential harm) for initiation of LLT in primary prevention. **Given that the PREVENT-ASCVD equations accurately predict ASCVD risk, the threshold for consideration of LLT in primary prevention was set at a PREVENT-ASCVD 10-year risk estimate of  $\geq 3\%$ .** ASCVD indicates atherosclerotic cardiovascular disease; CVD, cardiovascular disease; DM, diabetes; LLT, lipid-lowering therapy; NND, number-needed-to-treat to cause 1 case of incident diabetes in 10 years; NNT-benefit, number-needed-to-treat to prevent 1 ASCVD event; RCT, randomized controlled trial; and RRR, relative risk reduction. Adapted with permission from Khan et al.<sup>1,3</sup> © 2024 American Heart Association, Inc.

PREVENT-ASCVD equations are 40% to 50% lower than estimates from the PCE for the same risk factor profile.<sup>1,9</sup> Thus, the categories of risk (borderline, intermediate, high) tend to identify similar groups of individuals using the newer, lower thresholds for PREVENT-ASCVD equations and older, higher thresholds of the PCE (Table 12). The PCE overestimated ASCVD risk in many individuals.

3. *Potential impact of using newer 10-year PREVENT-ASCVD estimate risk thresholds for consideration of LLT on the number and proportion of US adults (overall and in demographic subgroups) considered for LLT in primary prevention.* Panel members compared the number of US adults who could be considered for LLT using a PCE threshold of  $\geq 5\%$  versus a PREVENT-ASCVD threshold of  $\geq 3\%$ .

**Table 12. Crosswalk Between 10-Year Risk ASCVD Estimates From PCE and PREVENT-ASCVD Equations**

| Risk Group   | Approximate Equivalent Ranges of 10-Year ASCVD Risk Estimates* |               |
|--------------|--|---------------|
|              | PCE  | PREVENT-ASCVD |
| Low          | <5%  | <3%           |
| Borderline   | 5% to <7.5%  | 3% to <5%     |
| Intermediate | 7.5% to <20%   | 5% to <10%    |
| High         | ≥20%   | ≥10%          |

\*The PREVENT-ASCVD equations generally provide 10-year risk estimates that are 40% to 50% lower than the PCE estimates because the PCE calculator often overestimated the risk for adults.

ASCVD denotes atherosclerotic cardiovascular disease; and PCE, pooled cohort equations. Adapted from Khan et al.<sup>1,3</sup>

Using NHANES data, these results were published recently. In brief, among 133 million US adults aged 40 to 75 years, it is estimated that 28 million were already taking statin medication, and an additional 15 million were eligible because of existing ASCVD or the presence of diabetes or LDL-C ≥190 mg/dL. Among the 70 million remaining adults who are potentially eligible for consideration of LLT based on ASCVD risk, 26 million would be identified by PCE at an estimated 10-year risk of ≥5%, whereas 25 million would be identified by PREVENT-ASCVD at an estimated risk of ≥3%.<sup>9</sup> Ten-year risk estimation has limitations for younger individuals due to its misalignment with the long latency periods (well beyond 10 years) between risk factor exposure, atherosclerosis development, and ASCVD endpoints. Thus, consideration of exposure to atherosclerosis determinants, as well as 30-year risk estimation, is warranted to guide decision-making approaches for those at low 10-year risk. Other factors should be considered in risk assessment, such as duration of exposure to atherogenic lipoproteins, risk enhancers, reproductive risk markers, and competing comorbidities (Figure 6).

In specific patient subgroups, quantitative risk assessment may aid in decisions regarding intensification of LLT. In persons >40 years of age who have diabetes or CKD, or who are living with human immunodeficiency virus (HIV), statin therapy has demonstrated benefits even among those at lower absolute ASCVD risk. However, there is a spectrum of risk in these patient subgroups and those at higher risk likely benefit from higher intensity LLT. Thus, in Sections 4.2.5, “Diabetes in Adults Without Established ASCVD,” 4.2.8.8, “Adults With CKD—Stage 3 or Higher,” and 4.2.8.9, “Persons Living With HIV,” the use of the PREVENT-ASCVD equations is recommended to identify individuals in those subgroups who may benefit from more intensive LLT. It is important to note that while the PREVENT equation risk estimates were derived from adults age 30 to 79 years, many relevant RCTs of LLT included patients within different age ranges, some more narrow

(eg, 40–75 years of age), and some without an upper age limit. Throughout this document, evidence-based treatment recommendations may include age ranges based specifically on clinical trial inclusion criteria and cardiovascular outcomes in these populations.


### Recommendation-Specific Supportive Text

1. For primary prevention in adults aged 30 to 79 years, 10-year ASCVD risk estimation using the PREVENT-ASCVD equations should be performed to initiate the benefit-risk discussion around LLT.<sup>1,4</sup> Given the demonstrated benefits of statins even among those with lower event rates and the low rates of potential harms, a net benefit threshold as low as a predicted ASCVD risk of 3% is now recommended for consideration of LLT. Net benefit increases, and the number-needed-to-treat to prevent 1 ASCVD event decreases, as predicted risk is higher. Conversely, as the predicted 10-year ASCVD risk approaches an estimate of 3%, net benefit becomes more marginal, and the number-needed-to-treat is higher. These factors should be taken into consideration in the clinician–patient discussion and consideration of individual risk enhancers. After calculation of 10-year estimated risk, the guideline recommends that each individual should be categorized based on their 10-year ASCVD risk estimate into low-risk (<3%), borderline-risk (3% to <5%), intermediate-risk (5% to <10%), or high-risk (≥10%) groups. If, after the clinician–patient discussion of predicted ASCVD risk and potential benefit of LLT, there is clinical uncertainty or patient indecision regarding the treatment approach, CAC measurement can be useful in adults at borderline or intermediate risk for enhanced reclassification of predicted risk. This approach has been described as the “CPR Framework” (Calculate–Personalize–Reclassify; Figure 5).

#### 4.2.3.3. Risk Enhancers

**Recommendations for Risk Enhancers**  
Referenced studies that support recommendations are summarized in the Evidence Table.

| COR | LOE  | Recommendations   |
|-----|------|---|
| 2a  | B-NR | 1. In adults without ASCVD with a borderline 10-y ASCVD risk estimate (3% to <5%) by the PREVENT-ASCVD equations, consideration of risk enhancers is reasonable to personalize risk assessment and the potential benefit of initiating LLT as an adjunct to lifestyle management to reduce ASCVD risk (Table 13). <sup>1–18</sup>   |
| 2a  | B-R  | 2. In adults without ASCVD with a borderline 10-y ASCVD risk estimate (3% to <5%) by the PREVENT-ASCVD equations, if high-sensitivity C-reactive protein (hsCRP) is measured and is ≥2 mg/L on 2 successive occasions with no identifiable underlying cause of hsCRP elevation, high-intensity statin therapy can be useful to reduce the risk of ASCVD events. <sup>4,15,19,20</sup> |



**Figure 5. CPR Framework for Risk Evaluation.**

CAC indicates coronary artery calcium; and CPR, Calculate–Personalize–Reclassify.

## Synopsis

Several patient characteristics, diagnoses, and laboratory values not included in the PREVENT-ASCVD equations are associated with increased long-term risk of ASCVD events (Table 13). These risk enhancers exhibit variable strengths of association with ASCVD risk, but whether LLT is effective at reducing their associated incremental risk requires further study. Autoimmune diseases may promote ASCVD through LDL-C–independent pathways, such as inflammation. Similarly, hsCRP is a marker of inflammation, yet the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial demonstrated high-intensity statin therapy reduces ASCVD events, with an effect size compatible with the LDL-C–lowering effect of statins alone.<sup>19,20</sup> Moderate-intensity statin therapy demonstrated benefit in RCTs in individuals at borderline estimated 10-year ASCVD risk (3% to <5% risk); however,

the number needed to treat is higher, and the decision to implement LLT should be made in the context of the benefit-risk discussion. The presence of risk enhancers may help to confirm a higher risk state and thereby support a decision to initiate or intensify statin therapy. However, an independent association between a risk-enhancer and ASCVD risk does not necessarily mean the risk enhancer improves risk prediction over the PREVENT-ASCVD equations.<sup>21</sup> The absence of risk enhancers should not be taken to indicate lower ASCVD risk than calculated using PREVENT-ASCVD equations and does not warrant delay or avoidance of LLT. Risk enhancers may also identify individuals with low estimated risk (<3%) by PREVENT-ASCVD equations who may be reasonable for consideration of LLT [eg, strong family history of premature CVD and/or very high Lp(a)] or may be included in the benefit-risk discussion for individuals at higher risk who have concerns about starting LLT.

**Table 13. Risk Enhancers**

| Risk Enhancers   |
|--|
| History of premature ASCVD in a parent or sibling (onset age <55 y for men, <65 y for women)   |
| Higher risk ancestry (eg, South Asian, Filipino)   |
| High polygenic risk (if measured) (Section 4.2.3.5, "Polygenic Risk Scores")   |
| Chronic inflammatory diseases (eg, systemic lupus, rheumatoid arthritis, advanced psoriasis, inflammatory arthritis)   |
| Lp(a) $\geq 125$ nmol/L or $\geq 50$ mg/dL   |
| hsCRP $\geq 2$ mg/L on $>1$ occasion (if measured)   |
| TG persistently $\geq 175$ mg/dL (2 mmol/L) (if nonfasting) and $\geq 150$ mg/dL (1.7 mmol/L) (if fasting)   |
| CKM syndrome   |
| LDL-C persistently $\geq 160$ – $189$ mg/dL (4.1–4.9 mmol/L), non-HDL-C $\geq 190$ – $219$ mg/dL or apoB $\geq 120$ mg/dL*   |
| Reproductive risk markers (premature menopause, preeclampsia, gestational diabetes, gestational hypertension, preterm delivery; Section 4.2.3.4, "Reproductive Risk Marker") |

Note that all available information should be included in risk estimates derived from the PREVENT-ASCVD equations, including albuminuria, HbA1c, and zip code for assessment of neighborhood-level social determinants of health. Given the recent publication of the PREVENT-ASCVD equations, it remains to be demonstrated for most risk enhancers that risk is incremental to the PREVENT-ASCVD equations.

\*Although LDL-C is not included in the PREVENT-ASCVD equations (total cholesterol and HDL-C are included), it is included here because persistent elevation of LDL-C may be a useful factor to include in risk-benefit discussions about LDL-C-lowering therapy, given that it is the target of that therapy. See Section 4.2.3.4, "Reproductive Risk Marker," for more detail regarding reproductive risk factors.

ApoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CKM, cardiovascular-kidney-metabolic; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein (a); and TG, triglycerides. Adapted with permission from Grundy et al.<sup>25</sup> Copyright 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

### Recommendation-Specific Supportive Text

1. The PREVENT-ASCVD equations do not include all factors that may increase individual-level risk, as not all potential risk markers are measured and available for study in derivation and validation cohorts. Thus, it can be beneficial to consider risk enhancers more qualitatively in patients at borderline risk during the benefit-risk discussion regarding the initiation of LLT. Risk enhancers are clinical conditions, demographic factors, or biomarker levels that can help guide decision-making about the need for pharmacotherapy or additional diagnostic testing. Their presence and number can help personalize decision-making about initiation of LDL-C-lowering therapy and the intensity of therapy, especially in adults at borderline risk. A variety of patient characteristics, diagnoses, and laboratory values have been associated with increased ASCVD risk and may be independent of elements included in the PREVENT-ASCVD equations.<sup>1,2,7–9,12,16–18,22–24</sup> The presence of  $\geq 1$

risk enhancers may indicate higher individual risk than is reflected in the risk estimate derived from the PREVENT-ASCVD equations; thus, they can be considered during the benefit-risk discussion to help identify individuals at borderline risk who are more likely to benefit from LLT. Clinician and patient awareness of these risk enhancers may also facilitate adoption of recommendations regarding initiation of LLT, when there is otherwise hesitation among patients or clinicians.

2. Individuals were selected for inclusion in the JUPITER trial based on an elevated hsCRP of  $\geq 2$  mg/dL and a median LDL-C of 108 mg/dL. Participants with secondary causes of elevated hsCRP were excluded (current use of postmenopausal hormone-replacement therapy, evidence of hepatic dysfunction [an alanine aminotransferase level  $>$ twice the upper limit of the normal range], a creatine kinase [CK] level  $>3$  times the upper limit of the normal range, a creatinine level  $>2.0$  mg/dL [176.8  $\mu$ mol/L], diabetes, uncontrolled hypertension [systolic blood pressure  $\geq 190$  mm Hg or diastolic blood pressure  $\geq 100$  mm Hg], cancer within 5 years before enrollment [with the exception of basal cell or squamous cell carcinoma of the skin], uncontrolled hypothyroidism [a thyroid-stimulating hormone level  $>1.5$  times the upper limit of the normal range], inflammatory conditions such as severe arthritis, lupus, or inflammatory bowel disease, patients taking immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids). Rosuvastatin 20 mg led to an RRR of 44% in MACE, and the absolute risk reduction (ARR) increased with higher levels of hsCRP; the study was stopped early after a mean follow-up of 1.9 years because of a decrease in total mortality.<sup>19,20</sup> Recent data identified the independent long-term predictive value of hsCRP, LDL-C, and Lp(a) in nearly 28 000 healthy women in the Women's Health Study.<sup>4</sup> When the top quintile was compared with the bottom quintile for each biomarker, the adjusted hazard ratios for a first MACE were 1.70 for hsCRP, 1.35 for LDL-C, and 1.33 for Lp(a). When data were censored at the time of statin initiation, the risk associated with hsCRP was similar to the risk associated with LDL-C, with hazard ratios of  $\sim 1.65$  for the top quintile compared with the bottom quintile. In the 20-year follow-up of a large prospective European cohort of initially healthy men and women, the multivariable-adjusted hazard ratios in a comparison of the top to bottom quintile were 1.78 for LDL-C, 1.55 for hsCRP, and 1.19 for Lp(a).<sup>15</sup>

**Table 14. Reproductive Risk Markers Associated With ASCVD Events**

| Adverse Pregnancy Outcomes* That Have a Stronger Association With ASCVD Events <sup>14</sup>           |
|--|
| Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension)                           |
| Gestational diabetes   |
| Small-for-gestational age <sup>23</sup> (birthweight below the 10th percentile <sup>24</sup> )         |
| Preterm delivery (before 37 wk gestation)  |
| Recurrent spontaneous pregnancy loss   |
| Other Reproductive Risk Markers <sup>11</sup>  |
| Early menarche (<10 y old) <sup>25</sup>   |
| Early menopause (<45 y old), <sup>18</sup> especially premature menopause (<40 y old) <sup>18,21</sup> |
| Polycystic ovarian syndrome and irregular menses <sup>26,27</sup>                                      |

\*See reference for a full list of Adverse Pregnancy Outcomes.<sup>28</sup> ASCVD indicates atherosclerotic cardiovascular disease.

#### 4.2.3.4. Reproductive Risk Markers

| Recommendation for Reproductive Risk Markers<br>Referenced studies that support the recommendation are summarized in the Evidence Table. |      |   |
|--|------|---|
| COR  | LOE  | Recommendation  |
| 2a   | B-NR | 1. In adults without ASCVD, consideration of reproductive risk markers, such as early menopause (<45 y) and history of adverse pregnancy outcomes (gestational hypertension, preeclampsia, gestational diabetes, preterm delivery) is reasonable to personalize ASCVD risk assessment when considering the potential benefit of initiating LLT as an adjunct to lifestyle management for primary ASCVD prevention. <sup>1-5</sup> |

### Synopsis

Reproductive risk markers<sup>6</sup> are associated with adverse cardiovascular profiles, increased risk of coronary atherosclerosis on imaging,<sup>7</sup> and ASCVD events.<sup>7-14</sup> Among the reproductive risk markers (Table 14), early menarche (<10 years of age), polycystic ovarian syndrome, early menopause (<45 years of age), premature menopause (<40 years of age), and adverse pregnancy outcomes (hypertensive disorders of pregnancy, gestational diabetes, preterm delivery, small-for-gestational age, and recurrent spontaneous pregnancy loss) have stronger associations with increased ASCVD events, after adjusting for conventional risk factors.<sup>1-5,9,11-13,15-18</sup> While assessing ASCVD risk and considering LLT, the presence of reproductive risk markers can be advantageous to the discussion when providing individualized risk assessment.<sup>8</sup> A comprehensive ASCVD risk assessment using traditional risk factors and reproductive risk markers<sup>6</sup> can add value to optimally identify risks that may disproportionately impact CVD event risk.<sup>8,19</sup>

### Recommendation-Specific Supportive Text

1. Reproductive risk markers can have an impact across the life course and are associated with dyslipidemia, other metabolic alterations, and increased ASCVD risk.<sup>8,11,20-22</sup> Including reproductive risk markers (Table 14) in CVD risk discussions supports personalized ASCVD risk assessment and patient education.<sup>11,19,21</sup> Throughout the life course, assessment of ASCVD risk for primary prevention begins with a detailed medical history, including reproductive and pregnancy history, assessment of conventional risk factors (eg, hypertension, diabetes), other risk markers, the use of applicable 10-year and 30-year risk estimation by the PREVENT-ASCVD equations, and consideration for subclinical atherosclerosis imaging (Section 4.2.3, "Primary Prevention in Adults").<sup>8,11,15,21</sup> Interventions to reduce ASCVD risk associated with reproductive risk markers include aggressive lifestyle management with the addition of LLT based on personalized ASCVD risk estimation.<sup>8,11,15,21</sup>

#### 4.2.3.5. Polygenic Risk Scores

### Synopsis

Multiple PRS have been developed to assess an individual's genetic risk of CAD and improve risk prediction for CAD beyond clinical and demographic risk factors alone.<sup>1-8</sup> Multi-ancestry PRS has improved performance across ancestry groups.<sup>3</sup> The magnitude of increased risk in those with high CAD PRS is greatest in adults <55 years.<sup>8,9</sup> High CAD PRS is enriched among individuals with a family history of premature CAD, and effects are additive.<sup>10,11</sup>

Post hoc analyses from randomized trials found significant associations between high CAD PRS and increased relative and absolute clinical benefit of LLT.<sup>12-14</sup> Knowledge of a high CAD PRS may improve lipid control.<sup>15-17</sup> A 2-fold increase in the relative risk of CAD by a validated CAD PRS is similar to other risk enhancers.<sup>18</sup> Not all CAD PRS are equivalent, given successively larger CAD genome-wide association studies and differences in both the training data used and methodologies applied. Different PRS may yield different risk estimates for some individuals.<sup>6,19-21</sup> Integrative methods may improve stability.<sup>21</sup> A low CAD PRS by one score does not guarantee a low genetic risk or overall low CAD risk.

#### 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis (Men ≥40 or Women ≥45 Years)

| Recommendations for Selective Imaging of Subclinical Atherosclerosis (Men ≥40 or Women ≥45 Years)<br>Referenced studies that the support recommendations are summarized in the Evidence Table. |     |  |
|--|-----|--|
| COR  | LOE | Recommendations  |
| 1  | B-R | 1. In adults at intermediate risk and select adults at borderline risk with no prior ASCVD, if the decision regarding LLT remains uncertain, a CAC score should be used for further risk stratification and to guide the decision to withhold, postpone, or initiate therapy. <sup>1-4</sup> |

| Recommendations for Selective Imaging of Subclinical Atherosclerosis (Men ≥40 or Women ≥45 Years) (Continued) |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 2a  | B-NR | 2. In adults at intermediate risk or select adults at borderline risk who undergo CAC testing, if the CAC score is 0 Agatston units (AU), and there is preference to avoid LLT and focus on lifestyle management, and no higher risk conditions (FH or severe hypercholesterolemia >190 mg/dL, diabetes and age >40 y, current cigarette smoking, strong family history of premature ASCVD) are present, it is reasonable to defer therapy and reassess with repeat CAC testing in 3 to 7 y to personalize management. <sup>5-8</sup> |
| 1   | B-NR | 3. In adults at intermediate risk and select adults at borderline risk, if the CAC score is >0 AU, it is recommended to initiate LLT, particularly if the CAC score is ≥100 AU or ≥75th standardized percentile to reduce ASCVD risk. <sup>5</sup>  |
| 2a  | B-NR | 4. In adults at intermediate or high risk with no prior ASCVD, if there is uncertainty about the intensity of LLT, a CAC score can be useful to refine treatment goals and decide whether to intensify LLT. <sup>9,10</sup>   |
| 1   | B-NR | 5. In adults with no prior ASCVD, if incidental CAC is identified on noncardiac computed tomography (CT) scans (eg, by visual estimation or a validated artificial-intelligence–based algorithm), the presence of coronary atherosclerosis should be considered during decision-making about initiation or intensification of LLT to reduce ASCVD risk. <sup>11,12</sup>  |
| 2b  | B-NR | 6. In adults with no prior ASCVD who are likely to have a high burden of noncalcified plaque (eg, inflammatory disorders, persons living with HIV, and diabetes), selective use of coronary computed tomography angiography (CCTA) may be useful to inform risk assessment and guide decisions regarding treatment intensity of LLT. <sup>13-17</sup>   |

## Synopsis

Assessment of subclinical coronary atherosclerosis provides valuable prognostic information in asymptomatic adults without known clinical ASCVD and is generally recommended for use in men ≥40 years and women ≥45 years of age. CAC testing is performed using non-contrast-gated cardiac CT, although there are techniques to estimate CAC burden from noncardiac CT scans. The CAC score is reported in AU and represents the overall amount of calcified coronary plaque. CAC is categorized as absent (0), minimal (1-9), mild (10-99), moderate (100-299), severe (300-999), and extensive (≥1000). When decisions about LLT are uncertain, CAC testing enhances cardiovascular risk assessment and can identify people without CAC who are less likely to benefit from statin therapy, compared with those with CAC who are more likely to benefit. Risk reclassification is strongest for intermediate-risk adults. Plaque burden may guide the intensity of various pharmacotherapy interventions. Radiation exposure is typically about 1 millisievert, similar to a mammogram. Incidental findings, such as pulmonary nodules, occur in <10% of adults, some of which require

additional follow-up.<sup>18</sup> Emotional distress or anxiety after receiving CAC results is uncommon, but the possibility should be discussed prior to ordering. Insurance coverage of CAC testing is variable with out-of-pocket costs ranging from \$50 to \$250. Calcium scoring is not indicated in individuals with FH as they are at high risk of ASCVD and benefit from statin therapy. CAC=0 may not be used to “de-risk” patients with FH or justify deferral of statin therapy in patients with FH.

## Recommendation-Specific Supportive Text

1. Risk scores based on traditional risk factors may overestimate or underestimate risk.<sup>19,20</sup> The CAC score improves risk assessment and can reclassify a large proportion of statin-eligible adults, particularly those at intermediate risk, into higher- or lower-risk categories. Observational studies reported that as many as 40% of intermediate-risk adults have CAC=0, with very low observed 10-year ASCVD event rates.<sup>1,2</sup> CAC=0 may be particularly helpful to risk stratify selected individuals who qualify for statin therapy but prefer to avoid pharmacotherapy.<sup>6,8,21</sup> In contrast, ~25% of intermediate-risk participants may have CAC ≥100 and experience 10-year ASCVD event rates comparable to high-risk adults.<sup>1,2</sup> CAC testing also has utility when applied to borderline-risk adults and younger adults with multiple risk factors.<sup>22</sup> Among adults with hypertension and a family history of premature ASCVD, CAC testing at age 36 years for men and age 49 years for women yielded a number needed to screen of 4 to detect CAC >0.<sup>23</sup> When CAC is identified, it is associated with initiation or intensification of preventive therapies<sup>24</sup> and improved adherence.<sup>25</sup> In a prospective randomized trial comparing CAC-guided care versus usual care among individuals at intermediate risk, knowledge of CAC resulted in greater use of pharmacotherapy, increased adherence to treatment, lower LDL-C, and decrease in plaque progression.<sup>26</sup>
2. An important feature of CAC scoring is that CAC=0 is strongly associated with a low 10-year risk of ASCVD.<sup>5</sup> It is, therefore, reasonable to defer statin therapy among intermediate- or lower-risk adults with CAC=0. Important exceptions include people with FH or severe hypercholesterolemia >190 mg/dL, diabetes, current tobacco use, and those with a strong family history of premature ASCVD. Among adults with diabetes, CAC=0 was associated with low 5-year event rates, but risk increased substantially thereafter.<sup>6</sup> In an observational study of adults referred for CAC testing, smokers with a CAC=0 experienced mortality rates similar to nonsmokers with mild-moderate CAC.<sup>7</sup> CAC testing should not be used to withhold statin therapy

in patients with these comorbidities. Adults with a CAC=0 and a first-degree relative with premature ASCVD experience low 10-year event rates.<sup>4</sup> However, the absence of CAC may not be that reassuring in those with multiple first-degree relatives with premature ASCVD. When statin therapy is deferred in the setting of CAC=0, it is reasonable to repeat CAC testing in the future as treatment decisions may change. The interval depends on a person's baseline risk and the desired yield of testing. In low-risk adults in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, about 20% to 25% develop CAC >0 in 5 to 7 years, whereas in intermediate-risk adults, 20% to 25% develop CAC in 3 to 5 years.<sup>8</sup>

3. There is a graded association between the CAC score and cardiovascular risk. Observational studies have consistently shown that among adults with CAC  $\geq 100$  the incident ASCVD event rate is  $>7.5\%$ , the threshold (using the PCE) above which statin therapy has been shown to be beneficial.<sup>5</sup> Therefore, in intermediate-risk or selected borderline-risk adults, it is recommended to initiate LLT if CAC  $>0$ , particularly if the CAC score is  $\geq 100$  or  $\geq 75$ th standardized percentile (currently based on age, sex, and race). In a registry of adults referred for CAC testing, a CAC  $\geq 100$  helped identify those with the greatest benefit from statin therapy.<sup>27</sup> Further, data from population-based cohort studies demonstrated that incident ASCVD event rates among those with CAC  $\geq 300$  were comparable to adults with established, treated ASCVD.<sup>10,28</sup> However, the presence of any CAC in younger people represents premature and prognostically important atherosclerosis. In the CARDIA (Coronary Artery Risk Development in Young Adults) study, CAC scores as low as 1 to 19 among adults ages 32 to 46 years were associated with an elevated risk of coronary events.<sup>29</sup> A CAC score  $\geq 75$ th standardized percentile should prompt consideration of LLT. Reference values to calculate CAC percentiles are available on the MESA website <https://internal.mesa-nhlbi.org/about/procedures/tools/cac-score-reference-values>. Among individuals aged 30 to 45 years, percentiles can be calculated based on <https://www.cac-tools.com>.<sup>30</sup> Once LLT is initiated, repeat CAC testing is not indicated because statin therapy often increases CAC scores, even though they may stabilize or reduce plaque volume by decreasing cholesterol and inflammation while improving clinical outcomes.
4. Given the graded association between the CAC score and incident ASCVD, adults with very high scores are at particularly high risk of future events. Adults with CAC  $\geq 300$  experience ASCVD event rates that are similar to adults with established, treated ASCVD.<sup>28</sup> Further, adults with CAC  $\geq 1000$

in the CAC Consortium experienced event rates that were more than double those with CAC 400 to 999.<sup>31</sup> The annualized CVD death rate of adults with CAC  $\geq 1000$  was similar to the placebo arm of the FOURIER trial, which enrolled high-risk adults (on excellent background medical therapy) with established ASCVD taking high-intensity statin therapy and at least 1 additional cardiovascular risk factor. The graded association between the CAC score and incident ASCVD is also seen among adults with diabetes.<sup>32</sup> MESA participants with CAC  $\geq 400$  and type 2 diabetes for  $>10$  years experienced an especially high event rate. In a study of adults with type 1 diabetes who underwent CAC testing at a mean age of 43 years, those with a CAC score  $\geq 100$  experienced a 4-fold higher risk of events than adults with CAC=0.<sup>33</sup> As a result, it is reasonable to treat patients found to have significantly elevated CAC scores with more aggressive lipid-lowering targets.

5. CAC scoring is typically performed on gated cardiac CTs to minimize motion artifact. However, improvements in spatial and temporal resolution have enabled the visualization of incidental CAC on non-cardiac nongated scans.<sup>34</sup> CAC scoring on noncardiac CTs can be performed with a visual assessment (minimal, mild, moderate, severe) or ordinal scoring based on the extent of CAC. Several studies have shown agreement between gated and nongated scans and a strong association between the severity of incidental CAC and prognosis. In the NLST (National Lung Screening Trial), all-cause mortality was almost 5-fold higher among those with severe incidental CAC compared with those without CAC.<sup>35</sup> More recently, investigators have validated machine-learning algorithms to quantify incidental CAC, demonstrating strong associations with all-cause mortality and cardiovascular outcomes.<sup>11</sup> A quality improvement project which utilized a validated deep learning algorithm identified incidental CAC on non-cardiac CTs, with patients and their clinicians notified of the results.<sup>36</sup> Statin prescription was 51.2% in participants who were notified of their results versus 6.9% in usual care ( $P<0.001$ ). However, an important potential limitation of nongated CTs is the false-negative rate, reported as high as 24%.<sup>37</sup> Accordingly, the absence of incidental CAC should not be a justification to withdraw or avoid LLT. The presence of carotid plaque on vascular imaging is also associated with an elevated ASCVD risk, even among patients with CAC=0.<sup>12,38,39</sup> It is, therefore, encouraged to initiate LLT among patients with carotid plaque.
6. CCTA provides additional information about coronary atherosclerosis beyond the CAC score, including the amount and severity of both noncalcified

and calcified plaque, and whether high-risk plaque features are present, such as low-attenuation plaque, positive remodeling, and spotty calcifications.<sup>40</sup> In SCAPIS (Swedish Cardiopulmonary Bioimage Study), among 25 182 asymptomatic adults aged 50 to 64 years who underwent CCTA, the presence of plaque was found in 42%; 5.5% of those with CAC=0 had noncalcified atherosclerosis.<sup>41</sup> In MiHeart (Miami Heart Study), 49% of asymptomatic adults aged 50 to 64 years had plaque, and 16% of those with no CAC had identifiable noncalcified plaque.<sup>42</sup> Multiple studies have demonstrated the prognostic value of CCTA in asymptomatic individuals.<sup>40,43</sup> Quantitative coronary plaque analysis may be used to quantify the overall amount of plaque,<sup>44,45</sup> which has the potential to further enhance prognosis.<sup>46</sup> Adults at higher risk for a large burden of noncalcified plaque include those with inflammatory disorders, HIV, and diabetes. CCTA can also be used to measure inflammation via the fat attenuation index, which has been shown in a large cohort study to have incremental prognostic value beyond risk factors and plaque severity.<sup>47,48</sup>


4.2.3.7. Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L)

| Recommendations for Primary Prevention in Adults 30 to 79 Years With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L)<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 1   | A    | 1. In adults being assessed for primary prevention of ASCVD, health behavior recommendations should be provided in addition to a benefit-risk discussion for consideration of LLT <sup>1-4</sup> (Section 4.1.2, "Dietary Approaches in Dyslipidemia").   |
| <b>Low (&lt;3%) Estimated 10-Year ASCVD Risk</b>  |      |   |
| 1   | A    | 2. In adults aged 30 to 59 y, at low (<3%) 10-y estimated risk for ASCVD who have an LDL-C <160 mg/dL (4.1 mmol/L) and a 30-y risk estimate of <10%, counseling on health behaviors is recommended to reduce LDL-C and risk for ASCVD. <sup>1-4</sup>   |
| 2a  | C-LD | 3. In adults aged 30 to 59 y, at low (<3%) 10-y estimated risk for ASCVD but with an LDL-C of 160 to 189 mg/dL (4.1-4.9 mmol/L) or a 30-y ASCVD risk ≥10% (for those aged 30-59 y), a moderate-intensity statin is reasonable to reduce cumulative exposure to atherogenic lipoproteins. <sup>5,6</sup> |
| <b>Borderline (3% to &lt;5%) and Intermediate (5% to &lt;10%) 10-Y ASCVD Risk</b>   |      |   |
| 2a  | A    | 4. In adults at borderline (3% to <5%) 10-y estimated risk for ASCVD in whom a decision is made to initiate statin therapy for primary prevention, a moderate-intensity statin is reasonable to achieve ≥30% to 49% LDL-C reduction and to reduce ASCVD risk. <sup>5</sup>                              |

| Recommendations for Primary Prevention in Adults 30 to 79 Years With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L) (Continued) |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 1  | A    | 5. In adults at intermediate (5% to <10%) 10-y estimated risk for ASCVD, at least a moderate-intensity statin is recommended to achieve ≥30% to 49% LDL-C reduction and to reduce ASCVD risk; for those in the higher end of this risk range, a high-intensity statin is beneficial to further reduce LDL-C by ≥50% and reduce ASCVD risk. <sup>5,7-10</sup> |
| 2a   | B-NR | 6. In adults at borderline (3% to <5%) or intermediate (5% to <10%) 10-y estimated risk for ASCVD in whom statin therapy is initiated, it is reasonable to treat to a goal of LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C <130 mg/dL (3.4 mmol/L) to reduce ASCVD risk. <sup>5,11,12</sup>   |
| <b>High (≥10%) 10-Year Estimated ASCVD Risk</b>  |      |  |
| 1  | A    | 7. In adults at high (≥10%) 10-y estimated risk for ASCVD in whom LLT is initiated for primary prevention, high-intensity statin therapy is recommended to achieve an LDL-C reduction of ≥50% to reduce the risk of ASCVD. <sup>5,7</sup>  |
| 2a   | B-R  | 8. In adults at high (≥10%) 10-y estimated risk for ASCVD in whom a decision to initiate statin therapy is made, it is reasonable to treat to a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) to reduce ASCVD risk. <sup>5,7,12</sup>   |
| 2a   | B-R  | 9. In adults at high (≥10%) 10-y estimated risk for ASCVD on maximally tolerated statin, it is reasonable to add ezetimibe if a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) is not achieved. <sup>13,14</sup>   |
| 2b   | B-NR | 10. In adults at high (≥10%) 10-y estimated risk for ASCVD on maximally tolerated statin with or without ezetimibe, it may be reasonable to add a PCSK9 mAb or bempedoic acid if a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) is not achieved to lower LDL-C and reduce ASCVD risk. <sup>15-17</sup>                         |
| <b>Special Considerations in Primary Prevention</b>  |      |  |
| 2b   | B-R  | 11. In individuals with a life expectancy of <1 y, it may be reasonable to discontinue LLT that was prescribed for primary prevention purposes to avoid unnecessary medication use or adverse medication effects. <sup>16,17</sup>   |
| 3: No Benefit  | B-NR | 12. In adults with a baseline untreated LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) and without additional ASCVD risk factors, initiation of LLT for primary prevention is unlikely to reduce ASCVD risk. <sup>18</sup>   |

Synopsis

After estimation of 10-year ASCVD risk by the PREVENT-ASCVD equations (Section 4.2.3.2, "PREVENT-ASCVD Equations"), as well as consideration of individual patient factors (Sections 4.2.3.3, "Risk Enhancers," 4.2.3.4, "Reproductive Risk Markers," and 4.2.3.5, "Polygenic Risk Scores"), a benefit-risk discussion is indicated to determine a decision regarding initiation of LLT. Factors that should be considered include short- and long-term risk, comorbidities, life expectancy, and



**Figure 6. Primary Prevention in Adults 30 to 79 Years Without ASCVD.**

\*For primary prevention recommendations for risk assessment and/or management in the following patient groups, please see the following: **Section 4.2.3.7, “Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8–4.9 mmol/L);” Section 4.2.4, “Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [4.9 mmol/L]);” Section 4.2.5, “Diabetes in Adults Without Established ASCVD;” Section 4.2.7, “Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 Years);” Section 4.2.8.8, “Adults With CKD–Stage 3 or Higher;” and Section 4.3.8.9, “Persons Living With HIV;”** ASCVD indicates atherosclerotic cardiovascular disease; CAC, coronary artery calcium; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and LLT, lipid-lowering therapy. Adapted with permission from Grundy et al.<sup>23</sup> © Copyright 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

patient preferences. The first line of treatment for the primary prevention of ASCVD (whether applied alone or in conjunction with pharmacotherapy) is health behavior counseling to be offered to individuals at every level of risk.<sup>1-4</sup> When the decision to initiate lipid-lowering pharmacotherapy for the primary prevention of ASCVD has been made, the first-line therapy for primary prevention of ASCVD is statin therapy. Although the variability of percentage LDL-C lowering with statin use is wide, its efficacy in ASCVD risk reduction is proportional to the magnitude of the LDL-C reduction achieved. If a decision is made to initiate statin therapy, LDL-C levels should be reduced by  $\geq 30\%$  and optimally by  $\geq 50\%$  in individuals at higher risk. If LDL-C reduction is inadequate, one should confirm patient adherence and consider statin intensification as well as the addition of other lipid-lowering agents based on patient ASCVD risk, LDL-C reduction needed, patient preference, and cost of pharmacotherapy. In most cases, the first nonstatin treatment should be ezetimibe based on data in select primary prevention populations (patients with established CKD), safety, tolerability, and accessibility.

### Recommendation-Specific Supportive Text

1. Suboptimal diet and other health behavioral factors are associated with elevated atherogenic lipoproteins, even in the absence of genetic predisposition, and should be a major focus of treatment (Section 4.1, "Lifestyle Management"). The "2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease" recommends a diet that emphasizes vegetables, fruits, legumes, nuts, whole grains, and fish to decrease ASCVD risk factors.<sup>19</sup> In addition, diets that are predominantly plant-based appear to have the greatest impact on LDL-C reduction.<sup>1</sup> A holistic approach to improving all aspects of health behaviors through the AHA Life's Essential 8 should be emphasized with particular focus on diet.
2. Health behavior counseling to reduce LDL-C and risk for ASCVD is essential to the treatment of adults who have an LDL-C  $< 160$  mg/dL (4.1 mmol/L) and are at low estimated risk for ASCVD either based on a 10-year risk estimate derived from the PREVENT-ASCVD equations of  $< 3\%$  or a 30-year risk estimate of  $< 10\%$ . These individuals still warrant a personalized approach to decisions about prevention strategies and consideration of medical therapy. However, counseling on health behaviors (particularly diet) is essential to avoid long-term exposure to atherogenic lipoproteins.<sup>1,19</sup>
3. Early life exposure to atherogenic lipid levels is a strong determinant of atherosclerosis development and future ASCVD event risk.<sup>6,20</sup> Prevention

approaches based exclusively on 10-year absolute risk estimation are poorly aligned with this long latency period between risk factor exposure, atherosclerosis initiation, progression, and eventual ASCVD events. Estimation of 30-year risk in those at low 10-year risk may help identify individuals who may benefit from LLT across longer time horizons. Similarly, individuals with elevated atherogenic lipid concentrations (LDL-C  $\geq 160$  mg/dL [4.1 mmol/L]) can benefit from earlier initiation of LLT than 10- and 30-year risk estimation would suggest.<sup>21</sup> RCTs of LLT initiation in individuals at  $< 3\%$  10-year risk due to either young age or modest risk factor burden have not been conducted due to the impracticality of very long follow-up times that would be required to detect an effect on health outcomes. Therefore, after a trial of health behavior optimization to reduce atherogenic lipid levels and the benefit-risk discussion, it is reasonable in individuals with a 30-year risk  $\geq 10\%$  or high atherogenic lipid levels to initiate LLT with the goal of reducing the cumulative exposure to atherogenic lipids across the life course, even if their 10-year estimated ASCVD risk is  $< 3\%$ . Similarly, other factors that may prompt consideration of LLT among low 10-year risk individuals include a high burden of risk enhancers or incidental finding of at least moderate CAC (Section 4.2.3.3, "Risk Enhancers," and Section 4.2.3.6, "Selective Imaging of Subclinical Atherosclerosis [Men  $\geq 40$  or Women  $\geq 45$  Years]").

4. Multiple RCTs and meta-analyses have demonstrated that statin therapy reduces the risk of ASCVD even among those with 5-year observed event rates  $< 5\%$ .<sup>5</sup> The CTT (Cholesterol Treatment Trialists) Collaboration meta-analysis observed significant ASCVD risk reduction among participants at lower risk treated with statins; in this group, the event rate per year in the placebo group was 0.2% for major coronary events and 0.1% for ischemic stroke per year, or approximately 3% at 10 years. Further, at an observed event rate of 3% in 10 years, the number needed to treat with a moderate-intensity statin is equivalent to the number needed to harm (considering incident diabetes as the harm endpoint); therefore, above this threshold, the expected benefit exceeds the potential for harm for most individuals.<sup>22</sup> Other serious adverse events from statin therapy are rare and tend to be dose-dependent and reversible. The increased precision of the PREVENT-ASCVD equations provides greater confidence in the accuracy of the risk estimates derived from the PREVENT-ASCVD equations, reducing the likelihood of overestimating 10-year risk, as was often observed when using the PCE. Given the consistent RRR in ASCVD

observed for first-line LLT agents, the higher the individual's baseline predicted risk, the greater the potential net benefit. The obverse is also true: the closer the predicted risk is to 3%, the more marginal the expected benefit—hence the need for shared decision-making. Thus, given the expected net benefit and cost-effectiveness of statin use in groups of patients with 10-year event rates  $\geq 3\%$ , in the context of the benefit-risk discussion, it is reasonable to initiate moderate-intensity statin therapy.

5. In primary prevention, for individuals with an intermediate risk (5% to  $<10\%$ ) based on the PREVENT-ASCVD equations, it is reasonable to initiate at least moderate-intensity statin therapy for an expected LDL-C lowering of  $\geq 30\%$  based on multiple RCTs showing benefit.<sup>7–10</sup> Consideration of high-intensity statins to lower LDL-C by  $\geq 50\%$  is also reasonable in individuals at intermediate risk. This is supported by the JUPITER trial, in which participants at intermediate ( $<10\%$ ) 10-year estimated ASCVD risk by the PCE achieved similar benefit to those who were at high risk, and event reduction correlated with percentage reduction in LDL-C. Wide individual variability in percentage LDL-C reduction was noted in the trial. Importantly, the magnitude of the percentage LDL-C reduction determined benefit. Consistent with RCT data, multiple observational studies illustrate the outcomes benefit of achieving and maintaining long-term low LDL-C levels.<sup>6</sup>
6. Although the benefit of LLT in RCTs was related to the percentage reduction in LDL-C based on statin intensity, it is also reasonable to consider goal attainment for the optimal reduction of event rates. In adults at either borderline (3% to  $<5\%$ ) or intermediate (5% to  $<10\%$ ) 10-year risk for ASCVD who are being initiated on statin therapy, it is reasonable to treat to an LDL-C goal of  $<100$  mg/dL (2.6 mmol/L) and non-HDL-C  $<130$  mg/dL. Data from the CARDIA cohort demonstrated that even modest incremental increases in LDL-C area under the curve were associated with a significant increase in ASCVD event rate noted over a median follow-up of 16 years. This is also illustrated in data from the FHS-OS (Framingham Heart Study Offspring) cohort, where cumulative exposure to hyperlipidemia in young adulthood increased the subsequent risk of coronary heart disease (CHD) in a dose-dependent fashion.<sup>20</sup> In addition, a systematic review and meta-analysis examining different lipid-lowering interventions showed that the relative risk of MACE was associated with the absolute reduction in LDL-C level and 5-year rates of major coronary events (coronary death or MI) associated with achieved LDL-C level, even in individuals being treated for primary prevention.<sup>6,12</sup>
7. High-intensity LLT is recommended as first-line LDL-C-lowering therapy for primary prevention of ASCVD in individuals at high risk ( $\geq 10\%$ ) for ASCVD,<sup>23</sup> with an expected LDL-C lowering of  $\geq 50\%$ . Data from 4 large-scale, exclusively primary-prevention RCTs demonstrated that moderate-intensity statin therapy<sup>7–10</sup> and high-intensity statin therapy are associated with ASCVD risk reduction, and those assigned to the high-intensity dose of rosuvastatin in the JUPITER trial achieved both greater LDL-C reduction and greater reduction in ASCVD outcomes.<sup>7</sup> Similarly, meta-analyses have demonstrated increased net benefit of evidence-based LDL-C-lowering therapy in those at risk if greater reductions in LDL-C were attained. The US Preventive Services Task Force systematic review of statin therapy in primary prevention showed a reduced risk of all-cause and cardiovascular death and ASCVD events and noted greater absolute benefits in those at greater baseline risk,<sup>24</sup> consistent with other high-quality systematic reviews and meta-analyses.<sup>25</sup> These observations underscore the need for aggressive and safe risk reduction, particularly in the highest-risk groups, and the need for follow-up LDL-C testing to determine adherence and adequacy of effect of the prescribed statin.<sup>23</sup>
8. When initiating statin therapy in adults at high ( $\geq 10\%$ ) 10-year risk for ASCVD, it is reasonable to treat to an LDL-C goal of  $<70$  mg/dL (1.8 mmol/L) and non-HDL-C  $<100$  mg/dL based on the likelihood of patient benefit and drug safety and efficacy. An analysis from CARDIA demonstrated that even small increments of LDL-C area under the curve were associated with a significant increase in event rate noted over 20 years, highlighting the potential for early intervention to improve long-term event rates. A systematic review and meta-analysis examining different lipid-lowering interventions showed that the relative risk of MACE was associated with the absolute reduction in LDL-C level, and 5-year rates of major coronary events (coronary death or MI) correlated with achieved LDL-C levels even in individuals being treated for primary prevention.<sup>12</sup> Similar to attainment of LDL-C goals in the borderline- and intermediate-risk groups, the concept is even more applicable in individuals at high risk who would potentially have greater risk reduction.
9. Individuals at high ( $\geq 10\%$ ) 10-year estimated risk for ASCVD, based on the PREVENT-ASCVD equations, have an event risk that is similar to patients with established ASCVD, warranting intensification of LLT, with the goal of attaining an LDL-C goal of  $<70$  mg/dL (1.8 mmol/L) and non-HDL-C  $<100$  mg/dL (2.6 mmol/L). Meta-analyses of multiple clinical trials show benefit in achieving low, sustained absolute LDL-C levels as well as benefit from

≥50% reduction in LDL-C. Combination therapies with statins and ezetimibe have also been shown to be effective and well tolerated, making it reasonable to consider high-intensity statins or statin combined with ezetimibe to achieve an optimal LDL-C reduction.<sup>26</sup> The SHARP (Study of Heart and Renal Protection) randomized participants to simvastatin 20 mg plus ezetimibe 10 mg versus matching placebo, showing an HR of 0.85 for MACE, but in a very select patient population (patients with CKD).<sup>13</sup> A matched cohort of primary prevention in a Korean National Health Insurance Service datasets that applied propensity matching noted that a moderate-intensity statin with ezetimibe combination was superior to high-intensity statin monotherapy in preventing the composite outcomes as well as individual outcomes of MI and stroke, whereas low-intensity statin with ezetimibe combination reduced the risk of composite but not individual outcomes.<sup>14</sup> A recent meta-analysis showed that early combination therapy in patients treated for secondary prevention improved LDL-C lowering and cardiovascular outcomes compared with monotherapy, with the same safety and tolerability in each arm.<sup>27</sup> Based on safety, efficacy, and observational data, it is reasonable to consider the addition of ezetimibe if needed to achieve LDL-C treatment goals for primary prevention in individuals at high ASCVD risk.

10. Beyond ezetimibe, additional agents can be considered as adjuncts to maximally tolerated statins in individuals at high risk for ASCVD. Bempedoic acid has been shown to reduce ASCVD events in high-risk primary prevention populations, demonstrating a significant reduction in MACE compared with placebo. Participants at high risk of ASCVD, being treated for primary prevention and enrolled in CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen), were unable to take recommended dose statins due to statin-attributed side effects and had advanced subclinical atherosclerosis, diabetes, or were at high risk for ASCVD.<sup>15</sup> Bempedoic acid was used predominantly as monotherapy, with few participants on moderate- or high-intensity statins combined with ezetimibe. Although bile acid sequestrants have evidence for reducing cardiovascular outcomes, their use is complicated by limitations in dosing regimen and issues with tolerability.<sup>28</sup> PCSK9 mAbs have outcomes data in secondary prevention; however, outcomes in primary prevention are pending the completion of the VESALIUS CV (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke) trial (NCT03872401). Inclisiran is safe and effective for LDL-C lowering, with outcomes data pending for secondary prevention from ORION 4 (A Randomized Trial Assessing the Effects

of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease) (NCT03705234) and VICTORION-2 PREVENT (Study of Inclisiran to Prevent Cardiovascular Events in Participants With Established Cardiovascular Disease) (NCT05030428), as well as in primary prevention from VICTORION-1 PREVENT (A Study of Inclisiran to Prevent Cardiovascular Events in High-Risk Primary Prevention Patients) (NCT05739383). Each of these therapies may be considered in the context of a benefit-risk discussion, and cost and patient preferences should be factored into the decision. The decision to treat with more expensive therapies should be reserved for those who are not likely to attain optimal lipid lowering and are more likely to benefit from LDL-C lowering.

11. High competing risks for non-ASCVD death can reduce the expected benefits of LLT for primary prevention. In addition, there are legitimate concerns regarding polypharmacy in individuals with limited life expectancy. Thus, it is unclear if continuation of statin therapy for those with limited life expectancy due to chronic disease or extremes of age provides benefit. Data to guide discontinuation of LLT for primary prevention in people with limited life expectancy are sparse. Recent observational data indicate that older patients who discontinued statin therapy for primary prevention experienced higher ASCVD event rates over a 5-year follow-up, although the differences in event rates were modest at 1 to 2 years.<sup>16</sup> One RCT of 381 adults (mixture of primary and secondary prevention patients) with an estimated life expectancy <1 year found that stopping statins led to improved quality of life (QOL) but not a significant increase in short-term mortality. Although predicting expected survival time is very difficult in clinical practice, it is reasonable to discontinue statin therapy in patients for whom the life expectancy is <1 year to avoid unnecessary medication use and risks for DDI or other adverse medication effects.<sup>17</sup>
12. The absolute benefits of LLT in primary prevention are driven by baseline ASCVD risk as well as the expected reduction in atherogenic lipid levels with therapy.<sup>12</sup> Pharmacological approaches that work through the LDL receptor mechanism (statins, bempedoic acid, ezetimibe, and PCSK9 therapeutics) provide predictable *percentage* reductions in LDL-C when compared with placebo or standard treatment groups. Thus, the *absolute* reductions in atherogenic lipids are modest when baseline levels of LDL-C are <70 mg/dL, as are the potential benefits of LLT in primary prevention when atherogenic lipid levels are this low. Further, few individuals with LDL-C <70 mg/dL were included in primary prevention trials, and post hoc analyses suggest

limited absolute benefit to treatment with statins at low baseline LDL-C.<sup>18</sup> Thus, in primary prevention, there is no clear net benefit to initiation of LLT for individuals with untreated LDL-C levels <70 mg/dL and non-HDL-C levels <100 mg/dL.

#### 4.2.4. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL [4.9 mmol/L])

##### 4.2.4.1. Role of Risk Assessment in HeFH

| Recommendations for Role of Risk Assessment in HeFH<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 2b   | B-NR | 1. In adults with HeFH, FH-specific risk scores may be useful in predicting short-term ASCVD risk. <sup>1-5</sup>  |
| 3: Harm  | C-EO | 2. In individuals with HeFH, standard risk assessment tools developed for the general population should not be used to calculate 10- or 30-y ASCVD risk. |

### Synopsis

HeFH is associated with a 2- to 4-fold lifetime risk of ASCVD events compared with the general population,<sup>6,7</sup> with young adults being at even higher risk (up to 17-fold).<sup>8</sup> Estimating ASCVD risk in individuals with HeFH is challenging, as standard risk estimation equations were developed in the general population, not in FH populations. General population risk equations (eg, PCE, PREVENT-ASCVD equations) likely underestimate ASCVD risk in individuals with HeFH.<sup>2</sup> Several FH-specific risk scores have been developed that show promise for assessing short-term ASCVD risk<sup>2,5</sup>; however, long-term validation in more diverse FH cohorts has yet to be performed. Calcium scoring is not indicated in individuals with FH, as they are at high risk of ASCVD and benefit from statin therapy. CAC=0 may not be used to “de-risk” patients with FH or justify deferral of statin therapy in persons with FH.

### Recommendation-Specific Supportive Text

- Several FH-specific scores have been created to estimate the ASCVD risk in adults with FH. The Montreal-FH-SCORE was derived from a cross-sectional analysis of French-Canadians with a confirmed pathogenic *LDLR* variant<sup>9</sup> and externally validated in another group of adults with HeFH, identifying prevalent ASCVD events with reasonably good accuracy.<sup>3</sup> Another score developed in SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) from prospective follow-up of patients treated for primary and secondary prevention with FH, followed for 5.5 years predicted incident ASCVD events with good performance.<sup>1,2</sup> Similar results were seen when validated in the REFERCHOL (National French

Registry of FH) cohort.<sup>5</sup> The FH-Risk Score was developed using the largest derivation population taken from 5 FH registries with a molecular or clinical diagnosis of HeFH without prior ASCVD.<sup>4</sup> The FH-Risk Score predicted incident ASCVD over 10 years of follow-up with better discrimination than the SAFEHEART risk equation. Subjects with an FH-Risk Score above the median had a substantially lower 10-year ASCVD-free survival, 10-year MACE-free survival, and up to 10-fold lower 30-year survival for cardiovascular mortality compared with the low-risk group.<sup>5</sup> The FH-Risk Score has not yet been validated in diverse populations, including non-European ethnic groups, nor assessed as a clinical tool to guide LLT recommendations.

- The risk of ASCVD in individuals with HeFH is 2- to 4-fold higher than the general population,<sup>6,7</sup> and ASCVD presents earlier than in those without HeFH; adults <35 years have up to a 17-fold higher lifetime ASCVD risk.<sup>8</sup> There is minimal literature on the use of general population risk scores in persons with HeFH<sup>2</sup>; risk equations such as the PREVENT-ASCVD equations were developed in populations without FH and likely significantly underestimate risk in persons with FH. Therefore, standard risk assessment tools developed for the general population should not be used to calculate 10- or 30-year ASCVD risk. LLT is recommended for individuals with HeFH to prevent ASCVD (Section 4.2.4.3, “Severe Hypercholesterolemia With LDL-C ≥190 mg/dL [4.9 mmol/L]”). Calcium scoring is not indicated in individuals with FH to defer LLT, as they are at high risk of ASCVD and should benefit from statin therapy; specifically, a CAC of 0 may not be used to “de-risk” patients with FH or justify deferral of statin therapy.

##### 4.2.4.2. Genetic Testing for FH

| Recommendations for Genetic Testing for FH<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 1   | B-NR | 1. In adults with possible, probable, or definite FH, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH is beneficial to identify individuals at highest risk of cardiovascular events and to facilitate cascade screening. <sup>1-4</sup>                                  |
| 2a  | B-NR | 2. In adults with severe hypercholesterolemia with an LDL-C ≥190 mg/dL (4.9 mmol/L) without an identified secondary cause, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH can be useful to identify those with FH who are at higher risk of ASCVD events. <sup>1,2</sup> |
| 2b  | B-NR | 3. In adults with an elevated LDL-C of 160 to 189 mg/dL (4.1–4.9 mmol/L) without an identified secondary cause, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH may be considered to identify those with FH who are at higher risk of events. <sup>1,2</sup>              |

### Synopsis

Panel-based genetic testing can identify variants in *LDLR*, *APOB*, or *PCSK9* that cause FH. The prevalence of monogenic FH is approximately 1:250, but FH is significantly underdiagnosed.<sup>5,6</sup> Regardless of LDL-C level, individuals with an FH-causing variant are at higher risk for CAD, including those with clinically diagnosed FH. Genetic testing may improve detection rates for FH, particularly in individuals without severely elevated LDL-C but who have other factors suggestive of FH. Among those with FH, genetic testing can identify adults at increased risk for ASCVD and may lead to improvements in the treatment of elevated LDL-C.

### Recommendation-Specific Supportive Text

- Panel-based genetic testing for rare variants for FH is useful to identify genetic variants in *LDLR*, *APOB*, and *PCSK9* that cause autosomal dominant HeFH, as well as more rare autosomal recessive forms of FH and conditions that mimic FH.<sup>7</sup> Among adults with clinically diagnosed FH, the presence of an FH-causing variant compared with the absence increases the risk of ASCVD beyond the risk associated with LDL-C levels.<sup>1,3,8,9</sup> Genetic testing can be used to facilitate cascade screening to identify relatives of individuals diagnosed with FH who also have FH. Although LDL-C testing is widely accessible and can be used for cascade screening, using LDL-C alone may miss individuals with FH who may have more moderate elevations in LDL-C levels.<sup>1,4,5,10</sup> Conversely, not all individuals with clinical FH have an identifiable pathogenic variant using current genetic testing approaches.<sup>1,11</sup> Although PRS for LDL-C have been derived, they are not considered in standard panel-based genetic testing for rare variants for FH, and their general clinical utility remains presently unclear. Lack of identification of a pathologic or likely pathologic variant does not completely rule out FH in a person who meets clinical criteria and should not dissuade LDL-lowering treatment. Poorly characterized variants in the literature, often observed among individuals of non-European ancestry, may lead to false-negative genetic tests.<sup>12,13</sup> Cascade screening in those without an identified genetic variant or those who do not have access to genetic testing can be performed using lipid testing.
- Among adults with severe hypercholesterolemia (LDL-C  $\geq 190$  mg/dL [ $\geq 4.9$  mmol/L]), and/or apoB  $\geq 140$  mg/dL, approximately 2.5% have a pathogenic/likely pathogenic rare variant for FH.<sup>2,5</sup> The presence of a genetic variant for FH is associated with a markedly higher risk of CAD in adults with severe hypercholesterolemia.<sup>2,8</sup> Although the prevalence of

a pathogenic/likely pathogenic rare variant for FH is substantially higher in those with clinically diagnosed FH, most persons with genetically confirmed FH do not meet clinical criteria for probable or definite FH despite being at increased risk of CAD.<sup>10,14</sup> Thus, screening only those who meet clinical criteria will leave many cases undiagnosed. In addition to improving risk stratification, identification of genetically confirmed FH may also lead to improved treatment of elevated LDL-C. Observational studies, including prospective evaluations, have shown improved rates of treatment for LDL-C in individuals with FH after return of genetic results.<sup>4,6,10</sup>

- Using an LDL-C cutoff of 190 mg/dL (4.9 mmol/L) may fail to identify many adults with FH. In 1 study in the United States, only 54% of those with an FH-causing variant had a documented LDL-C  $\geq 190$  mg/dL (4.9 mmol/L).<sup>5</sup> A lower cutoff for screening will increase the identification of cases at the expense of a lower diagnostic yield. Although approximately 2.5% of those with an LDL-C  $\geq 190$  mg/dL (4.9 mmol/L) have an FH variant, the prevalence in those with an LDL-C of 155 to 190 mg/dL (4.0-4.6 mmol/L) is 1.1%.<sup>5</sup> Given the large number of individuals with an LDL-C between 160 and 189 mg/dL (4.1-4.9 mmol/L), universal screening at an LDL-C  $\geq 160$  mg/dL (4.1 mmol/L) is impractical. However, the diagnostic yield is greater in those with clinical suspicion of FH and may be reasonable in those with a family history of premature CAD, early onset severe hypercholesterolemia, or descent from founder populations.<sup>1,13,15</sup>

#### 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq 190$ mg/dL (4.9 mmol/L)

| Recommendations for Severe Hypercholesterolemia With LDL-C $\geq 190$ mg/dL (4.9 mmol/L)*  |      |   |
|--|------|---|
| Referenced studies that support recommendations are summarized in the Evidence Table.  |      |   |
| COR  | LOE  | Recommendations   |
| 1  | B-NR | 1. In adults with severe hypercholesterolemia with an LDL-C $\geq 190$ mg/dL (4.9 mmol/L),* secondary causes of dyslipidemia should be excluded and addressed to reduce LDL-C (Table 15). <sup>1</sup>  |
| 1  | B-R  | 2. In adults with severe hypercholesterolemia with an LDL-C $\geq 190$ mg/dL (4.9 mmol/L),* treatment with maximally tolerated statin therapy is recommended to lower LDL-C and reduce ASCVD risk. <sup>2-5</sup>   |
| Severe Hypercholesterolemia in Primary Prevention (Without HeFH, Subclinical Atherosclerosis, and Additional ASCVD Risk Factors) |      |   |
| 1  | B-NR | 3. In adults with severe hypercholesterolemia with an LDL-C $\geq 190$ mg/dL (4.9 mmol/L)* and without clinical ASCVD,† additional ASCVD risk factors, HeFH, or subclinical atherosclerosis who are on maximally tolerated statin therapy, the addition of ezetimibe, <sup>6</sup> a PCSK9 mAb, <sup>7,8</sup> and/or bempedoic acid <sup>6</sup> is recommended to achieve a goal of LDL-C $< 100$ mg/dL (2.6 mmol/L) and a non-HDL-C goal of $< 130$ mg/dL (3.4 mmol/L) and to reduce ASCVD risk. |

Downloaded from http://ahajournals.org by on March 15, 2026

| Recommendations for Severe Hypercholesterolemia With LDL-C ≥190 mg/dL (4.9 mmol/L)* (Continued)     |     |   |
|---|-----|---|
| COR   | LOE | Recommendations   |
| Severe Hypercholesterolemia With HeFH, Subclinical Atherosclerosis, or With Additional Risk Factors |     |   |
| 1   | B-R | 4. In adults with severe hypercholesterolemia with an LDL-C ≥190 mg/dL (4.9 mmol/L)* without clinical ASCVD† but with clinical or genetic confirmation of HeFH,‡ additional ASCVD risk factors,§ or documented coronary calcification,§ who are on maximally tolerated statin therapy, the addition of ezetimibe, <sup>10</sup> a PCSK9 mAb, <sup>7b</sup> and/or bempedoic acid <sup>11</sup> to achieve a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L) is recommended to lower LDL-C and reduce ASCVD risk. |
| Severe Hypercholesterolemia With Clinical ASCVD   |     |   |
| 1   | B-R | 5. In adults with severe hypercholesterolemia with an LDL-C ≥190 mg/dL (4.9 mmol/L)* and clinical ASCVD who are on maximally tolerated statin therapy, the addition of ezetimibe, <sup>10</sup> a PCSK9 mAb, <sup>12,13</sup> and/or bempedoic acid <sup>11</sup> is recommended to achieve a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) to lower LDL-C and reduce ASCVD risk.   |
| Inclisiran in Severe Hypercholesterolemia   |     |   |
| 2a  | B-R | 6. In adults with severe hypercholesterolemia, with or without clinical ASCVD, and LDL-C ≥100 mg/dL (2.6 mmol/L) despite maximally tolerated statin with or without ezetimibe therapy, treatment with inclisiran <sup>14</sup> is reasonable to lower LDL-C.‡   |

\*Severe hypercholesterolemia with LDL-C >190 mg/dL, non-HDL-C >220 mg/dL, and/or apoB >140 mg/dL.

†Clinical ASCVD includes ACS, a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, lower-extremity PAD, or other atherosclerotic forms of PAD, including aortic aneurysm.

‡Cardiovascular outcomes trials are pending for inclisiran. It is indicated only to lower LDL-C and is considered a second-line PCSK9i at this time.

### Synopsis

Adults with severe hypercholesterolemia with LDL-C ≥190 mg/dL (4.9 mmol/L) and/or apoB ≥140 mg/dL are a population at high lifetime ASCVD risk. Management should include the prescription of evidence-based lifestyle habits and LDL-C-lowering drug therapy focused on ASCVD risk reduction. Cascade screening and panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH, if available, are indicated for those with possible or known FH. Maximally tolerated statin therapy is the first step in drug therapy. Use of add-on therapy, with preference given to those drugs with favorable ASCVD outcomes data in high-risk populations, should be allocated in accordance with absolute ASCVD risk, severity, and presumed duration of LDL-C elevation, the absence or presence of clinical ASCVD, tolerability, cost of treatment, and patient preference. Progressively lower LDL-C treatment goals should be employed in accordance with higher absolute ASCVD risk. In those unable to tolerate or gain access to drugs with favorable ASCVD out-

**Table 15. Physiological and Secondary Causes of Hypercholesterolemia Due to LDL-C**

|  |  |
|--|--|
| Dietary factors  |  |
| High saturated fat intake  |  |
| High trans-fat intake  |  |
| High cholesterol intake  |  |
| Weight gain  |  |
| Rapid weight loss  |  |
| Ketosis  |  |
| Metabolic factors  |  |
| Hypothyroidism   |  |
| Obstructive liver disease  |  |
| Chronic kidney disease   |  |
| Nephrotic syndrome   |  |
| Diabetes and other insulin-resistant states (excess small LDL particles) |  |
| Uncontrolled hyperglycemia   |  |
| Cushing syndrome   |  |
| Anorexia nervosa   |  |
| Obesity  |  |
| Drugs  |  |
| High-dose thiazide diuretics   |  |
| Glucocorticoids  |  |
| Estrogens  |  |
| Androgens  |  |
| Atypical antipsychotic drugs   |  |
| Cyclosporine   |  |
| Physiological  |  |
| Menopausal transition  |  |
| Pregnancy  |  |



LDL indicates low-density lipoprotein. Modified with permission from Virani et al.<sup>22</sup> © 2021 American College of Cardiology Foundation.

comes, drugs that lower LDL-C without ASCVD outcomes data may be considered. Lipoprotein apheresis may be indicated for select individuals (Table 16). For those with homozygous FH, consultation with a lipid specialist for consideration of advanced add-on therapies, including lomitapide, evinacumab, and/or lipoprotein apheresis, is recommended to lower LDL-C (Table 5, Section 4.2.1, "Pharmacological Therapy," Table 16, and Figure 7).

### Recommendation-Specific Supportive Text

1. In adults with severe hypercholesterolemia without clinical or genetic confirmation of FH and without ASCVD, evaluation to identify secondary causes of dyslipidemia (Table 15)<sup>1</sup> should be performed. These disorders should be addressed and treated whenever possible to reduce LDL-C. Simple carbohydrate-restricted eating patterns, such as the ketogenic diet, in which carbohydrate intake

**Table 16. Liposorber® (LA-15 System) FDA-Approved Indications for Lipoprotein Apheresis\***

| Patient Group | Criteria for Treatment  |
|---------------|---|
| Group A       | Clinically diagnosed familial hypercholesterolemic homozygotes with LDL-C >500 mg/dL  |
| Group B       | Clinically diagnosed familial hypercholesterolemic heterozygotes with LDL-C ≥300 mg/dL  |
| Group C       | Clinically diagnosed familial hypercholesterolemic heterozygotes with LDL-C ≥70 mg/dL and either documented coronary artery disease or documented peripheral artery disease                 |
| Group D       | Clinically diagnosed familial hypercholesterolemic heterozygotes with Lp(a) ≥60 mg/dL (or 130 nmol/L) and either documented coronary artery disease or documented peripheral artery disease |

\*As of January 2025; for updated indications for use, please review the web-site: <https://liposorber.com/posts/expanded-indication-for-kanekas-liposorber-la-15-system/>. The device listed is provided solely as an example of an FDA-approved device of this type and does not imply endorsement of any commercial product, process, service, or enterprise by the AHA or ACC.

FDA indicates US Food and Drug Administration; LDL-C, low-density lipoprotein-cholesterol; and Lp(a), lipoprotein(a).


is reduced to about 20 to 50 g/day, are often employed for weight loss. As most carbohydrates in these diets are replaced by fat, often saturated fat, some individuals, with or without lipid disorders, may manifest a severe hypercholesterolemia phenotype.<sup>15,16</sup> Therefore, all patients with severe hypercholesterolemia should receive a careful dietary history to exclude a high saturated fat diet as an etiology for their lipid disorder. Those who are found to have severe hypercholesterolemia due to ketogenic diet should be counseled on ways to mitigate the LDL-C elevation while still achieving the primary goal of the dietary change (Section 4.1, “Lifestyle Management”).

2. Patients with severe primary hypercholesterolemia have an increased risk of premature and recurrent coronary events that varies in proportion to the degree of elevation and the duration of exposure to an excessive concentration of LDL-C and apoB.<sup>17</sup> Although randomized ASCVD outcomes trials of statin therapy in exclusively hypercholesterolemic persons with LDL-C ≥190 mg/dL have not been conducted, an RCT of pravastatin 40 mg daily versus placebo in a hypercholesterolemic Scottish cohort of 6695 men with a mean baseline LDL-C level of 192 ± 17 mg/dL (4.9 mmol/L) showed that pravastatin reduced the incidence of MI and cardiovascular death over 4.9 years.<sup>2</sup> A post hoc analysis of this trial in 2560 primary prevention subjects with LDL-C ≥190 mg/dL (4.9 mmol/L) showed that pravastatin significantly reduced the risk of incident CHD and MACE during the initial trial and of CHD death, cardiovascular death, and all-cause mortality over 20 years of follow-up.<sup>3</sup> The benefit of statin therapy is further supported

by retrospective cohort studies demonstrating a reduced risk of incident MI, CHD, and all-cause mortality.<sup>4,5</sup> As high-intensity statins provide greater ASCVD risk reduction compared to moderate intensity statins,<sup>18</sup> maximally tolerated statin therapy is recommended for such patients.

3. Based on their high lifetime risk for clinical ASCVD,<sup>19</sup> patients with severe hypercholesterolemia, even in the absence of ASCVD, clinical or genetic confirmation of FH, additional ASCVD risk factors, or subclinical atherosclerosis, are at increased risk for ASCVD events. In addition to lifestyle counseling focusing on heart-healthy dietary patterns and regular physical activity, these patients should receive maximally tolerated statin therapy, with a minimal goal to lower their LDL-C and non-HDL-C levels to those considered optimal for the general population (LDL-C <100 mg/dL [2.6 mmol/L] and non-HDL-C <130 mg/dL [3.4 mmol/L]). For those individuals who require additional LLT to achieve those goals, ezetimibe,<sup>10</sup> a PCSK9 mAb,<sup>12,13</sup> and/or bempedoic acid<sup>6</sup> are evidence-based options to lower LDL-C and reduce ASCVD risk.
4. Individuals with severe hypercholesterolemia in the absence of clinical ASCVD, but with clinical or genetic confirmation of HeFH,<sup>7,20</sup> additional ASCVD risk factors,<sup>8</sup> and/or documented coronary calcification<sup>9</sup> harbor an even greater risk of clinical ASCVD than those without these factors. Consequently, a more aggressive approach to LLT should be undertaken. To achieve greater LDL-C lowering and greater ASCVD risk reduction in such patients, the addition of ezetimibe,<sup>10</sup> PCSK9 mAbs,<sup>12,13</sup> and/or bempedoic acid<sup>11</sup> to maximally tolerated statin therapy are additional therapeutic options to achieve their desired LDL-C goal of <70 mg/dL (1.8 mmol/L) and non-HDL-C goal of <100 mg/dL (2.6 mmol/L).
5. Patients with clinical ASCVD and severe hypercholesterolemia are among the highest-risk individuals for recurrent ASCVD events. The CASCADE-FH (Cascade Screening for Awareness and Detection) registry reported a 5.6-fold higher likelihood of incident ASCVD events in patients with FH and prior ASCVD compared with those without.<sup>20</sup> Such patients almost always require aggressive combination therapy to lower LDL-C and reduce the risk of recurrent coronary events. In addition to maximally tolerated statin therapy, evidence-based therapeutic options for such patients include ezetimibe,<sup>10</sup> PCSK9 mAbs<sup>12,13</sup> and/or bempedoic acid<sup>11</sup> to achieve an LDL-C goal of <55 mg/dL (1.4 mmol/L) and a non-HDL-C goal of <85 mg/dL (2.2 mmol/L). Because of the very high ASCVD risk harbored by these patients, it may be reasonable, once the LDL-C and non-HDL-C goals are

## Evaluation and Management of Severe Hypercholesterolemia



2026 Dyslipidemia

© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 7. Evaluation and Management of Severe Hypercholesterolemia.**

\*Related to Lipoprotein Goals for ASCVD Risk Reduction table. †Cardiovascular outcomes trials with inclisiran are pending. ApoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9.

achieved, to check apoB with a goal of <55 mg/dL to minimize residual risk due to excessive concentration of atherogenic particles.

6. The safety and efficacy of inclisiran were tested in a randomized, double-blind placebo-controlled trial involving 482 patients with HeFH.<sup>21</sup> The active drug or placebo was administered on day 1, at 3 months, and then at 2 subsequent 6-month intervals. The difference in LDL-C measured 60 days after the last injection was nearly 50%, favoring inclisiran,

and the drug was well tolerated, except for a higher incidence of mild-to-moderate injection site reactions. Cardiovascular outcomes trials are currently in progress, and pending these results, inclisiran remains a second-line PCSK9 mAb. The addition of inclisiran in patients with severe hypercholesterolemia and LDL-C  $\geq$ 100 mg/dL (1.8 mmol/L), who are receiving maximally tolerated statin therapy, with or without ezetimibe, is a reasonable option to further lower LDL-C.

#### 4.2.4.4. Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH

| Recommendations for Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
|---|------|--|
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. In adults with clinical and/or genetic confirmation of homozygous familial hypercholesterolemia (HoFH), consultation with a lipid specialist is recommended for consideration of advanced LDL-C-lowering drug therapies and/or lipoprotein apheresis to lower LDL-C. <sup>1,2</sup>                             |
| 1   | B-R  | 2. In adults with clinical or genetic confirmation of HoFH, treatment with maximally tolerated statin therapy is recommended to reduce ASCVD risk. <sup>3-6</sup>  |
| 2a  | B-R  | 3. In adults with clinical or genetic confirmation of HoFH currently on maximally tolerated statin therapy, the addition of ezetimibe, <sup>3</sup> PCSK9 mAb, <sup>4-6</sup> and/or bempedoic acid is reasonable to lower LDL-C.  |
| 2b  | B-R  | 4. In adults with clinical or genetic confirmation of HoFH currently on maximally tolerated statin therapy, ezetimibe, and PCSK9 mAb with an LDL-C $\geq 100$ mg/dL (2.6 mmol/L), <sup>7,8</sup> the addition of evinacumab <sup>1,9</sup> may be reasonable to lower LDL-C.                                       |
| 2b  | C-LD | 5. In adults with clinical or genetic confirmation of HoFH currently on maximally tolerated statin therapy, ezetimibe, and PCSK9 mAb with LDL-C $\geq 100$ mg/dL (2.6 mmol/L), <sup>7,8</sup> the addition of lomitapide <sup>2</sup> with regular monitoring for hepatic safety may be reasonable to lower LDL-C. |

### Synopsis

HoFH is an autosomal dominant genetic disorder characterized by marked elevation in LDL-C due to maternal and paternal pathogenic/likely pathogenic rare variants in the genes encoding for *LDLR*, *APOB*, *PCSK9*, and rarely *ARH* or *LDLRAP1*, with resultant severe elevation in LDL-C, premature ASCVD, and aortic valve disease. These patients have markedly reduced LDL affinity and clearance by LDL receptors and exhibit a severely blunted response or lack of response to traditional LDL-C-lowering therapies that act via increased expression of LDL receptors, including statins, ezetimibe, bempedoic acid, and PCSK9 mAbs and inclisiran. In such patients, combination therapy starting with statins, ezetimibe, and PCSK9 mAbs is usually initiated, but additional LDL-C-lowering therapies are generally required. For that reason, referral to a lipid specialist for the initiation of advanced therapies that lower LDL-C by mechanisms independent of LDL-C receptor activity, including lomitapide and/or evinacumab, is generally warranted. In those who exhibit suboptimal responses to the above therapies, referral for lipoprotein apheresis may be considered (Figure 8).



### Recommendation-Specific Supportive Text

1. Patients with HoFH have extreme elevations in LDL-C detectable from birth. Cholesterol deposition occurs in tendons, cutaneous tissues, the coronary arteries,

aortic valve and root, and in all major vascular beds, and premature ASCVD events are commonly seen. Early detection and treatment are critical to mitigate risk. Most currently available LLT (statins, cholesterol absorption inhibitors, PCSK9 mAbs, adenosine triphosphate citrate lyase inhibitors) lower LDL-C via an increase in LDL receptor expression. However, patients with HoFH have severe abnormalities in the expression or function of LDL receptors and exhibit blunted responsiveness or failure to respond to most commonly employed LDL-C-lowering drug therapies. Consultation with a lipid specialist with expertise in the use of less commonly employed therapies that act independently of the LDL receptor (lomitapide,<sup>2</sup> evinacumab,<sup>1</sup> and/or lipoprotein apheresis [Table 16]) is beneficial for patients with HoFH. In addition, because of the high risk for clinical ASCVD,<sup>7,8</sup> ongoing cardiology follow-up is advisable. Family cascade screening is necessary because both parents will often have HeFH (note: gene variants on 2 different chromosomes, such as *LDLR* and *APOB*, can be inherited from 1 or both parents).

2. Patients with HoFH have an increased risk of premature and recurrent coronary events that varies in proportion to the degree of elevation and the duration of endothelial exposure to an excessive concentration of LDL-C.<sup>10</sup> Although randomized ASCVD outcomes trials of statin therapy in HoFH subjects have not been done, an RCT of pravastatin 40 mg daily versus placebo in a hypercholesterolemic Scottish cohort of 6695 men with a mean baseline LDL-C level of  $192 \pm 17$  mg/dL (4.9 mmol/L) showed that pravastatin reduced the incidence of MI and cardiovascular death over 4.9 years.<sup>11</sup> A post hoc analysis of this trial in 2560 primary prevention subjects with LDL-C  $\geq 190$  mg/dL (4.9 mmol/L) showed that pravastatin significantly reduced the risk of incident CHD and MACE during the initial trial and of CHD death, cardiovascular death, and all-cause mortality over 20 years of follow-up.<sup>12</sup> The benefit of statin therapy is further supported by retrospective cohort studies demonstrating a reduced risk of incident MI, CHD, and all-cause mortality.<sup>13,14</sup> As high-intensity statins provide greater ASCVD risk reduction compared with moderate-intensity statins in a wide range of CVOTs,<sup>15</sup> maximally tolerated statin therapy is recommended for such patients because people with some residual low-density lipoprotein receptor activity do have a greater response to statin therapy.
3. Because of a very high short-term and lifetime ASCVD risk in adults with HoFH,<sup>7,8</sup> and because first MACE have been reported to occur at median ages of 37 and 25 years, respectively, in high-income versus lower-income countries, aggressive LDL-C-lowering therapy is warranted as soon as

## Evaluation and Management of HoFH



2026 Dyslipidemia  
© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 8. Evaluation and Management of HoFH.**

HoFH indicates homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; and PCSK9, proprotein convertase subtilisin/kexin type 9.

the diagnosis is made. In patients with HoFH, the addition of safe, effective, and well-tolerated therapies with randomized controlled cardiovascular outcomes trial evidence (ezetimibe,<sup>3</sup> alirocumab<sup>5</sup> and evolocumab,<sup>4</sup> and bempedoic acid<sup>6</sup>) is reasonable to lower LDL-C.<sup>16</sup> There is conflicting evidence on the efficacy of inclisiran for LDL-C lowering in HoFH; thus, a recommendation for use of this PCSK9i has not been made in this patient group.<sup>16</sup>

4. Inhibition of ANGPTL3 by the mAb evinacumab facilitates the hepatic uptake of VLDL remnants and intermediate-density lipoprotein particles before they are converted to LDL, effectively reducing LDL-C levels. This mechanism is particularly beneficial in patients with HoFH, where LDL receptor function is impaired, as it provides an alternative pathway for clearing atherogenic lipoproteins. Enhanced VLDL particle and remnant catabolism reduces LDL-C concentration by mechanisms that are independent of LDL receptors, a therapeutic strategy that is beneficial for those with HoFH. Based on RCT evidence that evinacumab lowers LDL-C levels by about 49% compared with placebo in patients with HoFH who were taking maximal lipid-lowering drug therapy and that it has a favorable safety profile,<sup>9</sup> the medication received approval for such patients in a dosage of 15 mg/kg by intravenous infusion once per month. In adults with HoFH with LDL-C  $\geq 100$  mg/dL (2.6 mmol/L) despite maximally tolerated statin, ezetimibe, and PCSK9 mAb, the addition of evinacumab may be considered to further lower LDL-C. The decision to use evinacumab for additional LDL-C lowering should be based on individual patient characteristics, tolerability, access to therapy, and patient preferences.
5. As an inhibitor of microsomal TG transfer protein, lomitapide reduces levels of all apoB-containing lipoproteins, including VLDL, LDL, and chylomicrons, and acts independently of the LDL receptor.<sup>17</sup> A systematic review of 18 studies (2 single-arm studies, 2 retrospective case series, and 14 case reports) identified 15 studies involving 106 adult patients with HoFH receiving lomitapide therapy. In the single-arm studies, LDL-C reduction was generally  $>50\%$ , and in the retrospective case series the reduction was  $>60\%$ .<sup>2</sup> Multiple drug interactions, gastrointestinal side effects, and the need to follow a low-fat diet to reduce steatorrhea may limit drug tolerability. Due to the mild-to-moderate liver fat accumulation and concomitant transaminase elevations, the FDA requires that this drug be prescribed using a Risk Evaluation and Mitigation Strategy with regular monitoring of liver function. The use of this drug may be considered in patients with HoFH to achieve further LDL-C lowering despite maximally tolerated statin, ezetimibe, and PCSK9 mAb therapy.

#### 4.2.5. Diabetes in Adults Without Established ASCVD

**Recommendations for Adults With Diabetes Without Established ASCVD**  
Referenced studies that support recommendations are summarized in the Evidence Table.

| COR | LOE  | Recommendations  |
|-----|------|--|
| 1   | A    | 1. In adults 40 to 75 y of age with diabetes and without clinical ASCVD, moderate-intensity statin therapy is indicated to achieve a $\geq 30\%$ to 49% reduction in LDL-C and a goal of LDL-C $< 100$ mg/dL (2.6 mmol/L) and non-HDL-C $< 130$ mg/dL (3.4 mmol/L) to reduce ASCVD risk. <sup>1,2</sup>  |
| 1   | B-R  | 2. In adults with diabetes who have statin-attributed side effects, initiation of ezetimibe and/or bempedoic acid or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk. <sup>3-6</sup>   |
| 2a  | B-R  | 3. In adults 40 to 75 y of age with diabetes who have multiple ASCVD risk factors, it is reasonable to prescribe high-intensity statin therapy to achieve a $\geq 50\%$ reduction in LDL-C and a goal of LDL-C $< 70$ mg/dL (1.8 mmol/L) and non-HDL-C $< 100$ mg/dL (2.6 mmol/L) to reduce ASCVD risk. <sup>1</sup>   |
| 2b  | B-R  | 4. In adults with diabetes without ASCVD but with additional ASCVD risk factor(s)* on a statin with an LDL-C $< 100$ mg/dL (2.6 mmol/L) and elevated fasting TG (150–499 mg/dL [1.7–5.6 mmol/L]), the addition of IPE may be considered to reduce ASCVD risk. <sup>7</sup>   |
| 2b  | C-LD | 5. In adults with diabetes and a 10-y ASCVD risk of $\geq 10\%$ by the PREVENT-ASCVD equations, it may be reasonable to add ezetimibe or a PCSK9 mAb to maximally tolerated statin therapy to achieve an LDL-C goal of $< 70$ mg/dL (1.8 mmol/L) and non-HDL-C $< 100$ mg/dL (2.6 mmol/L) to reduce ASCVD risk. <sup>8</sup>   |
| 2b  | C-LD | 6. In adults $> 75$ y of age with diabetes and an estimated life expectancy of at least 2.5 y, it may be reasonable to initiate moderate-intensity statin therapy after a clinician-patient discussion of potential benefits and risks to reduce ASCVD risk. <sup>9</sup>  |
| 2b  | C-LD | 7. In adults 20 to 39 y of age with diabetes of long duration ( $\geq 10$ y of type 2 diabetes, $\geq 20$ y of type 1 diabetes), albuminuria ( $\geq 30$ $\mu$ g of albumin/mg creatinine), estimated glomerular filtration rate (eGFR) $< 60$ mL/min/1.73 m <sup>2</sup> , retinopathy, neuropathy, or ankle-brachial index $< 0.9$ , it may be reasonable to initiate moderate-intensity statin therapy to reduce ASCVD risk. <sup>10,11</sup> |

\*As per REDUCE-IT inclusion criteria, high-risk features include men  $\geq 55$  years or women  $\geq 65$  years, cigarette smoking or stopped smoking within 3 months; hypertension (blood pressure  $\geq 140$  mm Hg systolic or  $\geq 90$  mm Hg diastolic) or on antihypertensive medication; high-density lipoprotein-cholesterol  $\leq 40$  mg/dL for men or  $\leq 50$  mg/dL for women; high-sensitivity C-reactive protein  $> 3.0$  mg/L (if measured); renal dysfunction: creatinine clearance  $> 30$  and  $< 60$  mL/min; retinopathy; albuminuria ( $\geq 30$   $\mu$ g of albumin/mg creatinine); ankle-brachial index  $< 0.9$  without symptoms of intermittent claudication (if measured).

#### Synopsis

Most adults 40 to 75 years of age with diabetes are at intermediate or high risk of a first ASCVD event.<sup>12-15</sup> Moderate-intensity statin therapy to achieve a  $\geq 30\%$  to 49% reduction in LDL-C provides ASCVD risk reduction in patients with diabetes.<sup>12,16-18</sup> However, given the increased

morbidity and mortality associated with a first event in diabetes, together with the evidence of benefit from high-intensity statin treatment to achieve a  $\geq 50\%$  reduction in LDL-C in primary prevention among men  $>50$  years of age and women  $>60$  years of age,<sup>19</sup> intensification of pharmacotherapy can be beneficial for patients with diabetes as they age or if they have risk enhancers. In patients unable to tolerate statin therapy, ezetimibe and/or bempedoic acid or a PCSK9 mAb are options to reduce LDL-C levels and ASCVD risk.<sup>3,4</sup> Adults 20 to 39 years of age are mostly at low 10-year risk, although moderate-intensity statin therapy may be reasonable in those with long-standing diabetes or a concomitant high-risk condition<sup>10,11,20</sup> (Table 17). ASCVD risk increases over time in patients with diabetes. Some young adults  $\geq 30$  years of age with diabetes may achieve borderline or intermediate-risk estimates by the PREVENT-ASCVD equations, and treatment should be guided by the primary prevention recommendations as in Section 4.2.3.7, "Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L)." Adults  $>75$  years of age with diabetes are at high risk,<sup>12,14</sup> and clinical trial evidence<sup>9</sup> suggests they are likely to benefit from moderate-intensity statin therapy, although this may be weighed against life expectancy and increased risk of adverse events. IPE may be an option to reduce residual risk associated with diabetes and for those currently on statin therapy<sup>7</sup> (Figure 9).

### Recommendation-Specific Supportive Text

1. Most adults 40 to 75 years of age with diabetes are at intermediate or high risk of ASCVD events.<sup>12-15</sup> Three of 4 double-blind, primary prevention RCTs of moderate-intensity statin therapy in large cohorts with diabetes in this age range showed significant reductions in ASCVD events.<sup>16-18,21</sup> A meta-analysis of these trials<sup>2</sup> found that moderate-intensity statin therapy is associated with a risk reduction of 25%, resulting in a risk level similar to that of people without diabetes, with no apparent difference in benefit between type 1 and 2 diabetes. Therefore, based on a high level of evidence, moderate-intensity statin therapy to achieve a 30% to 49% reduction in


- LDL-C is indicated in patients 40 to 75 years of age with diabetes for primary prevention.
2. In the CLEAR Outcomes trial,<sup>22</sup> conducted among participants with statin-attributed side effects, bempedoic acid use led to a 13% RRR in MACE in the overall trial. In the primary prevention stratum, which constituted 30% of the patients (65% and 67% of patients with diabetes in the bempedoic acid and placebo arms, respectively), there was a time-averaged 23-mg/dL reduction in LDL-C and a 30% RRR in MACE.<sup>23</sup> Patients with diabetes in this trial included women  $>65$  years or men  $>60$  years of age. Among patients with diabetes (primary or secondary prevention), a 17% RRR in MACE was noted.<sup>3</sup> Although not directly studied for improvement in cardiovascular outcomes in patients with statin intolerance, ezetimibe lowered LDL-C levels by 24% and improved cardiovascular outcomes in an RCT when used in combination with a statin.<sup>4</sup> In this RCT, 27% of the patients had diabetes, and the benefit of ezetimibe was noted to be more pronounced in these patients. The availability of ezetimibe as a multi-source generic medication in the United States is another distinct advantage in terms of cost. A fixed-dose combination of ezetimibe and bempedoic acid has been shown to reduce LDL-C levels by 38% compared with placebo.<sup>24</sup> Therefore, a combination of ezetimibe and bempedoic acid is also an option in patients with statin-attributed side effects who have diabetes based on the degree of LDL-C lowering desired. Both alirocumab and evolocumab have been demonstrated to effectively reduce LDL-C in patients with statin intolerance and to reduce the risk of MACE in high-risk patients with diabetes.<sup>5,6,25,26</sup>
3. The occurrence of the first ASCVD event in patients 40 to 75 years of age with diabetes is associated with increased morbidity and mortality compared with those without diabetes, which places a high premium on primary prevention in those with diabetes. Although trials using moderate-intensity statin therapy demonstrate significant benefit in such individuals, the residual risk in the statin treatment groups in these trials remained high (eg, 8.5% had MACE in 3.8 years).<sup>2</sup> The benefit of statin therapy is closely linked to both the overall level of cardiovascular risk and the intensity of treatment.<sup>21</sup> However, no RCTs have specifically evaluated high-intensity statin therapy in cohorts exclusively of patients with diabetes. Based on these considerations and the fact that patients with diabetes have a higher trajectory of lifetime risk than those without diabetes, high-intensity statin therapy to achieve a  $\geq 50\%$  reduction in LDL-C is reasonable in patients with diabetes as they age or develop diabetes-specific risk enhancers (Table 17). In specific patient subgroups, quantitative risk assessment may aid in decisions regarding intensification of LLT.

**Table 17. Diabetes-Specific Risk Enhancers Independent of Other Diabetes-Related Risk Factors**

| Risk Enhancers  |
|---|
| Long duration ( $\geq 10$ y for type 2 diabetes or $\geq 20$ y for type 1 diabetes) |
| Albuminuria $\geq 30$ $\mu$ g of albumin/mg creatinine                              |
| eGFR $<60$ mL/min/1.73 m <sup>2</sup>   |
| Retinopathy   |
| Neuropathy  |
| ABI $<0.9$  |

Reprinted with permission from Grundy et al.<sup>38</sup> © 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

ABI indicates ankle-brachial index; and eGFR, estimated glomerular filtration rate.



**Figure 9. Adults With Diabetes and Without ASCVD.**

apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; IPE, icosapent ethyl; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9. \*Refer to Table 17, "Diabetes-Specific Risk Enhancers Independent of Other Diabetes-Related Risk Factors." †In adults with diabetes who have statin-attributed side effects, initiation of ezetimibe and/or bempedoic acid and/or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk.

Downloaded from <http://ahajournals.org> by on March 15, 2026

- In persons >40 years of age with diabetes, statin therapy has demonstrated benefits even among those at lower absolute ASCVD risk. However, there is a spectrum of risk in these patient subgroups, and those at higher risk likely benefit from higher-intensity LLT. Thus, the use of the PREVENT-ASCVD equations is recommended to identify individuals in this group who may benefit from more intensive LLT.
- In the REDUCE-IT trial, which was performed in patients with elevated TG between 150 and 499 mg/dL (1.7-5.6 mmol/L) and LDL-C between 41 and 100 mg/dL (1.1-2.6 mmol/L) (~93% on moderate- to high-intensity statins), the use of high-dose EPA in the form of IPE, 2 g administered twice daily, showed a 25% RRR in MACE compared with a mineral oil placebo, which raised LDL-C and inflammatory markers.<sup>7</sup> TG levels were reduced by a median of ~19%. A larger percentage of patients in the IPE group were hospitalized for atrial fibrillation or flutter (3.1% versus 2.1%,  $P=0.004$ ) and had serious bleeding events (2.7% versus 2.1%,  $P=0.06$ ) compared with placebo. In the primary prevention stratum (patients with diabetes aged  $\geq 50$  with  $\geq 1$  cardiovascular risk factor), there was a nonsignificant 12% RRR in MACE (HR 0.8, 95% CI, 0.70-1.10) with no significant heterogeneity of effect between the primary and secondary prevention groups ( $P$  for interaction=0.14). In the STRENGTH (Outcomes Study to Assess Statin Residual Risk Reduction With EpaNova in High CV Risk Patients With Hypertriglyceridemia) trial<sup>27</sup> (56% of the patients with established ASCVD and 70% with diabetes), the use of a high dose of carboxylic acid formulation of EPA and DHA was not associated with a reduction in MACE compared with a corn oil placebo. Therefore, IPE may be considered in patients with diabetes and additional cardiovascular risk factors with persistently elevated TG for further ASCVD reduction, despite being optimized on statin therapy.<sup>7</sup>
  - According to a CTT meta-analysis,<sup>1</sup> the higher the 10-year ASCVD risk, the greater the cardiovascular risk reduction benefit of LDL-C lowering. This is supported by meta-analyses comparing high-intensity versus low-intensity statin therapy<sup>21</sup> and those comparing the benefit of statins and nonstatin LDL-lowering agents (ie, ezetimibe, bile sequestrants, PCSK9 mAb) that upregulate LDL receptors.<sup>8</sup> Therefore, a benefit-risk discussion may include the benefits of achieving a  $\geq 50\%$  LDL-C lowering in adults with diabetes who are at high risk. The addition of ezetimibe to moderate-intensity statin therapy can achieve the same percentage LDL-C lowering as that achieved with high-intensity statin therapy.<sup>4</sup> Thus, ezetimibe may be added to a moderate-intensity statin if a high-intensity statin cannot be tolerated or does not lower LDL-C by  $\geq 50\%$ . Similarly, although PCSK9 mAb have not been studied for primary ASCVD prevention in diabetes, these agents lower LDL-C by between 50% and 60% and are an option to lower LDL-C and ASCVD risk.<sup>28,29</sup> PCSK9 mAb lower relative risk of ASCVD events in patients with diabetes and ASCVD similar to those with ASCVD but without diabetes,<sup>5,6</sup> with a higher aRR in those with diabetes in the ODYSSEY Outcomes trial.<sup>6</sup> Cardiovascular outcomes trials are pending for inclisiran, though pooled analyses have demonstrated efficacy in LDL-C lowering across glycemic strata.<sup>30</sup>
  - ASCVD risk in patients with diabetes increases incrementally with age.<sup>12-14</sup> In 1 long-term cohort study of type 2 diabetes without ASCVD, incident rates of MI averaged 25.6 per 1000 person-years<sup>12</sup> in those >75 years of age, while another study in a type 1 diabetes cohort found the 10-year fatal CVD risk in those >75 years of age was 70% in men and 40% in women.<sup>14</sup> Although no controlled statin trials in people >75 years of age are available, a meta-analysis of the JUPITER and HOPE-3 (Heart Outcomes Prevention Evaluation) trials demonstrated similar benefits in ASCVD reduction among those >70 years of age versus <70 years of age.<sup>9</sup> Although this meta-analysis included few patients with diabetes, it does support a clinician-patient benefit-risk discussion about moderate- or high-intensity statin therapy for primary prevention in those patients >75 years of age with diabetes. The clinician should note that the benefit may be offset by limited life expectancy or increased susceptibility to adverse events in patients in this older age group.
  - There is limited information on ASCVD rates among individuals 20 to 39 years of age with diabetes and no information on whether statin therapy is beneficial for these individuals. Accurate assessment of lipid-associated risk, as well as mitigation of risk with healthy behavior optimization, is vitally important for improving individual and population health. Young adulthood represents a high-impact opportunity for ASCVD prevention, especially in those with diabetes. Evidence indicates that although rates of ASCVD are low in those with diabetes aged <30 years of age, the risk of ASCVD events increases with time.<sup>10,11,13,31</sup> Young individuals with diabetes may reach intermediate-risk levels by ages 30 to 39 years, especially in individuals with long-standing type 2 diabetes or persistently high LDL-C levels  $\geq 160$  mg/dL.<sup>10</sup> Patients with diabetes of long duration may have more advanced subclinical coronary atherosclerosis than those without diabetes.<sup>20,31</sup> ASCVD rates will also be influenced by hypertension, smoking, and diabetic microvascular complications, which may be prevalent in these age groups.<sup>31,32</sup> Thus, it may be reasonable to have a discussion about initiating moderate-intensity statin therapy with patients who have had type 2 diabetes

for at least 10 years or type 1 diabetes for at least 20 years, as well as with patients who have ≥1 major CVD risk factors or complications, such as diabetic retinopathy,<sup>33</sup> neuropathy,<sup>34</sup> nephropathy (eGFR <60 mL/min/1.73 m<sup>2</sup> or albuminuria ≥30 µg albumin/mg creatinine),<sup>35</sup> or an ankle-brachial index of <0.9 (Table 17).<sup>36,37</sup> In those individuals >30 years of age, calculation of 10- and 30-year risk by PREVENT-ASCVD equations should be used to guide treatment decisions according to the primary prevention algorithm (Figure 6, Section 4.2.3.7, “Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL [1.8-4.9 mmol/L]”).

**4.2.6. Secondary ASCVD Prevention**

| Recommendations for Secondary ASCVD Prevention  |     |  |
|---|-----|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |     |  |
| COR   | LOE | Recommendations  |
| <b>Clinical ASCVD Not at Very High Risk*</b>  |     |  |
| 1   | A   | 1. In adults with clinical ASCVD who are not at very high risk (Figure 10), high-intensity statin therapy should be initiated to achieve a ≥50% reduction in LDL-C and a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL to reduce the risk of recurrent ASCVD events. <sup>1-3</sup>  |
| 2a  | B-R | 2. In adults with clinical ASCVD who are not at very high risk and on maximally tolerated statin therapy, it is reasonable to add ezetimibe, a PCSK9 mAb, or bempedoic acid (selection depending on degree of LDL-C lowering needed and patient preference) to achieve a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL to reduce the risk of ASCVD events. <sup>4-6</sup>                |
| 2a  | B-R | 3. In adults with clinical ASCVD who are not at very high risk and on maximally tolerated statin therapy, it is reasonable to add ezetimibe, a PCSK9 mAb, or bempedoic acid (selection based on the degree of LDL-C lowering needed and patient preference) to achieve a goal LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) and to reduce the risk of ASCVD events. <sup>1,4-6</sup> |
| <b>Clinical ASCVD at Very High Risk*</b>  |     |  |
| 1   | A   | 4. In adults with clinical ASCVD* who are at very high risk (Figure 10 and Figure 11), high-intensity statin therapy should be initiated to achieve a ≥50% reduction in LDL-C and a goal LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) and to reduce the risk of ASCVD events. <sup>4,6-8</sup>  |
| 1   | A   | 5. In adults with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, ezetimibe and/or a PCSK9 mAb should be added (selected based on the degree of LDL-C lowering needed and patient preference) to achieve a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) to reduce risk of ASCVD events. <sup>4,6,7,9</sup>                              |
| 2a  | B-R | 6. In adults with clinical ASCVD who are at very high risk on maximally tolerated statin therapy, it is reasonable to add bempedoic acid, with or without ezetimibe and/or PCSK9 mAb, to reach an LDL-C goal <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) to reduce the risk of ASCVD events. <sup>5</sup>  |


| Recommendations for Secondary ASCVD Prevention (Continued)               |     |  |
|--|-----|--|
| COR  | LOE | Recommendations  |
| 2a   | B-R | 7. In adults with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with or without ezetimibe, it is reasonable to add inclisiran in those unable to tolerate or obtain evolocumab or alirocumab or have a strong preference for less frequent dosing to achieve an LDL-C goal <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L). <sup>10</sup> |
| <b>Heart Failure With Reduced Ejection Fraction (HFrEF) Due to ASCVD</b> |     |  |
| 2b   | B-R | 8. In adults with HFrEF attributable to ischemic heart disease who have a reasonable life expectancy (3–5 y) and are not already on a statin because of ASCVD, it may be reasonable to consider initiation of moderate-intensity statin therapy to reduce the occurrence of ASCVD events. <sup>11,12</sup>   |

\*The majority of patients with clinical ASCVD are likely to be at very high risk. Very high risk includes a history of multiple major ASCVD events (ACS within past 12 months, history of MI [other than ACS above] history of ischemic stroke, symptomatic PAD) or 1 major ASCVD event and multiple high-risk conditions (age >65 years of age, coronary artery revascularization, current smoker, diabetes, history of HF, hypertension, LDL-C >100 mg/dL despite maximally tolerated statin + ezetimibe).

†Cardiovascular outcomes trials are not completed with inclisiran. It is approved for LDL-C lowering only and is considered a second-line PCSK9i at this time.

**Synopsis**

Statin therapy is the foundation of lipid-lowering treatment for secondary prevention, given its proven efficacy, safety, tolerability, ease, and cost-effectiveness.<sup>1,2</sup> There is a graded association between the degree of LDL-C lowering and ASCVD risk reduction and additional evidence for achievement of lower LDL-C levels. More recent studies of combination therapy have reinforced the concept that “lower is better” with clinically proven therapies for LDL-C. Several RCTs demonstrated that the addition of ezetimibe or a PCSK9 mAb to statin therapy among patients at very high risk (defined in Figure 10) yielded further ASCVD risk reduction compared with statin monotherapy.<sup>4,6-8</sup> Since the “2018 Guideline for the Management of Blood Cholesterol” was published, extended safety data for PCSK9 mAb have been reported, and the cost has decreased substantially.<sup>13</sup> Accordingly, the revised recommendations no longer require that ezetimibe be added to statin therapy prior to initiating a PCSK9 mAb, and consideration of therapy may be based on degree of LDL-C required and patient preference. RCTs of 2 additional treatments have demonstrated meaningful LDL-C lowering and are clinically available. Bempedoic acid lowered LDL-C by approximately 20% and reduced ASCVD events in patients with statin intolerance.<sup>5</sup> Inclisiran lowered LDL-C by about 50%,<sup>10</sup> but cardiovascular outcomes trials are still ongoing (Figures 10 and 12). Evidence indicates long-term safety and efficacy of LDL-C to a median level of 30 mg/dL over 8 years of follow-up.<sup>8</sup> There is no signal to suggest that de-escalation of therapy is indicated for very low levels of achieved LDL-C.



**Figure 10. Clinical ASCVD: Criteria for Defining “At Very High Risk” in Adults.**

ACS indicates acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; Hx, history; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; and PAD, peripheral artery disease. Adapted with permission from Grundy et al.<sup>13</sup> © 2018 American Heart Association, Inc. and American College of Cardiology Foundation.


ASCVD at very high risk includes a history of multiple major ASCVD events (ACS within the past 12 months, history of MI [other than ACS above], history of ischemic stroke, symptomatic PAD) or 1 major ASCVD event and multiple high-risk conditions (age  $>65$  years, coronary artery revascularization, current smoker, diabetes, history of HF, hypertension, LDL-C  $>100$  mg/dL despite maximally tolerated statin + ezetimibe). The majority of patients with clinical ASCVD are likely to be at very high risk; however, recommendations are also provided for those individuals with ASCVD not at very high risk.

### Recommendation-Specific Supportive Text

1. A meta-analysis by the CTT, which included data from 39612 participants in RCTs comparing more-intensive versus less-intensive statin regimens, demonstrated an additional 15% reduction in major vascular events with more intensive therapy.<sup>1</sup> Higher- versus lower-intensity treatment also led to a 13% reduction in coronary death or nonfatal MI, a 19% reduction in coronary revascularization, and a 16% reduction in stroke. Although larger absolute reductions are seen at higher baseline LDL-C levels, the results are consistent across a wide range of baseline values.<sup>3</sup> High-intensity statin therapy (Figure 10, Section 4.2.6, “Secondary ASCVD Prevention”) typically lowers the LDL-C by  $\geq 50\%$ . CVOTs using high-intensity statin therapy demonstrate high adherence and

tolerability, justifying their use as a Class 1 indication. However, in clinical practice, moderate-dose statins may be preferred, and a nonstatin can be considered to augment the LDL lowering to optimize outcomes.


2. In IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) after ACS, adults with 2 of 9 potential risk indicators experienced a trend toward benefit with the addition of ezetimibe to simvastatin (ARR, 2.2% [95% CI,  $-0.3$  to 4.6]) over 6 years.<sup>9</sup> Those with 0 or 1 risk indicators did not appear to benefit. The study was not powered to detect differences between groups. However, prior studies have shown a continuous long-term reduction in ASCVD risk at progressively lower LDL-C levels and multiple nonstatin therapies, including ezetimibe, evolocumab, alirocumab, and bempedoic acid, have favorable safety profiles.<sup>1,4,6–8,14</sup> It is, therefore, reasonable to add any of these nonstatin therapies with favorable CVOT results in adults with ASCVD who are not at very high risk if they are unable to achieve an LDL-C  $<70$  mg/dL (1.8 mmol/L) and non-HDL-C  $<100$  mg/dL with statin monotherapy.
3. Based on clinician judgment and patient preference, it is reasonable to treat patients with ASCVD who are not at very high risk to an LDL-C goal of  $<55$  mg/dL (1.4 mmol/L) and non-HDL-C  $<85$  mg/dL. There is an incremental reduction in cardiovascular events at progressively lower LDL-C levels, even  $<30$  mg/dL, although the ARR is smaller



**Figure 11. Secondary ASCVD Prevention for Adults at Very High Risk.**

\*Two cardiovascular outcome studies in patients with ASCVD are ongoing with inclisiran. ASCVD indicates atherosclerotic cardiovascular disease; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9. Adapted with permission from Grundy et al.<sup>13</sup> © 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

Downloaded from <http://ahajournals.org> by on March 15, 2026



**Figure 12. Secondary ASCVD Prevention for Adults at Not Very High Risk.**

\*CVOTS pending; the majority of patients with ASCVD are at very high risk. ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9. Adapted with permission from Grundy et al.<sup>13</sup> © 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

and the number-needed-to-treat to reduce ASCVD events is higher when targeting lower LDL-C levels among adults who are not at very high risk.<sup>1</sup> Lower treatment targets are especially reasonable among younger patients with ASCVD. Even if they do not meet criteria for very high risk, many may have a longer cumulative exposure to LDL-C over their lifetime, which increases their risk of recurrent events.<sup>15</sup>

4. Individuals are considered to be at very high risk if they have a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions (Figure 10). Data from meta-analyses of statin clinical trials and more recent studies of nonstatin therapies have demonstrated a continuous reduction in ASCVD risk with lower LDL-C levels. Even when the baseline LDL-C was <2 mmol/L (77 mg/dL), an additional 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with a 21% reduction in ASCVD risk.<sup>1</sup> In RCTs evaluating the effect on cardiovascular outcomes with statins plus an additional LDL-lowering medication, the on-treatment LDL-C with ezetimibe was 53 mg/dL, 30 mg/dL with evolocumab, and 40 mg/dL with alirocumab, with apoB levels of 67, 39, and 49 mg/dL, respectively.<sup>4,7,16,17</sup> In all 3 trials, those randomized to the intervention arm experienced a reduction in ASCVD events. With evolocumab, there was a graded reduction in ASCVD risk with lower LDL-C, even among the 24% of the study population with an LDL-C <20 mg/dL. Given the relative safety, efficacy, and accessibility of ezetimibe and PCSK9 mAb, the goal LDL-C for those at very high ASCVD risk is lowered to <55 mg/dL (1.4 mmol/L) rather than <70 mg/dL (1.8 mmol/L).
5. IMPROVE-IT randomized patients recently hospitalized for ACS to simvastatin 40 mg plus ezetimibe versus simvastatin 40 mg plus placebo.<sup>4</sup> After a mean of 6 years of follow-up, there was a 2% ARR in cardiovascular events with simvastatin-ezetimibe in this very high-risk population that had a >30% event rate. In a secondary analysis, participants were stratified based on 9 high-risk indicators.<sup>9</sup> Those with ≥3 risk indicators experienced a significant 6.3% ARR in the primary outcome with simvastatin-ezetimibe versus simvastatin-placebo. There was no significant benefit among participants with 0 to 1 indicators, and a trend toward benefit in those with 2 indicators. FOURIER and ODYSSEY OUTCOMES randomized high-risk adults with ASCVD on statin therapy to the PCSK9 mAbs, evolocumab and alirocumab, respectively, or placebo.<sup>6,7,14</sup> After a median 2.2 to 2.8 years follow-up, there was a 1.4% to 1.6% ARR in the primary endpoint with evolocumab or alirocumab, with an approximately 15% event rate in placebo-treated individuals in that short time frame. In FOURIER-OLE (open-label extension)E, 6635 participants received evolocumab (median follow-up 5 years).<sup>8,18</sup> Incidences of muscle-related events, new-onset diabetes, and neurocognitive events with evolocumab were similar to those with placebo. Importantly, participants taking evolocumab in both FOURIER and FOURIER-OLE had a lower incidence of MACE compared with participants initially randomized to placebo and then switched to evolocumab. Using annual costs of \$5850, evolocumab and alirocumab were cost-effective, particularly among participants with LDL-C >100 mg/dL (2.6 mmol/L).<sup>19,20</sup>
6. In the CLEAR Outcomes trial of adults with statin-attributed side effects who had ASCVD or were at high risk for ASCVD, bempedoic acid decreased LDL-C by 20% compared with placebo, and there was a 1.6% ARR in the primary outcome compared with a placebo event rate of >13% over ≥3 years.<sup>5</sup> There are no CVOTs combining standard statin therapy and bempedoic acid, which is why bempedoic acid is given a Class 2a recommendation for patients with ASCVD. However, in a study of patients at high risk for ASCVD on statin therapy, treatment with bempedoic acid and ezetimibe decreased LDL-C by 38% compared with placebo.<sup>21</sup> Bempedoic acid is also available as a combination pill with ezetimibe.<sup>21</sup> Cost may be a significant barrier given that both bempedoic acid and the bempedoic acid-ezetimibe combination pill are still branded products.
7. In 2 phase 3 trials, ORION 10 (Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol) and ORION 11 (Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol), a total of 3660 adults with ASCVD or at high ASCVD risk who were on maximally tolerated statin therapy were randomized to inclisiran or placebo.<sup>10</sup> A subcutaneous injection was administered at baseline, 3 months, and then every 6 months thereafter. The LDL-C decreased by about 50% in both studies. In a prespecified exploratory analysis, inclisiran reduced the incidence of MACE compared with placebo (7.1% versus 9.4%; OR, 0.74 [95% CI, 0.58-0.94]).<sup>22</sup> Two CVOTs in adults with ASCVD are ongoing (ORION 4 and VICTORION 2P [Study of Inclisiran to Prevent CV Events in Participants With Established CVD]), with expected results in 2026 and 2027. Given the lack of CVOTs with inclisiran, evolocumab or alirocumab are currently the preferred PCSK9i for use in patients who require significant LDL-C lowering to reach their goal LDL-C. Other practical considerations besides less frequent dosing schedule with inclisiran include its administration by a clinician, which some patients may prefer, and its billing under medical benefit rather than pharmacy benefit coverage, which may affect the cost to the patient.

8. The CORONA (Crestor Versus Placebo in Subjects With HF) and GISSI HF (Effect of Rosuvastatin in Patients With Chronic HF) trials evaluated the efficacy and safety of rosuvastatin 10 mg daily compared with placebo in adults with HF<sup>11,12</sup>; neither trial met its primary outcome. However, only 45% of participants in GISSI HF had ischemic cardiomyopathy. Rosuvastatin reduced the risk of total hospitalizations, hospitalizations for a cardiovascular cause, and hospitalizations for worsening HF in CORONA. Post hoc analyses from CORONA showed that patients randomized to rosuvastatin with less-advanced HFrEF (lowest tertile of NT-proBNP) had a significant reduction in the primary outcome, but no benefit was seen among patients with more advanced HF. The CORONA and GISSI studies were notable for high overall and cardiovascular mortality rates, with MI occurring in a small minority. A subsequent patient-level analysis that pooled data from both these trials and accounted for competing causes of death showed a significant 19% reduction in the risk of MI with rosuvastatin in patients with ischemic HF, although the ARR was small.<sup>23</sup>

#### 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 Years)

| Recommendations for Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 Years)<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 1  | B-NR | 1. In adults with a CAC score of ≥1000 AU, treatment with LDL-C-lowering therapies with consideration of statin therapy as first line is recommended to achieve a ≥50% reduction in LDL-C and a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L). <sup>12</sup>   |
| 1  | B-R  | 2. In adults with a CAC score of ≥300 to 999 AU, treatment with LDL-C-lowering therapies, with consideration of statin therapy as first line, is recommended to achieve a ≥50% lowering in LDL-C and a goal LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L). <sup>3-7</sup>   |
| 1  | B-R  | 3. In adults with a CAC score of ≥100 to 299 AU or ≥75th standardized percentile, treatment with LLT, with consideration of statin therapy as first-line therapy, is recommended to achieve a ≥50% reduction in LDL-C and a goal LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L). <sup>7-10</sup>   |
| 2a   | B-R  | 4. In adults with a CAC score of 1 to 99 AU and <75th standardized percentile, or with an incidental finding of mild CAC on noncardiac CT scan, treatment with moderate-intensity statin therapy is reasonable to achieve a ≥30% to 49% reduction in LDL-C and a goal of LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C <130 mg/dL (3.4 mmol/L). <sup>7,10-12</sup> |


| Recommendations for Management of Adults With Subclinical Coronary Atherosclerosis (Men ≥40 or Women ≥45 Years) (Continued) |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 2a  | B-NR | 5. In adults with a CAC score of ≥300 to 999 AU, it is reasonable to intensify therapy by increasing the intensity of statin therapy or, if needed, adding ezetimibe, a PCSK9 mAb, or bempedoic acid to achieve a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L). <sup>4-6,10</sup>  |
| 2a  | B-NR | 6. Among adults with no prior ASCVD who have moderate-to-severe incidental coronary atherosclerosis identified on noncardiac CT scans (eg, by visual estimation or a validated artificial intelligence-based algorithm), it is reasonable to initiate high-intensity statin therapy to achieve at least a ≥50% reduction in LDL-C and a goal of LDL-C <70 mg/dL (1.8 mmol/L) and non-HDL-C <100 mg/dL (2.6 mmol/L); if mild incidental CAC, moderate-intensity statin therapy is reasonable to achieve a ≥30% to 49% reduction in LDL-C and a goal of LDL-C <100 mg/dL (2.6 mmol/L) and non-HDL-C goal <130 mg/dL. <sup>13-15</sup> |

### Synopsis

Atherosclerosis is a dynamic process that can progress over decades before causing clinical manifestations or cardiovascular events.<sup>16</sup> The presence and severity of subclinical atherosclerosis, as detected by CAC, provide robust prognostic information, with a nearly linear relationship between CAC scores and MACE.<sup>8,17</sup> Generally, in individuals at intermediate (5% to <10%) or in select individuals at borderline (3% to <5%) 10-year risk by PREVENT-ASCVD equations, CAC scoring may be considered in men age ≥40 years or women age ≥45 years in whom the decision to initiate LLT is uncertain. The CAC score, measured in AU, provides an estimate of overall coronary plaque burden and ranges from none (CAC=0) to severe (CAC=300–999) and extensive (CAC ≥1000) amounts of calcified coronary plaque. CAC scores are incremental to traditional risk factors in predicting ASCVD risk, regardless of the burden of dyslipidemia or the use of LLT.<sup>8</sup> The observed ASCVD risk in individuals with severe and extensive CAC scores is similar to the event rates seen in secondary prevention cohorts.<sup>6</sup> Accordingly, severe CAC has been used as an inclusion criterion in multiple clinical trials or other observational studies.<sup>18-20</sup> Additionally, for those individuals who are not on LLT and already have a baseline LDL-C below the recommended targets for CAC levels, treatment with LLT is still recommended with the caveat to achieve at least a ≥30% reduction in baseline LDL-C level (Figure 13).

### Recommendation-Specific Supportive Text

1. Data from the CAC Consortium showed individuals with a CAC score ≥1000 were most likely to have extensive multivessel CAC and more diffuse extra-coronary calcification compared with those with lower CAC scores. Additionally, these individuals with



**Figure 13. Managing Adults With Subclinical Atherosclerosis.**

apoB indicates apolipoprotein B; AU, Agatston Units; CAC, coronary artery calcium; CT, computed tomography; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.

a CAC score  $\geq 1000$  had a substantially increased risk of CVD, CHD, and all-cause mortality, with a nearly 2-fold higher risk of CVD mortality compared with individuals with a CAC score of 400 to 999.<sup>1</sup> Subsequent data from MESA demonstrated similar findings of extensive multivessel CAC and a markedly increased risk for CVD and CHD among those with a CAC score  $\geq 1000$ .<sup>2</sup> Compared with stable secondary prevention participants in the placebo arm of the FOURIER trial, the MACE rate was similar in MESA individuals who had CAC scores  $\geq 1000$ .<sup>2,21</sup> The addition of nonstatin therapies further reduces LDL-C in patients treated for secondary prevention of ASCVD.<sup>22–24</sup> PCSK9i significantly lowered LDL-C and reduced MACE events among patients treated

for secondary prevention who were treated with either evolocumab in the setting of stable ASCVD in the FOURIER trial or alirocumab after recent ACS in the ODYSSEY Outcomes trials, achieving LDL-C levels significantly below 70 mg/dL.<sup>23,24</sup> Based on these results in patients at high ASCVD risk, in adults with a CAC score of  $\geq 1000$  AU, treatment with LDL-C-lowering therapies to achieve a  $\geq 50\%$  reduction in LDL-C and a goal LDL-C  $< 55$  mg/dL (1.4 mmol/L) and non-HDL-C  $< 85$  mg/dL is advised.

- Individuals with a CAC score  $\geq 300$  have a similar estimated 10-year ASCVD risk and annualized risk as patients treated for secondary prevention.<sup>3,5,6,25</sup> In the CONFIRM (Coronary CT Angiography Evaluation

for Clinical Outcomes) registry, individuals without known CAD who had a CAC score  $\geq 300$  had a similar rate of events over a median follow-up of 4 years as those with established treated ASCVD.<sup>3</sup> In the CAC Consortium, people with CAC scores  $\geq 300$  and diabetes, as well as people with CAC scores ranging from 775 to 900, were at an elevated ASCVD mortality risk equivalent to the overall FOURIER trial population. Those with a CAC score  $\geq 300$  had similar annualized mortality risks as FOURIER participants categorized as stable secondary prevention with a single prior MI event.<sup>6</sup> Among study participants from the St. Francis Heart Study who were followed for a mean of 4.3 years, post hoc analyses demonstrated a significant reduction in MACE with statin treatment in the subset of individuals with a baseline CAC score of  $\geq 400$  and also in those with a family history of premature CAD and high CAC scores.<sup>4,26</sup> In a large prospectively observed cohort study of individuals without ASCVD, individuals with a CAC score  $\geq 400$  derived greater benefit from statin therapy with reduction in MACE events compared with those not treated with statins.<sup>9</sup> Based on comparable levels of risk and likelihood of benefit, in adults with a CAC score of  $\geq 300$ , treatment with LLT to achieve at least a 50% reduction in LDL-C and a goal LDL-C  $< 70$  mg/dL (1.8 mmol/L) and non-HDL-C  $< 100$  mg/dL is advised.

- Multiple studies have shown that annualized ASCVD risk rises linearly with increasing CAC scores. Data from MESA demonstrated that participants with a CAC score of 101 to 300 had an almost 8-fold increase in risk of coronary events compared with those without coronary artery calcification.<sup>10</sup> CAC scores further stratify risk regardless of the burden of dyslipidemia, and those with a CAC score  $\geq 100$  have event rates similar to secondary prevention, supporting the use of LDL-C-lowering therapies.<sup>5,8</sup> In a large prospectively observed cohort study of individuals without ASCVD who underwent CAC scoring, individuals with a CAC score  $\geq 100$  derived greater benefit from statin therapy, with reduction in MACE events compared with those not treated with statins. No benefit from statin therapy over a mean of 10 years was seen among those individuals who had a CAC score=0.<sup>9</sup> In the CAUGHT-CAD (CAC Score: Use to Guide Management of Hereditary CAD) trial, among those with a CAC score  $\geq 100$ , a CAC score-informed strategy resulted in lower LDL-C and was independently associated with decreased progression of total plaque volume on serial CCTA, even after adjustment for multiple risk factors.<sup>7</sup> Therefore, in adults with a CAC score of  $\geq 100$  AU or  $\geq 75$ th standardized percentile (currently based on age, sex, and race), treatment with LLT with consideration of a statin as first-line therapy, preferably to achieve a  $\geq 50\%$  reduction in LDL-C, and a goal LDL-C  $< 70$  mg/dL (1.8 mmol/L) and non-HDL-C  $< 100$  mg/dL is advised.

- Presence of CAC, regardless of race and ethnicity, is a strong predictor of CHD.<sup>10</sup> Data from MESA demonstrated that participants with a CAC score between 1 and 100 had an almost 4-fold increase in risk of coronary events compared with those without CAC.<sup>10</sup> The CAUGHT-CAD clinical trial demonstrated that using CAC scoring in the 1 to 400 range to guide statin therapy in patients at intermediate risk with a family history of premature CAD resulted in greater LDL-C reduction and less plaque progression compared with usual care, where CAC results were blinded.<sup>7</sup> CAC scores can further risk stratify younger and older adult patients who may benefit from LLT. Age-based discussions with patients regarding net benefit versus risk of drug therapy need to consider these lower LDL-C goals for younger patients, who will have longer lifetime exposure to cholesterol and elevated long-term risk compared with older adult patients. Young participants from the CARDIA study had elevated risks of CHD, even with CAC scores as low as 1 to 19 and 20 to 99 compared with those with a CAC score of 0.<sup>11</sup> Among the older patients from MESA (age 75-84 years), individuals with a CAC score of 1 to 100 had an 11-fold increased risk of CHD compared with those with a CAC score=0.<sup>12</sup> In adults with CAC scores of 1 to 99 AU and  $< 75$ th standardized percentile (currently based on age, sex, and race), or with an incidental finding of mild CAC on noncardiac CT scan, treatment with LDL-C-lowering therapies, with consideration of statins as first-line therapy, to achieve at least a 30% reduction in LDL-C and a goal LDL-C  $< 100$  mg/dL (apoB  $< 100$  mg/dL) is appropriate.
- Individuals with a CAC score  $\geq 300$  have a risk of future ASCVD events that is comparable to cohorts who have existing ASCVD.<sup>3,6</sup> Accordingly, it may be reasonable to reduce LDL-C to  $< 55$  mg/dL, which is the goal recommended for patients with established ASCVD (Section 4.3.2.7, "Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL [1.8-4.9 mmol/L]"). Several randomized studies and observational cohort studies have shown that more aggressive treatment of individuals with coronary atherosclerosis may be associated with improved outcomes<sup>4,27,28</sup> and less plaque progression.
- Although formal CAC scoring with electrocardiogram-gated CT is preferred, individuals undergo nongated chest CT scans for many other indications. The 2016 Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology outlined methods for quantifying CAC based on visual assessment into none, mild, moderate, and severe CAC.<sup>29</sup> Visual estimates of CAC on nongated chest CT scans, regardless of contrast administration, have been concordant with quantitative CAC scores.<sup>13</sup> Identification of moderate or severe CAC on these noncardiac CT scans,

even without a specific CAC score, has been associated with increased ASCVD risk and may inform decisions on LLT.<sup>14</sup> The NOTIFY-1 (Incidental CAC: Opportunistic Screening of Previous Nongated Chest CT Scans to Improve Statin Rates) randomized quality improvement project demonstrated the opportunistic nature of CAC screening on nongated chest CT. Participants with CAC who were randomized to have their primary care clinician and themselves notified of the results had a significant increase in appropriate statin prescriptions compared with those undergoing usual care.<sup>15</sup> Therefore, it is reasonable to initiate high-intensity statin therapy in adults with an incidental finding of moderate or severe coronary atherosclerosis identified on noncardiac CT scans (eg, by visual estimation or a validated artificial intelligence-based algorithm) and moderate-intensity statin therapy in those with mild coronary artery calcification. Detection of carotid plaque during vascular imaging is also linked to an elevated ASCVD risk.<sup>30–32</sup> Although LLT are beneficial for these patients, current evidence is not sufficient to recommend specific LDL-C and non-HDL-C goals.

## 4.2.8. Considerations in Patient Management

### 4.2.8.1. Children and Adolescents

| Recommendations for Children and Adolescents  |      |   |
|---|------|---|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |   |
| COR   | LOE  | Recommendations   |
| 1   | B-R  | 1. In children and adolescents with lipid abnormalities, lifestyle management is recommended to improve LDL-C, TG, and non-HDL-C. <sup>1–4</sup>  |
| 1   | B-R  | 2. In children and adolescents $\geq 8$ y of age with an LDL-C level persistently $\geq 160$ mg/dL (4.1 mmol/L) and a presentation consistent with FH who do not respond sufficiently after 3 to 6 mo of lifestyle management, initiation of statin and other LLT as necessary is recommended to lower LDL-C. <sup>5–9*</sup> |
| 2a  | B-NR | 3. In children and adolescents with a clinical presentation consistent with FH, panel-based genetic testing for pathogenic/likely pathogenic rare variants for FH can be useful to guide diagnosis, cascade testing, and treatment. <sup>10–13</sup>  |

\*Children with HoFH require specialized consideration, including aggressive LLT at the time of diagnosis, including in infancy (Section 4.2.4.4, “Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH”).

## Synopsis

Abnormal lipid levels (Table 18) are common in children and adolescents, affecting approximately 1 in 5 adolescents,<sup>14</sup> and 1 in 250 to 300 children and adolescents have a clinical presentation of severe hypercholesterolemia consistent with a diagnosis of HeFH (LDL-C  $\geq 160$  mg/dL [ $\geq 4.9$  mmol/L]).<sup>15,16</sup> Mendelian randomization studies show lifelong low LDL-C is associated with low lifetime ASCVD rates.<sup>17,18</sup> By contrast, significantly elevated cholesterol tracks from childhood to adulthood,<sup>15</sup>

**Table 18. Normal and Elevated Lipid Values in Childhood\***

|             | Acceptable, mg/dL | Borderline, mg/dL | Abnormal, mg/dL |
|-------------|-------------------|-------------------|-----------------|
| TC          | <170              | 170–199           | $\geq 200$      |
| TG: 0–9 y   | <75               | 75–99             | $\geq 100$      |
| TG: 10–19 y | <90               | 90–129            | $\geq 130$      |
| HDL-C       | >45               | 40–45             | <40             |
| LDL-C       | <110              | 110–129           | $\geq 130$      |
| Non-HDL-C   | <120              | 120–144           | $\geq 145$      |

Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non-HDL-C by 38.6; for TG, divide by 88.6.

\*Values for plasma lipid and lipoprotein levels are from the National Cholesterol Education Program Expert Panel on Cholesterol Levels in Children; non-HDL-C values equivalent to LDL-C are taken from the Bogalusa Heart Study.<sup>38</sup> The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.<sup>38</sup> Modified with permission from Grundy et al.<sup>42</sup> © 2018 American Heart Association, Inc. and American College of Cardiology Foundation.

HDL-C indicates high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; SI, Système international d'unités (International System of Units); TC, total cholesterol; and TG, triglyceride.

is associated with subclinical atherosclerosis in childhood,<sup>19,20</sup> and predicts risk of fatal and nonfatal cardiovascular events in middle age.<sup>7,21</sup> Childhood lipid screening can identify FH and other severe lipid disorders, as well as acquired dyslipidemia (Section 3.1, “Screening in Children and Adults”). Observational evidence shows lifestyle behavior counseling modestly improves lipid levels in childhood, without adverse effects on growth and maturation<sup>1,2</sup>; is associated with less subclinical atherosclerosis in childhood<sup>1,22</sup>; and has more favorable lipid profiles decades later.<sup>23</sup> However, effect sizes are small, differ by variable (eg, TG are more sensitive to lifestyle changes than LDL-C), and adherence may wane over time. In children and adolescents with severe hypercholesterolemia, statins and other LLT lower LDL-C with minimal adverse effects<sup>5</sup> and stabilize or reduce subclinical atherosclerosis.<sup>19</sup> Lower ASCVD event rates were reported in the late follow-up of 1 trial.<sup>6</sup> Children with other ASCVD risk factors or conditions likely also benefit from LLT.<sup>24</sup> Data are scant on pharmacotherapy of multifactorial lifestyle-related dyslipidemia, but lifestyle counseling can be helpful, and statins are sometimes used in the presence of high-risk conditions.<sup>24</sup> Individuals with HoFH can present with coronary obstruction in childhood and require evaluation by a pediatric cardiologist and an experienced lipid specialist; management includes aggressive LLT from diagnosis, often in infancy, in an individualized fashion (Section 4.2.4.4, “Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH”).

## Recommendation-Specific Supportive Text

1. Lifestyle management trials in childhood and adolescence show short- and long-term benefits, including improvements in lipid levels<sup>4,25–27</sup> and reductions

in subclinical atherosclerosis measures among children and adolescents with lipid disorders.<sup>22</sup> No adverse effects on growth or maturation have been demonstrated with lifestyle management, and lifestyle change can be durably maintained in subspecialty care.<sup>28,29</sup> The impact of lifestyle management on lipid levels and subclinical atherosclerosis is small, and no studies include sufficient follow-up duration to report ASCVD event rates. However, there are likely other unmeasured health benefits of lifestyle management for chronic disease outcomes (eg, obesity, diabetes, and cancer), supporting the recommendation to treat lipid disorders in children and adolescents with lifestyle management.

2. Randomized pediatric trials show statins,<sup>5</sup> ezetimibe,<sup>9</sup> PCSK9 mAbs,<sup>8,30</sup> inclisiran (not FDA-approved for use in children <18 years old),<sup>31,32</sup> and bile acid sequestrants<sup>33,34</sup> lower LDL-C in children and adolescents with FH and other conditions that

increase ASCVD risk (Table 19).<sup>24,35</sup> Statins lower LDL-C 30% to 50%, slow subclinical atherosclerosis progression,<sup>36</sup> and have minimal short- and medium-term adverse events in children and adolescents.<sup>5,35</sup> Late follow-up of 1 trial of pravastatin in youth with HeFH showed lower ASCVD events over 20 years compared with parental controls.<sup>6</sup> These data, including the reassuring safety profile of LLT in childhood<sup>5,37,38</sup> coupled with the risk of ASCVD in untreated FH, support the use of statins in children with HeFH beginning at ages  $\geq 8$  years if 3 to 6 months of lifestyle management is insufficient to lower LDL-C <160 mg/dL. Statins and other LLTs may be considered at younger ages (6 years) or at lower LDL-C cutpoints in the presence of concerning family history, extremely elevated LDL-C, pathogenic FH genetic variants, elevated Lp(a), or other risk conditions (eg, diabetes, CKD, childhood cancer treatment<sup>24</sup>) in the context of shared

**Table 19. Lipid-Lowering Agents in Childhood and Adolescents (eg, <Age 18 Years)**

| Medication                             | FDA Approved Dosing for Use in Childhood                                       | FDA Indicated Age   | Expected LDL-C Reduction at Maximum Pediatric Dose | Potential Adverse Effects  |
|--|--|---|--|--|
| Statins <sup>5</sup>                   |  |   |  |  |
| Atorvastatin                           | 5 mg, 10 mg, 20 mg, 40 mg, 80 mg PO/d  | $\geq 10$ y   | $\geq 50\%$  | Myalgias (rare), abdominal pain (rare), accelerated risk of diabetes type 2 (unknown, reported in adults), hepatotoxicity (very rare), HMG-CoA antibody myopathy (very rare) rhabdomyolysis (extremely rare) |
| Pitavastatin                           | 1 mg, 2 mg, 4 mg PO/d  | $\geq 8$ y  | 30–49%   |  |
| Pravastatin                            | 10 mg, 20 mg, 40 mg PO/d   | $\geq 8$ y  | 30–49%   |  |
| Simvastatin                            | 5 mg, 10 mg, 20 mg, 40 mg* PO/d  | $\geq 10$ y   | 30–49%   |  |
| Rosuvastatin                           | 5 mg, 10 mg, 20 mg PO/d  | $\geq 8$ y for 5 and 10 mg doses and $>10$ y for 20 mg dose | $\geq 50\%$  |  |
| Cholesterol absorption inhibitors      |  |   |  |  |
| Ezetimibe                              | 10 mg PO/d   | $\geq 10$ y   | 13–20% <sup>9,43</sup>                             | Myalgias, muscle weakness, fatigue, diarrhea (all very rare)   |
| Bile acid binding resin                | Colesevelam: 3.75 g PO/d as 1 packet or six 625 mg tablets divided twice daily | $\geq 10$ y   | 15% <sup>33,34</sup>                               | Significant drug interactions exist. Contraindicated if TG are elevated (will raise TG).<br>Abdominal pain, constipation (rare), pancreatitis (very rare)  |
| PCSK9 monoclonal antibodies            |  |   |  |  |
| Evolocumab                             | 140 mg SQ every 2 wk or 420 mg SQ every 2 wkt†                                 | $\geq 10$ y   | 38% (HeFH)<br>14% (HoFH) <sup>8</sup>              | Hypersensitivity (rare), nasopharyngitis (common), headache, sore throat (common)  |
| Alirocumab                             | Pediatric dosing by weight in 2- or 4-wk intervals SQ                          | $\geq 8$ y  | 34–44% (HeFH)<br>13% (HoFH) <sup>30,44</sup>       | Nasopharyngitis (common), tonsillitis (common), headache (common), injection site reaction (common). Attention and memory problems, syncope were rarely reported <sup>30</sup>                               |
| Other cholesterol-lowering medications |  |   |  |  |
| Evinacumab                             | 15 mg/kg IV q 4 wk   | $\geq 5$ y old HoFH only                                    | 48% (HoFH) <sup>45</sup>                           | Fatigue, pyrexia, headache, oropharyngeal pain, nasopharyngitis, abdominal pain  |
| Supplements                            |  |   |  |  |
| Psyllium fiber                         | 10 g PO/d  |   | 6–24% <sup>46</sup>                                | GI effects, although these tend to resolve with regular use  |
| Plant Stanol/Sterol                    | 2 g PO/d (available as capsules or as food additives)                          |   | 6–12% <sup>47</sup>                                | Diarrhea, steatorrhea  |

\*The 80 mg dose of simvastatin should not be used due to myopathy risk.

†The 420 mg dose of evolocumab is no longer manufactured for administration. Dosing information and contraindications from FDA-approved labeling available at <http://dailymed.nlm.nih.gov/dailymed/index.cfm><sup>48</sup>

HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; IV, intravenous; PO, per os; and SQ, subcutaneous.

decision-making. The intensity of lipid-lowering should be tailored to the patient’s clinical circumstances, considering patient and family preference. A reduction of ≥50% in LDL-C from baseline and a goal LDL-C of ≤130 mg/dL is generally advised; LDL-C can be lowered to ≤100 mg/dL in patients with additional risk factors.<sup>6,24</sup> Individuals with HoFH often develop coronary obstruction in early childhood and require individualized evaluation by a pediatric cardiologist and an experienced lipid specialist; LLT is started at diagnosis, often in infancy (Section 4.2.4.4, “Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH”).

3. The Centers for Disease Control and Prevention gave genetic testing for FH a Tier 1 indication in 2012,<sup>39</sup> and this has been recommended<sup>10</sup> as a way to confirm the diagnosis of FH, for cascade screening of first- and second-degree relatives and to guide treatment choice. Diagnostic criteria that rely primarily on phenotype may miss up to half of children with pathogenic/likely pathogenic rare variants for FH.<sup>13,40</sup> For example, whether to initiate LLT at LDL-C levels in borderline ranges, or with an unclear family history or clinical picture, may be informed by the presence of a pathogenic FH mutation. In children and adolescents with LDL-C insufficiently responsive to standard LLT, genetic testing can inform diagnosis (for example, bi-allelic semi-dominant hypercholesterolemia monogenic [single-gene variants], bi-allelic semi-dominant digenic [variants in 2 different genes], or bi-allelic recessive hypercholesterolemia [single-gene variants]<sup>41</sup>) and guide additional therapies. Care should be taken to engage the patient and family with a genetic counselor, if available, and to consider any financial and insurance coverage concerns. Although genetic testing in adults has a much lower yield, up to 70% to 80% of children with the clinical presentation of FH may have a pathogenic variant for FH identified.<sup>10,11</sup>

4.2.8.2. Young Adults Ages >18 to 39 Years of Age

| Recommendation for Young Adults Ages >18 to 39 Years of Age                              |      |  |
|--|------|--|
| Referenced studies that support the recommendation are summarized in the Evidence Table. |      |  |
| COR  | LOE  | Recommendation   |
| 1  | B-NR | 1. In young adults (>18–39 y of age), dietary, physical activity, and weight optimization recommendations should be provided to reduce cumulative atherogenic lipid exposure and lifetime ASCVD risk. <sup>1,2</sup> |

Synopsis

Primordial prevention of dyslipidemia is prioritized in cholesterol prevention guidelines, as early life lipid exposures are strong determinants of ASCVD risk across the life course.<sup>1–5</sup> The cumulative exposure to atherogenic lipids

in young adulthood is a determinant of atherosclerosis development and ASCVD events later in life.<sup>6</sup> Thus, atherogenic lipid exposure during early adult life should be minimized as much as possible through dietary, physical activity, and weight optimization approaches (Sections 4.1.2 to 4.1.6). This is particularly pertinent given the high burden of ASCVD risk factors and increasing rates of ASCVD events in young adults.<sup>7,8</sup> Accurate assessment of lipid-associated risk, as well as mitigation of risk with healthy behavior optimization, is vitally important for improving individual and population health. Young adulthood represents a high-impact opportunity for ASCVD prevention.

Recommendation-Specific Supportive Text

1. It is common for atherogenic lipid levels to increase (average rate of increase=1-2 mg/dL per year for LDL-C/non-HDL-C and 0.5 mg/dL/year for apoB) during young adulthood, although this normative increase should not be perceived as optimal.<sup>9</sup> The CARDIA study demonstrated strong associations between atherogenic lipid levels in young adults that are approximately 20 mg/dL lower for LDL-C and non-HDL-C compared with those seen in middle-aged adults and older adults with ASCVD. Thus, counseling around health behaviors to reduce atherogenic lipid exposure and ASCVD risk should begin even at lipid levels that would be considered normal for middle-aged adults.<sup>10</sup> Lipid-lowering pharmacotherapy is safe and appears cost-effective to use in young adults. See Section 4.2.3.7, “Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L)” for LLT use in adults ages 30 to 79 years and Section 4.2.5, “Diabetes in Adults Without Established ASCVD” for guidance in young adults with diabetes.<sup>11</sup> RCTs of LLT for young adults ages >18 to 29 years that demonstrate efficacy for ASCVD risk reduction have not been performed due to the long follow-up times that would be necessary to demonstrate benefit. The use of LLT in young adults ages >18 to 29 years with high atherogenic lipid burden and a high burden of risk enhancers is a matter of clinical judgment and patient preference in the absence of available evidence.

4.2.8.3. Older Adults

| Recommendations for Older Adults  |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | C-EO | 1. In older adults, the benefit-risk discussion should include patient priorities, functional status, multimorbidity, frailty, polypharmacy, and life expectancy, and should not be based solely on chronological age when considering the decision to discontinue LLT. <sup>1–3</sup> |

Downloaded from http://ahajournals.org by on March 15, 2026

| Recommendations for Older Adults (Continued) |      |   |
|--|------|---|
| COR  | LOE  | Recommendations   |
| 2b   | B-NR | 2. In adults aged >75 y with an estimated life expectancy of at least 2.5 y, it may be reasonable to initiate moderate-intensity statin therapy after a clinician–patient discussion of potential benefits and risks to reduce ASCVD risk. <sup>4–6,7</sup> |
| 2b   | B-R  | 3. In patients with a life expectancy of <1 y, it may be reasonable to discontinue LDL-lowering therapy to avoid unnecessary medication use or adverse medication effects. <sup>8,9</sup>   |
| 2b   | B-NR | 4. In adults aged >75 y with an estimated life expectancy of at least 2.5 y, and for whom the decision regarding LLT is uncertain, it may be reasonable to measure CAC to reclassify those with minimal (1–10) or no CAC to avoid LLT. <sup>10–13</sup>     |

## Synopsis

As adults grow older, they face increasing risks of mortality from both ASCVD and other causes, as well as complications from medical therapy. Decisions to initiate or continue LLT in older adults must balance the goal of preventing ASCVD events with risks from multimorbidity, frailty, polypharmacy, and functional decline. RCT data for adults aged >75 years are limited but support primary prevention with statin therapy to reduce ASCVD events, although relative reductions in risk may be lower than in younger populations, and there is no evidence of overall mortality benefit.<sup>4–6</sup> Decisions to not initiate or deprescribe LLT are reasonable in older adults when aligned with patient priorities and when potential risks outweigh potential benefits.<sup>1–3</sup> Time-to-benefit is a particularly important consideration for older adults, with 1 meta-analysis of adults up to age 75 years estimating a time-to-benefit from primary prevention statins of 2.5 years.<sup>6</sup> A CAC score of 0 in older adults suggests that the potential benefits of LLT are unlikely to outweigh potential risks.<sup>10–13</sup> One RCT of both primary and secondary prevention in adults with estimated life expectancy <1 year found that discontinuing statin therapy was safe and associated with improved QOL.<sup>9</sup> Two ongoing RCTs may clarify the role of statins in primary prevention for adults aged >70 years.<sup>14,15</sup> Additional recommendations for adults >75 years of age are included in Sections 4.2.3, “Primary Prevention in Adults,” 4.2.5, “Diabetes in Adults Without Established ASCVD,” and 4.2.6, “Secondary ASCVD Prevention.”

## Recommendation-Specific Supportive Text

1. Decisions to initiate, continue, or deprescribe LLT in older adults should balance the goals of preventing ASCVD events with the increasing risk of medication-related harms that come with aging, as well as competing risks of multimorbidity, frailty, and functional decline.<sup>1–3</sup> Neither initiation nor deprescribing decisions should be based solely on age or life

expectancy. Although some older adults may prefer to minimize pill burden, others may prefer to start or continue LLT precisely because they are at high cardiovascular risk, particularly if their life-limiting illness is ASCVD. Therefore, decisions about LLT should result from clinician–patient discussions, be revisited over time, and include patients' caregivers, primary care clinicians, and other specialists.<sup>1–3</sup> A chief concern of many older adults is preservation of function over prevention of specific conditions; however, data on the effects of LLT on functional status are unknown. Two ongoing large clinical trials of statins in adults aged ≥70 years, with planned 6-year follow-up, should provide additional evidence on the role of statins for the prevention of disability-free survival, MACE, and dementia.<sup>14,15</sup>

2. To date, few RCTs of LLT for primary prevention have focused on older adults.<sup>4–6,16</sup> The PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease) trial compared pravastatin 40 mg to placebo in 5804 adults aged 70 to 82 years with established or increased risk for ASCVD and found a lower hazard of major coronary events overall favoring pravastatin, but no differences in all-cause mortality or stroke, and no differences in the primary prevention subgroup.<sup>5</sup> Observational studies<sup>7</sup> and secondary analyses of individual RCTs have provided conflicting evidence.<sup>16–21</sup> A meta-analysis of individual participant data from 28 RCTs found that only 8% of participants in trials of preventive statin therapy were aged ≥75 years, and statin therapy in this group produced a 13% RRR in major vascular events per 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C, with reductions driven by fewer major coronary events but not overall mortality, vascular death, or stroke.<sup>4</sup> Thus, clinician–patient discussion of potential benefits and risks remains particularly important for older adults. Additionally, time-to-benefit from LLT is an important consideration, with 1 meta-analysis of RCTs of adults aged 50 to 75 years finding that 100 adults without known ASCVD may need to be treated for 2.5 years to prevent 1 MACE,<sup>6</sup> but similar studies for adults aged ≥75 years are lacking given limited RCT data in this population.
3. The decision to discontinue statin therapy, whether prescribed for primary or secondary prevention of ASCVD, rests on the balance of patient preferences, likelihood of harms and benefits, and side effects or harms experienced. This balance may shift in late life, as the development of new chronic conditions, functional impairments, and polypharmacy may increase the potential risks of LLT, while the development of life-limiting conditions may reduce the potential for benefit.<sup>2,9</sup> Patient preferences for preventive therapies may also shift over time, particularly in patients with very limited life expectancy. One RCT of 381

adults (mixed primary and secondary prevention individuals) with an estimated life expectancy <1 year (mean age 75 years) compared statin continuation with cessation and found that stopping statins was not associated with significantly higher short-term mortality and was associated with small improvements in QOL.<sup>9</sup> Thus, for patients with limited life expectancy, particularly from conditions unrelated to ASCVD (eg, malignancy, chronic liver disease, chronic lung disease), it may be reasonable for clinicians to initiate conversations about deprescribing of LLT, in conjunction with patients' caregivers and care teams. A variety of clinical decision tools have been developed to estimate life expectancy and frailty, many of which can be found at: <https://eprognosis.ucsf.edu/> and <https://efrailty.hsl.harvard.edu/>.

- Multiple studies have demonstrated that CAC measurement is a valuable tool for identifying the absence of atherosclerotic disease in older adults.<sup>10–13</sup> The BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population) study, which enrolled individuals with a 10-year ASCVD risk >7.5% by PCE (mean participant age 69 years), found that one-third of participants had a CAC score of 0. CAC-guided reclassification improved the specificity for CHD events by 22%, and participants with a CAC score of ≤10 could be appropriately reclassified to a lower-risk category, potentially avoiding LLT.<sup>11</sup> Thus, limiting LLT to older adults with CAC scores >10, while incorporating clinical judgment and patient preferences, may offer a more personalized approach to shared decision-making for older adults with intermediate 10-year ASCVD risk by the PREVENT-ASCVD equations, but this strategy remains to be tested in prospective clinical trials.

#### 4.2.8.4. Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating

| Recommendations for Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating |      |  |
|--|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table.                              |      |  |
| COR  | LOE  | Recommendations  |
| 1  | C-LD | 1. Persons of childbearing age with hypercholesterolemia who are not at high risk for ASCVD and plan to become pregnant should stop statin therapy 1 to 2 mo before attempting to become pregnant or as soon as pregnancy is discovered to avoid uncertain risks to the fetus. <sup>1–4</sup>                |
| 2a   | B-NR | 2. In pregnant or lactating individuals with HoFH, it is reasonable to undergo lipoprotein apheresis to lower LDL-C and reduce ASCVD risk. <sup>5–7</sup>  |
| 2a   | B-NR | 3. In pregnant individuals with severe fasting hypertriglyceridemia (TG ≥500 mg/dL [5.7 mmol/L]), the use of fibrates (after the first trimester) or high-dose omega-3 ethyl esters is reasonable as an adjunct to lifestyle management to lower TG levels and reduce the risk of pancreatitis. <sup>8</sup> |

| Recommendations for Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating (Continued) |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 2a   | C-EO | 4. In pregnant or lactating individuals with hypercholesterolemia but without hypertriglyceridemia, the use of bile acid sequestrants is reasonable to lower LDL-C.  |
| 2b   | C-LD | 5. In pregnant individuals with FH or a history of clinical ASCVD, it may be reasonable to continue statin therapy to lower LDL-C and ASCVD risk following an individualized benefit-risk discussion. <sup>9</sup> |

\*The use of a hydrophilic statin, such as pravastatin, should be considered if the benefit of continued statin therapy is deemed greater than potential risk based on results from available clinical trials.<sup>3</sup>

### Synopsis

CVD mortality rates among younger persons, including those of childbearing age and typically considered to be at low ASCVD risk, continue to rise.<sup>10</sup> Concurrently, maternal age is increasing in the United States. As individuals age, there is an increased risk of CVD and cardiovascular risk factors, such as hypertension and dyslipidemia, as well as higher plaque burden. Additionally, lipoprotein levels vary across the lifecycle, with physiological increases in TC, TG, and LDL-C seen during pregnancy.<sup>11</sup> The reproductive years represent a critical period during which preconception cardiovascular risk assessment and CVD risk factor modification are important. Identification of childbearing individuals who may be at increased risk for CVD or adverse pregnancy outcomes is crucial. Lifestyle management with diet and exercise (Section 4.1.2.2, “Lifestyle Management of Hypertriglyceridemia”) is paramount, and optimization of pharmacotherapy can modify cardiovascular risk in individuals considering pregnancy. Clinicians can also balance the cardiovascular risk of the pregnant individual against the potential in utero exposure to pharmacotherapy. Historically, the use of LLT has been limited to bile acid sequestrants during pregnancy and/or lactation based on observational and animal studies suggesting teratogenicity of statins.<sup>12</sup> In 2021, the FDA changed from providing recommendations for or against taking medicine to recommending individualizing risks and benefits regarding statin use during pregnancy (Table 20).

### Recommendation-Specific Supportive Text

- Statin use is generally not recommended during pregnancy or while lactating due to earlier animal and preclinical studies that raised concerns for teratogenicity in humans.<sup>1,2,13</sup> The statin doses used in animal studies were much higher than those often used in the clinical setting.<sup>2,13</sup> However, recent studies have shown conflicting results.<sup>3</sup> In a large retrospective cohort study of 469 pregnant individuals receiving statin therapy compared with 4690 controls, multivariable analysis demonstrated that statin

**Table 20. Lipid-Lowering Therapies During Pregnancy and Lactation**

|                         | Pregnancy   | Lactation   |
|-------------------------|---|---|
| Statins                 | Should be discontinued in most pregnancies<br>Can be considered in high-risk individuals (ASCVD or FH <sup>29</sup> )   | Avoid use <sup>30</sup>   |
| Ezetimibe               | Avoid use due to insufficient data regarding risk to fetus <sup>31</sup>  | Avoid use <sup>31</sup>   |
| Bile acid sequestrants  | Safe to use. No evidence of risk in humans due to lack of systemic absorption <sup>12</sup><br>Known to interfere with absorption of fat-soluble vitamins<br>High rate of gastrointestinal side effects | Not excreted in human milk <sup>12</sup><br>Caution if used—associated with malabsorption of fat-soluble vitamins (A, D, E, and K). Prenatal vitamins may not be sufficient |
| Niacin                  | Avoid use due to insufficient data regarding risk to fetus or clinical utility for the mother <sup>12</sup>   | Avoid use <sup>12</sup>   |
| Fibric acid derivatives | Can be considered (after the first trimester) for severe hypertriglyceridemia only if the potential benefit justifies the potential risk to the fetus <sup>12</sup>                                     | Avoid use during lactation. If taken during pregnancy, lactation can be resumed 5 days after last dose of fibric acid derivatives <sup>12</sup>                             |
| Omega-3 fatty acids     | Can be considered for severe hypertriglyceridemia <sup>12</sup>   | Known to be excreted in human milk. Effects on infants are unknown<br>Caution if used during lactation <sup>12</sup>  |
| Bempedoic acid          | Avoid use due to insufficient data regarding risk to fetus <sup>12</sup>  | Avoid use <sup>12</sup>   |
| PCSK9 mAb               | Avoid use due to insufficient data regarding risk to fetus <sup>12</sup>  | Avoid use <sup>12</sup>   |
| Inclisiran              | Avoid use due to insufficient data regarding risk to fetus <sup>29</sup>  | Avoid use <sup>29</sup>   |
| Evinacumab              | Avoid use due to insufficient data regarding risk to fetus <sup>32</sup>  | Avoid use <sup>32</sup>   |
| Lomitapide              | Avoid use due to risk of embryo-fetal toxicity <sup>31</sup>  | Avoid use <sup>33</sup>   |

Adapted with permission from Agarwala et al.<sup>12</sup> © 2024 Elsevier. Adapted with permission from Jacobson et al.<sup>31</sup> © 2015 Elsevier.

ASCVD indicates atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; mAb, monoclonal antibodies; and PCSK9, proprotein convertase subtilisin/kexin type 9.

exposure was associated with higher risk of preterm birth (RR, 1.99 [95% CI, 1.46-2.71];  $P < 0.001$ ), low birth weight (RR, 1.51 [95% CI, 1.05-2.16];  $P < 0.05$ ), and preeclampsia or eclampsia (RR, 2.78 [95% CI, 1.66-4.65];  $P < 0.001$ ) but not associated with congenital anomalies (RR, 1.24 [95% CI, 0.81-1.90]).<sup>3</sup> A meta-analysis of 6 studies (5 cohort studies and 1 case-control study) showed no significant difference in major congenital malformations among offspring whose mothers were treated with statin therapy compared with controls (aOR, 1.05 [95% CI, 0.84-1.31]).<sup>4</sup> Future large-scale clinical trials will hopefully provide additional information regarding maternal-fetal risks of statin use. At this time, it seems prudent to avoid statin therapy during pregnancy and while lactating, but to date, no significant teratogenicity has been observed.

- Patients with HoFH are at extremely high premature and lifetime ASCVD risk. Treatment is always with combination pharmacotherapy to achieve adequate LDL lowering and is commonly accompanied by concomitant use of lipoprotein-apheresis. Considering the length of time for conception, pregnancy, and lactation, an individual may have to defer systemic LLT (especially statins) use for a period of 1 year, and possibly, several years. The risk of pharmacotherapy deferral in these very high-risk individuals, even for a short duration, may be significant.<sup>14</sup> Lipoprotein-apheresis has been demonstrated to be a successful treatment in HoFH for LDL-C lowering

during pregnancy<sup>5-7,15-17</sup>; however, it is time consuming, expensive, and not widely available.

- During pregnancy, physiological increases in TG levels occur due to estrogen-mediated increased hepatic VLDL synthesis and decreased lipoprotein lipase activity.<sup>18</sup> Triglyceride levels can increase 2- to 4-fold during the third trimester.<sup>19</sup> Gestational hypertriglyceridemia is associated with adverse pregnancy outcomes. Although infrequent, severe gestational hypertriglyceridemia can lead to acute pancreatitis. In a large, retrospective cohort study, elevated TG levels early in pregnancy were associated with an increased risk of preterm delivery (8.54% versus 5.22%, adjusted odds ratio [AOR], 1.52 [95% CI, 1.21-1.90]), preeclampsia (4.79% versus 2.29%, AOR, 1.75 [95% CI, 1.29-2.36]), gestational diabetes (27.93% versus 12.44%, AOR, 1.95 [95% CI, 1.69-2.25]), and large-for-gestational age (31.36% versus 22.35%, AOR, 1.28 [95% CI, 1.12-1.46]).<sup>20</sup> Persistently elevated TG levels were associated with further increased risk of preeclampsia (AOR, 2.53 [95% CI, 1.66-3.84]), gestational diabetes (AOR, 1.97 [95% CI, 1.57-2.47]), and large-for-gestational age (AOR, 1.68 [95% CI, 1.37-2.07]), compared with women with TG levels that are always low.<sup>20</sup> TG-lowering medications can be used during pregnancy for persistently severe hypertriglyceridemia (TG level of  $\geq 500$  mg/dL [5.7 mmol/L]) despite lifestyle management after secondary causes for hypertriglyceridemia have been excluded. Several case reports have demonstrated

the use of high-dose prescription omega-3 fatty acids and fibrates (after the first trimester) to safely lower TG during pregnancy.<sup>8,19,21,22</sup>

4. There are limited data regarding the use of bile acid sequestrants in pregnant individuals. However, due to the lack of systemic absorption,<sup>23</sup> bile acid sequestrants are not expected to result in fetal exposure and therefore are considered safe to use during pregnancy for the management of hypercholesterolemia. In animal studies, colestevlam showed no evidence of fetal harm.<sup>24</sup> They should not be used when TG levels  $\geq 300$  mg/dL (3.4 mmol/L) and only prescribed after considering the impact of worsening bloating and constipation.
5. Statins may be considered in pregnant persons at very high risk for ASCVD (a history of ASCVD or FH with additional risk factors).<sup>25</sup> A small retrospective study of pregnant individuals with HoFH demonstrated that the rates of miscarriages (5.5%) and premature birth (11.1%) in the statin-exposed pregnancies were no different than the rates in healthy women (8%-20% and 5%-18%, respectively).<sup>9</sup> Clinicians caring for individuals at high ASCVD risk who desire pregnancy should engage in clinician-patient discussion regarding the use of statin therapy and potential side effects, clinical benefits, fetal risks, and risks of atherosclerotic disease progression without treatment. There has been recent interest in the role of statins in the prevention of preeclampsia.<sup>26,27</sup> A multicenter RCT enrolling 173 pregnant persons at risk for preeclampsia showed a significantly lower rate of preterm preeclampsia (<37 weeks) (13.8 versus 26.7%;  $P=0.03$ ; RR, 0.52 [95% CI, 0.27-0.97]) and preterm delivery (<37 weeks) (16% versus 36%;  $P=0.003$ ; RR, 0.45 [95% CI, 0.26-0.78]) among those treated with pravastatin compared with the control group.<sup>28</sup> Larger-scale clinical trials are needed to confirm the safety of statins in people of childbearing age and their efficacy in the prevention of preeclampsia. Due to limited clinical evidence, statins are not currently approved for the prevention of preeclampsia.

**4.2.8.5. Considerations Based on Ancestry**

**Synopsis**

Race and ethnicity have historically been included in cardiovascular risk assessment, but growing evidence suggests that, in contrast to genetically defined ancestry, race and ethnicity are social constructs. It is the influence of social determinants of health, rather than biological differences, that drives many health disparities. The PREVENT-ASCVD equations represent a shift toward a more individualized risk assessment that focuses on modifiable factors, such as lifestyle and environment, without specifically incorporating race or ethnicity.<sup>1</sup>

Empirical differences in CVD risks exist across ancestries, but the myriad factors driving these differences

**Table 21. Considerations According to Ancestry Groups**

|   |
|---|
| <p><b>Observed Higher Risk in Demographic Groups</b></p> <p>South Asian ancestry is a high-risk demographic group and considered a risk-enhancer.<sup>4,5,8-10</sup></p> <p>Increased prevalence of diabetes at lower BMI and waist circumferences across Asian populations.<sup>11-16</sup></p> <p>Increased CKM syndrome risk factors among Filipino American individuals, including hypertension, hyperlipidemia, and obesity.<sup>17</sup></p>  |
| <p><b>Variation in Lipid Measures</b></p> <p>Higher levels of Lp(a) are found in non-Hispanic Black individuals, but associated increase in CVD relative risk is similar to other groups.<sup>18</sup></p> <p>Elevated Lp(a) is associated with a higher population-attributed risk for MI among South Asian and Latin American people.<sup>19</sup></p> <p>Baseline CK levels are higher in non-Hispanic Black individuals but may not portend greater risk for statin-associated adverse events.<sup>20</sup></p> |
| <p><b>Statin Sensitivity</b></p> <p>Some individuals of Chinese, Japanese, or Korean ancestry have been observed to have higher plasma concentrations of rosuvastatin, resulting in heightened sensitivity, and may benefit from starting rosuvastatin therapy at a lower dose.<sup>21</sup></p>  |

BMI indicates body mass index; CK, creatine kinase; CVD, cardiovascular disease; Lp(a), lipoprotein (a); and MI, myocardial infarction.

remain poorly understood. There is significant heterogeneity in CVD risks and mortality among Asians from different regions, with South Asian individuals having the highest proportional mortality risk and CVD prevalence.<sup>2-4</sup> Urban and Western acculturation are associated with increased cholesterol levels in individuals of Asian Indian ancestry and obesity in adults of Filipino ancestry.<sup>5</sup> Native Hawaiians and Pacific Islanders have higher CVD mortality compared with Asian Americans, further highlighting the need to disaggregate Asian data within the United States for meaningful interpretation.<sup>3,6</sup> Similarly, disaggregated data are essential for Hispanic and Latino adults due to the lack of specificity among individuals from different regions.<sup>7</sup> Importantly, to maximize adherence, lifestyle recommendations should be comprehensive and tailored to cultural preferences for diet, exercise, and weight management. Table 21 reviews specific considerations that might play a role in the management of patients based on ancestry groups.

**4.2.8.6. Adults With Heart Failure**

| Recommendation for Adults With Heart Failure   |          |   |
|--|----------|---|
| Referenced studies that support recommendation are summarized in the Evidence Table. |          |   |
| COR  | LOE      | Recommendation  |
| <b>3: No Benefit</b>   | <b>A</b> | 1. In adults with HFrEF who do not have clinical ASCVD or another indication for LLT, initiation of LLT is not recommended to reduce clinical events or mortality. <sup>1-3</sup> |

**Synopsis**

The “2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol”<sup>4</sup> provided a weak

recommendation (COR 2b, LOE B-R) for consideration of statin therapy in patients with HF<sub>r</sub>EF due to ischemic heart disease. This recommendation was made on the basis of a meta-analysis of 2 large trials that showed modest benefit for initiation of moderate-intensity rosuvastatin in reducing risk for MI only in patients with HF<sub>r</sub>EF due to ischemic heart disease. That analysis also accounted for the large competing risk from non-ASCVD mortality in patients with HF<sub>r</sub>EF.<sup>5</sup> Subsequent data and meta-analyses of RCTs corroborate that benefit from statin therapy does not appear to accrue to patients with HF<sub>r</sub>EF without underlying indications for LLT, such as clinically manifest ASCVD.<sup>6,7</sup> Meta-analysis of observational data, which may be confounded, suggests reductions in total mortality, CVD death, and CVD hospitalization in patients with HF<sub>r</sub>EF or heart failure with preserved ejection fraction (HF<sub>p</sub>EF).<sup>7</sup> Trials of non-statin LLT have largely excluded patients with chronic HF. Further research is warranted to determine whether LLT may confer benefit in patients with HF<sub>p</sub>EF without clinical ASCVD.<sup>7,8</sup> However, it should be noted that the prevalence of significant CAD exceeds 50% in patients with either HF<sub>r</sub>EF or HF<sub>p</sub>EF.<sup>9–13</sup> In summary, the decision for LLT should be made based on other considerations (eg, need for secondary or higher-risk primary prevention of ASCVD, life expectancy) and not the presence of HF.

### Recommendation-Specific Supportive Text

- Two large RCTs examined therapy with 10 mg rosuvastatin versus placebo in patients with chronic HF<sub>r</sub>EF. The CORONA trial randomized 5011 older patients with New York Heart Association class II to IV HF symptoms and left ventricular ejection fraction <40% due to ischemic heart disease and observed a modest, nonsignificant reduction in hard ASCVD events with rosuvastatin (HR, 0.92 [95% CI, 0.83–1.02]; *P*=0.12).<sup>1</sup> The GISSI HF trial included 4631 adults with chronic HF from diverse etiologies and reported no benefit for the primary outcome of death or CVD hospitalization (HR, 1.02 [95% CI, 0.92–1.13]).<sup>2</sup> A third trial (PEARL [Effects of Pitavastatin in Japanese Patients With Chronic HF]) examined the clinical endpoint of death or hospitalization for worsening HF among 574 Japanese patients with New York Heart Association class II to III HF and left ventricular ejection fraction <45% without consideration of etiology; this trial used a PROBE design with randomization to pitavastatin 2 mg versus no statin and also observed no significant benefit.<sup>3</sup> A subsequent meta-analysis including published data from all 3 trials demonstrated no significant reduction in sudden cardiac death, total mortality, or hospitalization for HF.<sup>6</sup> A prior individual-level meta-analysis combined data from CORONA and GISSI-HF and did find a significant reduction in MI

with rosuvastatin in patients with HF<sub>r</sub>EF due to ischemic heart disease (HR, 0.81 [95% CI, 0.66–0.99]).<sup>5</sup>

#### 4.2.8.7. Adults With Chronic Inflammatory Diseases Synopsis

Adults with chronic inflammatory diseases (CID), including rheumatoid or psoriatic arthritis, systemic lupus erythematosus, systemic vasculitis, inflammatory bowel disease, and spondyloarthritis, have greater prevalence of ASCVD and risk factors for ASCVD, especially dyslipidemia.<sup>1–4</sup> Clinicians who care for those with CID should incorporate ASCVD risk assessment as an important part of their clinical care. Standard risk calculators tend to underestimate risk in this population, while CID-specific risk calculators have not been shown to outperform standard calculators.<sup>5</sup> However, the presence of clinical features may suggest higher ASCVD risk (eg, specific autoimmune disease(s), duration and disease activity, greater number of CID present), facilitating clinical decision-making.<sup>3,5</sup> ASCVD may manifest at younger ages, where CAC is more likely to be found in individuals with systemic lupus erythematosus and rheumatoid arthritis.<sup>6,7</sup> Observational data demonstrate that LLT can be used safely in adults with CID and effectively lower LDL-C.<sup>8</sup> Statins may have modest direct anti-inflammatory effects, but RCT evidence supporting the ability of LLT to reduce ASCVD risk in adults with CID is lacking. However, there are observational data demonstrating reduced ASCVD risk in adults taking statins and other LLT compared with cohorts not taking statins.<sup>9</sup> Anti-inflammatory therapy can have both lipid and nonlipid effects in adults with CID (eg, glucocorticoids, hydroxychloroquine, tocilizumab). Given their potential lipid-modifying effects, lipid monitoring is recommended in adults with CID on anti-inflammatory therapy, especially after change in therapy.

#### 4.2.8.8. Adults With CKD—Stage 3 or Higher

**Recommendations for Adults With CKD—Stage 3 or Higher**  
Referenced studies that support recommendations are summarized in the Evidence Table.

| COR | LOE  | Recommendations   |
|-----|------|---|
| 1   | B-R  | 1. In adults 40 to 75 y of age with CKD stage 3 or higher and an LDL-C of 70 to 189 mg/dL (1.8–4.9 mmol/L), moderate-intensity statin therapy or moderate-intensity statin combined with ezetimibe is recommended to reduce ASCVD risk. <sup>1,2</sup>  |
| 1   | B-R  | 2. In adults with CKD stage 3 or higher and clinical ASCVD, LLT with high-intensity statin therapy, with or without ezetimibe and/or a PCSK9 mAb, is recommended to achieve a ≥50% reduction in LDL-C levels and a goal of LDL-C <55 mg/dL (1.4 mmol/L) and non-HDL-C <85 mg/dL (2.2 mmol/L) to reduce ASCVD risk. <sup>1,3</sup> |
| 2b  | C-LD | 3. In adults with CKD who require maintenance hemodialysis, it may be reasonable to continue statin therapy to reduce the risk of ASCVD events. Treatment decisions should be individualized with consideration of expected survival, other comorbidities, and severity of ASCVD. <sup>1</sup>                                    |

## Synopsis

CKD is a risk factor for cardiovascular events in populations with or without established ASCVD, and people with moderate CKD not on dialysis have a similar risk of ASCVD events as those with established ASCVD.<sup>4</sup> In adults with elevated LDL-C, the presence of CKD favors initiation of LLT.<sup>1,2</sup> Among adults who have CKD and ASCVD, aggressive LLT has been shown to be effective and safe, including the addition of ezetimibe and PCSK9 mAb. In adults with CKD who require dialysis treatment, initiation of a statin has not been shown to be beneficial in 2 large randomized clinical trials<sup>5,6</sup> and in a subgroup analysis of a trial that included a group of patients on dialysis.<sup>1</sup> The use of LLT in such cases may be considered based on clinical judgment while considering a patient's projected longevity and other comorbidities. In adults with advanced kidney disease requiring dialysis who are already on LDL-lowering pharmacotherapy, it may be reasonable to continue treatment. The available clinical trial data have shown similar safety of statins, ezetimibe, and PCSK9 mAb among patients with or without CKD.<sup>2</sup> Although bempedoic acid has been associated with a small increase in creatinine and blood urea nitrogen in individuals with minimal or moderate renal impairment, its use has not been evaluated in individuals with severe CKD or those on dialysis.<sup>7</sup> A pooled analysis of ORION (O) -9, -10, and -11 compared the LDL-C-lowering efficacy and safety of inclisiran in 3658 patients with (45.2%) or without CKD.<sup>8</sup> Although too few patients had severe CKD to draw conclusions in that subgroup, inclisiran showed similar LDL-C-lowering efficacy and safety in patients with no or mild/moderate CKD.

## Recommendation-Specific Supportive Text

1. In a meta-analysis of 43 studies (41 273 participants) comparing treatment with statins versus placebo, statins reduced the risk of death, major cardiovascular events, and MI in people with CKD who did not require hemodialysis.<sup>2</sup> In this analysis, the assessment of potential harms was limited by a low level of evidence and a lack of systematic reporting. Statins, compared with placebo, had little or no effect on elevated liver enzymes or withdrawal due to adverse events. Few studies reported rhabdomyolysis or elevated CK; hence, the effect size could not be determined. However, the use of simvastatin 80 mg (a dose that is no longer recommended) was associated with myopathy among individuals with CKD. Statins with lower renal clearance, such as atorvastatin, may be preferable. In contrast, rosuvastatin concentrations may increase in patients with severe CKD (<30 mL/min/1.73 m<sup>2</sup>) and thus, dose modification (eg, doses of ≤10 mg) may be required. In the SHARP study,<sup>1</sup> the combination of simvastatin 20 mg daily and ezetimibe reduced the risk of major atherosclerotic events (coronary death, MI, nonhemorrhagic stroke, or any

revascularization) compared with placebo in persons with CKD stage 3 or greater.

2. Among patients with established ASCVD, CKD is an independent risk factor for adverse cardiovascular events. PCSK9i have been shown to be safe and effective in individuals who have mild or moderate CKD but have not been studied in those with GFR <20 mL/min/1.73 m<sup>2</sup>.<sup>9</sup> In the FOURIER trial, the absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD.<sup>3</sup> Adverse events were infrequent and similar regardless of CKD stage. In both the FOURIER and the ODYSSEY trials, the addition of PCSK9 mAb to statin therapy among individuals with impaired renal function was safe and effective, resulting in median LDL-C <50 mg/dL with ~60% LDL-C reduction.
3. In adults with CKD who require dialysis treatment, initiation of a statin has not been shown to be beneficial in 2 large randomized clinical trials<sup>5,6</sup> and in a subgroup analysis of a trial that included patients on dialysis.<sup>1</sup> In adults with advanced kidney disease requiring dialysis who are already on LDL-lowering pharmacotherapy, it may be reasonable to continue treatment<sup>10</sup> while considering a patient's expected survival, other comorbidities, and risk of ASCVD events.

### 4.2.8.9. Persons Living With HIV

**Recommendation for Persons Living With HIV**  
Referenced studies that support the recommendation are summarized in the Evidence Table.

| COR | LOE | Recommendation   |
|-----|-----|--|
| 1   | B-R | 1. In people living with HIV aged 40 to 75 y on stable combination antiretroviral therapy, statin therapy is recommended to reduce risk of a first ASCVD event and reduce the rate of coronary atherosclerosis progression. <sup>1</sup> |

## Synopsis

People living with HIV (PLHIV) are at increased risk of ASCVD events, independent of traditional risk factors.<sup>2-4</sup> This risk is due to increased rates of insulin resistance, atherogenic dyslipidemia, partial lipodystrophy, and abnormal innate and adaptive immunity in PLHIV, resulting in accelerated atherosclerosis and increased risk of thrombosis.<sup>5-7</sup> The REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial demonstrated that in PLHIV, pitavastatin 4 mg daily led to a 35% reduction in risk of the first MACE (cardiovascular death, MI, hospitalization for unstable angina, stroke, TIA, peripheral arterial ischemia, revascularization, or death from an undetermined cause) compared with placebo (95% CI, 0.48-0.90; *P*=0.002).<sup>1</sup> This trial enrolled patients with low to moderate risk of ASCVD and demonstrated consistent reduction in MACE across this population. Pitavastatin was evaluated in the REPRIEVE trial because its lack of metabolism through P450 Cyp3A4 reduces the risk

of potential drug interactions compared with other statin therapies (Table 22).

### Recommendation-Specific Supportive Text

1. The REPRIEVE trial evaluated pitavastatin 4 mg daily versus placebo in PLHIV aged 40 to 75 years over a median of 5.1 years and demonstrated a 35% relative reduction in first MACE compared with placebo (95% CI, 0.48-0.90;  $P=0.002$ ).<sup>1</sup> Results were consistent across a range of ASCVD risk scores and subgroups defined by age, sex, race, risk factor status, baseline LDL-C, and HIV disease characteristics. A substudy of REPRIEVE investigated progression of noncalcified plaque on CCTA. Pitavastatin resulted in 4.3 mm<sup>3</sup> less progression in noncalcified plaque than placebo overall in 2 years and a difference of 8.8 mm<sup>3</sup> among those with any noncalcified plaque on the baseline CCTA.<sup>8</sup> Of note, eligibility criteria for REPRIEVE did not include a lower bound on the 10-year risk of ASCVD based on the PCE or a lower bound on LDL-C level. Median PCE-determined 10-year risk was 4.5%, and median LDL-C was 108 mg/dL at study entry.<sup>1</sup>

DDI between LLT and antiretroviral therapies are an important consideration. Lovastatin, simvastatin, and atorvastatin are metabolized by cytochrome P450 CYP3A4 and fluvastatin by cytochrome P450 CYP2C9, which can commonly lead to DDI with antiretroviral therapy.<sup>9</sup> Pitavastatin was the statin studied in REPRIEVE because, along with rosuvastatin and pravastatin, it is primarily not metabolized by cytochrome P450 CYP3A4. For PLHIV <40 years of age, please refer to Section 4.2.3.7, "Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8-4.9 mmol/L)," and Section 4.2.8.2, "Young Adults Ages >18 to 39 Years," for additional guidance in primary prevention in young adults.

#### 4.2.8.10. Adults With Cancer or History of Cancer

| Recommendations for Adults With Cancer or History of Cancer                           |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. Adult cancer survivors with life expectancy of at least 2 y who otherwise qualify for LLT should be treated similarly to people without history of cancer to reduce the risk of ASCVD events. <sup>1-6</sup>    |
| 1   | B-NR | 2. In adults with active cancer currently on statin therapy, treatment should be continued to reduce ASCVD risk unless there is concern for a specific drug interaction or life expectancy is <1 y. <sup>7-9</sup> |
| 2b  | B-R  | 3. In adults with active cancer, initiation of statin therapy may be considered to prevent anthracycline-induced cardiotoxicity. <sup>10</sup>   |

### Synopsis

CVD is the second most common cause of death among people with a history of cancer and is the leading cause of death in longer-term survivors (eg, 5-10 years after diagnosis).<sup>1-4</sup> Published evidence indicates no increase in risk associated with statin therapy in patients with cancer, and observational studies show that statin treatment in patients with cancer history is associated with lower overall mortality and even cancer-related mortality.<sup>5</sup> Unfortunately, cancer survivors are more likely to discontinue statin therapy than people without cancer, despite increased risk of ASCVD.<sup>11</sup> Thus, special attention is needed by clinicians treating dyslipidemia to ensure that patients with cancer who are otherwise candidates for LLT do receive preventive treatment. This is particularly important when considering secondary prevention of ASCVD.<sup>7</sup> Emerging evidence indicates that statins may provide protection against chemotherapy-induced cardiomyopathy (particularly with anthracyclines and trastuzumab); thus, statins may be considered in patients at borderline or higher ASCVD risk when initiation of statin therapy was otherwise uncertain. In vitro and in vivo data suggest that statins may also enhance the activity of some anticancer treatments at certain cancer sites. This may occur due to the high requirement for cholesterol in rapidly dividing cells, alterations in protein geranylgeranylation, and other potential mechanisms. Clinical trials focused on statin therapy in relation to anticancer therapy and outcomes are needed.<sup>11-15</sup>

### Recommendation-Specific Supportive Text

1. The risk of ASCVD is elevated among cancer survivors relative to controls, with a standardized mortality ratio of fatal heart disease of 2.24 (95% CI, 2.23-2.25). Among 5-year cancer survivors at low oncologic risk, the risk of heart disease death over the next 5 years is greater than the risk of cancer death.<sup>2,3</sup> Guidelines from the National Comprehensive Cancer Network recommend following primary prevention guidelines for ASCVD in cancer survivors.<sup>6</sup> In Denmark, there was a lower risk of cancer-related mortality and all-cause mortality among statin users.<sup>5</sup> Patients with cancer and acute MI have better outcomes if prescribed a statin (HR, 0.56 [95% CI, 0.32-0.96]).<sup>7</sup> Among 2-year survivors of cancer with no metastatic disease, patients with lung and colorectal cancer are particularly vulnerable to statin nonadherence.<sup>14</sup> Discontinuation of statins selectively in the context of polypharmacy among older adults in a large observational study in Italy was associated with higher risk of HF hospitalization (HR, 1.24 [95% CI, 1.07-1.43]) and any cardiovascular outcome (HR, 1.14 [95% CI, 1.03-1.26]) and mortality (HR, 1.15 [95% CI, 1.02-1.30]).<sup>16</sup> Statins

**Table 22. Antiretroviral Therapy and Statin Drug Interactions**

| Statin  | Antiretroviral Drug                           | Recommendations  |
|---|---|--|
| <b>Protease Inhibitors</b>                            |   |  |
| Atorvastatin <sup>10</sup>                            | Atazanavir                                    | Titrate atorvastatin dose carefully and administer the lowest effective dose while monitoring for toxicities.  |
|   | Atazanavir/ritonavir                          |  |
|   | Atazanavir/cobicistat                         | Do not coadminister.   |
|   | Darunavir/cobicistat<br>Darunavir/ritonavir   | Titrate atorvastatin dose carefully and administer the lowest effective dose while monitoring for toxicities. Do not exceed atorvastatin 20 mg daily.                      |
|   | Lopinavir/ritonavir                           | Titrate atorvastatin dose carefully and administer the lowest effective dose while monitoring for toxicities. Do not exceed atorvastatin 20 mg daily.                      |
|   | Tipranavir/ritonavir                          | Do not co-administer.  |
| Lovastatin <sup>11</sup>                              | All protease inhibitors                       | Contraindicated.   |
| Pitavastatin <sup>12</sup>                            | All protease inhibitors                       | No dose adjustment needed.   |
| Pravastatin <sup>13</sup>                             | Atazanavir/ritonavir<br>Atazanavir/cobicistat | Titrate pravastatin dose carefully while monitoring for pravastatin-related adverse events.  |
|   | Darunavir/cobicistat<br>Darunavir/ritonavir   | Titrate pravastatin dose carefully while monitoring for pravastatin-related adverse events.  |
|   | Lopinavir/ritonavir                           | No dose adjustment needed.   |
|   |   |  |
| Rosuvastatin <sup>14</sup>                            | Atazanavir/ritonavir                          | Titrate rosuvastatin dose carefully and administer lowest effective dose while monitoring for rosuvastatin-related adverse events.   |
|   | Atazanavir/cobicistat                         | Do not exceed rosuvastatin 10 mg daily.  |
|   | Darunavir/cobicistat                          | Titrate rosuvastatin dose carefully and administer lowest effective dose while monitoring for rosuvastatin-related adverse events. Do not exceed rosuvastatin 20 mg daily. |
|   | Darunavir/ritonavir                           | Titrate rosuvastatin dose carefully and administer the lowest effective dose while monitoring for rosuvastatin-related adverse events.                                     |
|   | Lopinavir/ritonavir                           | Titrate rosuvastatin dose carefully and administer the lowest effective dose. Do not exceed rosuvastatin 10 mg daily.  |
|   | Tipranavir/ritonavir                          | No dose adjustment needed.   |
| Simvastatin <sup>15</sup>                             | All protease inhibitors                       | Contraindicated.   |
| <b>NNRTIs</b>   |   |  |
| Atorvastatin <sup>10</sup>                            | Doravirine                                    | No dose adjustment needed.   |
|   | Rilpivirine                                   |  |
|   | Efavirenz                                     | Adjust atorvastatin dose according to lipid response, but do not exceed the maximum recommended dose.  |
|   | Etravirine                                    |  |
|   | Nevirapine                                    | Adjust atorvastatin dose according to lipid response, but do not exceed the maximum recommended dose.  |
| Fluvastatin <sup>16</sup>                             | Doravirine                                    | No dose adjustment needed.   |
|   | Rilpivirine                                   |  |
|   | Nevirapine                                    |  |
|   | Efavirenz<br>Etravirine                       | Dose adjustments for fluvastatin may be necessary. Monitor for fluvastatin toxicity.   |
| Lovastatin <sup>11</sup><br>Simvastatin <sup>15</sup> | Doravirine                                    | No dose adjustment needed.   |
|   | Rilpivirine                                   |  |
|   | Efavirenz                                     | Adjust simvastatin dose according to lipid response, but do not exceed the maximum recommended dose.   |
|   | Etravirine<br>Nevirapine                      | Adjust lovastatin or simvastatin dose according to lipid response, but do not exceed the maximum recommended dose.   |
| Pitavastatin <sup>12</sup>                            | All NNRTIs                                    | No dose adjustment needed.   |
| Pravastatin <sup>12</sup>                             | Doravirine                                    | No dose adjustment needed.   |
|   | Rilpivirine                                   |  |
|   | Nevirapine                                    |  |
|   | Efavirenz                                     | Adjust statin dose according to lipid responses, but do not exceed the maximum recommended dose.   |
|   | Etravirine                                    |  |

(Continued)

**Table 22. Continued**

| Statin  | Antiretroviral Drug                        | Recommendations   |
|---|--|---|
| Rosuvastatin <sup>14</sup>                              | All NNRTIs                                 | No dose adjustment needed.  |
| NRTIs   |  |   |
| All statins   | All NRTIs                                  | No dose adjustment needed.  |
| Integrase Strand Transfer Inhibitors                    |  |   |
| Atorvastatin <sup>10</sup>                              | Bictegravir<br>Dolutegravir<br>Raltegravir | No dose adjustment needed.  |
|   | Elvitegravir/cobicistat                    | Titrate statin dose carefully and administer the lowest effective dose while monitoring adverse events. Do not exceed atorvastatin 20 mg daily. |
| Lovastatin <sup>11</sup>                                | Bictegravir<br>Dolutegravir<br>Raltegravir | No dose adjustment needed.  |
|   | Elvitegravir/cobicistat                    | Contraindicated.  |
| Pitavastatin <sup>12</sup><br>Pravastatin <sup>13</sup> | Bictegravir<br>Dolutegravir<br>Raltegravir | No dose adjustment needed.  |
|   | Elvitegravir/cobicistat                    | No data available for dose recommendation.  |
| Rosuvastatin <sup>14</sup>                              | Bictegravir<br>Dolutegravir<br>Raltegravir | No dose adjustment needed.  |
|   | Elvitegravir/cobicistat                    | Titrate statin dose carefully and use the lowest effective dose while monitoring for adverse events.  |
| Simvastatin <sup>15</sup>                               | Bictegravir<br>Dolutegravir<br>Raltegravir | No dose adjustment needed.  |
|   | Elvitegravir/cobicistat                    | Contraindicated.  |



Adapted from<sup>17</sup> and modified with permissions from Sarkar et al.<sup>18</sup> Copyright 2000–2025 MDTText.com, Inc. NNRTI indicates non-nucleoside reverse transcriptase inhibitor; and NRTI, nucleoside reverse transcriptase inhibitor.

do not increase risk of cancer recurrence.<sup>17–19</sup> A pooled analysis of alirocumab also showed no signal of increased recurrence of cancer in patients with a cancer history.<sup>20</sup>

- The time horizon for statins to reduce the risk of MACE in primary prevention is approximately 2.5 years.<sup>8</sup> In contrast, a randomized trial enrolling patients with life expectancy of <1 year, including half of whom had cancer, found that discontinuation of statin therapy was not associated with shorter survival and was associated with better QOL.<sup>9</sup> Statins have not been shown to increase cancer recurrence, and observational studies show lower cancer-related mortality in statin-treated patients. The only reasons to exclude patients with active cancer from the usual guideline recommendations for LLT are expected DDI or very limited life expectancy.
- A meta-analysis of 7 clinical trials including 887 patients scheduled to undergo anthracycline-based chemotherapy indicated a beneficial effect of statins in preventing anthracycline-induced cancer therapy-related cardiovascular dysfunction

(RR, 0.46 [95% CI, 0.29–0.72]; *P*<0.001). There was also a reduction in left ventricular end-diastolic diameter but no difference in ejection fraction after chemotherapy.<sup>21</sup> Atorvastatin 40 mg daily was the most commonly used regimen, although rosuvastatin 20 mg daily and simvastatin 40 mg daily were also studied. As noted above, cancer-related mortality has been observed to be lower among statin-treated patients with cancer than in untreated patients with cancer.

**4.2.9. Management of Hypertriglyceridemia**

| Recommendations for Management of Hypertriglyceridemia<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 1   | B-NR | 1. In adults with persistently elevated TG levels ≥150 mg/dL (1.7 mmol/L), after evaluation and management of secondary causes, <sup>1</sup> lifestyle management (consuming a diet that consists of low added sugars, as well as reduced alcohol and saturated fat intake, routine exercise, and weight loss of 5%–10% of body weight if overweight or obese) is recommended as a first-line approach to reduce TG levels (Figure 2). <sup>2,3</sup> |

| Recommendations for Management of Hypertriglyceridemia (Continued) |      |  |
|--|------|--|
| COR  | LOE  | Recommendations  |
| 1  | B-R  | 2. In adults with clinical ASCVD and LDL-C $\geq$ 55 mg/dL (1.4 mmol/L) and non-HDL-C $\geq$ 85 mg/dL on maximally tolerated statin with persistently elevated TG levels $\geq$ 150 to 999 mg/dL (1.7–11.3 mmol/L), intensification of LDL-C-lowering therapy is recommended to reduce ASCVD risk. <sup>4–6</sup>  |
| 1  | B-R  | 3. In adults with FCS and fasting TG $\geq$ 1000 mg/dL (11.3 mmol/L), olezarsen is recommended as an adjunct to diet to lower TG levels and reduce the risk of pancreatitis. <sup>78</sup>   |
| 2b   | B-R  | 4. In adults $\geq$ 50 y of age with clinical ASCVD or with diabetes and $\geq$ 1 ASCVD risk factors, with persistently elevated TG levels $\geq$ 150 to 499 mg/dL (1.7–5.6 mmol/L), and LDL-C $<$ 100 mg/dL (2.6 mmol/L) on maximally tolerated statin, the addition of IPE may be reasonable to lower ASCVD risk. (See Figure 9 in Section 4.2.5, "Diabetes in Adults Without Established ASCVD") <sup>9,10</sup>                                    |
| 1  | A    | 5. In adults aged 40 to 75 y without a history of ASCVD or diabetes who have persistently elevated TG levels $\geq$ 150 to 499 mg/dL ( $\geq$ 1.7–5.6 mmol/L), it is recommended to estimate 10-y ASCVD risk by the PREVENT-ASCVD equations to guide the benefit-risk discussion regarding further optimization of diet and lifestyle management as well as the potential initiation of statin therapy to reduce ASCVD risk (Figure 11). <sup>11</sup> |
| 2a   | B-NR | 6. In adults with severe hypertriglyceridemia (persistently elevated TG levels $\geq$ 500–999 mg/dL [5.7 mmol/L]) and especially with TG levels $\geq$ 1000 mg/dL (11.3 mmol/L) despite dietary intervention, the use of fibric acid derivatives or prescription omega-3 fatty acids is reasonable to lower TG levels and reduce the risk of pancreatitis (Figure 11). <sup>12,13</sup>  |
| 2a   | B-NR | 7. In adults with hypertriglyceridemia (TG $\geq$ 150 mg/dL), measurement of non-HDL-C or apoB is preferred over LDL-C to guide clinical decision-making. <sup>14–16</sup>   |

## Synopsis

Observational and genetic epidemiology consistently demonstrate a strong association between TG-rich lipoprotein remnants and increased ASCVD risk.<sup>17–19</sup> When hypertriglyceridemia is diagnosed, assessment and correction of any secondary causes, along with lifestyle management, are recommended before initiation of pharmacotherapy (Section 4.1.2.2, "Lifestyle Management of Hypertriglyceridemia"). Persistent hypertriglyceridemia is defined as fasting TG  $\geq$ 150 mg/dL (1.7 mmol/L) after evaluation and management of secondary causes, a minimum of 4 to 12 weeks of lifestyle management (Section 4.1.2.2, "Lifestyle Management of Hypertriglyceridemia"), and on a stable, maximally tolerated dose of statin if indicated based on ASCVD risk (Table 23). Cardiovascular risk associated with hypertriglyceridemia is highest in adults with TG levels of 500 to 880 mg/dL compared with 150 to 499 mg/dL

and those  $>$ 880 mg/dL, with the initial priority being ASCVD risk reduction with statin therapy. The risk of acute pancreatitis increases with TG levels  $\geq$ 500 mg/dL and is particularly high with TG levels  $\geq$ 1000 mg/dL.<sup>20</sup> In patients with TG levels  $\geq$ 1000 mg/dL, initial priority should be given to lowering TG to reduce the risk of pancreatitis.<sup>13</sup> The decision to initiate pharmacotherapy should consider the presence of clinical ASCVD, diabetes, patient age and, among those without diabetes or clinical ASCVD, the calculated ASCVD risk (Figures 14 to 17). Although fibric acid derivatives lower TG levels, they do not provide incremental ASCVD risk reduction when added to statin therapy.<sup>21–24</sup> Therefore, statins remain first-line therapy for patients with TG  $<$ 1000 mg/dL to reduce ASCVD risk. Statins can modestly lower TG by inhibiting VLDL assembly and secretion.<sup>25</sup>

## Recommendation-Specific Supportive Text

1. Lifestyle management is the first-line treatment in the management of hypertriglyceridemia (Figure 2). This includes alcohol reduction or elimination, a diet that is low in saturated fats, added sugars, and refined carbohydrates (Section 4.1.2.2, "Lifestyle Management of Hypertriglyceridemia"), weight loss (in overweight or obese individuals), and exercise. Evaluation and management of secondary causes of hypertriglyceridemia are also important (Table 23). Weight loss has a beneficial impact on cardiovascular risk factors and lipoprotein levels in obese individuals. A 5% to 10% weight loss can result in a reduction in TG of 20% to 30%.<sup>26</sup> In a meta-analysis of 73 RCTs including 32 496 patients, lifestyle management (diet, exercise, or both) resulted in a 4 mg/dL (0.05 mmol/L) reduction in TG level for every 1 kg of weight loss (95% CI,  $-5.24$  to  $-2.77$  mg/dL [ $-0.06$  to  $-0.03$  mmol/L]).<sup>2</sup> Aerobic exercise also lowers TG levels. In a meta-analysis of studies examining the impact of aerobic exercise on TG levels, moderate-intensity aerobic exercise was associated with a modest but significant reduction in TG levels of 0.21 mmol/L (95% CI,  $-0.286$  to  $-0.14$  mmol/L;  $-18.6$  mg/dL [95% CI,  $-25.33$  to  $-12.4$  mg/dL];  $P<0.0001$ ).<sup>3</sup> Current recommendations for aerobic exercise are for individuals to engage in at least 150 minutes weekly of moderate-intensity exercise or 75 minutes weekly of vigorous exercise.<sup>27</sup>
2. Among patients with clinical ASCVD and elevated LDL-C and persistent hypertriglyceridemia, LDL-C lowering remains the priority. For patients on maximally tolerated statin therapy, the addition of nonstatin therapies such as ezetimibe, PCSK9 mAb, or bempedoic acid reduces the risk of ASCVD in patients who need further LDL-C lowering to achieve goal LDL-C.
3. FCS is a rare monogenic disorder characterized by severe hypertriglyceridemia and an increased risk


**Table 23. Physiological and Secondary Causes of Hypertriglyceridemia**

| Categories              | Conditions and Medications Contributing to Hypertriglyceridemia   |
|-------------------------|---|
| Diseases                | <p>Poorly controlled diabetes</p> <p>Chronic kidney disease, nephrotic syndrome</p> <p>Lipodystrophy</p> <p>Uncontrolled hypothyroidism</p> <p>Cushing syndrome</p> <p>Glycogen storage disease, acute hepatitis</p> <p>Rheumatoid arthritis</p> <p>Psoriasis</p> <p>Systemic lupus erythematosus</p> <p>Multiple myeloma</p> <p>Sepsis (repeat measurement is recommended if lipids were measured during an episode of sepsis)</p>   |
| Diet/Lifestyle          | <p>History of alcohol abuse or alcohol excess</p> <p>Diets high in saturated fat, sugar, or high-glycemic-index foods</p> <p>Sedentary lifestyle</p> <p>Total parenteral nutrition with lipid emulsions</p>   |
| Drugs* (Medications)    | <p>Anesthesia:</p> <p>Propofol</p> <p>Cardiology:</p> <p>Beta-adrenergic–blocking agents</p> <p>Thiazide and loop diuretic agents</p> <p>Bile acid sequestrants (cholestyramine, colestipol, colesevelam)</p> <p>Endocrine:</p> <p>Glucocorticosteroids</p> <p>Anabolic steroids</p> <p>Oral estrogens</p> <p>Raloxifene</p> <p>Clomiphene citrate</p> <p>Estradiol</p> <p>Ethinyl estradiol</p> <p>Conjugated estrogens</p> <p>Tamoxifen</p> <p>Dermatology:</p> <p>Isotretinoin</p> <p>Infectious Disease:</p> <p>HIV protease inhibitors</p> <p>Oncology:</p> <p>Tamoxifen</p> <p>L-asparaginase</p> <p>Bexarotene</p> <p>Cyclophosphamide</p> <p>Psychiatry:</p> <p>Atypical antipsychotic agents (eg, olanzapine, mirtazapine, clozapine)</p> <p>Immunosuppressive agents:</p> <p>Tacrolimus</p> <p>Sirolimus</p> <p>Cyclosporine</p> <p>Interferons</p> |
| Disorders of metabolism | <p>Overweight and obesity</p> <p>Metabolic syndrome/insulin resistance</p> <p>Weight gain after weight loss</p>   |
| Physiological           | Pregnancy (especially during the third trimester, when pregnancy-associated TG elevation is peaking)  |

\*Caveats: TG-raising medications require careful monitoring; minimizing other conditions that raise TG; and, when clinically appropriate, using alternatives. TG indicates triglycerides. Adapted from Virani et al.<sup>13</sup>



Circulation



**Figure 14. Managing Adults With Hypertriglyceridemia.**


\*Conversion of TG from mg/dL to mmol/L: 150 mg/dL=1.7 mmol/L, 175 mg/dL=2 mmol/L, 500 mg/dL to 5.7 mmol/L, 1000 mg/dL=11.3 mmol/L. ASCVD indicates atherosclerotic cardiovascular disease; and TG, triglycerides. Adapted with permission from Virani et al.<sup>13</sup> © 2021 American College of Cardiology Foundation.

of acute pancreatitis. As a result of pathogenic variants in the gene encoding lipoprotein lipase (LPL), affected individuals have persistently reduced LPL activity, resulting in severely elevated TG levels.<sup>28</sup> Current management includes adoption of a very-low-fat diet to turn off chylomicron production. This dietary pattern includes reducing total fat intake from <10% to 15% of daily calories (ie, <20 g of fat per day), but long-term adherence to this strict dietary regimen can be difficult.<sup>29</sup> Standard LLT, including omega-3 fatty acids, fibrates, or statins, are minimally effective in FCS patients because their effect is at least partially via LPL-mediated TG clearance.<sup>30</sup> A phase 3 clinical trial enrolling patients with genetically confirmed FCS demonstrated a significant reduction in TG levels at 6 months with olezarsen 80 mg (an apoC3 antisense oligonucleotide) compared with placebo (−43.5% [95% CI, −69.1

to −17.9];  $P<0.001$ ).<sup>7</sup> There were also fewer episodes of pancreatitis in the olezarsen 80 mg group compared with placebo (rate ratio [pooled olezarsen groups versus placebo], 0.12; 95% CI, 0.02–0.66).<sup>7</sup> Olezarsen is currently FDA-approved as an adjunct to diet to reduce TG in adults with FCS.

4. Several RCTs have explored the efficacy of prescription omega-3 fatty acids on the risk of cardiovascular events, with negative results.<sup>31–33</sup> However, only trials of purified EPA have shown cardiovascular benefit. In the open-label JELIS (Japan EPA Lipid Intervention Study), TG decreased significantly but modestly from baseline in the EPA group compared with controls. The risk of major coronary events was significantly reduced by 19% in the EPA group compared with the statin-only group despite only a modest reduction in TG.<sup>10</sup> Cardiovascular benefit was also demonstrated in the REDUCE-IT trial, which randomized

## Adults With ASCVD and Hypertriglyceridemia




2026 Dyslipidemia  
© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 15. Adults With ASCVD and Hypertriglyceridemia.**

\*Conversion of triglyceride from mg/dL to mmol/L: 150 mg/dL=1.7 mmol/L, 175 mg/dL=2 mmol/L, 500 mg/dL to 5.7 mmol/L, 1000 mg/dL=11.3 mmol/L. ASCVD indicates atherosclerotic cardiovascular disease; ETOH, ethyl alcohol; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol. Adapted from Virani et al.<sup>13</sup>

8179 subjects age  $\geq 45$  years with ASCVD or  $\geq 50$  years with diabetes and 1 additional cardiovascular risk factor to 4 g of IPE or placebo. The primary composite outcome of cardiovascular death, nonfatal MI, stroke, coronary revascularization, or unstable angina was reduced by 25% in those randomized to IPE compared with those taking placebo.<sup>9</sup> The rates of hospitalization for new-onset atrial fibrillation were significantly higher in the IPE group compared with placebo, although the overall rates were low. Serious bleeding events also occurred at higher rates in the IPE group compared with the placebo group. In REDUCE-IT, among patients  $>50$  years of

age with diabetes and at least 1 additional ASCVD risk factor (29.3% of the study cohort), 12.2% in the IPE group experienced a primary endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization) (HR, 0.88 [95% CI, 0.70-1.10]) compared with 13.6% in the placebo group. However, a biomarker subanalysis of REDUCE-IT revealed that participants in the IPE group showed no significant improvement in atherogenic lipids, lipoproteins, or inflammatory markers. In contrast, those randomized to the mineral oil placebo experienced deleterious changes in these biomarkers, likely exaggerating



**Figure 16. Adults With Hypertriglyceridemia but Without ASCVD or Diabetes.**


\*Conversion of triglyceride from mg/dL to mmol/L: 150 mg/dL=1.7 mmol/L, 175 mg/dL=2 mmol/L, 500 mg/dL to 5.7 mmol/L, 1000 mg/dL=11.3 mmol/L. apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; ETOH, ethyl alcohol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and LLT, lipid-lowering therapy. Adapted with permission from Virani et al.<sup>13</sup> © 2021 American College of Cardiology Foundation.

the observed beneficial treatment effect and complicating the interpretation of the trial. Although it is imperative to weigh the benefits and risks of using IPE in light of the overall low, but significantly higher rates of bleeding and atrial arrhythmias that occurred in the IPE group, its use may be reasonable to lower the ASCVD risk in adults aged  $\geq 50$  years with persistently elevated TG or with diabetes and  $\geq 1$  ASCVD risk factors.

5. Among patients with moderate hypertriglyceridemia and no clinical ASCVD or diabetes, additional factors can guide appropriate management of cardiovascular risk and hypertriglyceridemia. For patients at low 10-year estimated ASCVD risk using the PREVENT-ASCVD equations, focusing

on diet and lifestyle management is important, with periodic reassessment of ASCVD risk (Figure 6).<sup>13</sup> Statins decrease concentrations of TG-rich lipoproteins and LDL-C. The higher the baseline level of TG, the greater the percentage TG reduction with statin treatment. Statins lower TG on average by 20% to 40%, and, along with lifestyle management, should be first-line therapy in patients with moderate hypertriglyceridemia who have borderline to intermediate 10-year estimated ASCVD risk.<sup>13</sup> Patients with moderate hypertriglyceridemia and high 10-year estimated ASCVD risk benefit from aggressive cardiovascular risk factor control, including lifestyle management and initiation or intensification of moderate- to high-intensity

## Managing Adults With Triglycerides $\geq 500$ mg/dL



2026 Dyslipidemia  
© 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 17. Managing Adults With Triglycerides  $\geq 500$  mg/dL.**

apoB indicates apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; ETOH, ethyl alcohol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and LLT, lipid-lowering therapy. Adapted with permission from Virani et al.<sup>13</sup> © 2021 American College of Cardiology Foundation.

statin therapy to lower LDL-C and apoB to reduce ASCVD risk.<sup>34</sup>

6. The risk of acute pancreatitis is increased in patients with severe hypertriglyceridemia (TG levels  $\geq 500$  mg/dL [5.6 mmol/L]), and particularly in those with TG  $\geq 1000$  mg/dL [11.3 mmol/L]).<sup>20</sup> For

patients with severe hypertriglyceridemia, a thorough reassessment for secondary causes should be performed. There may be a genetic cause for the severely elevated TG levels, and panel-based genetic testing for pathogenic/likely pathogenic rare variants should be considered to exclude MCS

or FCS. Clinicians can also use the North American Familial Chylomicronemia Syndrome scoring tool to help decide whether FCS is present, likely, or unlikely, and to help determine whether genetic testing may distinguish FCS from MCS.<sup>35</sup> However, if secondary causes are again excluded and/or optimally managed, the addition of fibric acid derivatives or prescription omega-3 fatty acids is reasonable to lower TG levels and reduce the risk of pancreatitis,<sup>13,23</sup> in addition to adoption of a very-low-fat diet for those with TG  $\geq 1000$  mg/dL (Section 4.1.2.2., “Lifestyle Management of Hypertriglyceridemia”) and lifestyle management. Fibric acid derivatives lower TG by 30% to 50%.<sup>36</sup> When selecting fibric acid derivatives, gemfibrozil is not recommended, and preference should be given to the use of fenofibrate due to fewer DDI and a lower risk of myopathy when fenofibrate is used in combination with statins.<sup>37</sup>

7. In patients with hypertriglyceridemia, when there is discordance between apoB and LDL-C, apoB and non-HDL-C are more accurate estimators of ASCVD risk than LDL-C (Section 3.3, “Measurement of ApoB”). In the context of hypertriglyceridemia, apoB can also aid in the identification and characterization of lipid phenotypes, such as inherited lipid disorders, including familial combined hyperlipidemia, familial dysbetalipoproteinemia, FCS and MCS, lipoprotein X, and glycerol kinase deficiency.

#### 4.2.10. Approach to Patients With Elevated Lp(a)

| Recommendations for the Approach to Patients With Elevated Lp(a)<br>Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
|---|------|--|
| COR   | LOE  | Recommendations  |
| 1   | B-NR | 1. In all individuals with elevated Lp(a) ( $\geq 125$ nmol/L or $\geq 50$ mg/dL), optimal early control of modifiable cardiovascular risk factors is recommended to reduce ASCVD risk. <sup>1-4</sup>   |
| 1   | B-R  | 2. In individuals with clinical ASCVD and elevated Lp(a) who have not achieved LDL-C and non-HDL-C treatment goals on maximally tolerated statin therapy, the addition of a PCSK9 mAb with proven cardiovascular benefit is recommended to achieve treatment goals and reduce ASCVD risk. <sup>4-7</sup> |

#### Synopsis

Because Lp(a) is associated with an increased lifetime risk of ASCVD, individuals with elevated Lp(a) should be advised to intensify modifiable risk factor management early. Relative risk derived from Lp(a) is multiplicative with other risk factors.<sup>8,9</sup> Although risk increases with higher Lp(a), an Lp(a) concentration of 50 mg/dL (125 nmol/L; affecting ~20% of the population) is considered elevated and corresponds to ~40% higher relative risk compared with a population median. An Lp(a) of ~80 to 100 mg/dL (~200-250 nmol/L) doubles the risk, while an Lp(a) of 180 mg/dL (~430 nmol/L) increases the risk by ~4-

fold, a risk equivalent to HeFH (Table 4).<sup>10,11</sup> Lifestyle management minimally impacts Lp(a) as it is mostly genetically determined.<sup>8</sup> An elevated Lp(a) favors initiating or intensifying LLT. Statins do not lower Lp(a),<sup>1</sup> whereas PCSK9 mAb and lipoprotein-apheresis lower Lp(a) as well as LDL-C. Based on observational data,<sup>12</sup> apheresis is FDA-approved for patients with Lp(a)  $\geq 60$  mg/dL (or 130 nmol/L) if they also have FH and CAD or PAD (Table 16). Post hoc analyses in 2 primary prevention trials found that aspirin reduced cardiovascular events in individuals with high Lp(a),<sup>13,14</sup> but prospective trials in individuals with elevated Lp(a) are needed. Specific Lp(a)-lowering therapies that target Lp(a) production (eg, mRNA therapies or oral small-molecule inhibitors) are being investigated in randomized clinical outcomes trials.

#### Recommendation-Specific Supportive Text

1. Management of modifiable risk factors as early as possible is essential for individuals with elevated Lp(a) in a manner consistent with the individual's overall risk, incorporating risks from both traditional risk factors and Lp(a)-related risk. Early management of modifiable risk factors is essential for individuals with elevated Lp(a), including more intensive control of lipids, blood pressure, and glycemic control. Lifestyle changes aligned with AHA's Life's Essential 8 (eg, smoking cessation, healthful diet, activity) are recommended to lower ASCVD risk and are associated with a 67% lower risk of ASCVD among individuals with elevated Lp(a).<sup>2</sup> In the JUPITER trial, high-intensity statin therapy had an approximately 30% to 40% RRR in events among individuals with elevated Lp(a) (on-treatment LDL-C 54 mg/dL).<sup>3</sup> Statins do not lower Lp(a) and may modestly increase Lp(a) in some individuals, although the average Lp(a) increase is generally small (mean absolute difference, 1.1 mg/dL higher compared with placebo)<sup>1</sup> and would not justify discontinuing the statin given the strong cardiovascular benefit of statins. When the LDL-lowering goal is not reached with the usual combinations of drugs (eg, statin, ezetimibe, bempedoic acid), adding a PCSK9i is an option depending on the individual's risk and Lp(a) concentration.<sup>4</sup> Patient referral to a specialist could be considered in select cases.
2. Lp(a) testing is rarely performed among patients with ASCVD, even though patients with ASCVD and elevated Lp(a) are at increased risk. Patients with ASCVD who underwent testing for Lp(a) had lower mortality than with those who did not get tested, likely due to more intensive lipid-lowering and antihypertensive treatment.<sup>5</sup> PCSK9i (mAbs and small-interfering RNA) substantially lower LDL-C and apoB and lower Lp(a) by ~15% to 30%. In high-risk patients with ASCVD and elevated Lp(a) who have not achieved

LDL-C or apoB treatment goals on maximal statin therapy, PCSK9i with proven cardiovascular benefit should be preferentially considered to reach treatment goals, with the potential additional benefit of moderate Lp(a) lowering. PCSK9i are not currently FDA-approved for Lp(a) lowering; however, post hoc analysis of the FOURIER trial<sup>6</sup> and prespecified analysis of the ODYSSEY Outcomes trial<sup>7</sup> suggested that patients with higher Lp(a) may derive greater benefit from PCSK9 mAb and that the Lp(a) lowering may have contributed to benefit. In a subgroup analysis of a post hoc pooled analysis from 10 ODYSSEY phase 3 trials comparing alirocumab with control (placebo or ezetimibe) and adjusting for LDL-C, the association between Lp(a) reduction and cardiovascular events was seen only in patients with Lp(a)  $\geq 50$  mg/dL (125 nmol/L) ( $P$  for interaction=0.05).<sup>4</sup>

#### 4.2.11. Management of Statin-Attributed Muscle Symptoms

| Recommendations for Management of Statin-Attributed Muscle Symptoms                   |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | C-LD | 1. In adults with statin-attributed muscle symptoms, assessment should include evaluation for secondary causes (Table 24), and in those with severe myalgias or weakness, objective clinical measures of muscle strength <sup>1</sup> and measurement of CK are recommended to assess severity of the condition.   |
| 1   | B-R  | 2. In adults with statin-attributed muscle symptoms, the clinician-patient discussion should acknowledge patient side effect concerns, inform the patient of the heightened ASCVD risk associated with statin discontinuation, and provide alternative treatment options to reduce ASCVD risk. <sup>2,3</sup>  |
| 1   | B-R  | 3. In adults with clinical ASCVD who experience statin-attributed muscle symptoms on the recommended intensity of statin therapy (secondary causes excluded) and are unable to achieve recommended treatment goals, use of a reduced statin dose (if tolerable) and the addition of bempedoic acid, <sup>3</sup> ezetimibe, <sup>4</sup> or a PCSK9 mAb, <sup>5,6</sup> alone or in combination, are recommended to lower LDL-C and reduce ASCVD risk.   |
| 1   | B-R  | 4. In adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms on the recommended intensity of statin therapy (secondary causes excluded) and are at high ASCVD risk based on the PREVENT-ASCVD equations of $\geq 10\%$ or a CAC score $\geq 300$ AU, or women $>65$ y of age or men $>60$ y of age with diabetes, the addition of bempedoic acid <sup>7</sup> and/or ezetimibe <sup>4</sup> is/are indicated to lower LDL-C to $<70$ mg/dL (1.8 mmol/L) and non-HDL-C $<100$ mg/dL (2.6 mmol/L) and to reduce ASCVD risk. |
| 1   | B-R  | 5. In adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms on the recommended intensity of statin therapy (secondary causes excluded) and are at high ASCVD risk based on the PREVENT-ASCVD equations of $\geq 10\%$ or a CAC score $\geq 300$ AU or diabetes and are unable to achieve recommended treatment goals, the addition of a PCSK9 mAb <sup>8</sup> is recommended to lower LDL-C. <sup>9</sup>   |

| Recommendations for Management of Statin-Attributed Muscle Symptoms (Continued) |      |   |
|---|------|---|
| COR   | LOE  | Recommendations   |
| 2a  | B-NR | 6. In adults with clinical ASCVD who experience statin-attributed muscle symptoms (secondary causes excluded) and are unable to achieve recommended treatment goals on bempedoic acid <sup>3</sup> with or without ezetimibe, <sup>4</sup> it is reasonable to add inclisiran in those unable to tolerate or obtain evolocumab or alirocumab or who have a strong preference for less frequent dosing to achieve an LDL-C goal $<55$ mg/dL (1.4 mmol/L) and non-HDL-C $<85$ mg/dL (2.2 mmol/L). <sup>10</sup>                                   |
| 2b  | B-R  | 7. In adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms on the recommended intensity of statin therapy (secondary causes excluded) and are at borderline to intermediate ASCVD risk based on the PREVENT-ASCVD equations of 3% to $<10\%$ , and in whom the decision to treat with ezetimibe and/or bempedoic acid is uncertain, coronary calcium scoring may be reasonable to aid in ASCVD risk stratification <sup>11,12</sup> to inform decision-making about add-on therapy to reduce ASCVD risk. |
| 2b  | B-NR | 8. In adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms on the recommended intensity of statin therapy (secondary causes excluded) and are at borderline or intermediate ASCVD risk based on the PREVENT-ASCVD equations of 3% to $<10\%$ , the addition of ezetimibe <sup>4</sup> and/or bempedoic acid <sup>7</sup> may be reasonable to lower LDL-C to $<100$ mg/dL (2.6 mmol/L) and non-HDL-C to $<130$ mg/dL (3.4 mmol/L) and reduce ASCVD risk.   |

**Table 24. Patients or Characteristics Associated With Increased Risk for Statin-Attributed Muscle Symptoms**

|  |
|--|
| 1. Age $\geq 65$ y   |
| 2. Low body mass index   |
| 3. Female sex  |
| 4. Obesity   |
| 5. Hypothyroidism  |
| 6. Diabetes  |
| 7. Chronic liver disease   |
| 8. Chronic kidney disease  |
| 9. Alcohol consumption   |
| 10. Vigorous exercise  |
| 11. High-dose statin therapy   |
| 12. Diseases associated with myalgia or muscle weakness (eg, fibromyalgia, polymyalgia rheumatica, polymyositis, primary myopathies) |
| 13. Pharmacotherapy affecting statin metabolism (Section 5.2, "Statin-Cardiovascular Drug Interactions")                             |
| 14. Gene variants affecting statin metabolism (eg, SLC01B1)  |

An increased risk of statin-attributed muscle symptoms is associated with the use of higher doses of a statin within the approved dosage range. The increase in risk is not attributed to the statin potency (higher potency statins do not have higher risk; high doses do have higher risk). Adapted from Wiggins et al.<sup>18</sup> Modified with permission from Stroes et al.<sup>19</sup> © 2015 Oxford University Press. Modified with permission via Creative Commons CC BY license from Bytyci et al.<sup>14</sup> © 2022 Oxford University Press.

## Synopsis

Complaints of myalgia or muscle weakness, or the fear of developing these symptoms, are the most frequently reported reasons for failure to tolerate or adhere to statin therapy. These symptoms may occur with or without CK elevation. They may be due to the prescribed statin alone, altered statin metabolism due to DDI, excessive muscular activity, primary muscle or metabolic disorders, or patient expectations that statin therapy is responsible. A statin-related etiology is supported by new-onset bilateral, symmetrical, proximal muscle pain or weakness that occurs within weeks after the initiation or increased dosing of a statin. Symptoms typically resolve within a similar period after statin discontinuation and may recur upon reinitiation of statin therapy. A systematic approach to LDL-C–lowering therapy should include maximization of lifestyle management, use of maximum tolerated daily or, if necessary, less-than-daily statins, and the addition of evidence-based nonstatins (Figure 18). In the great majority of patients, a well-tolerated regimen can be devised to successfully lower LDL-C and reduce ASCVD risk. The rarely reported clinical syndromes of rhabdomyolysis and statin-induced immune-mediated necrotizing myopathy were discussed in Section 4.2.11, “Management of Statin-Attributed Muscle Symptoms.”

## Recommendation-Specific Supporting Text

1. Despite the ASCVD risk reduction benefit associated with statin therapy for primary or secondary prevention, patients may report muscle symptoms that result in suboptimal medication adherence. Meta-analyses of RCTs conclude that the incidence of such symptoms is low,<sup>13</sup> while meta-analyses of observational studies suggest a considerably higher incidence.<sup>14</sup> In many cases, these symptoms are due to patient expectations that statins are responsible (the “drucebo effect”). Before concluding that such symptoms are due to statin therapy, the clinician should exclude excessive muscular activity, consider disease states associated with muscle pain or weakness, and DDI that raise statin blood levels (Table 23). For those with muscle weakness, a physical examination assessing muscle strength should be performed,<sup>1</sup> and when muscle symptoms are severe, a CK level should be measured. Although there are no absolute CK levels to guide therapy, adults with severe myalgia or muscle weakness and CK levels  $\geq 10$  times the upper limit of normal should be advised to withhold statin therapy, and if these levels persist, undergo neurologic consultation.
2. When patients report muscle symptoms while taking a statin, the first step is for the clinician to acknowledge the patient's concerns while reinforcing the increased risk for MACE associated


- with suboptimal LDL-C lowering.<sup>2,3</sup> The clinician–patient discussion may initially focus on the value of intensification of heart-healthy dietary patterns and the value of regular physical activity, but reinitiation of cardioprotective drug therapy is essential to achieve the greatest possible risk reduction. Patient willingness to restart an alternate statin, take less than daily dosing of a long-acting statin,<sup>15</sup> or add nonstatin therapies should be explored to align LLT with the patient's estimated ASCVD risk.
3. Adults with established ASCVD, with or without statin-attributed muscle symptoms, and with LDL-C  $\geq 70$  mg/dL (1.8 mmol/L) should receive lifestyle management, maximally tolerated statin therapy, and if necessary, add-on nonstatin therapies to provide additional reduction in atherogenic lipoproteins and reduce ASCVD risk. Ezetimibe<sup>4</sup> and PCSK9 mAb<sup>5,16</sup> have demonstrated ASCVD outcomes benefits in patients treated with statins who have established ASCVD. CLEAR Outcomes<sup>3</sup> demonstrated the effect of bempedoic acid 180 mg daily on cardiovascular outcomes in patients with ASCVD or at high risk for cardiovascular events with baseline LDL-C  $\geq 70$  mg/dL (1.8 mmol/L), who were unable or unwilling to take more than the starting dose of a statin due to medication-attributed side effects. After a median follow-up of 40.6 months, there was a significant reduction in LDL-C, hsCRP, and the composite outcomes of death from cardiovascular causes, nonfatal stroke, nonfatal MI, and coronary revascularization in those receiving bempedoic acid. Incident myalgia or muscle weakness was similar in both groups. Thus, 3 categories of nonstatin therapies with ASCVD outcomes benefit are recommended for consideration in such patients in accordance with their absolute ASCVD risk.
  4. A prespecified subgroup analysis of CLEAR Outcomes<sup>7</sup> examined the effects of therapy with bempedoic acid versus placebo over a median follow-up period of 39.9 months on the incidence of major adverse cardiovascular outcomes in 4206 patients treated for high-risk primary prevention, defined as having a 10-year Reynolds Risk score  $>30\%$ ; 10-year SCORE risk  $>7.5\%$ ; CAC score  $>400$  AU; or the presence of either type 1 or 2 diabetes in women  $>65$  years or men  $>60$  years. The study reported a statistically significant reduction in the incidence of 4-component MACE (2.3% ARR), and the number-needed-to-treat to prevent 1 primary event was 43. As the 10-year ASCVD risk estimate using the PREVENT equations is similar to that of the above high-risk groups, bempedoic acid pharmacotherapy is indicated in these patients. The therapeutic efficacy of ezetimibe in high-risk individuals was demonstrated in a large

### Adults With Statin-Attributed Muscle Symptoms

**LEGEND**

- COR 1
- COR 2a
- COR 2b
- COR 3-No Benefit
- COR 3-Harm

(Class of Recommendation)



2026 Dyslipidemia © 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.

**Figure 18. Adults With Statin-Attributed Muscle Symptoms.**

\*Cardiovascular outcomes for inclisiran pending results of ongoing RCTs. ASCVD indicates atherosclerotic cardiovascular disease; CAC, coronary artery calcium; FDA, US Food and Drug Administration; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; mAb, monoclonal antibody; and PCSK9, proprotein convertase subtilisin/kexin type 9.

RCT. This study, combined with its generic availability, supports the use of ezetimibe therapy in such patients with statin-attributed side effects.<sup>4</sup>

5. Two RCTs of PCSK9 mAb therapy for the treatment of hypercholesterolemia in subjects with reported statin-attributable side effects have

demonstrated the efficacy and safety of these agents in lowering LDL-C.<sup>9</sup> The ODYSSEY ALTERNATIVE (Study of Alirocumab in Patients With Primary Hypercholesterolemia and Moderate, High or Very High CV Risk, who are Intolerant to Statins) trial identified patients at moderate to high

risk for ASCVD who were unable to tolerate  $\geq 2$  statins. After a run-in period of 4 weeks, in which individuals reporting muscle symptoms while receiving placebo were withdrawn, 314 subjects were randomized to receive alirocumab, ezetimibe, or atorvastatin plus placebo and were followed for 24 weeks both for LDL-C lowering and the reported incidence of medication-attributed side effects. As expected, alirocumab therapy reduced LDL-C significantly more than ezetimibe but was also associated with significantly fewer musculoskeletal side effects than atorvastatin.<sup>8</sup> In GAUSS-3 (Goal Achievement After Utilizing an Anti-PCKS9 Antibody in Statin Intolerant Subjects), a similar 2-stage protocol was used (Phase A evaluated atorvastatin 20 mg versus placebo; Phase B involved randomization 2:1 to subcutaneous evolocumab 420 mg monthly or oral ezetimibe 10 mg daily). Among 491 patients with statin-attributed muscle symptoms, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction in LDL-C levels after 24 weeks and better tolerability compared with statins. Thus, the use of a PCSK9 mAb is recommended for those who require additional LDL-C lowering in the setting of statin-attributed side effects.

6. Cardiovascular outcomes trials for inclisiran are ongoing, and RCTs specifically in patients with statin intolerance have not been conducted. However, in a pooled analysis of ORION-10 (Inclisiran for Participants With ASCVD and Elevated LDL-C) and ORION-11 (Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated LDL-C), the safety and efficacy of inclisiran in patients with ASCVD and statin intolerance was evaluated.<sup>10</sup> Inclisiran was well-tolerated, and placebo-corrected reduction in LDL-C was 45.8% (95% CI, -52.2 to -39.4;  $P < 0.0001$ ). PCSK9 mAb remain the preferred PCSK9i in adults with clinical ASCVD who experience statin-attributed muscle symptoms (secondary causes excluded) and are unable to achieve recommended treatment goals on bempedoic acid with or without ezetimibe. However, in those patients unable to tolerate or obtain evolocumab or alirocumab, or who prefer a less frequent dosing schedule, use of inclisiran is reasonable.
7. Because of symptoms that initially occurred during statin therapy, some patients may be reluctant, or some clinicians may be hesitant, to reinstitute statins or other LLT. In these circumstances, a CAC score may be considered to aid in decisions about preventive therapy (Section 4.2.7, "Management of Adults With Subclinical Coronary Atherosclerosis [Men  $\geq 40$  or Women  $\geq 45$  Years]").<sup>11,17</sup> A CAC score of 0 AU, in the absence of diabetes or active cigarette smoking, particularly in men  $\geq 50$  years of age or postmenopausal women, may support the decision to defer

pharmacotherapy and proceed with lifestyle management alone for the next 5 years. Conversely, the finding of a CAC score of  $\geq 100$  AU or a score in the  $\geq 75$ th standardized percentile (currently based on age, sex, and race) serves to support the reinstitution of LLT.

8. Many patients with statin-attributed side effects who require additional LDL-C lowering are in the borderline to intermediate ASCVD risk group (3% to  $< 10\%$  10-year risk) based on the PREVENT equations. In the absence of clinical trial evidence informing preventive treatment in such patients, but in the presence of safe and well-tolerated therapeutic options with demonstrated ASCVD risk reduction benefit,<sup>3,4</sup> the use of either bempedoic acid or ezetimibe in such patients may be considered.

## 5. COMPLICATIONS OF MANAGEMENT

### 5.1. Medication Safety and Therapy-Associated Side Effects

| Recommendations for Medication Safety and Therapy-Associated Side Effects             |      |  |
|---|------|--|
| Referenced studies that support recommendations are summarized in the Evidence Table. |      |  |
| COR   | LOE  | Recommendations  |
| 1   | A    | 1. In adults with dyslipidemia, an individualized clinician-patient discussion prior to initiating lipid-lowering medication is recommended to review the benefits and risks of pharmacotherapy to promote patient engagement and medication adherence. <sup>1-4</sup> |
| 1   | A    | 2. In adults with elevated diabetes risk or new-onset diabetes, it is recommended to continue statin therapy, with added emphasis on adherence, net clinical benefit, and lifestyle management. <sup>5-8</sup>   |
| 2a  | B-R  | 3. In adults at elevated ASCVD risk with chronic, stable liver disease (including metabolic dysfunction-associated steatotic liver disease), it is reasonable to treat with statin therapy to reduce ASCVD risk. <sup>9-13</sup>                                       |
| 3: No Benefit   | B-R  | 4. In adults on statin therapy, routine use of coenzyme Q10 is not recommended to treat or prevent statin-attributed muscle symptoms. <sup>14-17</sup>   |
| 3: No Benefit   | A    | 5. In adults on statin therapy who do not have severe statin-attributed muscle symptoms, routine measurement of CK is not useful to assess safety. <sup>18,19</sup>  |
| 3: No Benefit   | B-NR | 6. In adults treated with statin therapy who do not have severe symptoms suggestive of hepatotoxicity (ie, jaundice, pruritus, fatigue, nausea and vomiting, abdominal pain), routine measurement of hepatic function is not useful to assess safety. <sup>20,21</sup> |

### Synopsis

Commonly used lipid-lowering medications (ie, statins, ezetimibe, PCSK9i, bempedoic acid) are usually well tolerated and safe (Table 25).<sup>22-26</sup> Statin-attributed side ef-

**Table 25. Safety Considerations for LDL-C-Lowering Medications**

| Medication Class  | Common Side Effects   | Contraindications*   | Comments   |
|---|---|--|--|
| HMG-CoA reductase inhibitors (statins)                          | Myalgia (normal CK level) is common and dose-related  | Acute liver failure; decompensated cirrhosis; lactation; severe underlying neuromuscular diseases (eg, dermatomyositis, muscular dystrophy)                                      | See Section 4.2.11, "Management of Statin-Attributed Muscle Symptoms"<br>Myositis/myopathy (CK >ULN) with concerning symptoms or objective weakness is rare; rhabdomyolysis (CK >10 times ULN with renal injury) is rare; immune-mediated necrotizing myopathy (with HMGCR antibodies) is very rare<br>Transaminase elevations (>3 times ULN) are rare<br>Postmarketing reports of cognitive impairment (eg, memory loss, forgetfulness) are rare, generally nonserious, reversible upon statin discontinuation, and not observed in prospective clinical trials<br>See Section 4.2.8.4, "Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating," pregnancy is not a contraindication, but statins should be avoided while lactating† |
| Cholesterol absorption inhibitor (ezetimibe)                    | Typically well tolerated  | Prior hypersensitivity to ezetimibe  | Not recommended in patients with moderate or severe hepatic impairment<br>Persistent elevations in hepatic transaminase (>3 times ULN) can occur when added to a statin; monitor hepatic transaminase levels before and after initiating statin with ezetimibe combination therapy   |
| PCSK9 inhibitor: monoclonal antibodies (alirocumab, evolocumab) | Injection site reactions  | Prior hypersensitivity to the PCSK9 monoclonal antibody  | Hypersensitivity reactions (including angioedema) are rare<br>Latex is in some evolocumab single-dose prefilled syringe covers; alicumab products do not contain latex   |
| ATP citrate lyase inhibitor (bempedoic acid)                    | Typically well tolerated  | Prior serious hypersensitivity reaction to bempedoic acid or any of the excipients   | Elevated BUN, creatinine, and uric acid have been reported (monitoring serum urate level necessary in patients with preexisting and untreated hyperuricemia)   |
| PCSK9 inhibitor: small-interfering RNA (inclisiran)             | Injection site reactions  | Prior serious hypersensitivity to inclisiran or any of the excipients  | Hypersensitivity reactions (including angioedema) are rare   |
| Bile acid sequestrants  | Abdominal pain, bloating, dyspepsia, nausea, and constipation are common  | TG >500 mg/dL (colesevelam); history of hypertriglyceridemia-induced pancreatitis; bowel obstruction   | Poor tolerability due to side effects and potential drug-drug interactions limits use; may decrease absorption of fat-soluble vitamins and folic acid; generally considered the safest medication in pregnancy   |
| Microsomal triglyceride transfer protein inhibitor (lomitapide) | Gastrointestinal effects (ie, diarrhea, nausea, vomiting, dyspepsia, abdominal pain) are common; elevated hepatic transaminases; increased hepatic fat; embryo-fetal toxicity | Pregnancy, concomitant use with a CPY3A4 inhibitor, moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests | Use is restricted to patients with HoFH<br>Available only through a restricted REMS program that ensures safe use requiring regular monitoring of liver function and other health parameters   |
| ANGPTL3 inhibitor (evinacumab)                                  | Serious hypersensitivity reactions; embryo-fetal toxicity   | History of serious hypersensitivity reactions to evinacumab-dgmb or to any of its excipients   | Use is restricted to patients with HoFH<br>Infusion rate can be slowed, interrupted, or discontinued if signs of adverse reactions, including infusion or hypersensitivity reactions are present during administration   |

\*Contraindications from FDA-approved labeling (available at: <http://dailymed.nlm.nih.gov/dailymed/index.cfm>)<sup>47</sup>

†The Food and Drug Administration has removed pregnancy as a contraindication to statin therapy.<sup>48</sup>

ANGPTL3 indicates angiopoietin-like protein 3; ATP, adenosine triphosphate; CK, creatine kinase; HMG-CoA, 3-hydroxy-3-methylglutaryl- coenzyme; HoFH, homozygous familial hyperlipidemia; mRNA, messenger ribonucleic acid; PCSK9, proprotein convertase subtilisin/kexin type 9; REMS, Risk Evaluation and Mitigation Strategy; RNA, ribonucleic acid; and ULN, upper limit of normal.

fects are possible, most commonly muscle symptoms.<sup>19</sup> Although most patients tolerate statin therapy, approximately 10% of patients may not tolerate maximum dose daily statin therapy in real-world populations.<sup>27</sup> Management of statin-attributed muscle symptoms (SAMS) is discussed in detail in Section 4.2.11, "Management of Statin-Attributed Muscle Symptoms." Statins slightly increase the risk of progression of prediabetes to new-onset type 2 diabetes in patients with predisposing diabetes risk factors,<sup>5-7,28</sup> but statin avoidance or discontinuation is not recommended on that basis because of

its strong ASCVD risk reduction benefit. Patients who experience statin-associated rhabdomyolysis may need to discontinue statin therapy indefinitely, although reversible causes should be managed, and rechallenge should be done with caution.<sup>29</sup> Statin-associated autoimmune myopathy (muscle weakness, marked and persistent CK elevation, presence of 3-hydroxy-3-methylglutaryl- coenzyme (HMG-CoA) reductase antibodies, necrotizing myopathy, and lack of or incomplete resolution on statin discontinuation) is rare but requires statin cessation, avoidance of all potential myotoxic pharma-

cotherapy, and may require additional therapy directed at the autoimmune process.<sup>30</sup> Other LDL-C-lowering therapies such as ezetimibe and PCSK9i are generally well tolerated. Bempedoic acid is well tolerated but elevated blood urea nitrogen and creatinine (without impaired kidney function) and increased uric acid levels have been reported and require monitoring. Bile acid sequestrants are not often used due to poor tolerability. Several TG-lowering medications are available, with their safety reviewed in Table 26.

### Recommendation-Specific Supportive Text

1. An individualized clinician–patient discussion focused on the overall benefits and risks of pharmacotherapy should precede the initiation of dyslipidemia medication in the context of patient-centered care.<sup>31</sup> Indications, clinical benefits related to cardiovascular events and lipoprotein improvements, medication-related side effects, and patient concerns and preferences should be included.<sup>32</sup> Future encounters should address response to therapy, emphasize medication adherence, and reaffirm benefit. Medication-associated symptoms should be comprehensively assessed, and most can be

effectively managed.<sup>1–4,33</sup> Due to the risks of medication discontinuation or inadequate treatment, the goal should be to optimize patient-centered strategies for ASCVD prevention.

2. Evidence indicates that statins slightly increase the risk of developing new-onset diabetes in individuals with predisposing risk factors for diabetes (ie, BMI  $\geq 30$  kg/m<sup>2</sup>, fasting blood glucose  $\geq 100$  mg/dL, metabolic syndrome, or HbA1C 6.0%–6.4%), especially with higher-intensity statin use.<sup>5–8,28</sup> Although specific mechanisms explaining statin-associated diabetes remain unclear, a small number of patients with predisposing risk factors cross the threshold to incident diabetes sooner after statin therapy is initiated. It is important to educate patients, especially those with predisposing risk factors, regarding the potential for progression to new-onset diabetes before initiating statin therapy. It is critical to explain to patients that the benefits of statin therapy demonstrated in CVOTs in adults with diabetes outweigh the risks of new-onset diabetes; therefore, potential new-onset diabetes is not a contraindication to statin therapy or indication for statin discontinuation.<sup>5,8,34,35</sup> The 2024 Cholesterol Treatment Trialists individual



**Table 26. Safety Considerations for Triglyceride-Lowering Medications**

| Medication Class   | Common Side Effects  | Contraindications*   | Comments  |
|--|--|--|---|
| Fibrates (fenofibrate, fenofibric acid, gemfibrozil)             | Myalgia; persistently elevated hepatic transaminases   | Severe renal dysfunction; active liver disease; gallbladder disease; during lactation; history of hypersensitivity to the fibrate product  | Fenofibrate and fenofibric acid can reversibly elevate serum creatinine<br>When given in combination with statin therapy can increase risk of muscle toxicity; gemfibrozil should not be used in combination with a statin; fenofibrate or fenofibric acid can be used in combination with statin with monitoring   |
| Omega-3 fatty acids (icosapent ethyl, omega-3-acid ethyl esters) | Eructation, dyspepsia, and taste perversion  | History of hypersensitivity to the omega-3 fatty acid product  | Side effects less with prescription omega-3 fatty acids compared to nonprescription fish oil supplements<br>New onset atrial fibrillation/flutter reported<br>Must monitor hepatic transaminases in patients with hepatic impairment<br>DHA-containing products (omega-3 acid ethyl esters) can raise LDL-C, but not apoB<br>Derived from fish and purified; use with caution in patients with known hypersensitivity to fish and/or shellfish<br>Possible increased bleeding when used in combination with an antithrombotic agent |
| Niacin   | Facial flushing, gastrointestinal symptoms (diarrhea, nausea, vomiting) are common; persistent hepatic transaminase and glucose elevations | Active liver disease (including unexplained persistent elevated hepatic transaminases), active peptic ulcer disease, arterial bleeding, known hypersensitivity to product components | Monitoring liver enzymes before and during treatment is necessary<br>May cause and/or exacerbate insulin resistance<br>Infrequently used owing to poor tolerability and lack of proven cardiovascular benefits; tolerability improved with long-acting products and by optimizing administration (slow titration, administering with food, pre-dosing with aspirin or an NSAID)<br>Serious muscle toxicity possible with statin use   |
| ApoC-III inhibitor: ASO-directed therapy (olezarsen)             | Injection site reactions   | Prior serious hypersensitivity to olezarsen or any of the excipients   | Use is restricted to patients with FCS<br>Decreased platelet count is possible but not common   |

\*Contraindications from FDA-approved labeling (available at: <http://dailymed.nlm.nih.gov/dailymed/index.cfm>).<sup>47</sup>

ApoC-III indicates apolipoprotein C-III; ASO, antisense oligonucleotide; DHA, docosahexaenoic acid; FCS, familial chylomicronemia syndrome; and NSAID, nonsteroidal anti-inflammatory drug.

patient-level data meta-analysis demonstrated a small clinically insignificant increase in HbA1C of 0.06% to 0.08% after statin therapy is started in patients with diabetes.<sup>8</sup> Individuals with normal fasting glucose may also progress to having elevated fasting glucose. Because this absolute increase is often small, the overall benefit of continuing statin therapy outweighs the risks and potential harms.<sup>8</sup>

3. Unlike in active liver disease, statins are not contraindicated in patients with chronic, stable liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD).<sup>36</sup> Available safety data reaffirm that statin therapy does not increase risk of hepatotoxicity or hepatic failure in patients with chronic, stable liver disease, including MASLD.<sup>9,12,37</sup> Moreover, some data suggest potential benefits of statin therapy in patients with MASLD, chronic liver disease, and unexplained persistent mild hepatic transaminase elevations.<sup>9–13,38,39</sup>
4. The clinical diagnosis of SAMS is challenging, given that the majority of symptoms are subjective, and definitive diagnostic criteria do not exist.<sup>40</sup> Multiple potential mechanisms have been suggested to contribute to SAMS, including depletion of ubiquinone (also known as coenzyme Q10). Although some analyses imply a small benefit of coenzyme Q10 supplementation to manage patients with SAMS,<sup>16</sup> the preponderance of evidence does not support the use of coenzyme Q10 supplementation for routine use in patients treated with statins or for the treatment of SAMS.<sup>14,15</sup> Because other well-recognized safe approaches are available to manage SAMS, coenzyme Q10 is not recommended.
5. The majority of SAMS are subjective myalgias in the absence of other findings.<sup>18,22,34,40,41</sup> Most patients with SAMS do not have elevated serum CK levels.<sup>29</sup> Further, CK levels may be elevated in asymptomatic individuals and may rise after exercise. Therefore, CK levels should not be routinely measured given the unlikely impact on clinical outcomes and the lack of established cost-effectiveness. In patients treated with statin therapy, measuring CK levels is recommended in individuals with severe SAMS to evaluate the presence of serious muscle-related side effects.<sup>34,40</sup>
6. Although measuring alanine aminotransferase prior to initiating statin therapy is suggested, recommendations for routine ongoing hepatic transaminase measurements to monitor for elevations were discontinued by the FDA in 2012.<sup>20</sup> Postmarketing safety data show that clinically apparent statin hepatotoxicity is very rare, and monitoring hepatic transaminases is not useful in preventing such rare toxicity. An asymptomatic increase in hepatic transaminases, while more common with MASLD, is infrequent with statin use.<sup>1,42,43</sup> When hepatic

transaminase elevations occur, it is generally within the first 3 months of statin initiation and returns to baseline in approximately 70% of patients with continued use.<sup>44</sup> Significant histopathological changes associated with minor aminotransferase elevations have not been seen in patients on statin therapy, and changes have been termed hepatic “adaptations” rather than injury.<sup>45</sup> About 3% of patients with aminotransferase elevation experience persistent elevation of >3 times the upper limit of normal, which is a reasonable threshold to investigate further and consider pausing statin therapy.<sup>44</sup> Serious hepatotoxicity occurs in approximately 1 in 100 000 individuals treated with statins.<sup>46</sup> Routinely measuring hepatic transaminases with statin therapy is unnecessary. Measuring hepatic transaminases, total bilirubin, and alkaline phosphatase should be reserved for statin-treated patients with symptoms of hepatotoxicity (jaundice, fatigue, pruritus, nausea and vomiting, abdominal pain) to evaluate for potential hepatotoxicity.

## 5.2. Statin-Cardiovascular Drug Interactions

| Recommendation for Managing Statin-Cardiovascular Drug Interactions                      |      |   |
|--|------|---|
| Referenced studies that support the recommendation are summarized in the Evidence Table. |      |   |
| COR  | LOE  | Recommendation  |
| 1  | B-NR | 1. In adults for whom the decision is made to initiate statin therapy, a review of concomitant medications and assessment for potential DDI with other cardiovascular medications is recommended to minimize the risk of statin-associated adverse events. <sup>1–3</sup> |

### Synopsis

Statins are frequently coprescribed with other cardiovascular medications and are susceptible to various DDI. A DDI occurs when  $\geq 1$  medications alter the pharmacokinetics or pharmacodynamics of another, leading to changes in drug metabolism and potentially modifying therapeutic efficacy or adverse effects. Most statin-related DDI are mediated through the cytochrome P450 enzyme system and drug transporters, including P-glycoprotein, organic anion-transporting polypeptide, and breast cancer resistance protein. Among CYP enzymes, CYP3A4 and CYP2C9 are the predominant subtypes involved in statin metabolism.<sup>1–5</sup> Lovastatin and simvastatin undergo significant CYP3A4 metabolism, while atorvastatin is metabolized through CYP3A4 to a lesser extent. Fluvastatin, pitavastatin, and rosuvastatin undergo significant metabolism through CYP2C9. Pravastatin does not undergo CYP450 metabolism. Because CYP3A4 is the most common enzyme involved in drug metabolism, lovastatin and simvastatin exhibit the highest number of clinically significant DDI among statins. More than 50%

**Table 27. Clinical Recommendations on Management of DDI With Statins and Cardiovascular Medications**

| Interacting Drug | Statin       | Clinical Recommendation for Management  |
|------------------|--------------|---|
| Amiodarone       | Lovastatin   | Limit dose of lovastatin to 40 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 20 mg daily  |
| Amlodipine       | Lovastatin   | Limit dose of lovastatin to 20 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 20 mg daily  |
| Bempedoic acid   | Pravastatin  | Limit dose of pravastatin to 40 mg daily  |
|                  | Simvastatin  | Limit dose of simvastatin to 20 mg daily  |
| Colchicine       | Atorvastatin | Closer monitoring for muscle-related toxicity is recommended when used in combination   |
|                  | Fluvastatin  |   |
|                  | Lovastatin   |   |
|                  | Pitavastatin |   |
|                  | Pravastatin  |   |
|                  | Rosuvastatin |   |
|                  | Simvastatin  |   |
| Conivaptan       | Lovastatin   | Avoid combination   |
|                  | Simvastatin  | Avoid combination   |
| Diltiazem        | Lovastatin   | Limit dose of lovastatin to 20 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 10 mg daily  |
| Dronedarone      | Lovastatin   | Limit dose of lovastatin to 10 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 10 mg daily  |
| Gemfibrozil      | Atorvastatin | Avoid combination   |
|                  | Lovastatin   | Avoid combination   |
|                  | Pitavastatin | Avoid combination   |
|                  | Pravastatin  | Avoid combination   |
|                  | Rosuvastatin | Avoid combination   |
|                  | Simvastatin  | Avoid combination   |
| Lomitapide       | Lovastatin   | Reduce dose of lovastatin by 50%  |
|                  | Simvastatin  | Reduce dose of simvastatin by 50% and limit dose to 20 mg daily   |
| Ranolazine       | Lovastatin   | Combination is acceptable to use if clinically indicated and an alternative non-CYP3A4 statin cannot be used. However, doses of lovastatin or simvastatin should not exceed 20 mg daily |
|                  | Simvastatin  |   |
| Ticagrelor       | Atorvastatin | Combination is acceptable without dose limitations  |
|                  | Lovastatin   | Limit dose of lovastatin to 40 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 40 mg daily  |
| Verapamil        | Lovastatin   | Limit dose of lovastatin to 20 mg daily   |
|                  | Simvastatin  | Limit dose of simvastatin to 10 mg daily  |

Modified with permission from Kellick et al.<sup>1</sup> © 2014 Elsevier. Modified with permission from Wiggins et al.<sup>3</sup> © 2016 American Heart Association, Inc. See additional references for prescribing information for each statin.<sup>7–13</sup>

DDI indicates drug–drug interaction.

of DDI listed in statin-prescribing information are supported by dedicated clinical DDI studies, while 34% are extrapolated from clinical data of other statins.<sup>6</sup> Given the high potential for DDI between statins and other cardiovascular medications, it is essential to screen patients

for potential interactions to minimize adverse events and optimize therapy.

### Recommendation-Specific Supportive Text

1. Statins are the first-line LLT for many patients with elevated cardiovascular risk or established ASCVD. Given the widespread use of statins and the prevalence of cardiovascular comorbidities, the risk of DDI with cardiovascular medications is common. The AHA emphasized the importance of evaluating statin DDI in its scientific statement on interactions between statins and common cardiovascular medications.<sup>3</sup> Statins metabolized through CYP3A4 (atorvastatin, lovastatin, simvastatin) pose the highest risk of DDI with both cardiovascular and noncardiovascular medications, as CYP3A4 is the most prevalent enzyme in drug metabolism. The National Lipid Association also provided clinical guidance on identifying and managing statin-related DDI.<sup>1</sup> Most DDI listed in statin-prescribing information have been evaluated in dedicated clinical DDI studies, while a smaller proportion has been extrapolated from data on other statins.<sup>6</sup> Specific clinically relevant statin-cardiovascular DDI with dosing recommendations are detailed in Table 27, supported by both clinical studies and prescribing information.<sup>7–13</sup> Given the common occurrence of clinically significant statin-cardiovascular medication DDI, it is essential to assess potential interactions prior to statin initiation to allow for avoidance and/or dose modifications, thereby minimizing risk of adverse events.

## 6. EVIDENCE GAPS AND FUTURE DIRECTIONS

### 6.1. Limitations and Knowledge Gaps

The management of dyslipidemia has been extensively studied in many clinical trials over the last 70 years, comprising tens of thousands of patients across a wide spectrum of risk, from primary prevention to high-risk secondary prevention of ASCVD events. Although contemporary management of dyslipidemia is guided by this robust database of clinical trials and has led to better outcomes among those at risk for ASCVD, there are unanswered questions and gaps in evidence that require further study. This section will address some of these important questions to be answered by future randomized clinical trials and will focus on the refinement of risk assessment beyond the PREVENT equations, including incorporation of genetic data. Most importantly, this section will address a critical step in the translation of knowledge about disease processes, treatment, and risk assessment into clinical care and refinement of the clinician–patient risk

discussion, which is the cornerstone of a long-term partnership between clinician and patient and is critical to improving future outcomes.

Additional research is needed on reproductive-age risk markers and risk enhancers to further elucidate mechanisms of ASCVD risk in relation to conventional risk factors and to develop potential interventions through public health approaches concerning social determinants of health and psychosocial stressors.<sup>1–4</sup> Advances in interventions and implementation science are needed to address the higher prevalence of some risk factors and markers of risk among racial/ethnic groups and associated disparities in ASCVD events. Finally, research is needed on lipid changes with gender-affirming hormone therapy and potential CVD risk among transgender individuals.<sup>2,5</sup>

## 6.2. Randomized Controlled Trials

ACC/AHA guidelines are based largely on the outcomes of randomized CVOTs. Cholesterol guidelines have fortunately benefited from a large number of RCTs of evidence-based LLTs. They have established that greater reductions in LDL-C are accompanied by greater reductions in the risk of ASCVD.<sup>1</sup> LDL lowering treats the underlying process of atherosclerosis, and robust CVOTs exist for both primary and secondary prevention. Most of the data from CVOTs have been obtained with statin therapy, although an increasing number of CVOTs have demonstrated the efficacy and safety of nonstatin therapies. Several important questions need to be addressed by additional RCTs.

1. What innovative and scalable approaches can better engage patients, community members, health systems, and clinicians in implementing the guidelines, improving adherence to therapy, and addressing therapeutic inertia?
2. Can LDL-C-lowering therapy be safely initiated and managed by pharmacists as part of the care team?
3. Does early institution of LLT reduce long-term risk in low- or borderline-risk individuals, such as younger individuals with subclinical atherosclerosis or with elevated atherogenic lipoproteins?
4. How valid are serial imaging measures of plaque and plaque regression as surrogate measures of reduction of ASCVD risk, such as CCTA-based plaque measures and intravascular ultrasound, compared with trials focused on ASCVD outcomes?
5. Should CCTA be used for screening in the primary prevention setting in higher-risk younger individuals with a CAC score=0?
6. Does pharmacological lowering of Lp(a) lead to lower ASCVD risk in populations with or without established ASCVD? What are the optimal thresholds for treatment across different populations?

7. How can clinical trials better incorporate apoB instead of or alongside LDL-C to guide future treatment recommendations?
8. How should the PRS be incorporated into risk assessment and selection for treatment?
9. Can we develop validated and effective scalable shared decision-making models to allow for personalized patient–clinician discussion of the risks and benefits of treatment?

## 6.3. Improving Cardiovascular Risk Assessment

Quantitative risk estimation involves the prediction of future probability of CVD, with limitations of applying population-level disease probabilities to individual patients (Section 4.2.4.1, “Role of Risk Assessment in HeFH”).<sup>1</sup> Nonetheless, given the accuracy and precision of current risk prediction algorithms (eg, PREVENT equations),<sup>2</sup> greater implementation of proven and effective preventive strategies would provide far greater societal and individual benefit than further refinements in risk scores. The search for additional impactful CVD risk biomarkers continues, although very few to date have provided incremental predictive value. Methods exist for recalibration of risk-prediction models to a specific population sample,<sup>3,4</sup> but this approach should not be undertaken routinely by individual institutions given potential for systematic misclassification of patients and unclear implications for use of guideline-recommended decision thresholds at the local level.<sup>5</sup> If local event rates appear to differ widely from the derivation population of PREVENT, better strategies would include more frequent use of effective reclassifying tools (eg, CAC score<sup>6</sup>) in the population of interest. Use of a dynamic risk prediction model, the Million Hearts Model,<sup>7</sup> that accounts for baseline risk and subsequent response to treatment, has been shown to reduce ASCVD events.<sup>8</sup> Further research on implementing such models is warranted,<sup>9</sup> as is investigation of optimal means for communicating risk and potential benefit to patients in preventive decision-making.<sup>10,11</sup>

## 6.4. Refining the Clinician–Patient Risk Discussion

Ongoing studies of how clinicians can best interact with patients to arrive at informed decisions are vital. This is particularly important because LDL-C-lowering therapy is meant to be a long-term or lifetime therapy. Refinement of individualized communication with patients about treatment options may have major implications for long-term treatment adherence and patient outcomes by fostering trust, buy-in, and engagement.

Decision-making in dyslipidemia management has become more intricate with the expanded number of non-statin therapies available, alongside a wider range of non-lipid preventive cardiovascular treatments. As clinicians

and patients navigate these choices together, there is an opportunity to develop and study tools, such as decision aids (Section 4.2.4.1, “Role of Risk Assessment in HeFH”), to help communicate trade-offs between treatment options. Future investigations may help to refine our approaches to individualizing communication to meet diverse patient needs, literacy levels, and cultural backgrounds.

Furthermore, as the health care delivery landscape evolves to incorporate more digital health tools, future studies may refine our understanding of how to balance traditional and digital care delivery, especially considering individualized benefit-risk discussions are often a series of discussions rather than one-time events. Future research can investigate how digital technologies may augment clinician–patient discussions and improve workflow for busy clinicians.

Due to the broad scope of economic value considerations for newer nonstatin LLT, including regional/national/international variations in drug pricing, differences in drug cost-effectiveness based on treatment populations, and rapidly evolving pricing structures, economic value statements are not included in this guideline. Ongoing and future analyses are critical to inform clinical decision-making as our therapeutic armamentarium expands and our health care systems and patients discern those treatments likely to have the greatest economic value in reducing the burden of ASCVD.

## PRESIDENTS AND STAFF

### **American College of Cardiology**

Christopher M. Kramer, MD, FACC, President  
 Cathleen C. Gates, Chief Executive Officer  
 Richard J. Kovacs, MD, MACC, Chief Medical Adviser  
 Justine Varieur Turco, Divisional Vice President, Scientific Publications & Guidelines  
 Mindy J. Saraco, MHA, Director, Clinical Policy and Guidelines  
 Grace D. Ronan, Senior Production and Operations Manager, Clinical Policy Publications  
 Leah Patterson, Project Manager, Clinical Content  
 Lauren N. Prestera, FNP-BC, Project Manager, Clinical Content

### **American College of Cardiology/American Heart Association**

Thomas S.D. Getchius, National Senior Director, Guidelines  
 Abdul R. Abdullah, MD, Director, Guideline Science and Methodology  
 Amy W. Talbot, MPH, Senior Science and Health Advisor, Joint Staff Guidelines  
 Shae Martinez, MLS, Reference Consultant, Medical Librarian

### **American Heart Association**

Stacey E. Rosen, MD, FAHA, President  
 Nancy Brown, Chief Executive Officer  
 Mariell Jessup, MD, FAHA, Chief Science and Medical Officer  
 Nicole Aiello Sapio, EdD, Executive Vice President, Office of Science Strategies and Operations  
 Radhika Rajgopal Singh, PhD, Senior Vice President, Office of Science and Medicine  
 Prashant Nedungadi, BPharm, PhD, National Vice President, Science and Medicine, Clinical Guidelines  
 Maggie Eaton, PhD, RN, Science and Medicine Advisor  
 Joseph W. Loftin III, National Director, Statements and Guidelines  
 Courtney Goodwin, MPH, Program Manager, Guidelines

## PEER REVIEW COMMITTEE MEMBERS

Anand Rohatgi, MD, FAHA, Co-Chair; Samuel M. Kim, MD, FACC, Co-Chair; Karen P. Alexander, MD, FACC; Cheryl Anderson, PhD, MPH, FAHA; Catherine P. Benziger, MD, MPH, FACC, FAHA; Dave L. Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS; Daniel Duprez, MD, PhD, FAHA, FACC, FNLA, FASPC\*; Keith C. Ferdinand, MD, FACC, FAHA, FNLA\*; Anne Carol Goldberg, MD, FACP, FAHA, FNLA; Parag Joshi, MD, FACC, FAHA; Joshua W. Knowles, MD, PhD, FACC, FAHA, FNLA; Carl (Chip) J. Lavie Jr, MD, FACC\*; Jane A. Linderbaum, MS, APRN, CNP, FACC, FPCNA\*; John William McEvoy, MB BCh BAO, MHS, MEd, PhD; Anurag Mehta, MD, FACC\*; C. Noel Bairey Merz, MD, MACC; Vijay Nambi, MD, MBBS, FACC, FAHA; Ariela R. Orkaby, MD, MPH\*; Jessica M. Peña, MD, MPH, FACC, FNLA, FAHA\*; Robert Rosenson, MD, FACC, FAHA, FNLA\*; Janelle Ruisinger, PharmD, FAPhA\*; Sigrid E. Sandner, MD; Stacey L. Schott, MD, MPH\*; Laurence (Larry) Sperling, MD, FACC, FAHA, MASPC; Neil J. Stone, MD, MACP, FAHA, FACC; Peter Toth, MD, PhD, FCCP, FAHA, FACC, FNLA; Adam L. Ware, MD, FAHA; Seamus Paul Whelton, MD, MPH; James Young, II, MPH\*

## ACC/AHA JOINT COMMITTEE ON CLINICAL PRACTICE GUIDELINES

Catherine M. Otto, MD, FACC, FAHA, Chair; Sunil V. Rao, MD, FACC, FSCAI, Chair-Elect; Joshua A. Beckman, MD, MS, FAHA, FACC, Immediate Past-Chair\*; Anastasia Armbruster, PharmD, FACC\*; Vanessa Blumer, MD; Leslie L. Davis, PhD, ANP-BC, FACC, FAHA; Sharlene M. Day, MD, FAHA; Dave L. Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS; Victor A. Ferrari, MD, FACC, MSCMR; Stephen E. Fremes, MD, MSc, FACC; Mario

\*Former Joint Committee on Clinical Practice Guidelines member; current member during the writing effort.

F.L. Gaudino, MD, PhD, MSCE, FEBCTS, FACC, FAHA; Adrian F. Hernandez, MD, MHS, FAHA; Hani Jneid, MD, FACC, FAHA, FSCAI; Heather M. Johnson, MD, MS, FAHA, FACC, FASPC\*; William Schuyler Jones, MD, FACC; Sadiya S. Khan, MD, MSc, FACC, FAHA; Michelle Maya Kittleson, MD, PhD, FACC, FAHA\*; Venu Menon, MD, FACC, FAHA; Debabrata Mukherjee, MD, MS, FACC, FAHA, MSCAI\*; Daniel Munoz, MD, MPA; Kristen K. Patton, MD, FACC; Garima Sharma, MBBS, FACC, FAHA; Daichi Shimbo, MD; Boback Ziaeeian, MD, PhD, FACC, FAHA\*

## ARTICLE INFORMATION

This document was approved by the American College of Cardiology Clinical Policy Approval Committee and the American Heart Association Science Advisory and Coordinating Committee in October 2025, the American College of Cardiology Science and Quality Committee in November 2025, and the American Heart Association Executive Committee in December 2025.

Supplemental Materials are available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000001423>

This article has been copublished in the *Journal of the American College of Cardiology*.

Copies: This document is available on the websites of the American Heart Association ([professional.heart.org](http://professional.heart.org)) and the American College of Cardiology ([www.acc.org](http://www.acc.org)). A copy of the document is also available at <https://professional.heart.org/statements> by selecting the "Guidelines & Statements" button. To purchase additional reprints, call 215-356-2721 or email [Meredith.Edelman@wolterskluwer.com](mailto:Meredith.Edelman@wolterskluwer.com).

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu near the top of the webpage, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

## REFERENCES

### Preamble

1. Kazi DS, Abdullah AR, Arnold SV, et al. 2025 AHA/ACC statement on cost/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2025;151:e332–e358.
2. Otto CM, Abdullah AR, Davis LL, et al. 2025 ACC/AHA guideline core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2025;152:e359–e370.
3. Jneid H, Abdullah AR, Ferrari V, et al. Guidance for incorporating FDA processes into the ACC/AHA clinical practice guideline methodology: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2025;152:e323–e331.

### Introduction

1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
2. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
3. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.

4. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
5. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678.
7. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
8. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2022;80:1366–1418.
9. ACC/AHA Joint Committee on Clinical Practice Guidelines. 2025 Methodology manual and policies of the ACC/AHA Joint Committee on Clinical Practice Guidelines. Accessed October 31, 2025. [https://professional.heart.org/en/-/media/PHD-Files/Guidelines-and-Statements/2025-Guideline-Methodology-Manual.pdf?sc\\_lang=en](https://professional.heart.org/en/-/media/PHD-Files/Guidelines-and-Statements/2025-Guideline-Methodology-Manual.pdf?sc_lang=en).

### 2.1. Definitions

1. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. *J Clin Hypertens (Greenwich)*. 2009;11:761–765.
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625.
3. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. *Circulation*. 2022;146:e18–e43.
4. Kawai K, Finn AV, Virmani R. Subclinical atherosclerosis: part 1: what is it? Can it be defined at the histological level? *Arterioscler Thromb Vasc Biol*. 2024;44:12–23.

### 3.1. Screening in Children and Adults

1. Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. *Lancet*. 2019;394:2173–2183.
2. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. *Circulation*. 2024;149:e347–e913.
3. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. *Pediatrics*. 2010;126:260–265.
4. Klancar G, Groselj U, Kovac J, et al. Universal screening for familial hypercholesterolemia in children. *J Am Coll Cardiol*. 2015;66:1250–1257.
5. Nuotio J, Laitinen TT, Magnussen CG, et al. Predictors in youth of adult cardiovascular events. *Pediatrics*. 2024;154:e2024066736.
6. McGill HC Jr, McMahan CA, Zieske AW, et al. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. *Arterioscler Thromb Vasc Biol*. 2000;20:1998–2004.
7. Singh A, Gupta A, Collins BL, et al. Familial hypercholesterolemia among young adults with myocardial infarction. *J Am Coll Cardiol*. 2019;73:2439–2450.
8. Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. *N Engl J Med*. 2016;375:1628–1637.
9. Wald DS, Bestwick JP. Reaching detection targets in familial hypercholesterolemia: comparison of identification strategies. *Atherosclerosis*. 2020;293:57–61.
10. Luijck IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. *N Engl J Med*. 2019;381:1547–1556.

11. Zhang Y, An J, Reynolds K, et al. Trends of elevated low-density lipoprotein cholesterol, awareness, and screening among young adults in the US, 2003–2020. *JAMA Cardiol.* 2022;7:1079–1080.
12. Perak AM, Ning H, Kit BK, et al. Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999–2016. *JAMA.* 2019;321:1895–1905.
13. Silverman MG, Ference BA, Im K, et al. Association between lowering Ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA.* 2016;316:1289–1297.
14. Guirguis-Blake JM, Evans CV, Coppola EL, et al. Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2023;330:261–274.
15. Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med.* 2022;386:1877–1888.
16. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. *JAMA Cardiol.* 2021;6:1406–1413.
17. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev.* 2019;2019(11):CD006401.
18. de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). *Circulation.* 2016;133:1067–1072.
19. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. *Circulation.* 2020;141:1742–1759.
20. Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab.* 2012;97:3956–3964.
21. Bucholz EM, Gooding HC, de Ferranti SD. Awareness of cardiovascular risk factors in US young adults aged 18–39 years. *Am J Prev Med.* 2018;54:e67–e77.
22. Chou R, Dana T, Blazina I, et al. Screening for dyslipidemia in younger adults: a systematic review for the US Preventive Services Task Force. *Ann Intern Med.* 2016;165:560–564.
23. Zhang Y, Woo JG, Urbina EM, et al. Low-density lipoprotein cholesterol trajectories and prevalence of high low-density lipoprotein cholesterol consistent with heterozygous familial hypercholesterolemia in US children. *JAMA Pediatr.* 2021;175:1071–1074.
24. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. *J Am Coll Cardiol.* 2015;65:1552–1561.
25. Thompson-Paul AM, Kraus EM, Porter RM, et al. Pediatric lipid screening prevalence using nationwide electronic medical records. *JAMA Netw Open.* 2024;7:e2421724.
26. Berger JH, Chen F, Faerber JA, et al. Adherence with lipid screening guidelines in standard- and high-risk children and adolescents. *Am Heart J.* 2021;232:39–46.
27. Ademi Z, Norman R, Pang J, et al. Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands. *JAMA Pediatr.* 2023;177:625–632.
28. Zuurbier LC, Defesche JC, Wiegman A. Successful genetic screening and creating awareness of familial hypercholesterolemia and other heritable dyslipidemias in the Netherlands. *Genes (Basel).* 2021;12:1168.
29. Raslova K, Donicova V, Gonova K, et al. Detecting familial hypercholesterolemia: an observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia. *J Clin Lipidol.* 2024;18:e537–e547.
30. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics.* 2011;128 Suppl 5:S213–S256.
31. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths—United States, 1999–2006. *MMWR Morb Mortal Wkly Rep.* 2010;59:29–33.
32. Kusters DM, Wiegman A, Kastelein JJ, et al. Carotid intima-media thickness in children with familial hypercholesterolemia. *Circ Res.* 2014;114:307–310.
33. Dai S, Fulton JE, Harrist RB, et al. Blood lipids in children: age-related patterns and association with body-fat indices: Project HeartBeat! *Am J Prev Med.* 2009;37:S56–S64.
34. Zhang Y, Dron JS, Bellows BK, et al. Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease. *Circulation.* 2023;147:1556–1559.
35. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J.* 2013;34:3478–3490a.
36. deGoma EM, Ahmad ZS, O'Brien EC, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. *Circ Cardiovasc Genet.* 2016;9:240–249.
37. Akiyama LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. *BMJ Open.* 2017;7:e016461.
38. Lee C, Rivera-Valerio M, Bangash H, et al. New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature. *Circ Genom Precis Med.* 2019;12:e002723.
39. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolemia versus case finding for familial hypercholesterolemia: a systematic review and cost-effectiveness analysis. *Health Technol Assess.* 2000;4:1–123.
40. Centers for Disease Control and Prevention (CDC). Tier 1 genomics applications and their importance to public health. Accessed August 10, 2025. [https://archive.cdc.gov/www\\_cdc\\_gov/genomics/implementation/toolkit/tier1.htm](https://archive.cdc.gov/www_cdc_gov/genomics/implementation/toolkit/tier1.htm).
41. Martin AC, Hooper AJ, Norman R, et al. Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolemia in Australia. *J Paediatr Child Health.* 2022;58:281–287.
42. Wald DS, Wald NJ. Integration of child-parent screening and cascade testing for familial hypercholesterolemia. *J Med Screen.* 2019;26:71–75.

### 3.2. Measurement of TC, LDL-C, HDL-C, TG, and non-HDL-C

1. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation.* 2008;118:2047–2056.
2. Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation.* 2008;118:993–1001.
3. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. *Arch Intern Med.* 2012;172:1707–1710.
4. Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). *Circulation.* 2014;130:546–553.
5. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. *Clin Chem.* 2011;57:482–489.
6. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. *J Am Coll Cardiol.* 2013;62:732–739.
7. Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. *JAMA Cardiol.* 2020;5:540–548.
8. Sajja A, Park J, Sathiyakumar V, et al. Comparison of methods to estimate low-density lipoprotein cholesterol in patients with high triglyceride levels. *JAMA Netw Open.* 2021;4:e2128817.
9. Blom DJ, O'Neill FH, Marais AD. Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations. *Clin Chem.* 2005;51:904–907.
10. Sniderman A, Tremblay A, Bergeron J, et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. *J Clin Lipidol.* 2007;1:256–263.
11. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. *JAMA.* 2013;310:2061–2068.
12. Sathiyakumar V, Park J, Golozar A, et al. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. *Circulation.* 2018;137:10–19.
13. Martin SS, Giugliano RP, Murphy SA, et al. Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER Trial. *JAMA Cardiol.* 2018;3:749–753.
14. Miller WG, Waymack PP, Anderson FP, et al. Performance of four homogeneous direct methods for LDL-cholesterol. *Clin Chem.* 2002;48:489–498.

15. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clin Chem*. 2010;56:977–986.
16. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med*. 2001;161:1413–1419.
17. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. *J Am Coll Cardiol*. 2009;55:35–41.
18. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*. 2008;117:3002–3009.
19. Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. *Lancet*. 2019;394:2173–2183.
20. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. *Circ Res*. 2016;118:547–563.
21. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(suppl 2):S49–S732959.
22. Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT equations. *Circulation*. 2024;149:430–449.
23. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625.
24. Nordestgaard BG. A test in context: lipid profile, fasting versus nonfasting. *J Am Coll Cardiol*. 2017;70:1637–1646.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499–502.
26. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123:2292–2333.
27. Driver SL, Martin SS, Gluckman TJ, et al. Fasting or nonfasting lipid measurements: it depends on the question. *J Am Coll Cardiol*. 2016;67:1227–1234.
28. Samuel C, Park J, Sajja A, et al. Accuracy of 23 equations for estimating LDL cholesterol in a clinical laboratory database of 5,051,467 patients. *Glob Heart*. 2023;18:36.
29. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. *Clin Chem*. 1995;41:1414–1420.
30. Ginsberg HN, Rosenson RS, Hovingh GK, et al. LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. *J Lipid Res*. 2022;63:100148.
31. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. *Clin Chem*. 1995;41:1427–1433.
32. Lavie CJ, Milani RV, O'Keefe JH. To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? *Mayo Clin Proc*. 2010;85:446–450.
33. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. *Circulation*. 2019;140:542–552.
34. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. *J Am Coll Cardiol*. 2008;52:626–632.
35. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA*. 2012;307:1302–1309.
36. Virani SS, Wang D, Woodard LD, et al. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. *J Clin Lipidol*. 2012;6:545–552.
37. Blaha MJ, Blumenthal RS, Brinton EA, et al. The importance of non-HDL cholesterol reporting in lipid management. *J Clin Lipidol*. 2008;2:267–273.
38. Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. *Clin Chem Lab Med*. 2020;58:496–517.
39. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. *J Am Coll Cardiol*. 2007;50:1735–1741.
40. Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. *Circulation*. 2009;119:2383–2395.
41. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. *Circulation*. 2009;119:2396–2404.
42. Robinson JG. What is the role of advanced lipoprotein analysis in practice? *J Am Coll Cardiol*. 2012;60:2607–2615.
43. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA*. 2007;298:776–785.
44. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*. 2009;119:931–939.
45. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*. 2009;302:1993–2000.

### 3.3. Measurement of ApoB

1. Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. *J Am Coll Cardiol*. 2021;77:1439–1450.
2. Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. *JAMA Cardiol*. 2022;7:250–256.
3. Hagstrom E, Steg PG, Szarek M, et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab. *Circulation*. 2022;146:657–672.
4. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. *J Am Heart Assoc*. 2014;3:e000759.
5. Sattar N, Williams K, Sniderman AD, et al. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. *Circulation*. 2004;110:2687–2693.
6. Wagner AM, Perez A, Calvo F, et al. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. *Diabetes Care*. 1999;22:812–817.
7. Sayed A, Peterson ED, Virani SS, et al. Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels. *JAMA Cardiol*. 2024;9:741–747.
8. Lawler PR, Akinkuolie AO, Ridker PM, et al. Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. *Clin Chem*. 2017;63:870–879.
9. Sniderman AD, Dufresne L, Pencina KM, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. *Eur Heart J*. 2024;45:2410–2418.
10. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. *Circulation*. 2019;140:542–552.
11. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. *PLoS Med*. 2020;17:e1003062.
12. Gonzales KM, Donato LJ, Shah P, et al. Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis. *J Clin Lipidol*. 2021;15:97–103.
13. Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. *Eur J Prev Cardiol*. 2015;22:1321–1327.
14. Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the Justification for the Use of

- status in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPTER) trial. *Circulation*. 2015;132:2220–2229.
- Sathiyakumar V, Park J, Quispe R, et al. Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-C and apolipoprotein B targets in selected worldwide dyslipidemia guidelines. *Circulation*. 2018;138:244–254.
  - Quispe R, Brownstein AJ, Sathiyakumar V, et al. Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines. *Am J Prev Cardiol*. 2021;7:100203.
  - Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes*. 2011;4:337–345.
  - Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. *Circulation*. 2005;112:3375–3383.

### 3.4. Measurement of Lp(a)

- Willeit P, Ridker PM, Nestel RJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet*. 2018;392:1311–1320.
- Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2021;41:465–474.
- Emerging Risk Factors C, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA*. 2009;302:412–423.
- Trinder M, Paruchuri K, Haidemota S, et al. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk. *J Am Coll Cardiol*. 2022;79:617–628.
- Trinder M, Uddin MM, Finneran P, et al. Clinical utility of LPA genetic characterization for primary prevention of atherosclerotic cardiovascular disease. *Atherosclerosis*. 2020;315:e15–e16.
- Hedegaard BS, Bork CS, Kaltoft M, et al. Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease. *J Am Coll Cardiol*. 2022;80:1998–2010.
- Raitakari O, Kartiosuo N, Pahkala K, et al. Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood. *Circulation*. 2023;147:23–31.
- Ellis KL, Perez de Isla L, Alonso R, et al. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. *J Am Coll Cardiol*. 2019;73:1029–1039.
- Miida T, Hirayama S, Fukushima Y, et al. Harmonization of lipoprotein(a) immunoassays using a serum panel value assigned with the IFCC-endorsed mass spectrometry-based reference measurement procedure as a first step towards apolipoprotein standardization. *J Atheroscler Thromb*. 2025;32:580–595.
- Marcovina SM, Navabi N, Allen S, et al. Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). *J Lipid Res*. 2022;63:100239.
- Tsimikas S, Fazio S, Viney NJ, et al. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. *J Clin Lipidol*. 2018;12:1313–1323.
- Cobbaert CM, Althaus H, Begcevic Brkovic I, et al. Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary/cross-sector collaboration. *Clin Chem*. 2021;67:478–489.
- MacDougall DE, Tybjaerg-Hansen A, Knowles JW, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. *Eur Heart J*. 2025;ehaf297.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J*. 2022;43:3925–3946.
- Trinder M, DeCastro ML, Azizi H, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. *J Am Coll Cardiol*. 2020;75:2682–2693.
- National Heart, Lung, and Blood Institute (NHLBI). Standardization for lipoprotein(a) measurement in humans. Accessed June 27, 2025. <https://www.nhlbi.nih.gov/events/2019/standardization-lipoproteina-measurement-humans>.
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(suppl 2):S1–S45.
- Ridker PM, Mora S, Rose L, et al. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. *Eur Heart J*. 2016;37:1373–1379.
- Virani SS, Aspry K, Dixon DL, et al. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: a joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. *J Clin Lipidol*. 2023;17:208–218.
- Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol*. 2019;4:206–213.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
- Jia X, Al Rifai M, Ramsey DJ, et al. Association between lipid testing and statin adherence in the Veterans Affairs Health System. *Am J Med*. 2019;132:e693–e700.
- Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. *Can J Cardiol*. 2012;28:574–580.
- Rana JS, Virani SS, Moffet HH, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. *Am J Med*. 2022;135:603–606.
- Jia X, Ramsey DJ, Rifai MA, et al. Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans Affairs Healthcare System). *Am J Cardiol*. 2020;125:874–879.
- Tran C, Vo V, Taylor P, et al. Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center. *J Clin Lipidol*. 2022;16:491–497.

### 4.1. Lifestyle Management

- Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. *Circulation*. 2022;146:e18–e43.
- Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. *N Engl J Med*. 2016;375:2349–2358.
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
- Hasbani NR, Lighthart S, Brown MR, et al. American Heart Association's Life's simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease. *Circulation*. 2022;145:808–818.
- Vadiveloo MK, Thorndike AN, Lichtenstein AH. Integrating diet screening into routine clinical care: the time is now. *J Am Heart Assoc*. 2023;12:e028583.

#### 4.1.1. Primordial Prevention of Dyslipidemia: Childhood Through Adulthood

- Webber BJ, Seguin PG, Burnett DG, et al. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001–2011. *JAMA*. 2012;308:2577–2583.
- Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol*. 2020;76:1507–1516.
- Dron JS, Patel AP, Zhang Y, et al. Association of rare protein-truncating DNA variants in APOB or PCSK9 with low-density lipoprotein cholesterol level and risk of coronary heart disease. *JAMA Cardiol*. 2023;8:258–267.
- Laitinen TT, Pahkala K, Magnussen CG, et al. Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2012;125:1971–1978.
- Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med*. 1998;338:1650–1656.

6. Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. *Circulation*. 2015;131:451–458.
7. Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med*. 2022;386:1877–1888.
8. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*. 2006;354:1264–1272.
9. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J Am Coll Cardiol*. 2016;67:2578–2589.
10. Pahkala K, Hietalampi H, Laitinen TT, et al. Ideal cardiovascular health in adolescence: effect of lifestyle intervention and association with vascular intima-media thickness and elasticity (the Special Turku Coronary Risk Factor Intervention Project for Children [STRIP] study). *Circulation*. 2013;127:2088–2096.
11. Stanton KM, Kienzle V, Dinnes DLM, et al. Moderate- and high-intensity exercise improves lipoprotein profile and cholesterol efflux capacity in healthy young men. *J Am Heart Assoc*. 2022;11:e023386.
12. Ambrozy T, Ryzdzik L, Obminski Z, et al. Effect of high-intensity strength and endurance training in the form of small circuits on changes in lipid levels in men aged 35–40 years. *J Clin Med*. 2022;11:5146.
13. Sabaka P, Kruzliak P, Balaz D, et al. Effect of short term aerobic exercise on fasting and postprandial lipoprotein subfractions in healthy sedentary men. *Lipids Health Dis*. 2015;14:151.
14. Gepner AD, Piper ME, Johnson HM, et al. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. *Am Heart J*. 2011;161:145–151.
15. Nam GE, Cho KH, Park YG, et al. Socioeconomic status and dyslipidemia in Korean adults: the 2008–2010 Korea National Health and Nutrition Examination Survey. *Prev Med*. 2013;57:304–309.
16. Izadi N, Yari-Boroujeni R, Soofi M, et al. Socioeconomic inequalities and dyslipidaemia in adult population of the Ravansar Non-Communicable Disease Cohort Study: the role of sex and age. *BMJ Open*. 2024;14:e085035.
17. Li L, Ouyang F, He J, et al. Associations of socioeconomic status and healthy lifestyle with incidence of dyslipidemia: a prospective Chinese governmental employee cohort study. *Front Public Health*. 2022;10:878126.
18. Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. *J Nutr*. 2010;140:304–310.
19. Tester JM, Laraia BA, Leung CW, et al. Dyslipidemia and food security in low-income US adolescents: National Health and Nutrition Examination Survey, 2003–2010. *Prev Chronic Dis*. 2016;13:E22.
20. Lemke MK, Apostolopoulos Y, Hege A, et al. Work, sleep, and cholesterol levels of US long-haul truck drivers. *Ind Health*. 2017;55:149–161.
21. Duthiel F, Baker JS, Mermillod M, et al. Shift work, and particularly permanent night shifts, promote dyslipidaemia: a systematic review and meta-analysis. *Atherosclerosis*. 2020;313:156–169.
22. Cakmak S, Lukina A, Dales R. The association between neighbourhood walkability and blood lipids: a Canadian population study. *Lipids Health Dis*. 2024;23:298.
23. Wang Q, Li X, Zhong W, et al. Residential greenness and dyslipidemia risk: dose-response relations and mediation through BMI and air pollution. *Environ Res*. 2023;217:114810.
24. Yang BY, Markevych I, Heinrich J, et al. Residential greenness and blood lipids in urban-dwelling adults: the 33 Communities Chinese Health Study. *Environ Pollut*. 2019;250:14–22.
5. Delgado-Lista J, Alcalá-Díaz JF, Torres-Pena JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet*. 2022;399:1876–1885.
6. Chiavaroli L, Vigiouliouk E, Nishi SK, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. *Nutrients*. 2019;11:338.
7. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378:.
8. Koch CA, Kjeldsen EW, Frikke-Schmidt R. Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. *Eur Heart J*. 2023;44:2609–2622.
9. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. *Circulation*. 2017;136:e1–e23.
10. Griffin BA, Mensink RP, Lovegrove JA. Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk? *Atherosclerosis*. 2021;328:108–113.
11. Guasch-Ferre M, Satija A, Blondin SA, et al. Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. *Circulation*. 2019;139:1828–1845.
12. Del Gobbo LC, Falk MC, Feldman R, et al. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. *Am J Clin Nutr*. 2015;102:1347–1356.
13. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69:30–42.

#### 4.1.2.2. Lifestyle Management of Hypertriglyceridemia

1. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378:.
2. Fechner E, Smeets E, Schrauwen P, et al. The effects of different degrees of carbohydrate restriction and carbohydrate replacement on cardiometabolic risk markers in humans—a systematic review and meta-analysis. *Nutrients*. 2020;12:991.
3. Reynolds A, Mann J, Cummings J, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019;393:434–445.
4. Santos FL, Esteves SS, da Costa Pereira A, et al. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. *Obes Rev*. 2012;13:1048–1066.
5. Fantino M, Paquette M, Blais C, et al. Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study. *Nutr Res*. 2022;101:43–52.
6. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2020;105:dga673.
7. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320–328.
8. Smart NA, Downes D, van der Touw T, et al. The effect of exercise training on blood lipids: a systematic review and meta-analysis. *Sports Med*. 2025;55:67–78.
9. Zhong Z, Miyachi M, Tanisawa K. The effect of upper- and lower-body exercise on next-day postprandial triglycerides in healthy young men. *Front Physiol*. 2024;15:1454731.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678.
11. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*. 2007;298:299–308.
12. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625.

13. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
14. Neuwenschwander M, Stadelmaier J, Eble J, et al. Substitution of animal-based with plant-based foods on cardiometabolic health and all-cause mortality: a systematic review and meta-analysis of prospective studies. *BMC Med*. 2023;21:404.
15. Rhodes KS, Kirkpatrick CF. The value of incorporating medical nutrition therapy by a registered dietitian nutritionist in clinical practice. *J Clin Lipidol*. 2018;12:1109–1110.
16. Ross LJ, Barnes KA, Ball LE, et al. Effectiveness of dietetic consultation for lowering blood lipid levels in the management of cardiovascular disease risk: a systematic review and meta-analysis of randomised controlled trials. *Nutr Diet*. 2019;76:199–210.
17. Johnson RK, Appel LJ, Brands M, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. *Circulation*. 2009;120:1011–1020.
18. Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr*. 1999;69:632–646.
19. Kodama S, Horikawa C, Fujihara K, et al. Relationship between intake of fruit separately from vegetables and triglycerides—a meta-analysis. *Clin Nutr ESPEN*. 2018;27:53–58.
20. Luna-Castillo KP, Olivares-Ochoa XC, Hernandez-Ruiz RG, et al. The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence. *Nutrients*. 2022;14:1104.
21. Williams L, Rhodes KS, Karmally W, et al. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. *J Clin Lipidol*. 2018;12:908–919.
22. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17:428–451.
23. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriglyceridemia: historical perspective and review of biological mechanisms. *Am J Clin Nutr*. 2000;71:412–433.
24. Brown JD, Buscemi J, Milson V, et al. Effects on cardiovascular risk factors of weight losses limited to 5–10%. *Transl Behav Med*. 2016;6:339–346.
25. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med*. 2002;347:1483–1492.

#### 4.1.3. Attainment and Maintenance of Healthy Weight in People With Dyslipidemia

1. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2020;105:dgaa673.
2. Kanbay M, Copur S, Siriopol D, et al. Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2023;25:3766–3778.
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389:2221–2232.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387:205–216.
5. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *J Clin Lipidol*. 2024;18:e320–e350.
6. Koch CA, Kjeldsen EW, Frikke-Schmidt R. Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. *Eur Heart J*. 2023;44:2609–2622.
7. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
8. Santos FL, Esteves SS, da Costa Pereira A, et al. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. *Obes Rev*. 2012;13:1048–1066.
9. Goldberg IJ, Ibrahim N, Bredefeld C, et al. Ketogenic diets, not for everyone. *J Clin Lipidol*. 2021;15:61–67.
10. Zhou C, Wang M, Liang J, et al. Ketogenic diet benefits to weight loss, glycemic control, and lipid profiles in overweight patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. *Int J Environ Res Public Health*. 2022;19:10429.
11. Bueno NB, de Melo IS, de Oliveira SL, et al. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr*. 2013;110:1178–1187.
12. Rotunda W, Rains C, Jacobs SR, et al. Weight loss in short-term interventions for physical activity and nutrition among adults with overweight or obesity: a systematic review and meta-analysis. *Prev Chronic Dis*. 2024;21:E21.
13. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17:428–451.
14. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320–328.

#### 4.1.4. Physical Activity

1. Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how? A scientific statement from the American Heart Association. *Hypertension*. 2021;78:e26–e37.
2. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a Presidential Advisory from the American Heart Association. *Circulation*. 2022;146:e18–e43.
3. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. *Lipids Health Dis*. 2017;16:132.
4. Jerome GJ, Boyer WR, Bustamante EE, et al. Increasing equity of physical activity promotion for optimal cardiovascular health in adults: a scientific statement from the American Heart Association. *Circulation*. 2023;147:1951–1962.
5. Paluch AE, Boyer WR, Franklin BA, et al. Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: a scientific statement from the American Heart Association. *Circulation*. 2024;149:e217–e231.
6. Bennie JA, De Cocker K, Teychenne MJ, et al. The epidemiology of aerobic physical activity and muscle-strengthening activity guideline adherence among 383,928 US adults. *Int J Behav Nutr Phys Act*. 2019;16:34.
7. Churilla JR, Johnson TM, Zippel EA. Association of physical activity volume and hypercholesterolemia in US adults. *QJM*. 2012;106:333–340.
8. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials. *J Mens Health Gen*. 2006;3:61–70.
9. Kelley GA, Kelley KS, Tran ZV. Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials. *J Womens Health (Larchmt)*. 2004;13:1148–1164.
10. Smart NA, Downes D, van der Touw T, et al. The effect of exercise training on blood lipids: a systematic review and meta-analysis. *Sports Med*. 2025;55:67–78.
11. Ballard AM, Davis A, Wong B, et al. The effects of exclusive walking on lipids and lipoproteins in women with overweight and obesity: a systematic review and meta-analysis. *Am J Health Promot*. 2022;36:328–339.
12. Sarzynski MA, Burton J, Rankinen T, et al. The effects of exercise on the lipoprotein subclass profile: a meta-analysis of 10 interventions. *Atherosclerosis*. 2015;243:364–372.
13. Xin C, Ye M, Zhang Q, et al. Effect of exercise on vascular function and blood lipids in postmenopausal women: a systematic review and network meta-analysis. *Int J Environ Res Public Health*. 2022;19:12074.
14. McLeod KA, Jones MD, Thom JM, et al. Resistance training and high-intensity interval training improve cardiometabolic health in high risk older adults: a systematic review and meta-analysis. *Int J Sports Med*. 2022;43:206–218.
15. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med*. 2002;347:1483–1492.
16. Alhazmi N. The effectiveness of physical exercise in reducing common risk factors of atherosclerosis: a systematic review. *Cell Physiol Biochem*. 2024;58:571–583.
17. Coleman KJ, Ngor E, Reynolds K, et al. Initial validation of an exercise "vital sign" in electronic medical records. *Med Sci Sports Exerc*. 2012;44:2071–2076.
18. Grogg KA, Giacobbi PR Jr, Blair EK, et al. Physical activity assessment and promotion in clinical settings in the United States: a scoping review. *Am J Health Promot*. 2022;36:714–737.

- CLINICAL STATEMENTS AND GUIDELINES**
19. Lobelo F, Rohm Young D, Sallis R, et al. Routine assessment and promotion of physical activity in healthcare settings: a Scientific Statement from the American Heart Association. *Circulation*. 2018;137:e495–e522.
  20. Wood G, Taylor E, Ng V, et al. Estimating the effect of aerobic exercise training on novel lipid biomarkers: a systematic review and multivariate meta-analysis of randomized controlled trials. *Sports Med*. 2023;53:871–886.
  21. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. *Sports Med*. 2014;44:211–221.
  22. Kraus WE, Slentz CA. Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect. *Obesity*. 2009;17:S21–S26.
  23. Gordon B, Chen S, Durstine JL. The effects of exercise training on the traditional lipid profile and beyond. *Curr Sports Med Rep*. 2014;13:253–259.
  24. Li Y, Zhai Q, Li G, et al. Effects of different aerobic exercises on blood lipid levels in middle-aged and elderly people: a systematic review and bayesian network meta-analysis based on randomized controlled trials. *Healthcare (Basel)*. 2024;12:1309.
  25. Yun H, Su W, Zhao H, et al. Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis. *Medicine (Baltimore)*. 2023;102:e33854.
  26. Kim KB, Kim K, Kim C, et al. Effects of exercise on the body composition and lipid profile of individuals with obesity: a systematic review and meta-analysis. *J Obes Metab Syndr*. 2019;28:278–294.
  27. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123:2292–2333.
  28. US Department of Health and Human Services. *Physical Activity Guidelines for Americans*. 2nd edition. US Department of Health and Human Services; 2018.
  29. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
  30. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
  31. Kelley GA, Kelley KS, Roberts S, et al. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. *Clin Nutr*. 2012;31:156–167.
  32. Kelley GA, Kelley KS, Roberts S, et al. Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. *BMC Med*. 2011;9:74.
  33. Khan KM, Weiler R, Blair SN. Prescribing exercise in primary care. *BMJ*. 2011;343:d4141.
  34. Exercise is Medicine. American College of Sports Medicine. Accessed February 14, 2025 <https://www.exerciseismedicine.org>.
  35. Lane-Cordova AD, Jerome GJ, Paluch AE, et al. Supporting physical activity in patients and populations during life events and transitions: a Scientific Statement from the American Heart Association. *Circulation*. 2022;145:e117–e128.
- #### 4.1.5. Dietary Supplements
1. Dehzad MJ, Ghalandari H, Amini MR, et al. Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. *Complement Ther Med*. 2023;75:102955.
  2. Du Y, Zhou H, Zha W. Garlic consumption can reduce the risk of dyslipidemia: a meta-analysis of randomized controlled trials. *J Health Popul Nutr*. 2024;43:113.
  3. Laffin LJ, Bruemmer D, Garcia M, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. *J Am Coll Cardiol*. 2023;81:1–12.
  4. Myhre PL, Berge T, Kalstad AA, et al. Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': a secondary analysis from the OMEMI trial. *Clin Nutr*. 2023;42:1657–1660.
  5. Assadourian JN, Peterson ED, Gupta A, et al. Use of dietary supplements among people with atherosclerotic cardiovascular disease in the United States: a population-based analysis from NHANES. *J Am Heart Assoc*. 2024;13:e033748.
  6. Bailey RL. Current regulatory guidelines and resources to support research of dietary supplements in the United States. *Crit Rev Food Sci Nutr*. 2020;60:298–309.
  7. Eslick GD, Howe PR, Smith C, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. *Int J Cardiol*. 2009;136:4–16.
  8. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. *Circulation*. 2019;140:e673–e691.
  9. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
  10. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023;148:e9–e119.
  11. Fateh HL, Amin SM. Effects of cinnamon supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr Res*. 2024;13:74–87.
  12. Trognanis E, Karalexi MA, Sergentanis TN, et al. Safety and efficacy of the consumption of the nutraceutical "red yeast rice extract" for the reduction of hypercholesterolemia in humans: a systematic review and meta-analysis. *Nutrients*. 2024;16:1453.
  13. Zamani M, Zarei M, Nikbaf-Shandiz M, et al. The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis. *Front Nutr*. 2022;9:1013055.
- #### 4.1.6. When to Refer to a Registered Dietitian Nutritionist
1. Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutrition therapy is the essential cornerstone for effective treatment of "refractory" severe hypertriglyceridemia regardless of pharmaceutical treatment: evidence from a lipid management program. *J Clin Lipidol*. 2015;9:559–567.
  2. Mohr AE, Hatem C, Sikand G, et al. Effectiveness of medical nutrition therapy in the management of adult dyslipidemia: a systematic review and meta-analysis. *J Clin Lipidol*. 2022;16:547–561.
  3. Sikand G, Cole RE, Handu D, et al. Clinical and cost benefits of medical nutrition therapy by registered dietitian nutritionists for management of dyslipidemia: a systematic review and meta-analysis. *J Clin Lipidol*. 2018;12:1113–1122.
  4. Sikand G, Handu D, Rozga M, et al. Medical nutrition therapy provided by dietitians is effective and saves healthcare costs in the management of adults with dyslipidemia. *Curr Atheroscler Rep*. 2023;25:331–342.
  5. Dong I, Klodas E. Healthcare cost implications of utilizing a dietary intervention to lower LDL cholesterol: proof of concept actuarial analysis and recommendations. *Curr Cardiol Rep*. 2020;22:138.
  6. Academy of Nutrition and Dietetics. Referrals to a registered dietitian nutritionist: a primary care provider (PCP) toolkit promoting the use of registered dietitian nutritionists (RDNs) in team based care for patients with obesity or diabetes. 2020. <https://www.eatrightpro.org/referrals-to-an-rdn-primary-care-provider-toolkit>.
  7. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
  8. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. *J Clin Lipidol*. 2012;6:409–412.
  9. Chait A. Multifactorial chylomicronemia syndrome. *Curr Opin Endocrinol Diabetes Obes*. 2024;31:78–83.
  10. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17:428–451.
- #### 4.2.1. Pharmacological Therapy
1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
  2. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
  3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
  4. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:341–350.

5. Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. *J Am Coll Cardiol*. 2020;75:565–574.
6. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis*. 2018;277:195–203.
7. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*. 2019;8:e011662.
8. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. *N Engl J Med*. 2014;371:2200–2206.
9. National Institute of Health, National Library of Medicine. DailyMed - All Drugs. Accessed June 13, 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>.
10. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2022;80:1366–1418.
11. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a Science Advisory from the American Heart Association. *Circulation*. 2019;140:e673–e691.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:23–33.
16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352:1425–1435.
17. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006;355:549–559.
18. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
19. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374:2021–2031.
20. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.

#### 4.2.1.1. Statins

1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
2. Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. *Eur Heart J Cardiovasc Pharmacother*. 2016;2:212–217.
3. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. *J Atheroscler Thromb*. 2017;24:19–25.
4. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016;388:2532–2561.
5. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a Scientific Statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2019;39:e38–e81.
6. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
7. American College of Cardiology. American College of Cardiology LDL-C manager. Accessed January 15, 2025. <http://tools.acc.org/ldl>.
8. Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Accessed January 15, 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor>.
9. National Institute of Health, National Library of Medicine. DailyMed - All Drugs. Accessed June 13, 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383–1389.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*. 1995;333:1301–1307.
12. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*. 1996;335:1001–1009.
13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*. 1998;279:1615–1622.
14. Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998;339:1349–1357.
5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2022;80:1366–1418.
2. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. *J Clin Lipidol*. 2022;16:361–375.
3. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
4. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. *Am J Cardiol*. 2008;101:1606–1613.
5. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. *Circulation*. 2022;146:1109–1119.
6. Goodman SG, Steg PG, Poulouin Y, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial. *J Am Heart Assoc*. 2023;12:e029216.
7. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
8. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
9. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. *Lancet Diabetes Endocrinol*. 2023;11:109–119.
10. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis*. 2018;277:195–203.
11. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*. 2019;8:e011662.
12. Gao Y, Shah LM, Ding J, et al. US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018. *J Am Heart Assoc*. 2023;12:e028205.
13. Lahoz R, Seshagiri D, Electricwala B, et al. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort. *Curr Med Res Opin*. 2024;40:15–25.
14. Sekkarie A, Park S, Therrien NL, et al. Trends in lipid-lowering prescriptions: increasing use of guideline-concordant pharmacotherapies, US, 2017–2022. *Am J Prev Med*. 2023;64:561–566.
15. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. *J Am Coll Cardiol*. 2019;74:1728–1731.
16. MacDougall DE, Baum SJ, Ahmed CD, et al. Trends in patient access to and utilization of prescribed PCSK9 inhibitors in a large US claims database from 2015 to 2021. *Circ Cardiovasc Qual Outcomes*. 2024;17:e009988.

- O'Neil A, Calderbank S, Brown J, et al. Quantification of utilization management barriers for patients initiating therapy to lower lipid levels. *JAMA Netw Open*. 2022;5:e2240513.

#### 4.2.1.3. TG-Lowering Medications

- Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
- HPS Thrive Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. *Eur Heart J*. 2013;34:1279–1291.
- Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366:1849–1861.
- Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563–1574.
- Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365:2255–2267.
- Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371:203–212.

#### 4.2.2. Referring to a Clinical Lipid Specialist

- Wierzbicki AS, Viljoen A, Viljoen S, et al. Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. *Int J Clin Pract*. 2018;72:e13242.
- Pinsdorf D, Messiha D, Petrikovich O, et al. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors. *J Clin Lipidol*. 2023;17:504–511.
- Jones LK, McMinn M, Kann D, et al. Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis. *Implement Sci Commun*. 2021;2:32.

#### 4.2.3. Primary Prevention in Adults

- Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol*. 2020;76:1507–1516.
- Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. *Circulation*. 2015;131:451–458.
- Zheutlin AR, Handoo F, Luebbe S, et al. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. *Eur Heart J*. 2025;eha472.
- Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med*. 2022;386:1877–1888.
- Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. *Circulation*. 2016;134:9–19.
- Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. *JAMA Cardiol*. 2021;6:1406–1413.
- Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380:581–590.
- Liu K, Wilkins JT, Colangelo LA, et al. Does lowering low-density lipoprotein cholesterol with statin restore low risk in middle-aged adults? Analysis of the observational MESA study. *J Am Heart Assoc*. 2021;10:e019695.

##### 4.2.3.1. Role of the Individualized Benefit-Risk Discussion

- Hopkin G, Au A, Collier VJ, et al. Combining multiple treatment comparisons with personalized patient preferences: a randomized trial of an interactive platform for statin treatment selection. *Med Decis Making*. 2019;39:264–277.
- Ahmed ST, Akeroyd JM, Mahtta D, et al. Shared decisions: a qualitative study on clinician and patient perspectives on statin therapy and statin-associated side effects. *J Am Heart Assoc*. 2020;9:e017915.
- Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4:CD001431.

- Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. *J Am Coll Cardiol*. 2015;65:1361–1368.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
- Brodney S, Valentine KD, Sepucha K, et al. Patient preference distribution for use of statin therapy. *JAMA Network Open*. 2021;4:e210661.
- Navar AM, Wang TY, Li S, et al. Patient-perceived versus actual risk of cardiovascular disease and associated willingness to consider and use prevention therapy. *Circ Cardiovasc Qual Outcomes*. 2021;14:e006548.
- Coronado-Vazquez V, Canet-Fajas C, Delgado-Marroquin MT, et al. Interventions to facilitate shared decision-making using decision aids with patients in primary health care: a systematic review. *Medicine (Baltimore)*. 2020;99:E21389.
- Mendez K, Rane M, Orkaby AR, et al. A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions. *Int J Cardiol Cardiovasc Risk Prev*. 2022;15:200159.

##### 4.2.3.2. PREVENT-ASCVD Equations

- Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT equations. *Circulation*. 2024;149:430–449.
- Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380:581–590.
- Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association. *Circulation*. 2023;148:1982–2004.
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(suppl 2):S1–S45
- Khan SS, Lloyd-Jones DM. Statins for primary prevention of cardiovascular disease with PREVENT, what's a clinician to do? *JAMA*. 2024;332:961–962.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:1269–1324. DOI: 10.1161/HYP.0000000000000666
- Khan SS, Huang X, Ndumele CE, et al. Statin eligibility according to atherosclerotic cardiovascular disease risk in the US. *JAMA Cardiol*. 2025;10:1071–1073.

##### 4.2.3.3. Risk Enhancers

- Mortensen MB, Jensen JM, Roennow Sand NP, et al. Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events. *J Am Coll Cardiol*. 2024;83:2643–2654.
- Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA*. 2012;308:788–795.
- Khera A, Budoff MJ, O'Donnell CJ, et al. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) coronary calcium atherosclerotic cardiovascular disease risk calculator. *Circulation*. 2018;138:1819–1827.
- Ridker PM, Moorthy MV, Cook NR, et al. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. *N Engl J Med*. 2024;391:2087–2097.

5. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation*. 2018;138:1100–1112.
6. Lloyd-Jones DM, Nam B-H, D'Agostino S, Ralph B, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. *JAMA*. 2004;291:2204–2211.
7. Patel J, Al Rifai M, Scheuner MT, et al. Basic vs more complex definitions of family history in the prediction of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). *Mayo Clin Proc*. 2018;93:1213–1223.
8. Pursnani S, Merchant M. South Asian ethnicity as a risk factor for coronary heart disease. *Atherosclerosis*. 2020;315:126–130.
9. Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. *J Am Coll Cardiol*. 2022;79:757–768.
10. van der Meer IM, de Maat MP, Kiliaan AJ, et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam study. *Arch Intern Med*. 2003;163:1323–1328.
11. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med*. 2012;367:1310–1320.
12. Seshadri S, Beiser A, Pikula A, et al. Parental occurrence of stroke and risk of stroke in their children. *Circulation*. 2010;121:1304–1312.
13. Rosenson RS, Hubbard D, Monda KL, et al. Excess risk for atherosclerotic cardiovascular outcomes among US adults with HIV in the current era. *J Am Heart Assoc*. 2020;9:e013744.
14. Freiberg MS, Chang C-CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013;173:614–622.
15. Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, et al. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. *Eur Heart J*. 2025;46:3875–3884.
16. Wong ND, Zhao Y, Quek RGW, et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. *J Clin Lipidol*. 2017;11:1223–1233.
17. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2021;41:465–474.
18. Naderian M, Norland K, Schaid DJ, et al. Development and evaluation of a comprehensive prediction model for incident coronary heart disease using genetic, social, and lifestyle-psychological factors: a prospective analysis of the UK biobank. *Ann Intern Med*. 2024;178:1–10.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
20. Ridker PM, MacFadyen J, Libby P, et al. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPEITER). *Am J Cardiol*. 2010;106:204–209.
21. Bhatia HS, Ambrosio M, Razavi AC, et al. AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK Biobank. *JAMA Cardiol*. 2025;10:810–818.
22. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med*. 2012;367:1310–1320.
23. Agarwala A, Liu J, Ballantyne CM, et al. The use of risk enhancing factors to personalize ASCVD risk assessment: evidence and recommendations from the 2018 AHA/ACC multi-society cholesterol guidelines. *Curr Cardiovasc Risk Rep*. 2019;13:18.
24. Akintoye E, Afonso L, Bengaluru Jayanna M, et al. Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC/AHA multisociety cholesterol treatment guidelines over the Pooled Cohort Equation: insights from 3 large prospective cohorts. *J Am Heart Assoc*. 2021;10:e019589.
25. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
26. Shostrom DCV, Sun Y, Oleson JJ, et al. History of gestational diabetes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women. *Front Endocrinol (Lausanne)*. 2017;8:144.
27. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003497.
28. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. *JAMA Cardiol*. 2016;1:767–776.
29. Yoshida Y, Chen Z, Baudier RL, et al. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9;374 postmenopausal women. *Diabetes Care*. 2021;44:2564–2572.
30. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
31. Sederholm Lawesson S, Swahn E, Pihlsgard M, et al. Association between history of adverse pregnancy outcomes and coronary artery disease assessed by coronary computed tomography angiography. *JAMA*. 2023;329:393–404.
32. Elder P, Sharma G, Gulati M, et al. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. *Am J Prev Cardiol*. 2020;2:100028.
33. Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet*. 2005;366:1797–1803.
34. Ahmed R, Dunford J, Mehran R, et al. Pre-eclampsia and future cardiovascular risk among women: a review. *J Am Coll Cardiol*. 2014;63:1815–1822.
35. Agarwala A, Michos ED, Samad Z, et al. The use of sex-specific factors in the assessment of women's cardiovascular risk. *Circulation*. 2020;141:592–599.
36. Kyriacou H, Al-Mohammad A, Muehlschlegel C, et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis. *Eur Heart J Open*. 2022;2:oeac0065.
37. Soendergaard MM, Hlatky MA, Stefanick ML, et al. Association of adverse pregnancy outcomes with risk of atherosclerotic cardiovascular disease in postmenopausal women. *JAMA Cardiol*. 2020;5:1390–1398.
38. Crump C, Sundquist J, McLaughlin MA, et al. Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study. *BMJ*. 2023;380:e072112.
39. Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75:2602–2618.
40. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. *Circulation*. 2023;148:1606–1635.
41. Bonamy A-KE, Parikh NI, Cnattingius S, et al. Birth characteristics and subsequent risks of maternal cardiovascular disease. *Circulation*. 2011;124:2839–2846.
42. Zhu D, Chung H-F, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. *Lancet Public Health*. 2019;4:e553–e564.
43. Wenger NK, Lloyd-Jones DM, Elkind MSV, et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. *Circulation*. 2022;145:e1059–e1071.
44. Esber Y, Gow ML, McLennan S, et al. Metabolic outcomes in women 6 months and 2 years after preeclampsia versus normotensive pregnancy: a P4 study. *Clin Obes*. 2025;15:e12706.
45. Freaney PM, Khan SS, Lloyd-Jones DM, et al. The role of sex-specific risk factors in the risk assessment of atherosclerotic cardiovascular disease for primary prevention in women. *Curr Atheroscler Rep*. 2020;22:46.
46. Zimodou JM, Mucha M, Berthold HK, et al. Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review. *Pharmacotherapy*. 2024;17:913.
47. Ngo AD, Roberts CL, Chen JS, et al. Delivery of a small-for-gestational-age infant and risk of maternal cardiovascular disease - a population-based record linkage study. *Heart Lung Circ*. 2015;24:696–704.
48. McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. *Am J Obstet Gynecol*. 2018;218:S855–S868.
49. Bakhtiani P, Geffner M. Early puberty. *Pediatr Rev*. 2022;43:483–492.

#### 4.2.3.4. Reproductive Risk Markers

1. Wu P, Gulati M, Kwok CS, et al. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. *J Am Heart Assoc*. 2018;7:e007809.

26. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. *J Clin Endocrinol Metab.* 2002;87:2013–2017.
27. Ollila M-M, Arffman RK, Korhonen E, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria: a prospective population-based cohort study. *Eur J Endocrinol* 2023;189:96–105.
28. Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a Scientific Statement from the American Heart Association. *Circulation.* 2021;143:e902–e916.

#### 4.2.3.5. Polygenic Risk Scores

1. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet.* 2022;54:1803–1815.
2. Busby GB, Kulm S, Bolli A, et al. Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments. *Nat Commun.* 2023;14:7105.
3. Patel AP, Wang M, Ruan Y, et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. *Nat Med.* 2023;29:1793–1803.
4. Samani NJ, Beeston E, Greengrass C, et al. Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting. *Eur Heart J.* 2024;45:3152–3160.
5. Truong B, Hull LE, Ruan Y, et al. Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. *Cell Genom.* 2024;4:100523.
6. Smith JL, Tcheandjieu C, Dikilitas O, et al. Multi-ancestry polygenic risk score for coronary heart disease based on an ancestrally diverse genome-wide association study and population-specific optimization. *Circ Genom Precis Med.* 2024;17:e004272.
7. Ye Y, Chen X, Han J, et al. Interactions between enhanced polygenic risk scores and lifestyle for cardiovascular disease, diabetes, and lipid levels. *Circ Genom Precis Med.* 2021;14:e003128.
8. Urbut SM, Cho SMJ, Paruchuri K, et al. Dynamic importance of genomic and clinical risk for coronary artery disease over the life course. *Circ Genom Precis Med.* 2023;18:e004681.
9. Marston NA, Pirruccello JP, Melloni GEM, et al. Predictive utility of a coronary artery disease polygenic risk score in primary prevention. *JAMA Cardiol.* 2023;8:130–137.
10. Saadatagah S, Naderian M, Dikilitas O, et al. Polygenic risk, rare variants, and family history: independent and additive effects on coronary heart disease. *JACC Adv.* 2023;2:100567.
11. Mars N, Lindbohm JV, Della Briotta Parolo P, et al. Systematic comparison of family history and polygenic risk across 24 common diseases. *Am J Hum Genet.* 2022;109:2152–2162.
12. Natarajan P, Young R, Stitzel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. *Circulation.* 2017;135:2091–2101.
13. Mega JL, Stitzel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. *Lancet.* 2015;385:2264–2271.
14. Marston NA, Kamani FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER Trial. *Circulation.* 2020;141:616–623.
15. Widen E, Junna N, Ruotsalainen S, et al. How communicating polygenic and clinical risk for atherosclerotic cardiovascular disease impacts health behavior: an observational follow-up study. *Circ Genom Precis Med.* 2022;15:E003459.
16. Maamari DJ, Brockman DG, Aragam K, et al. Clinical implementation of combined monogenic and polygenic risk disclosure for coronary artery disease. *JACC Adv.* 2022;1:100068.
17. Kullo IJ, Jouni H, Austin EE, et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES Clinical Trial). *Circulation.* 2016;133:1181–1188.
18. Aragam KG, Dobbyn A, Judy R, et al. Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease. *J Am Coll Cardiol.* 2020;75:2769–2780.
19. Abramowitz SA, Boulier K, Keat K, et al. Evaluating performance and agreement of coronary heart disease polygenic risk scores. *JAMA.* 2025;333:60–70.

20. Ding Y, Hou K, Burch KS, et al. Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification. *Nat Genet.* 2022;54:30–39.
21. Misra A, Truong B, Urbut SM, et al. Instability of high polygenic risk classification and mitigation by integrative scoring. *Nat Commun.* 2025;16:1584.

#### 4.2.3.6. Selective Imaging of Subclinical Atherosclerosis (Men $\geq 40$ or Women $\geq 45$ Years)

1. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol.* 2015;66:1657–1668.
2. Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and cv risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. *JACC Cardiovasc Imaging.* 2017;10:143–153.
3. Lindholt JS, Soegaard R, Rasmussen LM, et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. *N Engl J Med.* 2022;387:1385–1394.
4. Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: results from Multiethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging.* 2015;8:e003186.
5. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). *Eur Heart J.* 2018;39:2401–2408.
6. Valenti V, Hartaigh BO, Cho I, et al. Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. *Circ Cardiovasc Imaging.* 2016;9:e003528.
7. McEvoy JW, Blaha MJ, Rivera JJ, et al. Mortality rates in smokers and non-smokers in the presence or absence of coronary artery calcification. *JACC Cardiovasc Imaging.* 2012;5:1037–1045.
8. Dzaye O, Dardari ZA, Cainzos-Achirica M, et al. Warranty period of a calcium score of zero: comprehensive analysis from MESA. *JACC Cardiovasc Imaging.* 2021;14:990–1002.
9. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. *JAMA.* 2025;333:1403–1412.
10. Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall). *Circulation.* 2018;137:665–679.
11. Peng AW, Dudum R, Jain SS, et al. Association of coronary artery calcium detected by routine gated CT imaging with cardiovascular outcomes. *J Am Coll Cardiol.* 2023;82:1192–1202.
12. Mehta A, Rigdon J, Tattersall MC, et al. Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA. *Circ Cardiovasc Imaging.* 2021;14:e011701.
13. Kolossvary M, Schnittman SR, Zanni MV, et al. Pitavastatin, procollagen pathways, and plaque stabilization in patients with HIV: a secondary analysis of the REPRIEVE randomized clinical trial. *JAMA Cardiol.* 2025;10:254–264.
14. Soares C, Samara A, Yuyun MF, et al. Coronary artery calcification and plaque characteristics in people living with HIV: a systematic review and meta-analysis. *J Am Heart Assoc.* 2021;10:e019291.
15. Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. *Cardiovasc Res.* 2019;115:721–728.
16. Zhang YS, Shi R, Jiang YN, et al. The association between the triglyceride-glucose index and vulnerable plaques in patients with type 2 diabetes mellitus: insights from coronary computed tomography angiography. *Cardiovasc Diabetol.* 2025;24:169.
17. Yoon YH, Kim TO, Park GM, et al. Clinical significance of diabetes in asymptomatic individuals with zero coronary artery calcium score. *Am J Cardiol.* 2025;245:29–34.
18. Munden RF, Black WC, Hartman TE, et al. Managing incidental findings on thoracic CT: lung findings. A white paper of the ACR Incidental Findings Committee. *J Am Coll Radiol.* 2021;18:1267–1279.
19. Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after a myocardial infarction: partners YOUNG-MI Registry. *J Am Coll Cardiol.* 2017 doi: 10.1016/j.jacc.2017.11.007.

20. Scheuermann B, Brown A, Colburn T, et al. External validation of the American Heart Association PREVENT cardiovascular disease risk equations. *JAMA Netw Open*. 2024;7:e2438311.
21. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BiImage Study. *J Am Coll Cardiol*. 2016;68:881–891.
22. Miedema MD, Dardari ZA, Nasir K, et al. Association of coronary artery calcium with long-term, cause-specific mortality among young adults. *JAMA Netw Open*. 2019;2:e197440.
23. Dzaye O, Razavi AC, Dardari ZA, et al. Modeling the recommended age for initiating coronary artery calcium testing among at-risk young adults. *J Am Coll Cardiol*. 2021;78:1573–1583.
24. Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. *JACC Cardiovasc Imaging*. 2017;10:833–842.
25. Whitmore K, Zhou Z, Chapman N, et al. Impact of patient visualization of cardiovascular images on modification of cardiovascular risk factors. *JACC Cardiovasc Imaging*. 2023;16:1069–1081.
26. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. *JAMA*. Published online March 5, 2025. doi: 10.1001/jama.2025.0584.
27. Mitchell JD, Ferguson N, Gage BF, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. *J Am Coll Cardiol*. 2018;72:3233–3242.
28. Budoff MJ, Kinnering A, Gransar H, et al. When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM Registry. *JACC Cardiovasc Imaging*. 2023;16:1181–1189.
29. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. *JAMA Cardiol*. 2017;2:391–399.
30. Javadi A, Dardari ZA, Mitchell JD, et al. Distribution of coronary artery calcium by age, sex, and race among patients 30–45 years old. *J Am Coll Cardiol*. 2022;79:1873–1886.
31. Peng AW, Mirbolouk M, Orimoloye OA, et al. Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC  $\geq 1,000$ : results from the CAC Consortium. *JACC Cardiovasc Imaging*. 2020;13:83–93.
32. Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. *JAMA Cardiol*. 2017;2:1332–1340.
33. Budoff M, Backlund JC, Bluemke DA, et al. The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT/EDIC trials. *JACC Cardiovasc Imaging*. 2019;12:1341–1349.
34. Parsa S, Saleh A, Raygor V, et al. Measurement and application of incidentally detected coronary calcium: JACC review topic of the week. *J Am Coll Cardiol*. 2024;83:1557–1567.
35. Chiles C, Duan F, Gladish GW, et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. *Radiology*. 2015;276:82–90.
36. Sandhu AT, Rodriguez F, Ngo S, et al. Incidental coronary artery calcium: opportunistic screening of previous nongated chest computed tomography scans to improve statin rates (NOTIFY-1 Project). *Circulation*. 2023;147:703–714.
37. Raygor V, Hoeting N, Ayers C, et al. Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring. *J Cardiovasc Comput Tomogr*. 2023;17:453–458.
38. Tattersall MC, Hansen SL, McClelland RL, et al. Importance of age and sex in carotid artery plaque detection and cardiovascular disease risk. *JAMA Cardiol*. 2025;10:487–491.
39. Sillesen H, Sartori S, Sandholt B, et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. *Eur Heart J Cardiovasc Imaging*. 2018;19:1042–1050.
40. Bienstock S, Lin F, Blankstein R, et al. Advances in coronary computed tomographic angiographic imaging of atherosclerosis for risk stratification and preventive care. *JACC Cardiovasc Imaging*. 2023;16:1099–1115.
41. Bergstrom G, Persson M, Adiels M, et al. Prevalence of subclinical coronary artery atherosclerosis in the general population. *Circulation*. 2021;144:916–929.
42. Nasir K, Cainzos-Achirica M, Valero-Elizondo J, et al. Coronary atherosclerosis in an asymptomatic US population: Miami Heart Study at Baptist Health South Florida. *JACC Cardiovasc Imaging*. 2022;15:1604–1618.
43. Fuchs A, Kuhl JT, Sigvardsen PE, et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort. *Ann Intern Med*. 2023;176:433–442.
44. Narula J, Stuckey TD, Nakazawa G, et al. Prospective deep learning-based quantitative assessment of coronary plaque by computed tomography angiography compared with intravascular ultrasound: the REVEALPLAQUE study. *Eur Heart J Cardiovasc Imaging*. 2024;25:1287–1295.
45. Nurmohamed NS, Min JK, Anthopoulos R, et al. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. *Eur Heart J*. 2024;45:3735–3747.
46. Nurmohamed NS, Bom MJ, Jukema RA, et al. AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD. *JACC Cardiovasc Imaging*. 2024;17:269–280.
47. Chan K, Wahome E, Tsiachristas A, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the OR-FAN multicentre, longitudinal cohort study. *Lancet*. 2024;403:2606–2618.
48. Antoniadou C, Tousoulis D, Vavlukis M, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. *Eur Heart J*. 2023;44:3827–3844.

#### 4.2.3.7. Primary Prevention in Adults 30 to 79 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.8–4.9 mmol/L)

1. Koch CA, Kjeldsen EW, Frikke-Schmidt R. Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. *Eur Heart J*. 2023;44:2609–2622.
2. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. *Ann Intern Med*. 2006;145:1–11.
3. Smart NA, Downes D, van der Touw T, et al. The effect of exercise training on blood lipids: a systematic review and meta-analysis. *Sports Med*. 2025;55:67–78.
4. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2020;105:dga673.
5. Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380:581–590.
6. Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol*. 2020;76:1507–1516.
7. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
8. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374:2021–2031.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*. 1998;279:1615–1622.
10. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. *Lancet*. 2006;368:1155–1163.
11. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. *JAMA Cardiol*. 2021;6:1406–1413.
12. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316:1289–1297.
13. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011;377:2181–2192.
14. Jun JE, Jeong IK, Ahn KJ, et al. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. *Eur J Prev Cardiol*. 2024;31:1205–1213.
15. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
16. Thompson W, Morin L, Jarbol DE, et al. Statin discontinuation and cardiovascular events among older people in Denmark. *JAMA Netw Open*. 2021;4:e2136802.

17. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med.* 2015;175:691–700.
18. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. *JAMA.* 2018;319:1566–1579.
19. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
20. Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. *Circulation.* 2015;131:451–458.
21. Kohli-Lynch C, Thanassoulis G, Pencina M, et al. The causal-benefit model to prevent cardiovascular events. *JACC Adv.* 2024;3:100825.
22. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2014;129(suppl 2):S1–S45
23. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
24. Chou R, Dana T, Blazina I, et al. Screening for dyslipidemia in younger adults: a systematic review for the US Preventive Services Task Force. *Ann Intern Med.* 2016;165:560–564.
25. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376:1670–1681.
26. Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J.* 2010;160:785–794 e710.
27. Banach M, Jaiswal V, Ang SP, et al. Impact of lipid-lowering combination therapy with statins and ezetimibe vs statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis. *Mayo Clin Proc.* Published online March 23, 2025. doi: 10.1016/j.mayocp.2025.01.018.
28. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA.* 1984;251:351–364.

#### 4.2.4.1. Role of Risk Assessment in HeFH

1. Perez de Isla L, Arroyo-Olivares R, Alonso R, et al. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. *Rev Esp Cardiol (Engl Ed).* 2020;73:828–834.
2. Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). *Circulation.* 2017;135:2133–2144.
3. Paquette M, Brisson D, Dufour R, et al. Cardiovascular disease in familial hypercholesterolemia: validation and refinement of the Montreal-FH-SCORE. *J Clin Lipidol.* 2017;11:1161–1167.
4. Paquette M, Bernard S, Cariou B, et al. Familial hypercholesterolemia-risk score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* 2021;41:2632–2640.
5. Gallo A, Charriere S, Vimont A, et al. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. *Atherosclerosis.* 2020;306:41–49.
6. Zhang Y, Dron JS, Bellows BK, et al. Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease. *Circulation.* 2023;147:1556–1559.
7. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. *Circulation.* 2016;134:9–19.
8. Masana L, Zamora A, Plana N, et al. Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients. *J Clin Med.* 2019;8:1080.

9. Paquette M, Dufour R, Baass A. The Montreal-FH-SCORE: a new score to predict cardiovascular events in familial hypercholesterolemia. *J Clin Lipidol.* 2017;11:80–86.

#### 4.2.4.2. Genetic Testing for FH

1. Benn M, Watts GF, Tybjaerg-Hansen A, et al. Mutations causative of familial hypercholesterolemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. *Eur Heart J.* 2016;37:1384–1394.
2. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J Am Coll Cardiol.* 2016;67:2578–2589.
3. Tada H, Kawashiri MA, Nohara A, et al. Impact of clinical signs and genetic diagnosis of familial hypercholesterolemia on the prevalence of coronary artery disease in patients with severe hypercholesterolemia. *Eur Heart J.* 2017;38:1573–1579.
4. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolemia in the Netherlands. *Lancet.* 2001;357:165–168.
5. Abul-Husn NS, Manickam K, Jones LK, et al. Genetic identification of familial hypercholesterolemia within a single US health care system. *Science.* 2016;354:aaf7000.
6. Dikilitas O, Sherafati A, Saadatagah S, et al. Familial hypercholesterolemia in the electronic medical records and genomics network: prevalence, penetrance, cardiovascular risk, and outcomes after return of results. *Circ Genom Precis Med.* 2023;16:e003816.
7. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat.* 1992;1:445–466.
8. Clarke SL, Tcheandjieu C, Hilliard AT, et al. Coronary artery disease risk of familial hypercholesterolemia genetic variants independent of clinically observed longitudinal cholesterol exposure. *Circ Genom Precis Med.* 2022;15:e003501.
9. Trinder M, Francis GA, Brunham LR. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. *JAMA Cardiol.* 2020;5:390–399.
10. Zhang Y, Dron JS, Bellows BK, et al. Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease. *Circulation.* 2023;147:1556–1559.
11. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. *Am J Cardiol.* 2008;102:1187–1193, 1193.e1.
12. Molokhia M, Wierzbicki AS, Williams H, et al. Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolemia (FH): a cross-sectional database study in Lambeth, South London. *Atherosclerosis.* 2024;388:117353.
13. Sturm AC, Truty R, Callis TE, et al. Limited-variant screening vs comprehensive genetic testing for familial hypercholesterolemia diagnosis. *JAMA Cardiol.* 2021;6:902–909.
14. Alver M, Palover M, Saar A, et al. Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. *Genet Med.* 2019;21:1173–1180.
15. Mathews L. Variation in the prevalence of familial hypercholesterolemia around the world. American College of Cardiology. Published July 17, 2015. Accessed August 10, 2025. <https://www.acc.org/Latest-in-Cardiology/Articles/2015/07/17/08/23/Variation-in-the-Prevalence-of-Familial-Hypercholesterolemia-Around-the-World>.

#### 4.2.4.3. Severe Hypercholesterolemia With LDL-C $\geq$ 190 mg/dL (4.9 mmol/L)

1. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. *Am J Cardiol.* 2012;110:823–825.
2. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med.* 1995;333:1301–1307.
3. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. *Circulation.* 2017;136:1878–1891.
4. Verschmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. *BMJ.* 2008;337:a2423.

5. Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. *J Am Coll Cardiol*. 2016;68:252–260.
6. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. *JAMA*. 2023;330:131–140.
7. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J Am Coll Cardiol*. 2016;67:2578–2589.
8. Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). *Circulation*. 2017;135:2133–2144.
9. Miname MH, Bittencourt MS, Moraes SR, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. *JACC Cardiovasc Imaging*. 2019;12:1797–1804.
10. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
11. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
12. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. *Eur Heart J*. 2015;36:2996–3003.
13. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:331–340.
14. Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. *Circulation*. 2023;354–362.
15. Orringer CE, Blaha MJ, Blankstein R, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. *J Clin Lipidol*. 2021;15:33–60.
16. Antoniazzi L, Arroyo-Olivares R, Mata P, et al. Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia. *Curr Opin Lipidol*. 2022;33:89–94.
17. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316:1289–1297.
18. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
19. Bairey Merz CN, Pepine CJ, Walsh MN, et al. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. *Circulation*. 2017;135:1075–1092.
20. Duell PB, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. *Atherosclerosis*. 2019;289:85–93.
21. Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients With homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. *Circulation*. 2024;149:354–362.
22. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
5. Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. *J Am Coll Cardiol*. 2020;76:131–142.
6. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
7. Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolemia: retrospective cohort study. *Lancet*. 2022;399:719–728.
8. Cuchel M, Lee PC, Hudgins LC, et al. Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry. *J Am Heart Assoc*. 2023;12:e029175.
9. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. *N Engl J Med*. 2020;383:711–720.
10. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316:1289–1297.
11. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*. 1995;333:1301–1307.
12. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. *Circulation*. 2017;136:1878–1891.
13. Verschmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. *BMJ*. 2008;337:a2423.
14. Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. *J Am Coll Cardiol*. 2016;68:252–260.
15. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
16. Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients With homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. *Circulation*. 2024;149:354–362.
17. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. *Circulation*. 2014;129:1022–1032.

#### 4.2.5. Diabetes in Adults Without Established ASCVD

1. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists Collaboration. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008;371:117–125.
2. de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. *Drugs*. 2012;72:2365–2373.
3. Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. *Lancet Diabetes Endocrinol*. 2024;12:19–28.
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
5. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. *Lancet Diabetes Endocrinol*. 2017;5:941–950.
6. Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol*. 2019;7:618–628.
7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
8. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316:1289–1297.
9. Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. *Circulation*. 2017;135:1979–1981.

#### 4.2.4.4. Severe Hypercholesterolemia With Clinical or Genetic Confirmation of Homozygous FH

1. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. *N Engl J Med*. 2020;382:1520–1530.
2. Wei N, Hu Y, Li S, et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolemia: a systematic review. *Rev Cardiovasc Med*. 2022;23:151.
3. Gagne C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. *Circulation*. 2002;105:2469–2475.
4. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:341–350.

10. Constantino MI, Molyneux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. *Diabetes Care*. 2013;36:3863–3869.
11. Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. *Lancet Diabetes Endocrinol*. 2016;4:115–124.
12. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. *Diabetologia*. 2008;51:1639–1645.
13. Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. *J Gen Intern Med*. 2016;31:387–393.
14. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. *Diabetes Care*. 2006;29:798–804.
15. Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. *Diab Vasc Dis Res*. 2012;9:146–152.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685–696.
17. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet*. 2003;361:2005–2016.
18. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care*. 2006;29:1478–1485.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
20. Nezarat N, Budoff MJ, Luo Y, et al. Presence, characteristics, and volumes of coronary plaque determined by computed tomography angiography in young type 2 diabetes mellitus. *Am J Cardiol*. 2017;119:1566–1571.
21. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
22. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
23. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. *JAMA*. 2023;330:131–140.
24. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. 2020;27:593–603.
25. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA*. 2016;315:1580–1590.
26. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. *J Clin Lipidol*. 2020;14:88–97.e2.
27. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. *JAMA*. 2020;324:2268–2280.
28. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
29. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
30. Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials. *Diabetes Obes Metab*. 2024;26:3223–3237.
31. Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. *Diabetes*. 2006;55:1463–1469.
32. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. *JAMA*. 2017;317:825–835.
33. Guo VY, Cao B, Wu X, et al. Prospective association between diabetic retinopathy and cardiovascular disease: a systematic review and meta-analysis of cohort studies. *J Stroke Cerebrovasc Dis*. 2016;25:1688–1695.
34. Brownrigg JR, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. *Heart*. 2014;100:1837–1843.
35. Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. *Diab Vasc Dis Res*. 2013;10:520–529.
36. Ogren M, Hedblad B, Engstrom G, et al. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study 'Men born in 1914' from Malmö, Sweden. *Eur J Vasc Endovasc Surg*. 2005;29:182–189.
37. Pang XH, Han J, Ye WL, et al. Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. *Int J Endocrinol*. 2017;2017:9620513.
38. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625

#### 4.2.6. Secondary ASCVD Prevention

1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 2015;385:1397–1405.
3. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316:1289–1297.
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
5. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
6. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
7. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
8. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. *Circulation*. 2022;146:1109–1119.
9. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. *J Am Coll Cardiol*. 2017;69:911–921.
10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*. 2020;382:1507–1519.
11. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*. 2007;357:2248–2261.
12. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;372:1231–1239.
13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
14. Goodman SG, Steg PG, Poulouin Y, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial. *J Am Heart Assoc*. 2023;12:e029216.
15. Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol*. 2020;76:1507–1516.

16. Schwartz GG, Steg PG, Szarek M, et al. Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
  17. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. *J Clin Lipidol*. 2024;18:e647–e663.
  18. Gaba P, O'Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. *Circulation*. 2023;147:1192–1203.
  19. Bhatt DL, Briggs AH, Reed SD, et al. Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial. *J Am Coll Cardiol*. 2020;75:2297–2308.
  20. Fonarow GC, van Hout B, Villa G, et al. Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. *JAMA Cardiol*. 2019;4:691–695.
  21. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. *Eur J Prev Cardiol*. 2020;27:593–603.
  22. Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. *Eur Heart J*. 2023;44:129–138.
  23. Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. *Eur J Heart Fail*. 2015;17:434–441.
- 4.2.7. Management of Adults With Subclinical Coronary Atherosclerosis (Men  $\geq 40$  or Women  $\geq 45$  Years)**
1. Peng AW, Mirbolouk M, Orimoloye OA, et al. Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC  $\geq 1,000$ : results from the CAC Consortium. *JACC Cardiovasc Imaging*. 2020;13:83–93.
  2. Peng AW, Dardari ZA, Blumenthal RS, et al. Very high coronary artery calcium ( $\geq 1000$ ) and association with cardiovascular disease events, non-cardiovascular disease outcomes, and mortality. *Circulation*. 2021;143:1571–1583.
  3. Budoff MJ, Kinnering A, Gransar H, et al. When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM Registry. *JACC Cardiovasc Imaging*. 2023;16:1181–1189.
  4. Mulders TA, Sivapalaratnam S, Stroes ES, et al. Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. *JACC Cardiovasc Imaging*. 2012;5:252–260.
  5. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). *Eur Heart J*. 2018;39:2401–2408.
  6. Dzaye O, Razavi AC, Michos ED, et al. Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial. *Atherosclerosis*. 2022;347:70–76.
  7. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. *JAMA*. 2025;333:1403–1412.
  8. Martin SS, Blaha MJ, Blankstein R, et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease. *Circulation*. 2014;129:77–86.
  9. Mitchell JD, Fergestrom N, Gage BF, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. *J Am Coll Cardiol*. 2018;72:3233–3242.
  10. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N Engl J Med*. 2008;358:1336–1345.
  11. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. *JAMA Cardiol*. 2017;2:391–399.
  12. Tota-Maharaj R, Blaha MJ, Blankstein R, et al. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. *Mayo Clin Proc*. 2014;89:1350–1359.
  13. Raygor V, Hoeting N, Ayers C, et al. Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring. *J Cardiovasc Comput Tomogr*. 2023;17:453–458.
  14. Chiles C, Duan F, Gladish GW, et al. Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods. *Radiology*. 2015;276:82–90.
  15. Sandhu AT, Rodriguez F, Ngo S, et al. Incidental coronary artery calcium: opportunistic screening of previous non-gated chest computed tomography scans to improve statin rates (NOTIFY-1 Project). *Circulation*. 2023;147:703–714.
  16. Orringer CE, Blaha MJ, Blankstein R, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. *J Clin Lipidol*. 2021;15:33–60.
  17. Fuster V, Garcia-Alvarez A, Devesa A, et al. Influence of subclinical atherosclerosis burden and progression on mortality. *J Am Coll Cardiol*. 2024;84:1391–1403.
  18. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
  19. Bohula EA, Marston NA, Ruzza A, et al. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. *Am Heart J*. 2024;269:179–190.
  20. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373:2103–2116.
  21. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. *Circulation*. 2018;138:756–766.
  22. Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. *N Engl J Med*. 2015;373:1476–1477.
  23. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
  24. Schwartz GG, Steg PG, Szarek M, et al. Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
  25. Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall). *Circulation*. 2018;137:665–679.
  26. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. *J Am Coll Cardiol*. 2005;46:166–172.
  27. Shin S, Park HB, Chang HJ, et al. Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study. *JACC Cardiovasc Imaging*. 2017;10:437–446.
  28. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
  29. Hecht HS, Cronin P, Blaha MJ, et al. 2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. *J Cardiovasc Comput Tomogr*. 2017;11:74–84.
  30. Mehta A, Rigdon J, Tattersall MC, et al. Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA. *Circ Cardiovasc Imaging*. 2021;14:e011701.
  31. Tattersall MC, Hansen SL, McClelland RL, et al. Importance of age and sex in carotid artery plaque detection and cardiovascular disease risk. *JAMA Cardiol*. 2025;10:487–491.
  32. Sillesen H, Sartori S, Sandholt B, et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. *Eur Heart J Cardiovasc Imaging*. 2018;19:1042–1050.
- 4.2.8.1. Children and Adolescents**
1. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). *JAMA*. 1995;273:1429–1435.

2. Shannon BM, Tershakovec AM, Martel JK, et al. Reduction of elevated LDL-cholesterol levels of 4- to 10-year-old children through home-based dietary education. *Pediatrics*. 1994;94:923–927.
3. Madsen MTB, Landberg R, Nielsen DS, et al. Effects of wholegrain compared to refined grain intake on cardiometabolic risk markers, gut microbiota, and gastrointestinal symptoms in children: a randomized crossover trial. *Am J Clin Nutr*. 2024;119:18–28.
4. Te Morenga L, Montez JM. Health effects of saturated and trans-fatty acid intake in children and adolescents: systematic review and meta-analysis. *PLoS One*. 2017;12:e0186672.
5. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev*. 2019;2019(11):CD006401.
6. Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. *N Engl J Med*. 2019;381:1547–1556.
7. Wu F, Juonala M, Jacobs DR Jr, et al. Childhood non-HDL cholesterol and LDL cholesterol and adult atherosclerotic cardiovascular events. *Circulation*. 2024;149:217–226.
8. Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. *N Engl J Med*. 2020;383:1317–1327.
9. Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. *J Pediatr*. 2015;166:1377–1384.
10. Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. *J Am Coll Cardiol*. 2018;72:662–680.
11. Abul-Husn NS, Manickam K, Jones LK, et al. Genetic identification of familial hypercholesterolemia within a single US health care system. *Science*. 2016;354:aaf7000.
12. de Ferranti SD, Shrader P, Linton MF, et al. Children with heterozygous familial hypercholesterolemia in the United States: data from the Cascade Screening for Awareness and Detection-FH registry. *J Pediatr*. 2021;229:70–77.
13. Schmieder RS, Kreffting J, Ates S, et al. Clinical scores fail to sufficiently identify children with familial hypercholesterolemia. *Eur J Prev Cardiol*. 2025;zwaf301.
14. Perak AM, Ning H, Kit BK, et al. Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999–2016. *JAMA*. 2019;321:1895–1905.
15. Zhang Y, Woo JG, Urbina EM, et al. Low-density lipoprotein cholesterol trajectories and prevalence of high low-density lipoprotein cholesterol consistent with heterozygous familial hypercholesterolemia in US children. *JAMA Pediatr*. 2021;175:1071–1074.
16. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. *Circulation*. 2020;141:1742–1759.
17. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol*. 2012;60:2631–2639.
18. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. *J Am Coll Cardiol*. 2015;65:1552–1561.
19. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. *JAMA*. 2014;312:1055–1057.
20. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J*. 2015;36:2425–2437.
21. Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med*. 2022;386:1877–1888.
22. Laitinen TT, Nuotio J, Rovio SP, et al. Dietary fats and atherosclerosis from childhood to adulthood. *Pediatrics*. 2020;145:e20192786.
23. Pahkala K, Laitinen TT, Niinikoski H, et al. Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up. *Lancet Child Adolesc Health*. 2020;4:359–369.
24. de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. *Circulation*. 2019;139:e603–e634.
25. Schwingshackl L, Hobl LP, Hoffmann G. Effects of low glycaemic index/low glycaemic load vs. high glycaemic index/high glycaemic load diets on overweight/obesity and associated risk factors in children and adolescents: a systematic review and meta-analysis. *Nutr J*. 2015;14:87.
26. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification: benchmarking real-world practice. *J Am Coll Cardiol*. 2016;68:2122–2123.
27. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. *J Clin Lipidol*. 2014;8:181–186.
28. Gooding HC, Gauvreau K, Bachman J, et al. Improving cardiovascular health in a pediatric preventive cardiology practice. *J Pediatr*. 2021;232:282–286.
29. Mendelson MM, Regh T, Chan J, et al. Correlates of achieving statin therapy goals in children and adolescents with dyslipidemia. *J Pediatr*. 2016;178:149–155.
30. Santos RD, Wiegman A, Caprio S, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. *JAMA Pediatr*. 2024;178:283–293.
31. Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolemia. *Eur J Prev Cardiol*. 2022;29:1361–1368.
32. Warden BA, Duell PB. Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins. *J Cardiovasc Pharmacol*. 2021;78:e157–e174.
33. Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. *J Pediatr*. 1996;129:42–49.
34. Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. *J Pediatr*. 2010;156:231–236.
35. Guirguis-Blake JM, Evans CV, Coppola EL, et al. Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2023;330:261–274.
36. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 2004;292:331–337.
37. Groselj U, Sikonja J, Mlinaric M, et al. Analysis of insulin resistance among children and adolescents in Slovenia with hypercholesterolemia after treatment with statins. *JAMA Netw Open*. 2022;5:e2231097.
38. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128:S213–S256.
39. Centers for Disease Control and Prevention. Tier 1 Genomics Applications and their Importance to Public Health. Accessed August 10, 2025. [https://archive.cdc.gov/www\\_cdc\\_gov/genomics/implementation/toolkit/tier1.htm](https://archive.cdc.gov/www_cdc_gov/genomics/implementation/toolkit/tier1.htm).
40. Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. *N Engl J Med*. 2016;375:1628–1637.
41. Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolemia: new treatments and clinical guidance. *Eur Heart J*. 2023;44:2277–2291.
42. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
43. Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. *J Pediatr*. 2009;154:869–872.
44. Bruckert E, Caprio S, Wiegman A, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. *Arterioscler Thromb Vasc Biol*. 2022;42:1447–1457.
45. Wiegman A, Greber-Platzer S, Ali S, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. *Circulation*. 2024;149:343–353.

46. Lambeau KV, McRorie JW Jr. Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy. *J Am Assoc Nurse Pract.* 2017;29:216–223.
47. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. *Br J Nutr.* 2014;112:214–219.
48. National Institutes of Health, National Library of Medicine. DailyMed - all drugs. Accessed January 15, 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>.

#### 4.2.8.2. Young Adults Ages >18 to 39 Years

1. Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. *Circulation.* 2015;131:451–458.
2. Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol.* 2020;76:1507–1516.
3. Jacobs DR Jr, Woo JG, Sinaiko AR, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med.* 2022;386:1877–1888.
4. Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. *JAMA.* 2019;321:364–373.
5. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. *Circulation.* 2016;134:9–19.
6. Zhang Y, Fletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. *JAMA Cardiol.* 2021;6:1406–1413.
7. Arora S, Stouffer GA, Kucharska-Newton AM, et al. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. *Circulation.* 2019;139:1047–1056.
8. Aggarwal R, Yeh RW, Joynt Maddox KE, et al. Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020. *JAMA.* 2023;329:899–909.
9. Wilkins JT, Ning H, Sniderman A, et al. Analysis of apoB concentrations across early adulthood and predictors for rates of change using CARDIA study data. *J Lipid Res.* 2022;63:100299.
10. Wilkins JT, Ning H, Allen NB, et al. Prediction of cumulative exposure to atherogenic lipids during early adulthood. *J Am Coll Cardiol.* 2024;84:961–973.
11. Kohli-Lynch CN, Bellows BK, Zhang Y, et al. Cost-effectiveness of lipid-lowering treatments in young adults. *J Am Coll Cardiol.* 2021;78:1954–1964.

#### 4.2.8.3. Older Adults

1. Boyd C, Smith CD, Masoudi FA, et al. Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society guiding principles on the care of older adults with multimorbidity. *J Am Geriatr Soc.* 2019;67:665–673.
2. Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in older adults with cardiovascular disease. *J Am Coll Cardiol.* 2018;71:2149–2161.
3. Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. *J Am Coll Cardiol.* 2019;73:2584–2595.
4. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet.* 2019;393:407–415.
5. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet.* 2002;360:1623–1630.
6. Yourman LC, Censer IS, Boscardin WJ, et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. *JAMA Intern Med.* 2021;181:179–185.
7. Orkaby AR, Driver JA, Ho YL, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. *JAMA.* 2020;324:68–78.
8. Thompson W, Morin L, Jarbol DE, et al. Statin discontinuation and cardiovascular events among older people in Denmark. *JAMA Netw Open.* 2021;4:e2136802.
9. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med.* 2015;175:691–700.

10. Blaha MJ, Cainzos-Achirica M, Dardari Z, et al. All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: a long-term, competing risk analysis in the Coronary Artery Calcium Consortium. *Atherosclerosis.* 2020;294:72–79.
11. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BiImage Study. *J Am Coll Cardiol.* 2016;68:881–891.
12. Raggi P, Gongora MC, Gopal A, et al. Coronary artery calcium to predict all-cause mortality in elderly men and women. *J Am Coll Cardiol.* 2008;52:17–23.
13. Yano Y, O'Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. *JAMA Cardiol.* 2017;2:986–994.
14. Joseph J, Pajewski NM, Dolor RJ, et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale. *J Am Geriatr Soc.* 2023;71:1701–1713.
15. Zoungas S, Curtis A, Spark S, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). *BMJ Open.* 2023;13:e069915.
16. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. *Circulation.* 2019;140:992–1003.
17. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. *Ann Intern Med.* 2010;152:488–496, w174.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002;360:7–22.
19. Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). *Drugs Aging.* 2011;28:681–692.
20. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetes Care.* 2006;29:2378–2384.
21. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. *JAMA Intern Med.* 2017;177:955–965.

#### 4.2.8.4. Management of Dyslipidemia in Persons Planning Pregnancy, During Pregnancy, or While Lactating

1. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. *N Engl J Med.* 2004;350:1579–1582.
2. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. *Teratology.* 1994;50:387–394.
3. Chang JC, Chen YJ, Chen IC, et al. Perinatal outcomes after statin exposure during pregnancy. *JAMA Netw Open.* 2021;4:e2141321.
4. Karadas B, Uysal N, Erol H, et al. Pregnancy outcomes following maternal exposure to statins: A systematic review and meta-analysis. *Br J Clin Pharmacol.* 2022;88:3962–3976.
5. Kroon AA, Swinkels DW, van Dongen PW, et al. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. *Metabolism.* 1994;43:1164–1170.
6. Teruel JL, Lasuncion MA, Navarro JF, et al. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. *Metabolism.* 1995;44:929–933.
7. Beigel Y, Bar J, Cohen M, et al. Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange. *Acta Obstet Gynecol Scand.* 1998;77:603–608.
8. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. *J Clin Endocrinol Metab.* 2012;97:2589–2596.
9. Botha TC, Pilcher GJ, Wolmarans K, et al. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolemia: a retrospective review of 39 pregnancies. *Atherosclerosis.* 2018;277:502–507.

10. Vaughan AS, Schieb L, Casper M. Historic and recent trends in county-level coronary heart disease death rates by race, gender, and age group, United States, 1979-2017. *PLoS One*. 2020;15:e0235839.
  11. Patel N, Mittal N, Wilkinson MJ, et al. Unique features of dyslipidemia in women across a lifetime and a tailored approach to management. *Am J Prev Cardiol*. 2024;18:100666.
  12. Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the National Lipid Association. *J Clin Lipidol*. 2024;18:e664–e684.
  13. Minsker DH, MacDonald JS, Robertson RT, et al. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. *Teratology*. 1983;28:449–456.
  14. Mauricio R, Khera A. Statin use in pregnancy: is it time for a paradigm shift? *Circulation*. 2022;145:496–498.
  15. Blaha M, Lanska M, Blaha V, et al. Pregnancy in homozygous familial hypercholesterolemia—importance of LDL-apheresis. *Atheroscler Suppl*. 2015;18:134–139.
  16. Blaha M, Veletova K, Blaha V, et al. Pregnancy in homozygous familial hypercholesterolemia—a case series. *Ther Apher Dial*. 2022;26 Suppl 1:89–96.
  17. Ogura M, Makino H, Kamiya C, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion. *Atherosclerosis*. 2016;254:179–183.
  18. Lee J, Goldberg IJ. Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction. *J Clin Lipidol*. 2008;2:63–66.
  19. Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: a practical approach for clinicians. *Obstet Med*. 2015;8:158–167.
  20. Xue RH, Wu DD, Zhou CL, et al. Association of high maternal triglyceride levels early and late in pregnancy with adverse outcomes: a retrospective cohort study. *J Clin Lipidol*. 2021;15:162–172.
  21. Tsai EC, Brown JA, Veldee MY, et al. Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: a case report. *BMC Pregnancy Childbirth*. 2004;4:27.
  22. Takaishi K, Miyoshi J, Matsumura T, et al. Hypertriglyceridemic acute pancreatitis during pregnancy: prevention with diet therapy and omega-3 fatty acids in the following pregnancy. *Nutrition*. 2009;25:1094–1097.
  23. US Food and Drug Administration. Welchol (colesevelam hydrochloride) [package insert]. Accessed March 4, 2025. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/022362s0071bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022362s0071bl.pdf).
  24. Marquis JK, Dagher R, Baker BA, et al. Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits. *Reprod Toxicol*. 2006;21:197–207.
  25. US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy, still advises most pregnant patients should stop taking statins. Accessed February 28, 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy>.
  26. Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. *Am J Obstet Gynecol*. 2016;214:720.
  27. Costantine MM, West H, Wisner KL, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. *Am J Obstet Gynecol*. 2021;225:666.e661.
  28. Akbar MIA, Azis MA, Riu DS, et al. INOVASIA study: a multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high-risk patients. *Am J Perinatol*. 2024;41:1203–1211.
  29. US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. Accessed August 25, 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy>.
  30. Lwin EMP, Leggett C, Ritchie U, et al. Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations. *Drug Des Devel Ther*. 2018;12:3645–3651.
  31. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. *J Clin Lipidol*. 2015;9:S1–S122.
  32. EVKEEZA (evinacumab-dgng) [package insert]. Regeneron Pharmaceuticals, Inc; 2023.
  33. JUXTAPIDTM (lomitapide) [package insert]. MAP, Inc.; 2012.
- #### 4.2.8.5. Considerations Based on Ancestry
1. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association. *Circulation*. 2023;148:1982–2004.
  2. Jose PO, Frank AT, Kappahn KI, et al. Cardiovascular disease mortality in Asian Americans. *J Am Coll Cardiol*. 2014;64:2486–2494.
  3. Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. *Circulation*. 2025;25:e41–e660.
  4. Kalra D, Vijayaraghavan K, Sikand G, et al. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2021;15:402–422.
  5. Li Y, Zhu A, Le A, et al. Association of acculturation with cardiovascular risk factors in Asian-American subgroups. *Am J Prev Cardiol*. 2023;13:100437.
  6. Woodruff RC, Kaholokula JK, Riley L, et al. Cardiovascular disease mortality among Native Hawaiian and Pacific Islander adults aged 35 years or older, 2018 to 2022. *Ann Intern Med*. 2024;177:1509–1517.
  7. Rodriguez CJ, Allison M, Daviglius ML, et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States. *Circulation*. 2014;130:593–625.
  8. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a Scientific Statement from the American Heart Association. *Circulation*. 2018;138:e1–e34.
  9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
  10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
  11. American Diabetes Association. Standards of medical care in diabetes—2015 abridged for primary care providers. *Clin Diabetes*. 2015;33:97–111.
  12. U. S. Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;326:736–743.
  13. Aggarwal R, Bibbins-Domingo K, Yeh RW, et al. Diabetes screening by race and ethnicity in the United States: equivalent body mass index and age thresholds. *Ann Intern Med*. 2022;175:765–773.
  14. Lee CM, Huxley RR, Wildman RP, et al. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *J Clin Epidemiol*. 2008;61:646–653.
  15. Adesoba TP, Brown CC. Trends in the prevalence of lean diabetes among US Adults, 2015-2020. *Diabetes Care*. 2023;46:885–889.
  16. Araneta MR, Kanaya AM, Hsu WC, et al. Optimum BMI cut points to screen Asian Americans for type 2 diabetes. *Diabetes Care*. 2015;38:814–820.
  17. Satish P, Sadaf MI, Valero-Elizondo J, et al. Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States. *Am J Prev Cardiol*. 2021;7:100219.
  18. Dudum R, Huang Q, Yan XS, et al. Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels. *J Am Coll Cardiol Adv*. 2024;3:100940.
  19. Pare G, Caku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. *Circulation*. 2019;139:1472–1482.
  20. George MD, McGill NK, Baker JF. Creatine kinase in the US population: Impact of demographics, comorbidities, and body composition on the normal range. *Medicine (Baltimore)*. 2016;95:e4344.
  21. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clin Pharmacol Ther*. 2005;78:330–341.

#### 4.2.8.6. Adults With Heart Failure

1. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*. 2007;357:2248–2261.
2. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;372:1231–1239.
3. Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). *Circ J*. 2013;77:917–925.
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625
5. Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. *Eur J Heart Fail*. 2015;17:434–441.
6. Al-Gobari M, Le HH, Fall M, et al. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. *PLoS One*. 2017;12:e0171168.
7. Bielecka-Dabrowa A, Bytyci I, Von Haehling S, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. *Lipids Health Dis*. 2019;18:188.
8. Sotomi Y, Hikoso S, Nakatani D, et al. Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model. *Heart*. 2023;109:1231–1240.
9. Chamberlain AM, Boyd CM, Manemann SM, et al. Risk Factors for heart failure in the community: differences by age and ejection fraction. *Am J Med*. 2020;133:e237–e248.
10. Gheorghiade M, Sopko G, De Luca L, et al. Navigating the crossroads of coronary artery disease and heart failure. *Circulation*. 2006;114:1202–1213.
11. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2014;63:2817–2827.
12. Roger VL. Epidemiology of heart failure: a contemporary perspective. *Circ Res*. 2021;128:1421–1434.
13. Rush CJ, Berry C, Oldroyd KG, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *JAMA Cardiol*. 2021;6:1130–1143.

#### 4.2.8.7. Adults With Chronic Inflammatory Diseases

1. DiGregorio H, Avenatti E, Gullapelli R, et al. Burden of atherosclerotic disease risk factors in patients with and without rheumatologic disease: a retrospective cohort study. *Am J Cardiol*. 2024;230:37–40.
2. Bello N, Meyers KJ, Workman J, et al. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. *Lupus*. 2023;32:325–341.
3. Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *Lancet*. 2022;400:733–743.
4. Weber BN, Paik JJ, Aghayev A, et al. Novel imaging approaches to cardiac manifestations of systemic inflammatory diseases: JACC Scientific Statement. *J Am Coll Cardiol*. 2023;82:2128–2151.
5. Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. *Rheumatology (Oxford)*. 2017;56:1102–1110.
6. Kiani AN, Magder LS, Post WS, et al. Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. *Rheumatology (Oxford)*. 2015;54:1976–1981.
7. Giles JT, Szklo M, Post W, et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. *Arthritis Res Ther*. 2009;11:R36.
8. An J, Alemao E, Reynolds K, et al. Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis. *J Rheumatol*. 2016;43:1989–1996.

9. Yu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. *Atherosclerosis*. 2015;243:11–18.

#### 4.2.8.8. Adults With CKD—Stage 3 or Higher

1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011;377:2181–2192.
2. Tunnicliffe DJ, Palmer SC, Cashmore BA, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev*. 2023;2023.
3. Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. *J Am Coll Cardiol*. 2019;73:2961–2970.
4. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351:1296–1305.
5. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 2009;360:1395–1407.
6. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. 2005;353:238–248.
7. Ray KK, Bloedon L, Li N, et al. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation authors' reply. *Lancet Diabetes Endocrinol*. 2024;12:228–229.
8. Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. *Mayo Clin Proc*. 2020;95:77–89.
9. Igweonu-Nwakile EO, Ali S, Paul S, et al. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. *Cureus*. 2022;14:e29140.
10. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2022;80:1366–1418.

#### 4.2.8.9. Persons Living With HIV

1. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. *N Engl J Med*. 2023;389:687–699.
2. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin Endocrinol Metab*. 2007;92:2506–2512.
3. Freiberg MS, Chang C-CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013;173:614–622.
4. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. *Aids*. 2011;25:1637–1646.
5. Longenecker CT, Sullivan C, Baker JV. Immune activation and cardiovascular disease in chronic HIV infection. *Curr Opin HIV AIDS*. 2016;11:216–225.
6. Kearns A, Gordon J, Burdo TH, et al. HIV-1-associated atherosclerosis: unraveling the missing link. *J Am Coll Cardiol*. 2017;69:3084–3098.
7. Perkins MV, Joseph SB, Dittmer DP, et al. Cardiovascular disease and thrombosis in HIV infection. *Arterioscler Thromb Vasc Biol*. 2023;43:175–191.
8. Lu MT, Ribaldo H, Foldyna B, et al. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial. *JAMA Cardiol*. 2024;9:323–334.
9. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
10. Lipitor [package insert]. Pfizer Pharmaceutical Corp; 2007.
11. Mevacor [package insert]. Merck & Co, Inc; 2014.
12. Livalo [package insert]. Kowa Pharmaceuticals; 2019.
13. Pravachol [package insert]. Bristol-Myers Squibb; 2022.
14. Crestor [package insert]. Aztra- Zeneca Pharmaceuticals; 2023.
15. Zocor [package insert]. Merck & Co, Inc; 2014.

16. Lescol, Lescol XL [package insert]. Novartis Pharmaceuticals Corp; 2012.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Accessed August 24, 2025. <https://www.ncbi.nlm.nih.gov/sites/books/NBK586306/>.
18. Sarkar S, Brown TT. Lipid disorders in people with HIV. Table 5. Interaction of antiretroviral therapy and statins. In: Feingold KR, Ahmed SF, Anawalt B, et al, editors. *Endotext*. MDText.com, Inc.; 2000. Accessed November 21, 2025. [https://www.ncbi.nlm.nih.gov/books/NBK567198/table/lipid\\_hiv.Tinteraction\\_of\\_antiretrovira](https://www.ncbi.nlm.nih.gov/books/NBK567198/table/lipid_hiv.Tinteraction_of_antiretrovira).

#### 4.2.8.10. Adults With Cancer or History of Cancer

1. Ramin C, Schaeffer ML, Zheng Z, et al. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. *J Natl Cancer Inst*. 2021;113:137–145.
2. Madhav K, Fan J, Hyslop T, et al. Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US. *JAMA Network Open*. 2023;6:e2323115.
3. Stoltzfus KC, Zhang Y, Sturgeon K, et al. Fatal heart disease among cancer patients. *Nat Commun*. 2020;11:2011.
4. Gon Y, Zha L, Sasaki T, et al. Heart disease mortality in cancer survivors: a population-based study in Japan. *J Am Heart Assoc*. 2023;12:e029967.
5. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. *N Engl J Med*. 2012;367:1792–1802.
6. Overholser LS, Callaway C. Preventive health in cancer survivors: what should we be recommending? *J Natl Compr Canc Netw*. 2018;16:1251–1258.
7. Stepien K, Nowak K, Kachnic N, et al. Statin use in cancer patients with acute myocardial infarction and its impact on long-term mortality. *Pharmaceuticals (Basel)*. 2022;15:919.
8. Yourman LC, Cenzer IS, Boscardin WJ, et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. *JAMA Intern Med*. 2021;181:179–185.
9. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med*. 2015;175:691–700.
10. Felix N, Nogueira PC, Silva IM, et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials. *Eur J Intern Med*. 2024;126:43–48.
11. Chidwick K, Strongman H, Matthews A, et al. Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink. *BMC Cancer*. 2018;18:1018.
12. Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. *Blood*. 2022;139:165–176.
13. Juarez D, Buonò R, Matulis SM, et al. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors. *Cancer Res Commun*. 2023;3:2497–2509.
14. Lim WJ, Lee M, Oh Y, et al. Statins decrease programmed death-ligand 1 (Pd-1) by inhibiting akt and  $\beta$ -catenin signaling. *Cells*. 2021;10:2488.
15. Dang Y, Zhang Y, Wang Z. The role of statins in the regulation of breast and colorectal cancer and future directions. *Front Pharmacol*. 2025;16:1578345.
16. Roy S, Saad F, Sun Y, et al. Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: exploratory analysis of the SPARTAN trial. *Eur J Cancer*. 2024;211:114197.
17. Lu YC, Huang DW, Chen PT, et al. Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. *Breast Cancer Res Treat*. 2021;185:773–783.
18. Bowles EJA, Yu O, Ziebell R, et al. Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. *BMC Cancer*. 2019;19:270.
19. Brannvall E, Eloranta S, Ekberg S, et al. Statin use and prognosis in 12;865 non-Hodgkin lymphoma patients treated in the rituximab-era. *Hematol Oncol*. 2017;35:230–232.
20. Mohammadi KA, Brackin T, Schwartz GG, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: a pooled, post hoc, competing risk analysis of alirocumab clinical trials. *Cancer Med*. 2023;12:16859–16868.
21. Lund JL, Gupta P, Amin KB, et al. Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts. *J Geriatr Oncol*. 2021;12:72–79.

#### 4.2.9. Management of Hypertriglyceridemia

1. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320–328.
2. Hasan B, Nayfeh T, Alzuabi M, et al. Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2020;105:dga673.
3. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. *Sports Med*. 2004;34:371–418.
4. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
5. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. Odyssey Outcomes Committee Investigators. *N Engl J Med*. 2018;379:2097–2107.
6. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
7. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. *N Engl J Med*. 2024;390:1781–1792.
8. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med*. 2025;392:127–137.
9. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22.
10. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*. 2007;369:1090–1098.
11. Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT equations. *Circulation*. 2024;149:430–449.
12. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. *J Cardiovasc Risk*. 1997;4:385–391.
13. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78:960–993.
14. Wilkins JT, Li RC, Sniderman A, et al. Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. *J Am Coll Cardiol*. 2016;67:193–201.
15. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. *J Clin Lipidol*. 2024;18:e647–e663.
16. Glavinovic T, Thanassoulis G, de Graaf J, et al. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk. *J Am Heart Assoc*. 2022;11:e025858.
17. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet*. 2013;45:1345–1352.
18. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J*. 2015;36:539–550.
19. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J Cardiovasc Risk*. 1996;3:213–219.
20. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. *Curr Opin Lipidol*. 2009;20:497–504.
21. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366:1849–1861.
22. Accord Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563–1574.
23. Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). *Circulation*. 2001;103:2828–2833.

24. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. *N Engl J Med*. 2022;387:1923–1934.
  25. Ginsberg HN. Effects of statins on triglyceride metabolism. *Am J Cardiol*. 1998;81:32B–35B.
  26. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. *Int J Obes Relat Metab Disord*. 1997;21:S5–S9.
  27. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678
  28. Brahm AJ, Hegele RA. Chylomicronaemia: current diagnosis and future therapies. *Nat Rev Endocrinol*. 2015;11:352–362.
  29. Falko JM. Familial chylomicronemia syndrome: a clinical guide for endocrinologists. *Endocr Pract*. 2018;24:756–763.
  30. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score". *Atherosclerosis*. 2018;275:265–272.
  31. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. *N Engl J Med*. 2019;380:23–32.
  32. Ascend Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. *N Engl J Med*. 2018;379:1540–1550.
  33. Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. *Circulation*. 2021;143:528–539.
  34. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association. *Circulation*. 2023;148:1982–2004.
  35. National Lipid Association. North American Familial Chylomicronemia Calculator or NAFCS Scoring Tool. Accessed August 31, 2025. <https://www.lipid.org/nla/north-american-familial-chylomicronemia-calculator-or-nafcs-scoring-tool>.
  36. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol*. 2011;5:338–367.
  37. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
- 4.2.10. Approach to Patients With Elevated Lp(a)**
1. de Boer LM, Oorthuys AOJ, Wiegman A, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2022;29:779–792.
  2. Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study. *Atherosclerosis*. 2017;256:47–52.
  3. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. 2014;129:635–642.
  4. Ray KK, Vallejo-Vaz AJ, Ginsberg HN, et al. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials. *Atherosclerosis*. 2019;288:194–202.
  5. Sturzebecher PE, Schorr JJ, Klebs SHG, et al. Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses. *Atherosclerosis*. 2023;367:24–33.
  6. O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. *Circulation*. 2019;139:1483–1492.
  7. Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. *J Am Coll Cardiol*. 2020;75:133–144.
  8. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J*. 2022;43:3925–3946.
  9. Shiyovich A, Berman AN, Besser SA, et al. Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the Mass General Brigham Lp(a) registry. *J Am Heart Assoc*. 2024;13:e034493.
  10. Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet*. 2018;392:1311–1320.
  11. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. *Arterioscler Thromb Vasc Biol*. 2021;41:465–474.
  12. Gianos E, Duell PB, Toth PP, et al. Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a Scientific Statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2024;44:e304–e321.
  13. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. *Atherosclerosis*. 2009;203:371–376.
  14. Lacaze P, Bakshi A, Riaz M, et al. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. *J Am Coll Cardiol*. 2022;80:1287–1298.
- 4.2.11. Management of Statin-Attributed Muscle Symptoms**
1. Rosenson RS, Miller K, Bayliss M, et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. *Cardiovasc Drugs Ther*. 2017;31:179–186.
  2. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. *J Am Coll Cardiol*. 2017;69:1386–1395.
  3. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med*. 2023;388:1353–1364.
  4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397.
  5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722.
  6. Schwartz GG, Steg PG, Szarek M, et al. Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.
  7. Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. *JAMA*. 2023;330:131–140.
  8. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol*. 2015;9:758–769.
  9. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA*. 2016;315:1580–1590.
  10. McQuillan B, Wright R, Kallend D, et al. Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). *Heart Lung Circ*. 2023;32:S299.
  11. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2015;66:1657–1668.
  12. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. *JAMA*. Published online March 5, 2025. doi: 10.1001/jama.2025.0584.
  13. Cholesterol Treatment Trialists Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet*. 2022;400:832–845.
  14. Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. *Eur Heart J*. 2022;43:3213–3223.
  15. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. *Ann Pharmacother*. 2013;47:398–404.
  16. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107.

17. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial. *JAMA*. 2025;333:1403–1412.
18. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
19. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015;36:1012–1022.

### 5.1. Medication Safety and Therapy-Associated Side Effects

1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013;2013:CD004816.
2. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. *BMJ*. 2021;374:n1537.
3. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA*. 2016;315:1580–1590.
4. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol*. 2015;9:758–769.
5. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*. 2012;380:565–571.
6. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet*. 2010;375:735–742.
7. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. *Am J Cardiol*. 2013;111:1123–1130.
8. Cholesterol Treatment Trialists' Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. *Lancet Diabetes Endocrinol*. 2024;12:306–319.
9. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet*. 2010;376:1916–1922.
10. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. *Am J Gastroenterol*. 2011;106:71–77.
11. Yun B, Park H, Lee J, Kim BK, Yoon JH. Statin use and liver-related prognosis among patients with MASLD. *JHEP Rep*. 2025;7:101313.
12. Brill F, Portillo Sanchez P, Lomonaco R, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. *J Clin Endocrinol Metab*. 2017;102:2950–2961.
13. Yun B, Park H, Lee J, et al. Statin use and liver-related prognosis among patients with MASLD. *JHEP Rep*. 2025;7:101313.
14. Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. *Atherosclerosis*. 2015;238:329–335.
15. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. *Mayo Clin Proc*. 2015;90:24–34.
16. Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. *J Am Heart Assoc*. 2018;7:e009835.
17. Chen W, Ochs-Balcom HM, Ma C, et al. Coenzyme Q10 supplementation for the treatment of statin-associated muscle symptoms. *Future Cardiol*. 2022;18:461–470.
18. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. *Am Heart J*. 2014;168:6–15.
19. Cholesterol Treatment Trialists Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet*. 2022;400:832–845.
20. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 2-28-2012. Accessed March 1, 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs#sa>.
21. Reuben A, Koch DG, Lee WM, et al. Drug-induced acute liver failure: results of a US multicenter, prospective study. *Hepatology*. 2010;52:2065–2076.
22. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016;388:2532–2561.
23. Wang Y, Zhan S, Du H, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. *BMJ Med*. 2022;1:e000134.
24. Mu G, Xiang Q, Zhou S, et al. Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials. *Adv Ther*. 2020;37:1496–1521.
25. Mirghani H, Albalawi BH, Alshehri MS, et al. The efficacy and safety of inclisiran for low-density lipoprotein (LDL) in patients with atherosclerotic cardiovascular disease (ASCVD): a systematic review of randomized controlled trials. *Cureus*. 2024;16:e70411.
26. Lin Y, Parco C, Karathanos A, et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. *BMJ Open*. 2022;12:e048893.
27. Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. *Eur Heart J*. 2022;43:3213–3223.
28. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA*. 2011;305:2556–2564.
29. Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17:19–39.
30. Mammen AL. Statin-associated autoimmune myopathy. *N Engl J Med*. 2016;374:664–669.
31. Goldfarb MJ, Saylor MA, Bozkurt B, et al. Patient-centered adult cardiovascular care: a Scientific Statement from the American Heart Association. *Circulation*. 2024;149:e1176–e1188.
32. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. *J Am Coll Cardiol*. 2015;65:1361–1368.
33. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. *Ann Intern Med*. 2014;160:301–310.
34. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. *J Am Coll Cardiol*. 2016;67:2395–2410.
35. Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. *Ann Intern Med*. 2013;159:688–697.
36. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81:492–542.
37. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology*. 2004;126:1287–1292.
38. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. *Int J Cardiol*. 2013;168:3846–3852.
39. Bea S, Oh IS, Kim JH, et al. High-intensity statin reduces the risk of mortality among chronic liver disease patients with atherosclerotic cardiovascular disease: a population-based cohort study. *J Am Heart Assoc*. 2023;12:e028310.
40. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015;36:1012–1022.
41. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. *Circulation*. 2013;127:96–103.

42. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374:2021–2031.
43. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.
44. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. *Clin Liver Dis*. 2007;11:597–613, vii.
45. Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. *Gastroenterol Hepatol (N Y)*. 2013;9:605–606.
46. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. *J Hepatol*. 2012;56:374–380.
47. National Institute of Health, National Library of Medicine. DailyMed - All Drugs. Accessed June 13, 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>.
48. US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins: Breastfeeding not recommended in patients who require statins. 7-20-2021 FDA Drug Safety Communication. Accessed March 1, 2025. <https://www.fda.gov/media/150774/download?attachment>.

## 5.2. Statin-Cardiovascular Drug Interactions

1. Kellick KA, Bottorff M, Toth PP, et al. A clinician's guide to statin drug-drug interactions. *J Clin Lipidol*. 2014;8:S30–S46.
2. Lamprecht DG Jr, Saseen JJ, Shaw PB. Clinical conundrums involving statin drug-drug interactions. *Prog Cardiovasc Dis*. 2022;75:83–89.
3. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2016;134:e468–e495.
4. Damiani I, Corsini A, Bellosa S. Potential statin drug interactions in elderly patients: a review. *Expert Opin Drug Metab Toxicol*. 2020;16:1133–1145.
5. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2019;39:e38–e81.
6. Mease J, Ramamoorthy A, Yang X, et al. Statin drug-drug interactions: pharmacokinetic basis of FDA labeling recommendations and comparison across common tertiary clinical resources. *J Clin Pharmacol*. 2024;64:704–712.
7. Lescol, Lescol XL [package insert]. Novartis Pharmaceuticals Corp; 2012.
8. Mevacor [package insert]. Merck & Co, Inc; 2014.
9. Zocor [package insert]. Merck & Co, Inc; 2014.
10. Lipitor [package insert]. Pfizer Pharmaceutical Corp; 2007.
11. Livalo [package insert]. Kowa Pharmaceuticals; 2019.
12. Pravachol [package insert]. Bristol-Myers Squibb; 2022.
13. Crestor [package insert]. Aztra-Zeneca Pharmaceuticals; 2023.

## 6.1. Limitations and Knowledge Gaps

1. Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. *Circulation*. 2023;147:1471–1487.

2. Elder P, Sharma G, Gulati M, et al. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. *Am J Prev Cardiol*. 2020;2:100028.
3. Agarwala A, Michos ED, Samad Z, et al. The use of sex-specific factors in the assessment of women's cardiovascular risk. *Circulation*. 2020;141:592–599.
4. Cho L, Davis M, Elgendy I, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75:2602–2618.
5. Freaney PM, Khan SS, Lloyd-Jones DM, et al. The role of sex-specific risk factors in the risk assessment of atherosclerotic cardiovascular disease for primary prevention in women. *Curr Atheroscler Rep*. 2020;22:46.


## 6.2. Randomized Controlled Trials

1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–1681.

## 6.3. Improving Cardiovascular Risk Assessment


1. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*. 2019;73:3153–3167.
2. Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association's PREVENT equations. *Circulation*. 2024;149:430–449.
3. Mishra A, McClelland RL, Inoue LYT, et al. Recalibration methods for improved clinical utility of risk scores. *Med Decis Making*. 2022;42:500–512.
4. Pennells L, Kaptoge S, Wood A, et al. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. *Eur Heart J*. 2019;40:621–631.
5. Swaminathan A, Srivastava U, Tu L, et al. Against reflexive recalibration: towards a causal framework for addressing miscalibration. *Diagn Progn Res*. 2025;9:4.
6. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2015;66:1657–1668.
7. Lloyd-Jones DM, Huffman MD, Karmali KN, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*. 2017;69:1617–1636.
8. Blue L, Kranker K, Markovitz AR, et al. Effects of the Million Hearts model on myocardial infarctions, strokes, and Medicare spending: a randomized clinical trial. *JAMA*. 2023;330:1437–1447.
9. Tajew GS, Joynt Maddox K, Brewer LC. Million Hearts cardiovascular disease risk reduction model. *JAMA*. 2023;330:1430–1432.
10. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention. *J Am Coll Cardiol*. 2015;65:1361–1368.
11. Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communication for cardiovascular disease prevention. *Curr Opin Cardiol*. 2016;31:537–544.

**Appendix 1. Writing Committee Relationships With Industry and Other Entities– 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APH/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia**

| Committee Member              | Employment   | Consultant   | Speakers Bureau               | Ownership/ Partnership/ Principal      | Personal Research  | Institutional, Organizational, or Other Financial Benefit                                    | Expert Witness |
|-------------------------------|--|--|-------------------------------|--|--|--|----------------|
| Roger S. Blumenthal (Chair)   | Johns Hopkins Medicine–Professor of Medicine   | None   | None                          | None                                   | None   | None   | None           |
| Pamela B. Morris (Vice-Chair) | Medical University of South Carolina–Professor of Medicine   | None   | None                          | None                                   | None   | NOT RELEVANT<br>• Cardiometabolic Health Congress  | None           |
| Timothy S. Anderson           | University of Pittsburgh–Assistant Professor of Medicine; VA Pittsburgh Healthcare System–Physician Health Services Researcher | NOT RELEVANT<br>• AMSA Foundation*   | None                          | None                                   | NOT RELEVANT<br>• AHA*<br>• NIA*   | NOT RELEVANT<br>• JAMA Internal Medicine   | None           |
| Vera A. Bittner               | University of Alabama–Professor of Medicine  | None   | None                          | None                                   | NOT RELEVANT<br>• Eli Lilly (DSMB)†<br>• NIA*<br>• Verve Therapeutics (DSMB)*<br>RELEVANT<br>• Amgen*<br>• Novartis* | NOT RELEVANT<br>• ACC Foundation*<br>• ASCP<br>• NIH*<br>• NLA RELEVANT<br>• Sanofi          | None           |
| Ron Blankenstein              | Brigham and Women’s Hospital–Senior Physician and Director, Cardiac Computed Tomography  | NOT RELEVANT<br>• HeartFlow*<br>RELEVANT<br>• Amgen<br>• Caristo Diagnostics<br>• Nanox AI<br>• Novartis | None                          | None                                   | RELEVANT<br>• Amgen*<br>• Novartis*  | None<br> | None           |
| LaPrincess C. Brewer          | Mayo Clinic–Associate Professor of Medicine  | NOT RELEVANT<br>• Bristol Myers Squibb Foundation  | None                          | None                                   | NOT RELEVANT<br>• AHA*<br>• Miami Heart Research Institute*<br>• NIDDK*<br>• NIMHD*<br>• PCORI*                      | None   | None           |
| Leslie Cho                    | Cleveland Clinic–Section Head, Prevention and Cardiac Rehab  | NOT RELEVANT<br>• Idorsia<br>RELEVANT<br>• AstraZeneca<br>• Esperion                                     | RELEVANT<br>• Daiichi Sankyo* | NOT RELEVANT<br>• Belvoir Media Group* | RELEVANT<br>• Eli Lilly (PI)*<br>• Esperion (Steering Committee)†<br>• Novartis (Executive Committee, Co-PI)*        | None   | None           |
| Sarah D. de Ferranti          | Boston Children’s Hospital–Senior Associate Cardiologist   | None   | None                          | NOT RELEVANT<br>• UpToDate*            | NOT RELEVANT<br>• Family Heart Foundation*<br>• NHLBI*   | NOT RELEVANT<br>• Family Heart Foundation/ Regeneron†  | None           |
| Mario Gaudino (JC Liaison)    | Weill Cornell Medicine–Stephen and Suzanne Weiss Professor of Cardiothoracic Surgery   | None   | None                          | None                                   | NOT RELEVANT<br>• NIH Clinical Center*<br>• PCORI*   | None   | None           |
| Eugenia Gianos                | Northwell Health–Director, Cardiovascular Prevention   | NOT RELEVANT<br>• Cardiometabolic Center Alliancet   | None                          | None                                   | NOT RELEVANT<br>RELEVANT<br>• Amgen<br>• Lilly<br>• Novartis   | None   | None           |


(Continued)

## Appendix 1. Continued

| Committee Member                | Employment  | Consultant  | Speakers Bureau          | Ownership/ Partnership/ Principal                                  | Personal Research  | Institutional, Organizational, or Other Financial Benefit  | Expert Witness |
|---------------------------------|---|---|--------------------------|--|--|--|----------------|
| Ty J. Gluckman                  | Providence Heart Clinic—Cardiologist  | NOT RELEVANT<br>• Optum Rx*   | None                     | None   | NOT RELEVANT<br>• Edwards Lifesciences*<br>• Pfizer*<br>RELEVANT<br>• Amgen*                     | None   | None           |
| Kristen Gradney                 | LCMC Health—Chief Wellness Officer  | None  | None                     | None   | None   | NOT RELEVANT<br>• AHA†   | None           |
| Ijeoma Isiadinso                | Emory University School of Medicine—Professor of Medicine   | None  | None                     | None   | NOT RELEVANT<br>• Abbott Laboratories (DSMB)†<br>• University of Texas at Houston (DSMB)         | NOT RELEVANT<br>• Eli Lilly<br>• Novartis<br>• University of Florida<br>• Women Heart  | None           |
| Heather M. Johnson (JC Liaison) | Baptist Health South Florida—North Medical Group—Director of Preventive Cardiology for Women's Services   | NOT RELEVANT<br>• Medtronic<br>• Vasculearn Network†<br>RELEVANT<br>• Amgen<br>• Esperion*<br>• Novartis  | RELEVANT<br>• Esperion*  | None   | None   | None   | None           |
| Donald M. Lloyd-Jones           | Northwestern University—Professor of Preventive Medicine, Medicine, and Pediatrics, and Chair, Department of Preventive Medicine                                  | None  | None                     | None   | NOT RELEVANT<br>• NIH*   | NOT RELEVANT<br>• AHA<br>  | None           |
| Joel C. Marrs                   | University of Tennessee Health Science Center—Professor and Coordinator of Clinical Outreach; University of Colorado Denver—Visiting Clinical Associate Professor | None  | None                     | None   | None   | None   | None           |
| Seth S. Martin                  | Johns Hopkins Medicine—Professor of Medicine  | NOT RELEVANT<br>• Boehringer Ingelheim<br>• Care Access<br>• Chroma Medicine<br>• HeartFlow<br>• Premier Healthcare<br>• Verve Therapeutics<br>RELEVANT<br>• Amgen<br>• Arrowhead Pharmaceuticals<br>• AstraZeneca<br>• Kaneka Pharma<br>• Merck<br>• NewAmsterdam Pharma<br>• Novartis<br>• Sanofi | NOT RELEVANT<br>• Pfizer | NOT RELEVANT<br>• Prevent Medical*<br>RELEVANT<br>• Corrie Health* | NOT RELEVANT<br>• ACC Foundation (PI)*<br>• AHA*<br>• NIH (DSMB)<br>• NIH (PI)*<br>• PCORI (PI)* | NOT RELEVANT<br>• AHA (PI)†<br>• American Journal of Preventive Cardiology<br>• European Journal of Preventive Cardiology<br>• Journal of Clinical Lipidology<br>• NLA | None           |

(Continued)

**Appendix 1. Continued**

| Committee Member    | Employment  | Consultant   | Speakers Bureau | Ownership/ Partnership/ Principal   | Personal Research   | Institutional, Organizational, or Other Financial Benefit  | Expert Witness |
|---------------------|---|--|-----------------|---|---|--|----------------|
| Kellie H. McLain    | Medical University of South Carolina—Adult Nurse Practitioner   | RELEVANT<br>• Esperion<br>• NewAmsterdam Pharma  | None            | None  | None  | None   | None           |
| Laxmi S. Mehta      | Ohio State University—Professor of Cardiovascular Medicine  | None   | None            | None  | None  | NOT RELEVANT<br>• ACC Foundation†<br>• AHA<br>• Healthcare Professional Well-being Academic Consortium†<br>• Ohio Government Resource Center<br>• NLA† | None           |
| Samia Mora          | Brigham and Women’s Hospital—Associate Physician  | NOT RELEVANT<br>• Medscape Education   | None            | None  | NOT RELEVANT<br>• NHLBI*<br>• NIDDK                                 | NOT RELEVANT<br>• AHA*<br>• Health Effects Institute*<br>• International Atherosclerosis Society†<br>• Medscape Education                              | None           |
| Wudeneh M. Mulugeta | Kaiser Permanente—Internal Medicine and Obesity Medicine Physician; Cambridge Health Alliance—Obesity Medicine Physician; Harvard Medical School—Instructor | None   | None            | None  | None  | NOT RELEVANT<br>• <i>Obesity Pillars</i><br>                       | None           |
| Pradeep Natarajan   | Massachusetts General Hospital—Director of Preventive Cardiology  | NOT RELEVANT<br>• Bain Capital, LP<br>• Blackstone Life Sciences<br>• Creative Educational Concepts<br>• CRISPR Therapeutics<br>• Foresite Capital<br>• Foresite Labs<br>• Genentech*<br>• GV<br>• HeartFlow<br>• Magnet Biomedicine<br>• TenSixteen Bio*<br>• Tourmaline Bio<br>RELEVANT<br>• Allelica<br>• AstraZeneca<br>• Bristol-Myers Squibb<br>• Eli Lilly<br>• Esperion<br>• Merck<br>• Novartis<br>• Novo Nordisk<br>• Precisel | None            | NOT RELEVANT<br>• Bolt<br>• TenSixteen Bio<br>• The Regents of the University of California<br>RELEVANT<br>• MyOme<br>• Preciseli | NOT RELEVANT<br>• Genentech*<br>RELEVANT<br>• Allelica*<br>• Amgen* | NOT RELEVANT<br>• Vertex Pharmaceuticals (Spouse)  | None           |

(Continued)

## Appendix 1. Continued

| Committee Member    | Employment  | Consultant  | Speakers Bureau | Ownership/ Partnership/ Principal                                      | Personal Research  | Institutional, Organizational, or Other Financial Benefit  | Expert Witness |
|---------------------|---|---|-----------------|--|--|--|----------------|
| Ann Marie Navar     | UT Southwestern—Associate Professor   | NOT RELEVANT <ul style="list-style-type: none"> <li>Boehringer Ingelheim</li> <li>Bristol Myers Squibb</li> <li>Genentech*</li> <li>Idorsia (spouse)*</li> <li>Pfizer</li> </ul> RELEVANT <ul style="list-style-type: none"> <li>Amgen*</li> <li>Arrowhead Pharmaceuticals</li> <li>AstraZeneca</li> <li>Bayer*</li> <li>Eli Lilly*</li> <li>Esperion*</li> <li>Johnson &amp; Johnson*</li> <li>Merck*</li> <li>Miga Health</li> <li>NewAmsterdam Pharma*</li> <li>Novartis</li> <li>Novo Nordisk*</li> <li>Sanofi</li> <li>Silence Therapeutics</li> </ul> | None            | RELEVANT <ul style="list-style-type: none"> <li>Miga Health</li> </ul> | NOT RELEVANT <ul style="list-style-type: none"> <li>Arrowhead Pharmaceuticals (DSMB)</li> <li>Boston Scientific (DSMB, spouse)*</li> <li>Eli Lilly*</li> </ul> RELEVANT <ul style="list-style-type: none"> <li>Amgen</li> <li>Amgen (Co-PI, spouse)*</li> <li>Esperion</li> <li>Esperion (Co-PI, spouse)*</li> <li>Johnson &amp; Johnson (spouse)*</li> <li>Merck*</li> <li>NewAmsterdam*</li> <li>Novartis</li> <li>Novo Nordisk</li> <li>Silence Therapeutics</li> </ul> | NOT RELEVANT <ul style="list-style-type: none"> <li>ASPC†</li> <li>JAMA Cardiology</li> </ul>  | None           |
| Carl E. Orringer    | Naples Comprehensive Health—Cardiologist  | None  | None            | None   | None   | NOT RELEVANT <ul style="list-style-type: none"> <li>European Heart Journal†</li> <li>Case Western Reserve University School of Medicine</li> </ul>   | None           |
| Tamar S. Polonsky   | University of Chicago Medicine—Associate Professor of Medicine                        | None  | None            | None   | NOT RELEVANT <ul style="list-style-type: none"> <li>NHLBI*</li> <li>NIA*</li> </ul>  | None   | None           |
| Harmony R. Reynolds | NYU Grossman School of Medicine—Professor   | NOT RELEVANT <ul style="list-style-type: none"> <li>HeartFlow</li> </ul>  | None            | None   | NOT RELEVANT <ul style="list-style-type: none"> <li>Abbott Vascular</li> <li>AHA*</li> <li>Doris Duke Charitable Foundation</li> <li>NHLBI*</li> <li>Philips</li> <li>SHL Telemedicine</li> <li>Siemens*</li> </ul>  | None   | None           |
| Joseph J. Saseen    | University of Colorado—Professor of Clinical Pharmacy                                 | None  | None            | None   | NOT RELEVANT <ul style="list-style-type: none"> <li>Amgen (DSMB)</li> </ul>  | None   | None           |
| Michael D. Shapiro  | Wake Forest University—Fred M. Parrish Professor of Cardiology and Molecular Medicine | NOT RELEVANT <ul style="list-style-type: none"> <li>Agepha</li> <li>Tourmaline</li> </ul> RELEVANT <ul style="list-style-type: none"> <li>Amgen</li> <li>Arrowhead</li> <li>Esperion</li> <li>Ionis*</li> <li>Merck</li> <li>NewAmsterdam Pharma</li> <li>Novartis*</li> <li>Novo Nordisk</li> <li>Regeneron*</li> </ul>  | None            | None   | None   | NOT RELEVANT <ul style="list-style-type: none"> <li>Amgen*</li> <li>Arrowhead*</li> <li>Cleery*</li> <li>Eli Lilly*</li> <li>Esperion*</li> <li>Ionis*</li> <li>Merck*</li> <li>NewAmsterdam Pharma*</li> <li>Novartis*</li> </ul> | None           |

(Continued)

Appendix 1. Continued

| Committee Member   | Employment  | Consultant   | Speakers Bureau     | Ownership/ Partnership/ Principal                          | Personal Research   | Institutional, Organizational, or Other Financial Benefit   | Expert Witness                               |
|--------------------|---|--|---------------------|--|---|---|--|
| Daniel E. Soffer   | Penn Medicine—Associate Professor of Medicine                         | NOT RELEVANT<br>• HeartFlow<br>RELEVANT<br>• Amryt Pharma<br>• Endless Health†<br>• GENinCodet<br>• Ionis Pharmaceuticals<br>• NewAmsterdam<br>• Regeneron | RELEVANT<br>• Ionis | NOT RELEVANT<br>• Partnership for Health Analytic Research | NOT RELEVANT<br>• Amgen (DSMB)  | NOT RELEVANT<br>• Akcea Therapeutics<br>• Amgen<br>• Amryt Pharma<br>• HeartFlow*<br>• Ionis Pharmaceuticals<br>• NIH<br>• Lilly USA<br>• Novartis<br>• PCORI*<br>• Regeneron<br>• Verve Therapeutics | Reviewer for plaintiff, 2024/2025            |
| Sheila A. Tynes    | Tynes Consulting Services, LLC—President/Owner                        | None   | None                | None   | None  | None  | None   |
| Chloé D. Villavaso | Tulane University—Instructor of Medicine                              | None   | None                | None   | None  | NOT RELEVANT<br>• Novartis<br>• PCNA†   | None   |
| Salim S. Virani    | Aga Khan University—Professor and Vice Provost, Research              | None   | None                | None   | NOT RELEVANT<br>• NIH*<br>• NIHR*<br>• Tahir and Jooma Family*<br>• Asharia Family Endowment*<br>• US Department of Veterans Affairs* | NOT RELEVANT<br>• <i>Current Atherosclerosis Reports</i><br>• <i>Current Cardiology Reports</i><br>• <i>Journal of Clinical Lipidology</i><br><small>American Heart Association</small>               | None   |
| John T. Wilkins    | Northwestern Medicine Feinberg School of Medicine—Associate Professor | NOT RELEVANT<br>• 3M*  | None                | None   | NOT RELEVANT<br>• NIH*  | None  | NOT RELEVANT<br>• Defense, malpractice, 2024 |

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.

ABC indicates Association of Black Cardiologists; ACC, American College of Cardiology; ADA, American Diabetes Association; AHA, American Heart Association; AMSA, American Medical Student Association; ASPC, American Society of Preventive Cardiology; DSMB, data and safety monitoring board; NHLBI, National Heart, Lung, and Blood Institute; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; NIHR, National Institute for Health and Care Research; NIMHD, National Institute on Minority Health and Health Disparities; NLA, National Lipid Association; PCNA, Preventive Cardiovascular Nurses Association; and PCORI, Patient-Centered Outcomes Research Institute.

**Appendix 2. Peer Review Committee Relationships With Industry and Other Entities—2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia**

| Reviewer                | Representation           | Consultant   | Speakers Bureau | Ownership/ Partnership/ Principal | Personal Research   | Institutional, Organizational, or Other Financial Benefit  | Expert Witness   |
|-------------------------|--------------------------|--|-----------------|-----------------------------------|---|--|--|
| Anand Rohatgi, Co-chair | AHA Official Reviewer    | <ul style="list-style-type: none"> <li>• Pozman University of Medical Sciences*</li> <li>• Raydel</li> <li>• Sansar</li> </ul>                         | None            |                                   | None  | <ul style="list-style-type: none"> <li>• Circulation*</li> <li>• CSL Behring*</li> <li>• Eli Lilly and Company†</li> <li>• NIH*</li> </ul>   | None   |
| Samuel M. Kim, Co-chair | ACC Official Reviewer    | None   | None            | None                              | None  | <ul style="list-style-type: none"> <li>• Amgen‡</li> <li>• Novartis‡</li> <li>• Novo Nordisk‡</li> <li>• Silence Pharmaceuticals‡</li> </ul>   | None   |
| Karen P. Alexander      | ACC Content Reviewer     | None   | None            | None                              | None  | <ul style="list-style-type: none"> <li>• National Institute on Aging *</li> </ul>  | None   |
| Cheryl Anderson         | AHA/ACC Content Reviewer | <ul style="list-style-type: none"> <li>• AstraZeneca</li> <li>• Dal-cor (Spouse)</li> <li>• Intellia (Spouse)</li> <li>• Merck</li> </ul>              | None            | None                              | NHLBI (DSMB)  | <ul style="list-style-type: none"> <li>• ADA*</li> <li>• AHA*</li> <li>• AHA (Spouse)*</li> <li>• McCormick Foundation*</li> <li>• NHLBI*</li> <li>• WW International*</li> </ul>  | None   |
| Catherine P. Benziger   | ACC Content Reviewer     | <ul style="list-style-type: none"> <li>• Novartis*</li> </ul>  | None            | None                              | None  | <ul style="list-style-type: none"> <li>• Agency for Healthcare Research and Quality*</li> <li>• Amgen†</li> <li>• NIH†</li> <li>• Novartis*</li> </ul>   | None   |
| Dave L. Dixon           | AHA Content Reviewer     | None   | None            | None                              | Pharmacy Times CE*  | <ul style="list-style-type: none"> <li>• American Pharmacists Association*</li> <li>• Boehringer Ingelheim*</li> </ul>   | None   |
| Daniel Duprez           | JCPM Content Reviewer    | None   | None            | None                              | None  | <ul style="list-style-type: none"> <li>• Amgen*</li> <li>• Arrowhead Pharmaceuticals*</li> <li>• NHLBI*</li> <li>• Novartis*</li> </ul>  | None   |
| Keith C. Ferdinand      | ABC Content Reviewer     | None   | None            | None                              | None  | <ul style="list-style-type: none"> <li>• Amgen</li> <li>• Boehringer Ingelheim</li> <li>• Janssen Biotech, Inc.</li> <li>• Janssen Global Services, LLC</li> <li>• Medtronic USA, Inc.</li> <li>• Novartis</li> </ul>  | None   |
| Anne Carol Goldberg     | ACC Content Reviewer     | <ul style="list-style-type: none"> <li>• Piper Sandler</li> </ul>  | None            | None                              | None  | <ul style="list-style-type: none"> <li>• Amgen</li> <li>• Arrowhead Pharmaceuticals</li> <li>• Eli Lilly and Company†</li> <li>• Esperion Therapeutics, Inc.†</li> <li>• Ionis Pharmaceuticals†</li> <li>• Marea Therapeutics</li> <li>• NLA*</li> <li>• New Amsterdam Pharma</li> <li>• Novartis†</li> <li>• Pediatric Endocrine Society</li> </ul> | None   |
| Parag Joshi             | AHA/ACC Content Reviewer | <ul style="list-style-type: none"> <li>• Kaneka Pharma America LLC</li> <li>• New Amsterdam</li> <li>• Novartis Pharmaceuticals Corporation</li> </ul> | None            | None                              | <ul style="list-style-type: none"> <li>• Kaneka Pharma America LLC</li> </ul> | <ul style="list-style-type: none"> <li>• AHA</li> <li>• Eli Lilly and Company*</li> <li>• Kaneka Pharma America LLC*</li> <li>• Novartis</li> </ul>  | CMV Law*- Defendant, Coronary Artery Disease Testing, 2024 |

(Continued)

## Appendix 2. Continued

| Reviewer                  | Representation           | Consultant   | Speakers Bureau | Ownership/ Partnership/ Principal  | Personal Research  | Institutional, Organizational, or Other Financial Benefit   | Expert Witness |
|---------------------------|--------------------------|--|-----------------|--|--|---|----------------|
| Joshua W. Knowles         | AHA Content Reviewer     | <ul style="list-style-type: none"> <li>• Arrowhead</li> <li>• Mammoth Biosciences</li> <li>• Wave Life</li> </ul>  | None            | None   | None   | <ul style="list-style-type: none"> <li>• AHA*</li> <li>• Circulation GPM editor*</li> <li>• NIH (NIDDK, NHLBI)*</li> <li>• Novartis†</li> <li>• The Family Heart Foundation†</li> </ul>   | None           |
| Carl (Chip) J. Lavie, Jr. | AACVPR Content Reviewer  | <ul style="list-style-type: none"> <li>• Amgen</li> <li>• Esperion Therapeutics, Inc.</li> <li>• Goed</li> </ul>   | None            | None   | None   | None  | None           |
| Jane A. Linderbaum        | PCNA Content Reviewer    | None   | None            | None   | None   | <ul style="list-style-type: none"> <li>• PCNA†</li> </ul>   | None           |
| John Bill McEvoy          | AHA/ACC Content Reviewer | None   | None            | None   | None   | None  | None           |
| Anurag Mehta              | ASPC Content Reviewer    | None   | None            | None   | None   | <ul style="list-style-type: none"> <li>• Amgen*</li> <li>• Novartis*</li> </ul>   | None           |
| C. Noel Bairey Merz       | AHA/ACC Content Reviewer | None   | None            | <ul style="list-style-type: none"> <li>• iRhythm*</li> </ul>   | None   | <ul style="list-style-type: none"> <li>• iRhythm*</li> </ul>  | None           |
| Vijay Nambi               | ACC Content Reviewer     | None   | None            | <ul style="list-style-type: none"> <li>• Abbott Laboratories</li> <li>• Insera Therapeutics</li> </ul>   | None   | <ul style="list-style-type: none"> <li>• Abbott Laboratories*</li> <li>• ACC</li> <li>• AHA</li> <li>• ASPC</li> <li>• Ionis Pharmaceuticals†</li> <li>• NLA</li> <li>• Novartis</li> </ul>   | None           |
| Ariela Orkaby             | AGS Content Reviewer     | None   | None            | None   | National Institute on Aging                                | <ul style="list-style-type: none"> <li>• National Institute on Aging*</li> <li>• US Department of Veterans Affairs*</li> </ul>  | None           |
| Jessica M. Peña           | NLA Content Reviewer     | <ul style="list-style-type: none"> <li>• Turning Point Healthcare</li> </ul>   | None            | <ul style="list-style-type: none"> <li>• Current Atherosclerosis Reports</li> </ul>  | <ul style="list-style-type: none"> <li>• NIH*</li> </ul>   | <ul style="list-style-type: none"> <li>• Collegiate School†</li> <li>• Novartis</li> <li>• Novo Nordisk Inc.*</li> </ul>  | None           |
| Robert Rosenson           | ADA Content Reviewer     | <ul style="list-style-type: none"> <li>• Amgen Inc.*</li> <li>• Arrowhead Pharmaceuticals*</li> <li>• Avilar Therapeutics</li> <li>• Eli Lilly and Company*</li> <li>• GlaxoSmithKline</li> <li>• Intercept Pharmaceuticals, Inc.*</li> <li>• Life Extension</li> <li>• New Amsterdam</li> <li>• Novartis</li> <li>• Organon</li> <li>• Rona Therapeutics, Inc.</li> </ul> | None            | <ul style="list-style-type: none"> <li>• MediMergent LLC*</li> </ul>   | None   | <ul style="list-style-type: none"> <li>• Amgen Inc.*</li> <li>• Arrowhead Pharmaceuticals*</li> <li>• 89Bio*</li> <li>• Eli Lilly and Company*</li> <li>• Merck Sharp &amp; Dohme Corporation*</li> <li>• NIH</li> <li>• Novartis*</li> <li>• Novo Nordisk*</li> <li>• Shanghai Argo Biopharma*</li> <li>• Wolters Kluwer*</li> </ul> | None           |
| Janelle Ruisinger         | APhA Content Reviewer    | None   | None            | None   | <ul style="list-style-type: none"> <li>• Amgen*</li> </ul> | <ul style="list-style-type: none"> <li>• McKesson Corporation</li> </ul>  | None           |
| Sigrid E. Sandner         | AHA/ACC Content Reviewer | None   | None            | None   | None   | <ul style="list-style-type: none"> <li>• Annals of Thoracic Surgery</li> <li>• EACTS†</li> <li>• Interdisciplinary Cardiovascular and Thoracic Surgery</li> </ul>   | None           |
| Stacey L. Schott          | ACPM Content Reviewer    | <ul style="list-style-type: none"> <li>• ACPM</li> <li>• AHA†</li> </ul>   | None            | <ul style="list-style-type: none"> <li>• BioNTech</li> <li>• Eli Lilly and Company</li> <li>• Merck</li> <li>• Novo Nordisk</li> <li>• Pfizer</li> </ul> | None   | <ul style="list-style-type: none"> <li>• Maryland Department of Health and Mental Hygiene</li> </ul>  | None           |

(Continued)

**Appendix 2. Continued**

| Reviewer                  | Representation           | Consultant | Speakers Bureau | Ownership/ Partnership/ Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit   | Expert Witness |
|---------------------------|--------------------------|------------|-----------------|-----------------------------------|-------------------|---|----------------|
| Laurence (Larry) Sperling | AHA/ACC Content Reviewer | None       | None            | None                              | None              | None  | None           |
| Neil J. Stone             | AHA/ACC Content Reviewer | None       | None            | None                              | None              | None  | None           |
| Peter Toth                | AHA/ACC Content Reviewer | • Merck*   | None            | None                              | None              | • Amgen Inc.*<br>• Eli Lilly and Company*<br>• Novo Nordisk | None           |
| Adam Ware                 | AHA/ACC Content Reviewer | None       | None            | None                              | None              | • None  | None           |
| Seamus Paul Whelton       | AHA/ACC Content Reviewer | • CVS*     | None            | None                              | None              | • NHLBI<br>• NIH*   | None           |
| James Young II            | AHA/ACC Content Reviewer | None       | None            | None                              | None              | None  | None           |

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$5000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\*Significant ( $> \$5000$ ) relationship.

†No financial relationship.

‡This disclosure was entered under the Clinical Trial Enroller category.

ABC indicates Association of Black Cardiologist; ACC, American College of Cardiology; ACCP, American College of Clinical Pharmacy; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; CART, Clinical Assessment Reporting and Tracking; DSMB, data and safety monitoring board; HRS&D, Health Services Research and Development; JCPM, Joint Committee on Performance Measures; LSU, Louisiana State University; MMC, medical monitoring committee; NHLBI, a National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NLA, National Lipid Association; NYU, New York University; PCNA, Preventive Cardiovascular Nurses Association; PHRI, Population Health Research Institution; PI, principal investigator; SCAI, Society for Cardiovascular Angiography & Interventions; UCLA, University of California, Los Angeles; VA, Veterans Affairs; and VHA, Veterans Health Administration.

# Circulation